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 I 
Abstract 
In recent years, a number of newly discovered tick-borne viruses exhibiting a wide 
spectrum of diseases in humans have been ascribed to the Phlebovirus genus of the 
Bunyaviridae family. These viruses have a tripartite RNA genome composed of two 
negative-sense RNA segments (medium and large) and one ambisense segment (small), 
which encode four structural proteins and one non-structural protein (NSs). The NSs 
protein is the major virulence factor of bunyaviruses, and acts as an antagonist of a key 
component of the first line of defence against viral infections: the interferon (IFN) system 
(Bridgen et al., 2001; Weber et al., 2002). The work presented herein describes the 
characterization of tick-borne phlebovirus NSs proteins as IFN antagonists. The 
development of a reverse genetics system for the apathogenic tick-borne Uukuniemi 
phlebovirus (UUKV) enabled the recovery of infectious UUKV entirely from cDNA. A 
recombinant UUKV lacking NSs induced higher amounts of IFN in infected cells 
compared to wild-type UUKV, suggesting a role of NSs in modulating the IFN response. 
The weak IFN antagonistic activity of UUKV NSs was evident using transient transfection 
reporter assays in comparison to the NSs protein of either pathogenic Heartland virus 
(HRTV) or Severe fever with thrombocytopenia syndrome virus (SFTSV). The sensitivity 
of UUKV, HRTV and SFTSV to exogenous and virus-induced IFN, as well as their growth 
kinetics in IFN-competent cells were examined. The molecular mechanisms employed by 
UUKV, HRTV and SFTSV NSs proteins to evade antiviral immunity were investigated 
using reporter assays, immunofluorescence, and immunoprecipitation studies. Collectively, 
these assays showed that UUKV NSs was able to weakly inhibit IFN induction but not IFN 
signalling, through a novel interaction with MAVS (mitochondrial antiviral signalling 
protein). On the other hand, HRTV and SFTSV NSs proteins potently inhibited IFN 
induction through an interaction with TBK1, and type I but not type II IFN signalling via 
an interaction with STAT2. Finally, the development of a minigenome system for HRTV in 
conjunction with minigenomes developed for UUKV and SFTSV (Brennan et al., 2015) 
provided preliminary data to assess possible outcomes of tick-borne phlebovirus 
reassortment. In summary, the results described in this thesis offer insights into how tick-
borne phlebovirus pathogenicity may be linked to the capacity of their NSs proteins to 
block the innate immune system. The data presented also illustrate the plethora of viral 
immune evasion strategies utilized by emerging phleboviruses, and provide an insight into 
the possibility of tick-borne phlebovirus reassortment.  
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Chapter 1 
INTRODUCTION
1. Introduction 2 
1 Introduction 
The following chapter will review the basic characteristics of the molecular biology of the 
Bunyaviridae, with particular attention to the Phlebovirus genus, followed by a brief 
history of the methods employed to manipulate the genome of bunyaviruses. A discussion 
of emerging tick-borne phleboviruses, as well as a short review of the host innate immune 
responses and countermeasures employed by phleboviruses to supress these responses is 
also described. 
1.1 Molecular biology of the Bunyaviridae 
1.1.1 Classification of the Bunyaviridae 
The Bunyaviridae is the largest family of RNA viruses, and it comprises over 350 
members. All bunyaviruses share similar genetic, morphological and replication strategies: 
they are enveloped, single strand RNA viruses with tripartite genomes of negative- or 
ambi-sense polarity, they replicate exclusively in the host cell cytoplasm and virus 
particles are of 80-120 nm diameter. Additionally, bunyaviruses are characterised by their 
maturation and budding at the Golgi complex (Kuismanen et al., 1984; 1982; Murphy et 
al., 1973).  
The Bunyaviridae was recognised as a family by the International Committee on 
Taxonomy of Viruses (ITCV) in 1975 (Elliott and Blakqori, 2012), and was further 
classified into 5 genera: Orthobunyavirus, Nairovirus, Hantavirus, Phlebovirus and 
Tospovirus according to their genomic and antigenic similarities. Members of the 
Bunyaviridae family are commonly referred to as bunyaviruses. However, the terms 
orthobunyaviruses, nairoviruses, hantaviruses, phleboviruses and tospoviruses refer to the 
particular genera, respectively. Some members of these genera are important plant, animal, 
or human pathogens with a worldwide distribution (Table 1-1). 
In general, bunyaviruses are known as arthropod-borne viruses (arboviruses), with the 
exception of hantaviruses, which are transmitted by rodents via aerosolized excreta. 
Additionally, all bunyaviruses are known to infect vertebrate hosts, except for 
tospoviruses, which are the sole group of plant-infecting viruses within the family and are 
transmitted by thrips. It must be mentioned that some viruses, such as Gouléako virus 
(GOLV) or Herbert virus (HEBV), are putatively recognized as insect-specific viruses 
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(Marklewitz et al., 2015). However, GOLV and HEBV RNA was detected in pigs in South 
Korea, suggesting that these viruses may also infect vertebrates (Chung et al., 2014). 
 Like other arboviruses, arthropod-transmitted bunyaviruses are maintained in nature by 
enzootic cycles involving haematophagous invertebrate vectors of transmission (such as 
mosquitoes, sandflies, thrips or ticks) and susceptible vertebrate hosts (Figure 1-1). The 
diversity of hosts, vectors and disease manifestation of the members of this family, and 
their remarkable ability to replicate in cells of disparate phylogeny is of interest. These 
characteristics give an insight into the heterogeneity of virus-host interactions that this 
family has evolved at the molecular level.  
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Table 1-1. Pathogenic viruses within the Bunyaviridae family. 
* Crimean-Congo Haemorrhagic Fever, °Severe Fever with Thrombocytopenia Syndrome 
  
Virus Vector Host Geographic 
distribution 
Disease manifestation 
Orthobunyavirus 
  Bunyamwera 
  Oropouche 
   La Crosse 
  Cache Valley 
 
Schmallenberg 
 
Mige, mosquito 
Midge 
Mosquito 
Midges, 
mosquito 
Midges 
 
Human 
Human 
Human 
Cattle, sheep 
 
Cattle, sheep, 
goats 
 
Africa 
North America 
North America 
North America 
 
Europe 
 
Acute febrile illness, 
encephalitis 
Fever, myalgia, 
arthralgia, encephalitis 
Fever, encephalitis 
Febrile illness, 
encephalitis 
 
Stillbirths and birth 
defects 
Hantavirus 
  Hantaan 
  Puumala 
  Sin Nombre 
 
Field mouse 
Bank vole 
Deer Mouse 
 
Human 
Human 
Human 
 
Eurasia 
Eurasia 
North America 
 
Haemorrhagic fever with 
renal syndrome 
Nephromathia epidemica 
Hantavirus pulmonary 
syndrome 
Nairovirus 
  CCHF* 
  Dugbe 
 
Tick 
Tick, mosquito 
 
Human 
Human, cattle 
 
Africa, Eurasia 
Worldwide 
 
Haemorrhagic fever  
 
Abortion in cattle, fever 
and thrombocytopenia in 
humans 
Tospovirus 
Tomato spotted       
wilt 
 
Thrip 
 
Plants (weeds, 
field crops) 
 
Worldwide 
 
Spotting and wilting of 
plants  
Phlebovirus 
  Rift Valley fever 
  Toscana 
  SFTS° /Heartland 
 
Mosquito 
Sandfly 
Tick 
 
Human, cattle 
Human 
Human, sheep, 
cattle, dogs, 
birds 
 
Africa 
Europe 
South East Asia/ 
North America 
 
Retinitis, encephalitis, 
haemorrhagic fever 
Fever, myalgia 
Fever, thrombocytopenia, 
leukocytopenia, 
hemorragic fever 
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Figure 1-1. Simplified schematic of arbovirus transmission.  
Arboviruses can be maintained in nature in two cycles. (A) The enzootic sylvatic transmission 
cycles involves blood-feeding arthropods and wild vertebrates. In rare cases, a spill-over event can 
occur from the enzootic cycle to humans, which are considered the dead-end hosts. (B) Some 
viruses are capable of being maintained in an urban cycle. These viruses are able to infect humans 
and cause high viraemia, which allows humans to act as the main reservoir of arboviruses, allowing 
infection of new vectors. Close contact between the sylvatic and urban cycles can result in virus 
spill-over from one cycle to another. Figure modified from (Petersen and Busch, 2010). 
 
  
A B Sylvatic cycle Urban cycle 
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1.1.2 Virion structure 
Bunyavirus virions are composed of only four structural proteins: the two surface 
glycoproteins embedded in a lipid envelope, the nucleocapsid protein (N) and the RNA-
dependent RNA polymerase (RdRp, L). The latter two are tightly associated with the three 
RNA segments to form ribonucleoprotein (RNP) complexes (Figure 1-2 A). These RNPs 
have been found in virions in a circular panhandle form, with a pseudo-helical structure 
(Figure 1-2 B) (Obijeski et al., 1976; Pettersson and Bonsdorff, 1975; Samso et al., 1975). 
The general view of a bunyavirus particle containing three genome segments has now been 
revisited, as a recent study used single molecule fluorescence in situ hybridization to show 
that RVFV genome packaging is a non-selective process (Wichgers Schreur and 
Kortekaas, 2016). This study confirmed that in reality, the majority of mature virions lack 
one or more genome segments, despite the intracellular S, M and L genome segments 
averaging a 1:1:1 ratio. Additionally, although the general view is that only genomic 
segments are packaged into virions, a fraction of antigenomic replication intermediates 
have been reported to be packaged in Rift Valley Fever (RVFV) and Uukuniemi (UUKV) 
viral particles (Brennan et al., 2014; Ikegami et al., 2005b; Simons et al., 1990). 
Cryo-electron microscopy (cryo-EM) of a number of bunyaviruses has demonstrated that 
members of different genera exhibit some differences in their morphology, with virion 
diameter ranging from 80 to 120 nm (Figure 1-2 C). The virion diameter of a number of 
bunyaviruses has been determined: 108 ± 8 nm for Bunyamwera virus (BUNV) (Bowden 
et al., 2013), 75-115 nm for La Crosse virus (LACV) (Talmon et al., 1987), 95-125 nm for 
UUKV (Overby et al., 2008; Pettersson and Bonsdorff, 1975), 100 nm for RVFV (Freiberg 
et al., 2008; Sherman et al., 2009) and 120-160 nm for Tula virus (TULV) (Huiskonen et 
al., 2010). Virions are composed of a 4-7 nm thick lipid bilayer envelope, which originates 
from the host cell Golgi cisternae and is embedded by the heterodimers of the viral 
glycoproteins Gn and Gc that can be visualised as 5-10 nm protrusions from the envelope 
by EM (Huiskonen et al., 2009; Overby et al., 2008). As bunyaviruses lack a matrix 
protein, it is thought that the arrangement of the Gn-Gc heterodimers is crucial in 
determining virion morphology (Huiskonen et al., 2009; Overby et al., 2008). BUNV 
glycoprotein spikes were found to follow a tripodal arrangement (Bowden et al., 2013), 
while UUKV and RVFV Gn-Gc heterodimers exhibit an ordered icosahedral T=12 
symmetry (Freiberg et al., 2008; Overby et al., 2008). Comparatively, hantavirus virions 
have homotetrametic Gn complexes interconnected with Gc homodimers, creating a square 
grid-like surface pattern (Hepojoki et al., 2010; Martin et al., 1985) (Figure 1-2 D). 
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Figure 1-2. Bunyavirus virion structure.  
(A) Schematic representation of the morphology a bunyavirus virion. Virions are composed of a 
lipid bilayer embedded by the viral glycoproteins Gn and Gc, which envelopes RNPs composed of 
the genomic RNA (S, M or L segments) encapsidated by the nucleocapsid protein in association 
with the RNA-dependent RNA polymerase. (B) Circular panhandle forms of purified UUKV S (i) 
M (ii) and L (ii) RNPs are shown. Scale bars represent 0.25 nm. Images were modified from 
(Hewlett et al., 1977). (C) Morphology of RVFV (i), UUKV (ii), and TULV (iii) virions, visualised 
by cryo-electron microscopy. Scale bars represent 100 nm. Images modified from (Huiskonen et 
al., 2010; 2009; Overby et al., 2008). (D) Schematic representation of the surface arrangement of 
Gn and Gc spikes in virions of the Orthobunyavirus (i), Phlebovirus (ii) and Hantavirus (iii) genus. 
The figures were adapted from (Bowden et al., 2013). RNP: Ribonucleoprotein; UUKV: 
Uukuniemi virus; RVFV: Rift Valley Fever Virus; TULV: Tula virus. 
  
(ii) (iii) 
C 
A 
B 
(i) 
(ii) (iii) (i) 
D (ii) (iii) (i) 
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1.1.3 Genome organization and coding strategy 
Bunyaviruses have a segmented single-strand RNA genome of negative- or ambi- sense 
polarity. The segments are named according to their nucleotide length, namely the S 
(small), M (medium) and L (large) segments. Each segment is composed of a coding 
region flanked by viral 3’ and 5’ untranslated regions (UTRs). The termini of these UTRs 
are complementary, and it is this complementarity that enables their self-annealing and 
results in the formation of the characteristic panhandle-like structure that gives a circular 
conformation to viral RNPs. These regions have also recently been shown to be important 
for binding of the RdRp to form the RNPs (Gerlach et al., 2015). RNA secondary 
structures within the viral UTRs function as cis-acting elements to drive transcription and 
replication of the viral genome (Dunn et al., 1995; Elliott and Blakqori, 2011; Lowen and 
Elliott, 2005). Importantly, for phleboviruses, the 3’ and 5’ UTR of all three genome 
termini contain eight nucleotides that are conserved across most phleboviruses (3’-
ACACAAAG…CUUUGUGU-5’) (Elliott and Blakqori, 2011).  
The genome segments encode four structural proteins: the S segment encodes the 
nucleocapsid protein (N), the M segment encodes the glycoprotein precursor, which is co-
translationally cleaved to generate the glycoproteins (Gn and Gc), and the L segment 
encodes the viral RdRp (L). In addition, non-structural proteins are encoded by the S 
segment of most orthobunyaviruses, phleboviruses and tospoviruses (named NSs), and by 
the M segment of orthobunyaviruses, tospoviruses and some phleboviruses (named NSm) 
(Bouloy, 2011). The coding capacity of representative viruses from each of the genera is 
depicted in Figure 1-3. 
The M and L segments of phleboviruses are of negative-sense (genomic) polarity, which 
means that following virus infection, the genomic RNA (gRNA) serves as a template for 
transcription of positive-sense mRNA for the translation of the glycoprotein precursor or 
the L protein. In addition, gRNA can be replicated into anti-genomic RNA (agRNA), 
which can serve as a template for the generation of more gRNA copies (Figure 1-4 A). 
Their S segment, however, utilizes an ambi-sense coding strategy to encode N in the 
negative-sense and NSs in the positive-sense from separate sub-genomic mRNAs. 
Specifically, N is translated from subgenomic mRNA transcribed from the genomic-sense 
RNA, whereas NSs is translated from subgenomic mRNA transcribed from agRNA  
(Figure 1-4 B) (Bouloy and Weber, 2010). The ambi-sense nature of phlebovirus S 
segments has implications in the temporal expression of N and NSs proteins. Because NSs 
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mRNA is generated from agRNA, the transcription of NSs mRNA occurs only after 
replication of the viral gRNA into agRNA (Figure 1-4 B). In fact, studies using pulse-
chase analysis have shown that the N protein of UUKV is synthesized as early as 4 h p.i., 
whereas NSs is only synthesized at 8 h p.i. (Simons et al., 1992). Tospovirus M and S 
segments also employ an ambi-sense coding strategy, where the Gn-Gc and NSm open 
reading frames (ORFs) or N and NSs ORFs (respectively) have opposite polarities. In 
contrast, most members of the Orthobunyavirus genus do not utilize an ambi-sense coding 
strategy, but can encode NSs in an overlapping reading frame with the N sequence, thus 
both proteins can be translated from the same mRNA transcript (Figure 1-3) (Elliott and 
Schmaljohn, 2013).  
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Figure 1-3. Coding capacity of the Bunyaviridae.  
Schematic representation of the coding capacity for all Bunyaviridae genera in comparison to the 
Phlebovirus genus, represented by RVFV. BUNV, DUGV, HTNV and TSWV genomes are 
depicted, representing the Orthobunyavirus, Nairovirus, Hantavirus and Tospovirus genera, 
respectively. The viral RNA segment is shown as a naked line with the 3’ and 5’ termini shown. 
The viral mRNA is shown with a host-derived 5’ terminal cap (!) and an arrow (" ) representing 
the orientation of transcription elongation (5’ to 3’). Note that the length of the genomes are not 
represented to scale, genome lengths vary between genera. The molecular weight of the encoded 
proteins is shown below the mRNA. RVFV: Rift Valley Fever Virus; BUNV: Bunyamwera virus; 
DUGV: Dugbe virus; HTNV: Hantaan virus; TSWV: Tomato spotted wilt virus. Figure adapted 
from (Elliott and Schmaljohn, 2013). 
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Figure 1-4. Negative- and ambi-sense coding strategies employed by phleboviruses. 
Transcription and replication strategies employed by phleboviruses for negative- (A) or ambi-sense 
(B) segments are shown. In negative-sense genomes (such as M or L segments of phleboviruses), 
subgenomic mRNA is transcribed directly from the viral genome, which also serves as a template 
for genome replication and the generation of the positive-sense replication intermediate 
(antigenome). In genomes with an ambisense coding strategy, subgenomic mRNA can also be 
transcribed after genome replication using the anti-genomic replication intermediate as a template. 
Only ORFs in the positive sense are shown. The viral genomic or antigenomic-sense RNA 
segments are shown as a naked line with the 3’ and 5’ termini. Viral mRNA is shown with a host-
derived 5’ terminal cap (!) and an arrow (" ) representing the orientation of transcription 
elongation (5’ to 3’). Illustration modified from (Elliott and Brennan, 2014). 
  
A 
B 
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1.1.4 Gene products and their function 
(i) Nucleocapsid (N) protein 
The N protein is encoded in the genomic-sense S segment RNA of bunyaviruses and plays 
an indispensable role in the viral life cycle. Following infection of a host cell, N is the most 
abundant protein expressed by the virus. This is presumably because of its primary 
function, which entails protecting the viral genome from degradation and tightly binding to 
viral RNA for the formation of RNPs along with the viral polymerase (L) (Bouloy, 2011). 
The N protein also plays a major role in the replication and transcription of viral RNA by 
the viral polymerase, and in packaging of the genome into virions (Elliott and Schmaljohn, 
2013). Given that bunyaviruses replicate exclusively in the cytoplasm, it is not surprising 
that the N protein of bunyaviruses is localized to the cytoplasm, which was demonstrated 
for UUKV, SFTSV and RVFV (Brennan et al., 2015; 2011a; Katz et al., 2010). Although 
between genera the homology of the N protein is minimal, the function of this protein to 
encapsidate the viral genome is conserved.  
Initial structural studies showed that UUKV and RVFV N proteins formed dimers and 
higher oligomers through aromatic residues at the N terminus of the protein (Katz et al., 
2010; Le May et al., 2005). The availability of a crystal structure for RVFV and TOSV N 
proteins provided structural insights into the RNA encapsidation mechanism of 
phleboviruses. Initially it was shown that an RNA-free form of RVFV N was composed of 
a dimer in which the amino-terminal “arm” domain of RVFV N was folded into a 
predicted RNA-binding pocket of the C-terminal globular domain (Raymond et al., 2010). 
Further studies showed that in the presence of RNA, TOSV and RVFV N proteins form 
ring-shaped hexameric conformations stabilised by the N-terminal arm, which was bound 
to a hydrophobic pocket of the globular C-terminal domain of an adjacent subunit through 
inter-molecular interactions (Figure 1-5) (Ferron et al., 2011; Olal et al., 2014). A number 
of positively charged residues located in a deep groove formed by the hexameric structures 
were shown to enable the binding of a single RNA molecule in a sequence-independent 
manner, with six RNA bases binding to each monomer (and thus a total of 36 RNA bases 
per hexamer) (Ferron et al., 2011; Olal et al., 2014; Raymond et al., 2012). Additionally, 
RNA binding to TOSV N was shown to induce an inter-subunit rotation which enabled the 
transition from a hexameric form to a helical RNP-like assembly through the opening up 
the RNA-binding tunnel (Figure 1-5 B)(Olal et al., 2014).  
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Figure 1-5. Crystal structures of RVFV and TOSV N.  
The electrostatic surface potential of RVFV and TOSV N hexamers is shown. (A) A patch of 
positively charged residues (blue) is observed in the inner part of the hexameric ring for RVFV N. 
(B) The positively charged RNA binding groove for TOSV N is depicted in red in both the model 
of a left-handed helical RNP (left) and in the hexameric ring viewed from the top (right). RVFV: 
Rift Valley Fever Virus; TOSV: Toscana Virus; RNP: Ribonucleoprotein. Images taken from 
(Ferron et al., 2011; Olal et al., 2014). 
 
 
 
 
 
 
  
A 
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(ii) Viral RNA-dependent RNA polymerase (L) 
The L protein of bunyaviruses functions as the viral RdRp, and derives its name because it 
is the largest encoded protein by the bunyavirus genome (Figure 1-3). The L protein plays 
an essential role in the virus life cycle, as it is responsible for catalyzing viral RNA 
synthesis in both, transcription and replication processes (H. Jin and Elliott, 1993a; 1991). 
While the molecular weight of phlebovirus, hantavirus and orthobunyavirus L proteins is 
about 250 kDa, tospoviruses encode L proteins of approximately 330 kDa, while 
nairoviruses encode L proteins of approximately 460 kDa (Figure 1-3). Although little 
homology is found in the amino acid sequence of L proteins between genera, four main 
domains that are known as the ‘polymerase module’, were found to be conserved (Aquino 
et al., 2003; H. Jin and Elliott, 1991; Müller et al., 1994). These domains are also common 
in RdRps of other positive, negative and double strand RNA viruses (Poch et al., 1989).  
Jin and Elliott first identified the ability of the L protein to catalyze viral RNA synthesis in 
1991, using a recombinant vaccinia virus expression system for BUNV L (H. Jin and 
Elliott, 1991). This was followed by the discovery of host-cell derived, capped sequences 
at the 5’ ends of DUGV viral mRNA transcripts, which suggested that the L protein had, in 
addition, an endonuclease activity (H. Jin and Elliott, 1993b). A PD-(D/E)XK motif 
identified in the N-terminus of LACV (and also present in the Influenza virus polymerase)  
is conserved amongst all Bunyaviridae, and was shown to be important for LACV L 
endonuclease activity in vitro (Reguera et al., 2010). It is now known that endonuclease 
activity of the RdRp is responsible for an important step in the viral life cycle, termed ‘cap-
snatching’. Cap-snatching is utilised by the RdRp of many negative sense RNA viruses to 
cleave 5’ caps of about 10-18 nucleotides in length from host cell pre-mRNAs, in order to 
prime transcription of the viral genome and the synthesis of 5’ capped, translatable viral 
mRNAs (Bishop et al., 1983; Bouloy et al., 1990; Kormelink et al., 1992; Simons and 
Pettersson, 1991). 
In terms of subcellular localization, the L protein of a number of bunyaviruses has been 
shown to be cytoplasmic (Di Bonito et al., 1999; Kukkonen et al., 2004). The generation 
of recombinant BUNV and RVFV with a V5-tagged L protein showed that in infected 
cells, N and L proteins co-localise in the cytoplasm forming so-called ‘viral factory’ 
structures, which are thought to be the site of viral replication (Brennan et al., 2011a; Shi 
and Elliott, 2009).  
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(iii) Glycoproteins (Gn and Gc) 
The viral glycoproteins Gn and Gc are encoded by the genomic M segment of 
bunyaviruses, and are translated as a polyprotein precursor from a single mRNA molecule 
(Figure 1-3). They serve an essential role in attachment, entry, packaging and budding of 
the virus. As they are exposed on the surface of the virion, the glycoproteins are 
recognized by the immune system and elicit the production of neutralising antibodies 
against glycoprotein epitopes (Bouloy, 2011).  
Processing of the polyprotein precursor, which is co-translationally cleaved by host cell 
proteases, is crucial for viral attachment, as well as virion maturation and budding (Elliott 
and Schmaljohn, 2013; Shi et al., 2016). The mature Gn and Gc proteins are both type I 
integral transmembrane proteins, and are trafficked as heterodimers from the 
endoplasmatic reticulum (ER) to the Golgi compartment, which is the site of virus 
assembly (Bowden et al., 2013; Persson and Pettersson, 1991; Shi et al., 2016; 2005). 
Viral attachment is thought to occur via an interaction between oligomannose-type glycans 
present on virion glycoproteins and a tetrametic C-type lectin, called DC-SIGN (DC 
[Dendritic Cell] specific ICAM [intracellular adhesion molecule]-3 grabbing non-integrin) 
(Hofmann et al., 2013; Lozach et al., 2011). A glycome analysis of the UUKV virion 
revealed differential processing of Gn and Gc, with both proteins displaying poly-N-
acetylactosamines, consistent with the assembly of virions in the medial Golgi complex. 
However, oligomannose-type glycans required for DC-SIGN cellular attachment were 
predominant in UUKV Gc (Crispin et al., 2014). N-linked glycans have also been shown 
to support RVFV infection via DC-SIGN (Phoenix et al., 2016). In addition, N-linked 
glycosylation of bunyavirus glycoproteins has been shown to be play a pivotal role in 
protein folding and intracellular packaging (Shi et al., 2005; Shi and Elliott, 2004). The 
importance of glycosylation is illustrated by failure to rescue BUNV lacking a N-terminal 
Gn N-glycosylation site, which was shown to result in protein misfolding the inability to 
traffic both Gn and Gc to the Golgi complex (Shi and Elliott, 2004).  
The crystal structure of RVFV Gc revealed a class II fusion protein architecture, similar to 
those found in flaviviruses and alphaviruses and enabled to identify Gc as the membrane 
anchor that acts as the effector of the fusion between the virus and host cell endosomal 
membranes(Dessau and Modis, 2013), a hypothesis previously suggested for BUNV, 
LACV and HTNV (Ogino et al., 2004; Plassmeyer et al., 2005; Shi et al., 2009). 
Additionally, the crystal structure of the ectodomain of SFTSV Gc identified Histidine 
1. Introduction 16 
residues that are important in triggering a pH-dependent conformational change required to 
facilitate fusion of viral and endosomal membranes (Halldorsson et al., 2016).  
Virus-like particle studies on UUKV and BUNV suggested that the cytoplasmic tails of 
UUKV Gn and BUNV Gn and Gc had a critical role in genome packaging into the virus 
envelope (by a close interaction with viral RNPs), whereas the cytoplasmic tail of UUKV 
Gc was found to be important for particle generation and budding (Overby et al., 2007; Shi 
et al., 2007). 
(iv) Non-structural protein NSm 
The M segment of some bunyaviruses encodes an accessory non-structural protein, named 
‘NSm’. The precise role of this non-essential protein is not well-defined. BUNV NSm is 
co-translationally cleaved from the polyprotein precursor along with Gn and Gc, localises 
to the Golgi, and its N terminus is involved in virus assembly and morphogenesis (Nakitare 
and Elliott, 1993; Shi et al., 2006). The NSm protein of RVFV has been suggested to 
supress virus-induced apoptosis by inhibiting the activation of cellular caspase-8, which 
plays an important role in the initiation of the mitochondrial pathway to apoptosis (Won et 
al., 2007). 
While within the Phlebovirus genus the M segment of viruses transmitted by dipterans 
encode a NSm protein, the M segment of those transmitted by ticks do not (Bouloy, 2011; 
Elliott and Brennan, 2014). The coding sequence of the NSm protein of dipteran-borne 
phleboviruses is located in the pre-Gn region of the polyprotein precursor, at the N 
terminus. Interestingly, while some viruses such as PTV and TOSV encode a unique NSm 
protein of 30 kDa (Di Bonito et al., 1999; Ihara et al., 1985), the glycoprotein precursor of 
RVFV can generate two NSm proteins: a 78 kDa NSm protein, also known as p78, and a 
14 kDa NSm protein termed NSm (Bouloy, 2011).  The two RVFV NSm proteins are 
generated by alternative usage of in-frame AUG codons present in the precursor: while p78 
synthesis is initiated by the use of the first AUG, the second AUG is utilised for synthesis 
of the smaller NSm (Figure 1-6). The larger, p78 protein can be regarded as an NSm 
protein that remains fused to Gn, as the N terminus of Gn is not cleaved at its signal 
peptide (Figure 1-6) (Suzich et al., 1990). NSm has been attributed a number of roles in the 
replication of RVFV in mosquitoes. For instance, a study has shown that RVFV NSm is 
important for allowing the virus to cross the mosquito mid-gut barrier, and the replicaion 
of recombinant RVFV lacking NSm was attenuated in mosquitos (Crabtree et al., 2012; 
1. Introduction 17 
Kading et al., 2014). Additionally, the p78 version of RVFV NSm appears to act as a 
major determinant of virus dissemination in infected mosquitoes (Kreher et al., 2014). 
 
Figure 1-6. Polyprotein precursor synthesis and processing of phleboviruses.  
Schematic representation of polyprotein precursor synthesis and processing, encoded by the 
genomic M segment of mosquito-borne Rift Valley fever virus (RVFV) and Punta Toro virus 
(PTV), and tick-borne Uukuniemi virus (UUKV). The viral mRNA is shown with a host-derived 5’ 
terminal cap (!) and an arrow (" ) representing the orientation of transcription (5’ to 3’). AUG 
codons are shown on the mRNAs. The signal peptidase cleavage sites are represented by a scissor. 
This figure was adapted from (Bouloy, 2011).   RVFV: Rift Valley fever virus; PTV: Punta Toro 
virus; UUKV: Uukuniemi virus.  
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(v) Non-structural protein NSs 
The non-structural protein NSs is encoded in the S segment of some bunyaviruses, and 
although the NSs protein shares little homology within and between genera, the major 
function of NSs as an antagonist of the interferon (IFN) system appears to be conserved 
(Elliott and Blakqori, 2012; Wuerth and Weber, 2016). The NSs protein of a number of 
orthobunyaviruses (BUNV, SBV, LACV, OROV) has been shown to be a non-essential 
gene product that acts as an IFN antagonist (Blakqori and Weber, 2005; Elliott et al., 2013; 
Tilston-Lunel et al., 2016; Varela et al., 2013; Weber et al., 2002). While the generation of 
recombinant BUNV, SBV and OROV viruses lacking NSs demonstrated some attenuation 
of replication kinetics compared to wild-type viruses in IFN incompetent cells, this was not 
the case for LACV (Blakqori and Weber, 2005; Elliott et al., 2013; Tilston-Lunel et al., 
2016; Weber et al., 2002). These observations suggest that perhaps the NSs proteins of 
BUNV, SBV and OROV but not LACV play a non-essential role in facilitating virus 
replication. NSs proteins have also been identified for Tula and Puumala viruses within the 
Hantavirus genus, and were reported to act as antagonists of IFN induction (Jääskeläinen 
et al., 2007). Recently, a NSs protein was also identified in the S segment of Crimean 
Congo haemorrhagic fever virus (CCHFV), which disrupts the mitochondrial membrane 
potential and induces apoptosis (Barnwal et al., 2016). Within the Tospovirus genus, the 
NSs protein of TSWV acts as a suppressor of the RNAi pathway in plant cells and is also 
implicated in persistent infection and transmission by thrips (Margaria et al., 2014; 
Oliveira et al., 2011). Phleboviral NSs proteins characterised as IFN antagonists include 
those belonging to RVFV, TOSV, PTV and SFTSV (Billecocq et al., 2004; Chaudhary et 
al., 2015; Gori-Savellini et al., 2010; Lihoradova et al., 2013; Ning et al., 2015; Perrone et 
al., 2007; Santiago et al., 2014).  
The NSs protein of BUNV and RVFV were shown to inhibit host cell mRNA transcription, 
which is facilitated by their nuclear localization (Billecocq et al., 2004; Leonard et al., 
2006; van Knippenberg and Elliott, 2015). BUNV NSs was shown to interact with MED8, 
a component of the Mediator complex that regulates RNA polymerase II-mediated 
transcription, in order to supress host cell mRNA transcription as a strategy to inhibit the 
IFN response (Leonard et al., 2006; Thomas et al., 2004). Specifically, this interaction was 
shown to result in the ultimate shut off of host cell protein synthesis by the inhibiting the 
phosphorylation of the C-terminal domain of RNA polymerase II, which is known to 
regulate its activity (Leonard et al., 2006).  Initially, it was believed that the broad 
inhibition of host cell mRNA transcription of RVFV NSs was also a strategy to inhibit the 
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IFN response, by blocking the transcription of IFN-related genes (Billecocq et al., 2004). 
The mechanism by which RVFV NSs blocks host cell mRNA transcription was 
demonstrated to be by inhibiting the assembly of the basal transcription factor IIH (TFIIH). 
Briefly, RVFV NSs was shown to sequester the p44 subunit of TFIIH within characteristic 
nuclear filaments formed by RVFV NSs, therefore preventing its interaction with the XPD 
subunit of TFIIH (natural partner of the p44 subunit) and thus inhibiting the helicase 
activity of XPD (Le May et al., 2004). Additionally, RVFV NSs was shown to halt host 
cell transcription by promoting the proteasomal degradation of the TFIIH p62 subunit at 
early stages of infection through a ΩXaV motif (Ω: aromatic, 266 X: any, a: acidic, V: 
valine), found at the C-terminal region of RVFV NSs (Cyr et al., 2015; Kalveram et al., 
2011). Recently, the RVFV NSs-driven proteasomal degradation of p62 was demonstrated 
to occur by an interaction of RVFV NSs with the F-box protein FBXO3 (Kainulainen et 
al., 2014; Le May et al., 2004), a subunit of E3 ubiquitin ligases, which mediate 
ubiquitination for rapid degradation by the proteasome. It was later shown that RVFV NSs 
is capable of supressing IFN- β mRNA synthesis specifically, using a separate mechanism 
to that utilized to supress general host cellular transcription (Le May et al., 2008). Details 
about the molecular mechanism of RVFV NSs to inhibit the induction of IFN- β mRNA 
synthesis are described in Section 1.4.4. The general host cell transcription suppression by 
RVFV NSs likely induces an unfavourable environment for viral replication within host 
cells. However, RVFV NSs was shown to also alter the unfavourable environment to 
support virus replication by promoting the post-transcriptional proteasome-dependent 
down-regulation of the double-stranded RNA-dependent protein kinase (PKR), which 
prevents the inhibition of translation (Ikegami et al., 2009a; 2009b). Because this function 
is a strategy utilized as a countermeasure of the IFN response, further details regarding the 
RVFV NSs-induced proteasomal degradation of PKR (and the IFN antagonist activity of 
other phlebovirus NSs proteins) are discussed in Section 1.4.4. 
In addition to antagonizing the innate immune system, the NSs protein of BUNV, LACV 
and SFTSV inhibit minigenome activity (described in Section 1.2.2) in a dose-dependent 
manner and have been suggested to regulate the activity of the RdRp L (Blakqori et al., 
2003; Brennan et al., 2015; Weber et al., 2001). A similar effect by RVFV NSs on the 
RVFV S segment-based minigenome was reported (Brennan et al., 2011a). However, 
contrasting data showing that RVFV NSs promotes viral replication and transcription in 
minigenome sytems derived from all viral segments were also shown (Ikegami et al., 
2005a).  
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1.1.5 Replication cycle 
(i) Attachment and entry 
Bunyaviruses utilise similar mechanisms to other enveloped viruses to enter host cells. As 
discussed earlier, the glycoproteins Gn and Gc are exposed on the surface of virions and 
their glycosylation patterns have been shown to play a role in virus entry (Hofmann et al., 
2013; Lozach et al., 2011) (Ludwig et al., 1991; Phoenix et al., 2016). Interactions 
between the viral glycoproteins and cellular receptors mediate host cell attachment (Step 1; 
Figure 1-7), and will determine the tropism of the virus (Elliott and Schmaljohn, 2013). 
Recent progress has been made to characterize receptors and cellular factors utilised by 
bunyaviruses to enter host cells. It is not surprising that the receptors utilised for 
attachment by hantaviruses (which are transmitted by aerosols) are different to those 
employed by viruses belonging to the other genera, which are transmitted through 
arthropod bites (Albornoz et al., 2016). Upon inhalation, hantaviruses encounter the 
epithelium of the lung, and infection of the capillary network endothelial cells tightly 
attached to epithelial cells results in capillary permeability and vascular leakage, causing 
haemorrhagic fever in infected patients. So far, receptors such as integrins β1, β2, and β3 
(Gavrilovskaya et al., 1999; 1998; Matthys et al., 2010; Raftery et al., 2014), as well as 
Decay Accelerating Factor (DAF)/C55 and gC1QR/p32 (Choi et al., 2008; Krautkrämer 
and Zeier, 2008) have been documented for hantavirus attachment to endothelial and 
epithelial cells. In contrast, arthropod-borne bunyaviruses enter the skin dermis of 
mammalian hosts via the bite of an infected arthropod and encounter dermal macrophages 
and dendritic cells at the site of infection (Léger and Lozach, 2015). DC-SIGN, highly 
expressed on dermal dendritic cells, has been shown to promote attachment and entry of 
the orthobunyavirus Germiston virus (Lozach et al., 2011), the nairovirus CCHFV (Suda et 
al., 2016), and phleboviruses SFTSV, UUKV, TOSV, PTV, and RVFV (Hofmann et al., 
2013; Lozach et al., 2011). As well as DC-sign, phleboviruses UUKV, TOSV and RVFV 
have been shown to exploit another C-type lectin expressed in liver endothelial cells, 
Liver-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin (L-SIGN), as an 
attachment receptor (Léger et al., 2016).  
Heparan sulfate is ubiquitously expressed in virtually all mammalian tissues and is known 
to be a polysaccharide that serves as a non-specific first docking site for many viruses 
through low affinity electrostatic interactions, in comparison to the more specific and 
multivalent virus-receptor interactions (Albornoz et al., 2016). So far, heparan sulfate has 
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been shown to promote infection of phleboviruses RVFV and TOSV (de Boer et al., 
2012a; Pietrantoni et al., 2015), however its role in attachment for other bunyaviruses 
remains to be determined.  
Following attachment, bunyaviruses rely on endocytic processes for their uptake into the 
host cell (Step 2 in Figure 1-7). While studies with orthobunyaviruses OROV and LACV 
(Hollidge et al., 2012; Santos et al., 2008), hantavirus HTNV (Jin et al., 2002) and 
nairovirus CCHFV (Simon et al., 2009) have suggested that virion internalization likely 
occurs through clathrin-mediated endocytosis, UUKV internalization was shown to be 
mainly clathrin-independent (Lozach et al., 2010). Upon internalization, virions must be 
released from vesicles in order to allow viruses to access the host cell machinery. Lozach 
et al. utilized UUKV as a model bunyavirus, to show that endocytised virions are sorted 
into vesicles, which are trafficked through the host cell endocytic machinery from Rab5a+ 
early endosomes (pH~6.5) to Rab7a+ late endosomes (pH ~5.5–5.0) (Lozach et al., 2010).  
Acidification of late endosomes occurred 20-40 min after internalization, and triggered 
fusion of the viral and endosomal membranes, consequently enabling the release of RNPs 
into the host cell cytoplasm for transcription and replication (Step 3 in Figure 1-7).  
As mentioned in section 1.1.3, fusion of viral and host cell endosomal membranes is 
mediated by bunyavirus glycoproteins, which also function as fusion proteins. Early 
studies on UUKV showed a pH-dependent conformation in UUKV glycoproteins (Overby 
et al., 2008). Acid-activated structural reorganization of the RVFV Gc fusion protein was 
also observed, and was suggested to be triggered by protonation of conserved histidine 
residues (de Boer et al., 2012b). Similar histidine residues identified in the structure of 
SFTSV Gc were also found to be important in the pH-dependent conformational change of 
Gc	(Halldorsson et al., 2016). Thus, it is thought that acidification of endosomes triggers a 
conformational change in pre-fusion glycoproteins, which facilitates the fusion of the viral 
and endosomal membranes. 
(ii) Primary transcription and translation 
For negative-strand RNA viruses, the classical view is that following virus infection, the 
genomic RNA is transcribed into mRNA by the incoming viral polymerase or transcriptase 
(Elliott and Schmaljohn, 2013). However, unlike other negative-strand RNA viruses such 
as influenza, which replicate in the cell nucleus, the site of RNA synthesis for 
bunyaviruses is localised to the cytoplasm (Elliott and Schmaljohn, 2013; Rossier et al., 
1986). 
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Figure 1-7. Life cycle of bunyaviruses.  
Schematic representation of the stages of the bunyavirus life cycle. 1. Attachment is mediated via 
the interaction of cell surface proteins and viral glycoproteins. 2. Internalization of the viruses 
occurs via endocytosis, which can be clathrin-dependent or independent. 3. Acidification of the 
endosomes results in fusion of the endosomal and virion membranes, leading to virion uncoating. 
4.  Primary transcription of viral mRNAs from genomic RNA occurs, which enabled the translation 
of viral proteins (5). 6. The translated viral proteins replicate the viral genome to generate positive-
sense antigenome intermediates, which can serve for the replication and generation of more 
progeny negative-sense viral genome. Ribonucleoprotein (RNPs) are transported to the Golgi 
complex (7), the site of viral glycoprotein maturation. Virus particles bud into Golgi membrane-
derived vesicles, which migrate to the cell surface (8). Fusion of the Golgi-derived vesicle and the 
plasma membrane (9) results in the release of infectious virions (10). Illustration modified from 
(Elliott, 2014).  
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The first event following release of viral RNPs to the cytoplasm is primary transcription 
from genomic RNA (Step 4 in Figure 1-7). Primary transcription involves cap-snatching of 
10-18 nucleotide long caps from host cell pre-mRNAs by the endonuclease domain of the 
L protein (Bishop et al., 1983; Bouloy et al., 1990; Kormelink et al., 1992; Simons and 
Pettersson, 1991) (Patterson et al., 1984). The 5’ 7-methylguanosine cap cleaved from the 
host cell pre-mRNAs is transferred to the 5’ end of the viral transcript by the L protein, and 
this allows the generation of mRNA that can be recognized by host cell ribosomes (Figure 
1-8). 
 Minigenome assays have shown that naked RNA alone cannot act as a template for 
transcription, but both N and L are necessary for transcription to occur (Dunn et al., 1995; 
Elliott and Blakqori, 2011; Lopez et al., 1995; Lowen and Elliott, 2005). Additionally, the 
viral UTRs enable binding of the L protein to the RNPs (Gerlach et al., 2015). Base pairing 
of complementary viral UTRs and their secondary structures have been shown to 
determine promoter strength by acting as cis-acting elements to drive RNA synthesis 
(Dunn et al., 1995; Elliott and Blakqori, 2011; R. Flick et al., 2002; Lowen and Elliott, 
2005). 
While viral mRNA transcripts are not polyadenylated at their 3’ ends, the mRNAs have 
been shown to be shorter than their respective genome template, suggesting that 
transcription termination signal sequences are present within the genome (Barr et al., 2006; 
Plassmeyer et al., 2005; Vera-Otarola et al., 2010). Although no consensus sequence has 
been identified as a transcription termination signal for all bunyaviruses, some sequences 
have been identified for specific viruses (Barr et al., 2006; Ikegami et al., 2007; Vera-
Otarola et al., 2010). A conserved sequence motif acting as a transcription termination 
signal (3′-C1-3GUCG/A-5′) for the ambisense S segment of phleboviruses RVFV, SFSV 
and TOSV was found in the intergenic region (Albariño et al., 2007; Ikegami et al., 2007; 
Lara et al., 2011). 
Following primary transcription, translation is initiated on the growing mRNA strands 
(Step 5 in Figure 1-7, and Figure 1-8). Coupled transcription and translation has been 
suggested to be obligatory, as otherwise early transcription termination would result in the 
generation of truncated transcripts (Barr, 2007). Specifically, ribosomes translating nascent 
mRNAs prevent the interactions of RNA termination signals in the coding region of the 
viral genome template RNA and the nascent complementary mRNA, which are required 
for transcription termination. Termination signals found in the viral UTRs however are 
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active, as these regions are not translated, therefore allowing RNA interactions to occur 
and stop transcription (Barr, 2007).  
(iii) Genome replication 
Primary transcription occurs prior to the replication of the viral genome, as N and L 
proteins generated from primary transcription and translation are required to encapsidate 
the RNA replication product for the formation of RNPs. During replication, the viral 
genome RNA (gRNA) is used as a template to synthesize the exact copy of the viral 
genomic RNA, in a positive, antigenomic sense (Figure 1-4 A). The antigenomic RNA 
(agRNA) can then be utilized as a template to generate more progeny gRNA that can either 
serve as a secondary transcription template or be assembled into virions (Step 6 in Figure 
1-7). In the case of genomes that employ ambi-sense coding strategy (such as that of the 
Phlebovirus S segment), agRNA can not only be utilised for replication and the generation 
of gRNA, but also serves as a template for transcription of subgenomic mRNA encoded in 
the positive sense in the viral genome (Figure 1-4 B). 
Unlike transcription, replication is cap-independent and full-length copies of the template 
are generated. The nascent antigenome transcript is encapsidated by N, which prevents 
translation (Elliott and Schmaljohn, 2013). Because the viral polymerase is responsible for 
transcription and replication, the ability to regulate the switch between these two processes 
is still undefined, yet host and viral factors have been implicated in this regulation. For 
instance, RVFV NSs has been shown to bind to the p44 subunit of the host cell 
transcription factor TFIIH (as explained in Section 1.1.4) (Le May et al., 2004). 
Consequently, impairment of host cell mRNA transcription by RVFV NSs favours cap-
independent replication over cap-dependent transcription. In this way, the subsequent 
impairment of host cell mRNA transcription would favour cap-independent replication 
over cap-dependent transcription. It must be mentioned that encapsidation by the N protein 
may also play a role in regulating the switch from transcription to replication, as suggested 
for other negative-strand RNA viruses (Kolakofsky and Lamb, 2001; Rose and Whitt, 
2001). 
 
  
1. Introduction 25 
 
Figure 1-8. Transcription initiation of viral mRNA and coupled translation.  
(A) The endonuclease activity of the viral L protein enables the cleavage of the host cell pre-
mRNA 5’ 7-methylguanosine cap. (B) The host-cell derived 5’ cap is used to initiate the 
transcription of viral mRNA transcripts from the viral genome. The 5’ cap serves to recruit host 
cell ribosomes to the nascent mRNA strand, to initiate the translation of viral proteins. Figure 
adapted from (Mir et al., 2008).  
A 
B 
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(iv) Assembly, budding and release 
In order to generate an infectious particle, at least one of each of the genome segments 
needs to be packaged into a virion. Little is known about genome packaging of 
bunyaviruses. Minigenome studies of BUNV demonstrated that the UTR regions of BUNV 
are required for packaging (Kohl et al., 2006). A recent study on RVFV genome packaging 
has revealed that the majority of mature virions lack one or more genome segments, 
suggesting that bunyavirus genome packaging is a non-selective process (Wichgers 
Schreur and Kortekaas, 2016). However, other studies investigating the role of the viral 
UTRs in co-packaging have indicated that specific intermolecular interactions between the 
UTRs of the viral segments drive copackaging of the three viral RNA segments to produce 
infectious RVFV (Terasaki et al., 2011). 
EM studies for UUKV and BUNV suggested that bunyaviruses bud from the Golgi 
apparatus, as viral factories could be visualised at this site within infected cells 
(Kuismanen et al., 1982; Salanueva et al., 2003). The viral glycoproteins are post-
translationally modified by N-linked glycosylation in the ER and are targeted to and 
accumulate in the Golgi apparatus, where virus assembly takes place (Step 7 in Figure 1-7) 
(Elliott and Schmaljohn, 2013; Shi et al., 2005; Shi and Elliott, 2004). Studies using 
UUKV or BUNV virus-like particles suggested RNPs are targeted to glycoprotein-rich 
regions in the Golgi membrane, where the RNPs closely interact with the cytoplasmic tails 
of the viral glycoproteins, which promotes budding of Golgi-derived vesicles (Step 8 in 
Figure 1-7) (Overby et al., 2007; Shi et al., 2007). This is in comparison to other negative-
strand RNA viruses that assemble and bud from the plasma membrane, such as influenza 
viruses. However, RVFV and the hantaviruses Sin Nombre virus (SNV) and Black Creek 
Canal virus (BCCV) have been shown to bud from both the Golgi and plasma membranes 
(Anderson and J. F. Smith, 1987; Goldsmith et al., 1995; Ravkov et al., 1997).  
Progeny virions derived from the Golgi apparatus are transported to the plasma membrane 
to be consequently released to the extracellular space via the exocytic pathway (Steps 9 
and 10 in Figure 1-7). These steps were visualized by the generation of recombinant 
BUNV with a Green Fluorescent Protein (GFP) -tagged Gc (Shi et al., 2010).  
Finally, the NSs protein of SFTSV has been shown to form unique cytoplasmic structures 
that are believed to be derived from the endosomal pathway because the structures 
colocalize with the endosomal marker Rab5 (Santiago et al., 2014). A recent study 
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suggested that the cytoplasmic structures formed by SFTSV NSs harbour infectious virus, 
and are secreted to the extracellular space to mediate the receptor-independent endocytosis 
of SFTSV to neighbouring cells (Silvas et al., 2015). 
1.2 Reverse genetics of bunyaviruses and its applications 
1.2.1 cDNA-based rescue of bunyaviruses  
Reverse genetics is an approach to investigate the phenotypic effects caused by the 
modification of a target gene, and thus allows to infer gene functions. Reverse genetics 
systems for RNA viruses proved to be difficult because they require the conversion of viral 
RNA into cDNA for the introduction of mutations, due to the instability of the RNA 
molecule. Until 1996, reverse genetics system of negative strand segmented RNA viruses 
did not exist, and bunyavirus research was limited to utilising forward genetics as an 
approach to determine the genetic basis of a virus phenotype. This was mostly carried out 
by generating and isolating temperature-sensitive virus mutants (Gahmberg, 1984; Pringle, 
2011). Although useful, this method to investigate virus phenotype did not allow the 
targeted alteration and manipulation of the virus genome. 
The first non-segmented negative-sense RNA virus recovered entirely from cDNA clones 
was rabies virus in 1994, where authors showed that recovery of an infectious negative-
sense virus required the cDNA copies of the viral genome to be in an antigenomic 
(positive) sense (Schnell et al., 1994). This was because in order to form RNPs, ‘helper’ 
expression plasmids encoding protein components of the rabies RNP (nucleocapsid 
protein, phosphoprotein, and the RdRp) needed to be provided along with cDNA plasmids 
encoding the cDNA copies of the genomic (negative) sense RNA genome. However, such 
experimental setup would result in simultaneous transcription of the genomic sense RNA 
from cDNA copies of the viral genome and antigenomic sense RNA from helper plasmids, 
leading to RNA-RNA hybridization and interfering with encapsidation of the genomic 
RNA and thus subsequent transcription and replication. 
 It was in 1996, that Bridgen and Elliott pioneered the recovery of an infectious bunyavirus 
(specifically, BUNV) entirely from cDNA clones (Bridgen and Elliott, 1996), which paved 
the way for the development of reverse genetics systems for other negative strand, 
segmented RNA viruses such as influenza A virus (Fodor et al., 1999; Neumann et al., 
1999). The system was based on that already described for rabies virus (Schnell et al., 
1994), and uses transcription plasmids encode cDNA copies of the three viral segments in 
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the antigenomic sense, under the control of a bacteriophage T7 RNA polymerase (T7 
RNAP) promoter. The 3’ UTR of the antigenome cDNA is directly followed by a 
Hepatatis δ ribozyme (Hδr) and a T7 terminator sequence. The function of the Hδr is to 
allow self-cleavage of the antigenome transcript to generate the exact 3’ end of the viral 
segment (Figure 1-9 A). Three plasmids (henceforth referred to as ‘rescue plasmids’) 
encoding antigenomic cDNA copies of the viral S, M and L RNA segments cDNA clones 
of the viral segments S, M and L are transfected into cells which were provided T7 RNAP 
in trans, or cells constitutively expressing the T7 RNAP, such as the BSR-T7/5 cell line 
(Buchholz et al., 1999). Following transfection, the T7 RNAP generates antigenome 
(positive-sense) RNA transcripts (Bridgen and Elliott, 1996).  Helper expression plasmids 
encoding the viral proteins N and L can be transfected, in order to increase the efficiency 
of RNP formation following transcription of the T7 RNAP-driven rescue plasmids (Bouloy 
and R. Flick, 2009; Neumann and Kawaoka, 2004). However, since BUNV was 
successfully recovered by the transfection of rescue plasmids only, and because transcripts 
generated by the T7 RNAP are neither capped nor polyadenylated, ‘leaky’ translation of 
the antigenome-sense RNA copies of the viral segments must occur that would be enough 
for the generation of N and L proteins required for RNP formation, replication and 
transcription (Billecocq et al., 2008). The RNPs can then be assembled and packaged into 
virions, as it occurs following virus infection of a host cell (Figure 1-9 B). Some T7 RNAP 
systems utilize rescue plasmids in which the T7 RNAP promoter sequence is immediately 
followed by a single G residue or two G residues, which was shown to increase the 
efficiency by which the T7 RNAP utilizes the T7 promoter (Billecocq et al., 2008). 
It must be noted that bunyavirus reverse genetic systems driven by the cellular RNA 
polymerase I (Pol I) have also been demonstrated. This system was initially developed for 
negative-strand RNA viruses that replicate in the nucleus such as influenza A virus (Fodor 
et al., 1999; Neumann and Kawaoka, 2004). The use of a Pol I-driven system for the 
rescue of bunyaviruses can be regarded as disadvantageous, because bunyaviruses replicate 
exclusively in the cytoplasm. However, a minigenome and virus-like particle system for 
UUKV (R. Flick and Pettersson, 2001; Överby et al., 2006) and the rescue of RVFV and 
AKAV(Billecocq et al., 2008; Ogawa et al., 2007) have all been reported to work under 
the control of Pol I. Importantly, a comparative study of the Pol I- and the T7 RNAP- 
driven RVFV rescue systems demonstrated that infectious RVFV could only be generated 
in the absence of helper plasmids expressing N and L using the T7 RNAP system, but not 
Pol I (Billecocq et al., 2008). 
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Figure 1-9. The bunyavirus rescue system.  
(A) Schematic representation of the T7 RNAP-driven transcription plasmids encoding the full-
length cDNA of each of the three segments S, M or L, in the antigenomic sense. The plasmid also 
contains a T7 promoter, Hepatitis δ ribozyme and T7 terminator sequences. The G residue in the 
T7 promoter sequence (shown in bold) increases T7 transcription efficiency. The terminal 
sequences of genome segments, which are strictly conserved within a genus are shown within the 
UTR termini (using representative Phlebovirus terminal sequences). (B) Three transcription 
plasmids encoding the full-length S, M and L cDNAs shown in (A) are transfected into T7 RNAP-
expressing cells, where transcription and ribozyme self-cleavage occurs. mRNA is produced from 
antigenome-sense RNA through leaky translation, which allows translation of viral proteins. 
Production of N and L enables the formation of RNPs, to initiate replication of agRNA to gRNA. 
gRNA can then be packaged into virions and  infectious virus is produced. UTRs: Untranslated 
regions; T7RNAP: T7 RNA polymerase; RNP: Ribonucleoprotein; agRNA: antigenome RNA; 
gRNA: genome RNA. 
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To date, the rescue of a number of bunyaviruses has been reported, such as BUNV 
(Bridgen and Elliott, 1996), LACV (Blakqori and Weber, 2005), RVFV (Ikegami et al., 
2006), AKAV(Ogawa et al., 2007), SBV (Elliott et al., 2013; Varela et al., 2013), SFTSV 
(Brennan et al., 2015), CCHFV (Bergeron et al., 2015) and OROV (Tilston-Lunel et al., 
2016). Intriguingly, no rescue of viruses belonging to the Hantavirus or Tospovirus genera 
has been reported. Nevertheless, the rescue of other bunyaviruses entirely from cDNA 
clones has proven to be an invaluable tool for the field of bunyavirus research. For 
example, the ability to manipulate the viral genome has allowed the fusion of GFP with 
BUNV Gc, and enabled the investigation of virus entry, budding and morphological 
changes in the Golgi complex in real time using live-cell imaging (Shi et al., 2010). 
Introduction of targeted mutations in the viral genome allowed the investigation of the role 
of various proteins, such as NSs, in the virus life cycle (Weber et al., 2002). The 
generation of RVFV encoding a luciferase reporter gene as also been reported (Ikegami et 
al., 2006). Finally, the remarkable flexibility of bunyavirus genomes has also been 
demonstrated by the creation of a RVFV with a 2- or 4- segmented genome (Brennan et 
al., 2011b; Wichgers Schreur et al., 2014), the exchange of BUNV UTR sequences 
(Lowen et al., 2005), the shortening of BUNV UTR sequences (Mazel-Sanchez and Elliott, 
2012), or by the creation of BUNV with an ambisense S segment (van Knippenberg and 
Elliott, 2015). These examples are only a few that highlight the enormous contribution that 
the reverse genetics systems of bunyaviruses have provided to fundamental virus research. 
1.2.2 Minigenome and virus-like particle assays 
While the plasmid-based recovery of infectious virus has allowed the study of virus life 
cycles in their entirety, minigenomes and virus-like particles provide insights into specific 
steps of the virus life cycle, without the need to generate infectious virus. These systems 
also prove to be useful in the study of highly pathogenic viruses, such as CCHFV, outside 
of high biosafety laboratory conditions. They are based on the expression of the viral N 
and L proteins, along with a transcription plasmid encoding a reporter gene, flanked by the 
viral UTRs in the genomic sense. The expressed N and L proteins can encapsidate, 
replicate and transcribe the negative-sense reporter genes to generate artificial RNPs, 
utilising the viral UTRs as promoters of replication and transcription. Thus, activity of the 
reporter gene serves as a measure to assess the functionality of the viral UTRs, as well as 
the viral protein N and L (Figure 1-10 A). The system has served as a key tool to 
understand bunyavirus encapsidation (Dong et al., 2013; Eifan and Elliott, 2009), promoter 
strength (K. Flick et al., 2004; Gauliard et al., 2006), recognition of viral UTRs by the 
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polymerase (Mazel-Sanchez and Elliott, 2015),  and many other transcriptional and 
replicative processes.  
Including a plasmid expressing the viral glycoprotein precursor in the minigenome assay 
enables the generation of transcription-competent virus-like particles (VLPs) (Figure 1-10 
B), which enables the study of virus maturation, assembly and egress. Following the 
formation of artificial RNPs, these can be packaged into VLPs using similar processes that 
occur during virus assembly, through interactions with the cytoplasmic tails of the viral 
glycoproteins (Overby et al., 2007; Shi et al., 2007). The VLPs can be used to infect naïve 
cells to deliver the packaged RNPs, which can undergo transcription and replication. A 
study comparing authentic UUKV virions and UUKV VLPs showed that their morphology 
is identical (Overby et al., 2008). Since VLPs package the reporter minigenome RNP, and 
not genome segments encoding essential viral proteins required for virus replication, they 
can only undergo a single-cycle infection. However, VLPs can be amplified by infection of 
cells that were pre-transfected with plasmids encoding viral L, N, and the glycoprotein 
precursor, as shown for CCHFV, which can be used as a tool for the development of 
vaccines and antivirals (Devignot et al., 2015). 
Minigenome and VLP assays are also of crucial significance before attempting virus 
rescue, to ensure all viral components required for the rescue are functional. This is best 
exemplified by the inability to rescue OROV. Through the development of the 
aforementioned assays, the inability to rescue infectious OROV entirely from cDNA 
clones was found to be attributed to a mistake in the published sequence of the OROV S 
segment (Acrani et al., 2015). The revised OROV S segment sequence had a longer 3’ 
UTR that resulted in an active minireplicon system (unlike the published sequence), and 
later enabled the successful rescue of OROV entirely from cDNA clones (Tilston-Lunel et 
al., 2016).  
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Figure 1-10. Minigenome and virus-like particle systems.  
(A) Schematic diagram of the bunyavirus minireplicon system. The minigenome plasmid for a 
specific segment contains a reporter gene (Renilla) flanked by the viral UTRs in the genomic 
(negative) sense orientation, relative to the T7RNAP promoter.  Co-transfection with expression 
plasmids encoding N and L in T7 RNAP-expressing cells will result in the formation of an active 
minigenome RNP if the viral UTRs, and the N and L proteins are functional. (B) Schematic 
diagram on a virus-like particle assay. If the minigenome assay is supplemented with an expression 
plasmid encoding the viral glycoprotein precursor, virus-like particles containing the minigenome 
reporter produced in donor cells can be used to infect naïve recipient cells upon nuclease treatment 
of the supernatant from donor cells. Infection can be confirmed by measuring reporter activity in 
recipient cells. UTRs: Untranslated regions; T7RNAP: T7 RNA polymerase; RNP: 
Ribonucleoprotein 
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1.3 The Phlebovirus genus 
This section will give a brief overview of the Phlebovirus genus, and describe the 
emergence of a number of tick-borne phleboviruses concerning this PhD study: Uukuniemi 
virus, Heartland virus, Severe fever with thrombocytopenia syndrome virus.  
1.3.1 Classification and transmission  
The Phlebovirus genus comprises over 70 viruses, with 10 species and 33 tentative species 
(Plyusnin et al., 2001) that can be broadly divided into two groups based on their 
antigenic, vector and genomic similarities: the Sandfly fever (or Phlebotomus) group and 
the Uukuniemi-like virus group (Bouloy, 2011).  Initially, UUKV and related viruses were 
classified as a separate genus within the Bunyaviridae (UUKuvirus), but due to their 
genetic and antigenic similarities, these viruses were reclassified as members of the 
Phlebovirus genus (Plyusnin et al., 2001). While all recognized Uukuniemi-like viruses are 
transmitted by ticks, phlebotomines or mosquitoes transmit those belonging to the sandfly 
fever group. In addition to vector differences, an important difference noted at the 
molecular level between these two groups is the lack of the non-structural protein NSm in 
Uukuniemi-like viruses, which is encoded at the N terminus of the glycoprotein precursor 
in the M segment of sandfly fever viruses.  
Important pathogens within the Sandfly fever group include RVFV (recognised as the type 
species) (Plyusnin et al., 2001), Punta Toro virus (PTV) Sandfly fever Sicilian virus 
(SFSV), sandfly fever Naples virus (SFNV) and Toscana virus (TOSV). Notable 
Uukuniemi-like group viruses include the prototype UUKV, Bhanja virus (BHAV) and the 
recently emerged Heartland virus (HRTV) and severe fever with thrombocytopenia 
syndrome virus (SFTSV). In recent years many novel and emerging viruses have been 
assigned to the Phlebovirus Uukuniemi-like group, including Lone Star virus (LSV) (Nasci 
et al., 2014), Hunter Island Group virus (HIGV) (Gauci et al., 2015), Malsoor virus 
(MALV) (Mourya et al., 2014), Antigone virus (ANTV) (Papa et al., 2016), blacklegged 
tick phlebovirus (BTPV) and American dog tick phlebovirus (ADTPV) (Tokarz et al., 
2014). Recently, a virus that appears to be restricted to arthropod hosts only (specifically to 
mosquitoes) named Gouléako virus (GOLV) was discovered and found to be closely 
related to the genus Phlebovirus (Marklewitz et al., 2011). Interestingly, the GOLV 
genome does not encode an NSm protein, unlike the genome of other mosquito-borne 
phleboviruses. GOLV was also suggested to constitute a tentative novel genus within the 
Bunyaviridae (Marklewitz et al., 2011). 
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In light of the growing number of novel tick-borne phleboviruses identified, a recent study 
characterized the Uukuniemi-like group using full-length genome sequences, including 
newly discovered viruses (Palacios et al., 2013). Phylogenetically, Uukuniemi-like group 
viruses clustered together, separate from those phleboviruses transmitted by 
phlebotomines. A representative phlebovirus phylogenetic tree (of the M segment ORF) is 
shown in Figure 1-11. Based on phylogenic and serologic relationships, the authors 
proposed that Uukuniemi-like group viruses should be assigned to seven different species, 
namely the Uukuniemi, Murre, SFTSV/HRTV, Precarious Point, Grand Arbaud, Manawa 
and Bhanja species. The continuing identification of novel tick-borne phleboviruses, as 
well as their increasing host range and movement into naïve geographical locations 
highlights the risk posed to human and animal health by these emerging viruses. 
1.3.2 Geographic distribution 
Phleboviruses are emerging pathogens that are geographically distributed according to the 
distribution of their vectors in North and South America, Europe, Asia and Africa (Bouloy, 
2011). This is illustrated by the distribution of SFSV and SFNV, which concomitantly 
agrees with the geographical distribution of sandflies, extending from the Mediterranean 
basin to the Arabian Peninsula and as far east as Pakistan and India (Elliott and 
Schmaljohn, 2013). TOSV, a virus transmitted by phlebotomines which can cause aseptic 
meningitis and meningoencephalitis, has been isolated in central Italy, Spain, France, 
Portugal, Cyprus and other countries in the Mediterranean basin (Cusi, 2010). RVFV is 
transmitted mainly by Aedes and Culex mosquito species and is widespread in Africa, 
causing recurrent epizootics and epidemics particularly in East and West Africa. However, 
in the year 2000 it extended its geographic rage to reach Yemen and Saudi Arabia, leading 
to human deaths and major livestock losses (Chevalier et al., 2010). 
Until recently, only a few phleboviruses transmitted by ticks had been identified. UUKV 
was known to be distributed in central and eastern Europe (Hubálek and Rudolf, 2012). 
BHAV cases were reported in southern and central Asia, Africa, and southern Europe 
(Hubálek, 2009). With the discovery of HRTV, SFTSV, LSV, HIGV, MALV, ANTV, 
BTPV and ADTPV, it became apparent that tick-borne phleboviruses have a global 
distribution (Figure 1-12). A sensitive RT-PCR system was recently developed, which can 
target a broad range of tick-borne phleboviruses (Matsuno et al., 2015). This tool will aid 
surveillance efforts to detect known and unidentified tick-borne phleboviruses in diverse 
geographic locations.  
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Figure 1-11. Phylogenetic tree of the phlebovirus glycoprotein precursor.  
The phylogenetic tree shows 133 phleboviral sequences of the M segment open reading frame, 
analysed by a Neighbour-Joining analysis. Tentative species of the Uukuniemi-like group 
(transmitted by ticks) are shown. SFSV: sandfly fever Sicilian virus; SFNV: sandfly fever Naples 
virus. Modified from (Palacios et al., 2013). 
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Figure 1-12. Geographical distribution of tick-borne phleboviruses.  
Circles indicate the location where the tick-borne phleboviruses have been found. Dashed circles 
represent areas where the noted viruses are endemic. Red circles depict the distribution of viruses 
that are relevant to this study UUKV, HRTV and SFTSV). UUKV: Uukuniemi virus; HRTV: 
Heartland virus; SFTSV: Severe fever with thrombocytopenia syndrome virus.  Modified from 
(Matsuno et al., 2015). 
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1.3.3 Disease caused by phleboviruses. 
It is important to note the broad spectrum of clinical outcomes elicited by phlebovirus 
infections in humans. Among the Sandfly fever group, a number of viruses can cause 
disease. While SFSV and SFNV are aetiologic agents of an acute, self-limiting illness that 
involves fever, myalgia and malaise, TOSV can cause aseptic meningitis and 
meningoencephalitis (Cusi, 2010; Hemmersbach-Miller et al., 2004; Sanbonmatsu-Gámez 
et al., 2009). TOSV infection has also been reported to result in asymptomatic infections, 
and influenza-like symptoms during the summer season (Hemmersbach-Miller et al., 2004; 
Portolani et al., 2002). RVFV is perhaps the phlebovirus that poses most concern for 
human and animal health (Mandell and R. Flick, 2010). Disease in ruminants (the principal 
amplifying host of RVFV) (Gerdes, 2004) manifests itself with febrile illness, diarrhea, 
and abortion (Ikegami and Makino, 2011). In newborn lambs, the mortality rate of RVFV 
may reach 90-100%, resulting in a significant socio-economic burden to society (Bouloy, 
2011). Infection in humans primarily leads to a benign self-limited febrile illness, however 
a small proportion of infected patients develop haemorrhagic fever, neurological disorders 
and blindness (Rolin et al., 2013). 
Until the emergence of highly pathogenic HRTV and SFTSV, Uukuniemi-like group 
viruses were not recognised as a public health threat, as no human illness caused by these 
viruses had been reported even though antibodies to some of the members of this group 
have been detected in humans in serologic surveys (Bouloy, 2011; Hubálek and Rudolf, 
2012; Saikku and Brummer-Korvenkontio, 1973; Traavik and Mehl, 1977). This is with 
the exception of BHAV, which can induce neurotropic disease in young ruminants (Mádr 
et al., 1984) and in some cases a febrile-like illness in humans (Calisher and Goodpasture, 
1975). Serological surveys have suggested that BHAV is endemic in Eastern Europe, 
however causing asymptomatic human infections (Punda et al., 1987). 
Understanding the differences in the molecular mechanisms of virulence of different tick-
borne phleboviruses is of interest to elucidate the determinants that contribute to the wide 
spectrum of disease outcomes. The following sections present an overview of the current 
knowledge of the molecular biology of UUKV (apathogenic in humans), HRTV and 
SFTSV (both of which can cause serious disease in humans). 
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1.3.4 Uukuniemi virus 
UUKV is the prototype of the Uukuniemi-like virus group. It was originally isolated from 
a tick (Ixodes ricinus species) in southern Finland (Oker-Blom et al., 1964). Subsequent 
isolations of UUKV were also reported in central and eastern Europe, as well as in 
Norway, southern Russia and central Asia (CDC Arbovirus catalog 
[wwwn.cdc.gov/arbocat]). While antibodies to UUKV (or UUKV-like viruses) have been 
isolated in humans and other vertebrates such as birds, rodents and cows (Hubálek and 
Rudolf, 2012; Saikku and Brummer-Korvenkontio, 1973), no clinical signs of disease have 
been reported in these species.  
Various strains of UUKV have been isolated from ticks collected in nesting areas of 
seabirds and passerine birds, or from tick nymphs collected on migrant birds (S. R. Moss, 
1986; Nuttall et al., 1981; 1984; Traavik and Mehl, 1977; Watret and Elliott, 1985), which 
could suggest that birds may act as hosts of UUKV and could play a role in the widespread 
distribution of tick-borne viruses in Europe (Hubálek and Rudolf, 2012). 
UUKV has served as a prototype virus to understand basic characteristics of viruses within 
the Bunyaviridae family. In fact, UUKV was the first bunyavirus shown to consist of a 
tripartite negative-sense RNA genome, a distinctive feature of the Bunyaviridae 
(Pettersson et al., 1977). An icosahedral T=12 symmetry of Gn-Gc heterodimers was first 
observed in UUKV virions, a unique arrangement not previously observed for viruses and 
later found in RVFV (Freiberg et al., 2008; Overby et al., 2008). UUKV has also served as 
a model phlebovirus to investigate phlebovirus entry in mammalian and tick cell lines 
(Lozach et al., 2010) (Mazelier et al., 2016). Lozach et al. showed that unlike other 
bunyaviruses, UUKV internalization in mammalian cells was mainly clathrin-independent 
(Lozach et al., 2010). UUKV minigenome systems have aided the understanding of role of 
the non-coding regions of bunyaviruses.  Flick et al. showed that complementarity at the 5’ 
and 3’ ends of the viral UTRs are crucial for promoter activity and that the IGR in the 
ambisense S segment serves as a regulator of transcription termination (K. Flick et al., 
2004). Finally, UUKV-like particles have been used to understand bunyavirus genome 
packaging and budding, and it was shown that UUKV Gn had a critical role in genome 
packaging by a close interaction with viral RNPs, while its Gc was important for budding 
(Overby et al., 2007). Although a minigenome and a virus-like particle system for UUKV 
exist, there is a need to develop a reverse genetics system that allows the rescue of UUKV 
entirely from cDNA. Such a tool could serve to allow UUKV to be utilized as a 
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comparative model for other more pathogenic tick-borne phleboviruses, to understand the 
molecular basis for their virulence and pathogenicity. 
1.3.5 Severe fever with thrombocytopenia syndrome virus 
Severe fever with thrombocytopenia syndrome virus (SFTSV) (also known as 
Huaiyangshan virus, DaBie Mountain virus and Henan fever virus) was the first tick-borne 
phlebovirus discovered that caused severe disease in humans. Between 2007 and 2010, 
patients in the Henan and Hubei provinces of China were presenting gastrointestinal 
symptoms, joint pain, thrombocytopenia, leukocytopenia, haemorrhagic manifestations and 
multi-organ dysfunction as a result of an unknown infectious disease, which was causing a 
fatality rate of 12-30% (Yu et al., 2011). The causative agent was identified as the novel 
tick-borne phlebovirus SFTSV (Stone, 2010; Xu et al., 2011; Yu et al., 2011; Zhang et al., 
2012a; 2011). SFTSV was later identified in patients presenting with similar symptoms in 
Japan and South Korea (Kim et al., 2013; Takahashi et al., 2014). 
Sequencing of the SFTSV genome revealed low similarity to other phleboviruses, with 
33%, 30-41% 11-13% and 30-36% similarity to RVFV or UUKV L, N, NSs and 
glycoprotein precursor proteins, respectively ( Yu et al., 2011). However, as with other 
tick-borne phleboviruses, the SFTSV genome does not encode an NSm protein. 
Phylogenetic studies ( Yu et al., 2011; Zhang et al., 2011) subsequently supported by 
serological studies  (Palacios et al., 2013) have thus suggested that the novel virus 
represents a distinct lineage within the Phlebovirus genus. 
The primary vector of SFTSV in China is the Haemaphysalis longicornis species of ticks, 
as both infectious virus and viral RNA has been isolated from this species (Yu et al., 2011; 
Zhang et al., 2012b). The wide geographical distribution of these ticks throughout China 
and other parts of Asia and Oceania such as Korea, Japan, Australia and Fiji (Hoogstraal et 
al., 1968) poses a concern for the potential spread of the virus to these locations (Y. Wu 
and Gao, 2013; Xiong et al., 2012). It is not entirely clear which is the vertebrate host of 
SFTSV. In a survey of domesticated animals in China, SFTSV-specific antibodies and 
viral RNA were detected in sheep (69.5%), cattle (60.5%), dogs (3.1%), pigs (3.1%) and 
chickens (47.4%) (Niu et al., 2013). Others have also found SFTSV-specific antibodies in 
goats (66.8%), rodents (4.4%) and hedgehogs (2.7%) (Li et al., 2014; Ni et al., 2015). 
Furthermore, antibodies against SFTSV were detected in two migratory bird species in 
China (Li et al., 2016). Yun et al. recently analysed phylogenetic relationships of SFTSV 
and migratory bird routes in Asia and proposed that migratory birds, well-known carriers 
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of ticks, could be a potential source of the spread of SFTSV across China, South Korea and 
Japan (Yun et al., 2015). Finally, some evidence exists for human-to human transmission 
of SFTSV, as documented in a family cluster in China (Bao et al., 2011; Jiang et al., 
2015). 
The emergence of SFTSV focused research interests on understanding its underlying 
molecular mechanisms of pathogenicity. The virus was able to infect and replicate in the 
human monocytic cell line THP-1 without causing a cytopathic effect (CPE) (B. Qu et al., 
2012), in comparison to severe CPE caused by RVFV (Won et al., 2007). The authors 
reported that the virus was able to supress IFN and NF-κB responses. In addition to the 
NSs protein, SFTSV N was also able to inhibit the activation of the IFN-β promoter and 
NF-κB responses (B. Qu et al., 2012). The mechanisms employed by SFTSV to inhibit the 
human IFN system have been extensively studied, and are described in Section 1.4.4. 
Expression of the SFTSV glycoproteins in lentiviral and rhabdoviral pseudotypes showed 
that entry into a broad range of human and animal cell lines, including human 
macrophages and dendritic cells, is mediated by these proteins in a pH-dependent-manner 
(Hofmann et al., 2013). Additionally, the authors showed that DC-SIGN served as a 
receptor for the viral pseudotypes (Hofmann et al., 2013), which was subsequently 
confirmed with wild-type SFTSV (Tani et al., 2016). Unlike RVFV (Ikegami et al., 
2009b), SFTSV was shown to be unable to shut off host cell protein synthesis (Brennan et 
al., 2015). An infectious model for SFTS which resulted in the hallmark symptoms of 
thrombocytopenia and leukopenia was established in B57/BL6 mice (Jin et al., 2012). 
Interestingly, while viral RNA was detected in blood, spleen, liver and kidneys, virus 
replication was only observed in the spleen of the mice. Additionally, the authors reported 
that SFTSV was found to adhere to mouse platelets, which results in phagocytosis by 
primary macrophages. Thus, thrombocytopenia induced by SFTSV is presumed to be 
caused by clearance of virus-bound platelets by macrophages (Jin et al., 2012). Finally, the 
development of a reverse genetics system for SFTSV (Brennan et al., 2015) now serves an 
invaluable tool to manipulate the viral genome in order to further characterize the 
molecular biology of SFTSV. 
1.3.6 Heartland virus 
Following the identification of SFTSV, Heartland virus (HRTV) was isolated from two 
patients living in Northwestern Missouri, who reported tick bites prior to disease and 
presented with fever, fatigue, anorexia, diarrhea, thrombocytopenia and leukocytopenia 
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(McMullan et al., 2012). Seven additional cases were later reported in Missouri, Tennesse 
and Oklahoma, two of which were fatal (Muehlenbachs et al., 2014; Williams, 2014). 
Despite being most closely related to SFTSV, comparison of the viral L and N (the two 
most conserved proteins within the Bunyaviridae) showed 27% and 38% difference with 
SFTSV (McMullan et al., 2012).  
A study on field-collected arthropods detected HRTV RNA in 10 pools of Amblyomma 
americanum ticks (lone star tick), 8 of which yielded infectious virus. This finding 
implicated lone star ticks as the primary vector of HRTV (Savage et al., 2013). The 
authors in this study also suggested that presumably the ticks become infected by feeding 
on a viremic host during their larval stage, and transmission to humans occurs when 
nymphs are host seeking during spring and summer seasons. Though initially associated 
with disease in Missouri, Tennessee and Oklahoma, a serological survey suggested a more 
widespread distribution of HRTV in the United States, with seropositive wildlife detected 
in 13 different states in Central and Eastern United States (Riemersma and Komar, 2015). 
Seropositive wildlife in this study included deer, raccoons, coyotes and moose. A recent 
serological survey examined 8 mammalian species and 26 bird species to identify 
candidate vertebrate amplification hosts of HRTV (Bosco-Lauth et al., 2015). HRTV-
specific antibodies were identified in racoons and deer as in the previous study, as well as 
horses, dogs and opossums, but not in any bird species. The authors suggested that the high 
antibody prevalence in deer and racoons, as well as their high abundance in northwest 
Missouri indicates that these species may act as the vertebrate amplification hosts of 
HRTV (Bosco-Lauth et al., 2015).  
To date, there is a lack of understanding of the molecular determinants of virulence of 
HRTV. However, a recent study assessed the viremic potential of a number of vertebrates 
(raccoons, goats, chickens, rabbits, hamsters, mice and IFN -α/β/γ receptor–deficient mice) 
following HRTV infection (Bosco-Lauth et al., 2016). Although all animals showed 
immune responses against HRTV following primary or secondary exposure, only IFN-
α/β/γ receptor–deficient mice showed viremia and associated illness, indicating that the 
innate immune response mounted following virus infection plays an important role in the 
development disease. The understanding of the molecular biology of HRTV could be aided 
by the availability of a reverse genetics system. 
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1.4  Host innate immune responses to virus infection and viral 
countermeasures 
1.4.1 The human innate immune system 
Following infection of a susceptible vertebrate host, viruses confront two major types of 
host defense mechanisms: the adaptive and the innate immune systems. Adaptive immune 
responses are composed of humoral immunity (mediated by the production of antibodies 
by B lymphocytes), and T-cell mediated immunity (which involves the induction of 
apoptosis in virus-infected cells displaying epitopes of the foreign antigen). Although the 
adaptive immune response is crucial to develop immunological memory and enables 
enhanced long-lasting anti-viral responses in subsequent exposures to the pathogen, it is a 
slow response because it requires the activation of specific B and T cells, which can take a 
week to become effective (Alberts et al., 2014). 
Instead, vertebrate hosts depend on innate immunity as the first line of defence against 
viral infections. Unlike adaptive immune responses, which are highly specific, innate 
immune responses are non-specific, and begin immediately or within a few hours 
following exposure to a pathogen. The IFN system plays an important role in innate 
immunity, and is capable of controlling most virus infections in the absence of adaptive 
immunity (Goodbourn et al., 2000; Randall and Goodbourn, 2008). IFNs were discovered 
in 1957 by Isaacs and Linderman, and were described by the authors as a factor that was 
inducing interference with the growth of live influenza A virus in chick chorio-allantoic 
membranes which were pre-treated with heat-inactivated influenza virus (Isaacs and 
Lindenmann, 1957). IFNs are now known as a group of cytokines that are responsible for 
myriad of roles in innate as well as adaptive immunity. IFNs are produced and secreted by 
cells following the recognition of foreign molecular patterns associated with infection, 
known as pathogen associated molecular patterns (PAMPs). There are three types of IFN: 
type I, II and III, grouped according to their sequence homology. In humans, type I IFNs 
are encoded on chromosome 9 and include IFN-α (includes 13 different subtypes), IFN-β, 
IFN-ε, IFN-κ, and IFN-ω (Pestka, 1987; Pestka et al., 2004). IFN-α and IFN-β are well-
known to be induced en masse as a response to virus infection in many different cell types, 
whereas the role of other type I IFNs is less well-defined (Randall and Goodbourn, 2008; 
Taniguchi and Takaoka, 2002). A single member of type II IFN exists, IFN-γ, which is 
encoded on the human chromosome 10 and is structurally different from type I IFNs (Chen 
et al., 2004; Pestka et al., 1997; Platanias and Fish, 1999). Type III IFNs are composed of 
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three subtypes of IFN-λ. Following the induction of IFNs by mechanisms described in 
Section 1.4.2, secreted IFNs activate intracellular signalling cascades in neighbouring cells 
by binding to receptors on the cell surface, which subsequently leads to the induction of an 
antiviral state through the up-regulation of a number of genes that can have anti-viral 
activity (Goodbourn et al., 2000; Hoffmann et al., 2015; Randall and Goodbourn, 2008; 
Schneider et al., 2014). These genes are known as IFN-stimulated genes (ISGs). Type I, 
type II and type III IFNs have evolved to bind to distinct receptors on the cell surface, and 
while type I and type III IFNs can activate the same signalling pathway, the pathway 
activated by type II IFNs differs slightly (described in section 1.4.2) (Uzé and Monneron, 
2007).  
1.4.2 Interferon induction 
In order to recognize pathogens, host cells must discriminate between self- and viral 
RNAs. RNA viruses produce products such as double-stranded (ds) RNA and 5′-
triphosphorylated single-stranded (ss) uncapped RNAs during replication of their viral 
genome. These products, or PAMPs, are detected as ‘non-self RNA’ by pattern recognition 
receptors (PRRs), including transmembrane Toll-like Receptors (TLRs) and cytosolic host 
cell DExD/H box RNA helicases such as melanoma differentiation-associated gene-5 
(MDA-5) or retinoic acid-inducible gene-I (RIG-I) (Goodbourn et al., 2000; Randall and 
Goodbourn, 2008). TLRs are mainly expressed in antigen-presenting cells, such as 
dendritic cells and localise to the plasma membrane, with the exception of TLR3, TLR7 
and TLR9, which are embedded in endosomal compartments and can detect dsRNA upon 
virus endocytosis (Nishiya and DeFranco, 2004; Schaefer et al., 2004). On the other hand, 
cytosolic RIG-I and MDA-5 are widely expressed in many cell types. While RIG-I 
recognizes 5′-triphosphorylated, uncapped RNA (Rehwinkel et al., 2010), both RIG-I and 
MDA-5 can detect short and long dsRNA molecules, respectively, allowing them to detect 
distinct classes of RNA viruses (Kato et al., 2008; 2006). Negative-strand RNA viruses, 
such as bunyaviruses, produce little or undetectable amounts of dsRNA during replication 
(Weber et al., 2006). Thus, it is hypothesised that these viruses are sensed mainly by RIG-
I, by generation of ssRNA with uncapped 5’ triphosphate ends (Hornung et al., 2006; 
Pichlmair et al., 2006).  
Binding of viral RNA to RIG-I results in its activation and the initiation of downstream 
signalling pathways. Upon binding viral RNA, polyubiquitination of the N-terminus of 
RIG-I by the tripartite motif-containing protein 25 (TRIM25) E3 ubiquitin ligase is crucial 
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for its activation (Gack et al., 2007; Zeng et al., 2009). RNA-bound RIG-I is believed to 
undergo a conformational change that exposes the N terminus of RIG-I consisting of 
tandem caspase activation and recruitment domains (CARD), which are repressed when 
inactive (Saito et al., 2007). The exposed CARDs promote multimerization, but also 
interactions with the CARD domains of the adaptor mitochondrial antiviral signalling 
protein (MAVS, also known as IPS-1, Cardif or VISA) (Saito et al., 2007). Activation of 
MAVS through CARD-CARD interactions induces the formation of prion-like aggregates 
(Hou et al., 2011). These functional MAVS polymers acts as a scaffold to recruit and 
activate cytosolic kinases Inhibitor of nuclear factor kappa-B kinase (IKK) and tank 
binding kinase 1 (TBK1). The activation of TBK1/IKKε and IKKα/IKKβ subsequently 
leads to the activation of interferon regulatory factor 3 (IRF-3) and nuclear factor κ-light-
chain-enhancer of activated B cells (NF-κB), respectively and their translocation to the 
nucleus. Although IRF-3 and NF-κB play a role in the induction of IFN, other members of 
the IRF family, such as IRF-7, have been shown to be involved in IFN induction (Honda 
and Taniguchi, 2006). Activation of IRF-3 occurs through the phosphorylation at its C 
terminus, which results in its dimerization and exposure of a nuclear localization signal 
(NLS) (Dragan et al., 2007; Lin et al., 1998). On the other hand, the NLS of NF-κB, which 
is located within its p65 subunit, is unveiled once its inhibitor molecule IκB (inhibitor of 
NF-κB) becomes phosphorylated and degraded by proteasomes (J. Hu et al., 2005). Once 
in the nucleus, IRF-3 and NF-κB can assemble on the promoter of the IFN-α/β gene, in a 
cooperative manner along with other factors, to form the multi-protein enhanceasome 
complex, which promotes the assembly of the host cell transcriptional machinery for the 
initiation of IFN-α/β mRNA synthesis (Figure 1-13) (Randall and Goodbourn, 2008). 
TLR-3 signalling follows a slightly different route to that of RIG-I and MDA-5. Briefly, 
following TLR-3 activation, the Toll-interleukin (IL)-1-resistance (TIR) domain-
containing adaptor inducing IFN-β (TRIF) induces the activation of TBK1/IKKε, 
subsequently leading to the phosphorylation and nuclear translocation of IRF-3 (García-
Sastre and Biron, 2006; Hoffmann et al., 2015). 
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Figure 1-13. Simplified representation of RIG-I–mediated IFN induction.  
Viral RNA products generated during virus replication (such as dsRNA or 5’-triphosphorylated, 
uncapped single-stranded ssRNA) are detected by RNA helicases RIG-I or MDA-5. Binding of 
RNA triggers a conformational change in RIG-I that results in the exposure of N-terminal CARD 
domains. CARD-CARD interactions enable the recruitment of the adaptor protein MAVS. MAVS 
acts as a scaffold to recruit and activate cytosolic kinases IKK and TBK1. The activation of kinases 
subsequently leads to the activation and nuclear translocation of IRF-3 or IRF-7 and NF-κB, 
respectively. While IRF-3 translocation is driven by the phosphorylation-induced dimerization, 
NF-κB is free to translocate to the nucleus upon phosphorylation and degradation of its inhibitor 
molecule IκB. Once in the nucleus, IRF-3, IRF-7 and NF-κB can act as transcription factors to 
enhance the transcription of the IFN- β promoter gene. Adapted from (Randall and Goodbourn, 
2008). dsRNA: double-stranded RNA; ssRNA: single-stranded RNA; RIG-I, retinoic acid-
inducible gene I; MDA-5: melanoma differentiation-associated gene-5; CARD: caspase 
recruitment domain; MAVS: mitochondrial antiviral signalling protein; IKK: inhibitor of nuclear 
factor kappa-B kinase; TBK1: TANK-binding kinase 1, IRF: IFN-regulatory factor; NF-κB: 
nuclear factor κ-light-chain-enhancer of activated B cells. 
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1.4.3 Interferon signalling 
Following IFN induction, secreted IFN activates the IFN signalling pathway in 
neighbouring cells by binding to IFN receptors. Type I IFN engages with the type I IFN 
receptor (IFNAR), which has a broad cell type distribution and is composed of two 
subunits: IFNAR1 and IFNAR2. Type II IFN (or IFN-γ) binds to the type II IFN receptor 
(IFNGR), which is also has broad cell type distribution but is a tetrameric complex, 
composed of two subunits of IFNGR1 and two subunits of IFNGR2. Type III IFN signals 
through binding to the type III IFN receptor (IFNλR), a heterodimeric receptor formed by 
IFNLR1 and IL10R2 subunits (Kotenko et al., 2003). Importantly, while IL10R2 is 
expressed in a wide range of cell types and forms part of a separate receptor (namely the 
IL-10 cytokine receptor complex), IFNLR1 is primarily restricted to epithelial cells, 
limiting cell-specific responsiveness and explaining why many other cell types respond 
poorly to type III IFN stimulation (Sommereyns:2008ez; de Weerd and Nguyen, 2012). 
Once IFN binds to their cognate receptors, the receptor chains come into close proximity 
and propagate the signal through the JAK/STAT signalling pathway, for the ultimate 
induction of ISGs. A simplified illustration of the JAK/STAT signalling pathway is shown 
in Figure 1-14. Type I and Type III IFN signalling cascades have some redundancy, as 
they signal using the canonical JAK/STAT pathway, utilising identical JAKs (Janus 
activated kinase) and STATs (signal transducer and activator of transcription) (de Weerd 
and Nguyen, 2012). While the cytoplasmic tails of IFNAR1 and IL10R2 are constitutively 
associated with the JAK family tyrosine kinase 2 (TYK2) (Uzé et al., 1990), IFNAR 2 and 
IFNLR1 are associated with JAK1 (Chen et al., 2004; Darnell et al., 1994). Studies have 
shown that STAT-2 may also be associated with the receptors, and weakly bound to 
STAT1 prior to IFN stimulation (Stancato et al., 1996). The IFNGR1 and IFNGR2 
subunits of the type II IFN receptor are, comparatively, associated with JAK1 and JAK2, 
respectively.  
Ligand-induced rearrangement and dimerization of the IFN receptors causes the receptor-
associated kinases to transphosphporylate the cytoplasmic receptor chains, which enables 
the activation of STATs (Figure 1-14). For instance, following type I IFN binding to the 
IFNAR receptor, TYK2 phosphorylates Tyr466 on the cytosolic tail of IFNAR1, which 
generates a docking phosphorylation site for STAT2. STAT2 is consequently 
phosphorylated at Tyr 690 by TYK2 and STAT1 at Tyr701 by JAK1 (Müller et al., 1993). 
The phosphorylation of the STATs induces their dimerization via SH2-phosphotyrosine 
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interactions, and results in the generation of a novel NLS (Banninger and Reich, 2004; 
Fagerlund et al., 2002). In addition, monomeric IRF-9 is acetylated by IFNAR2, and 
assembles with STAT1-STAT2 heterodimers to form a heterotrimer complex, named 
Interferon-stimulated gene factor 3 (ISGF3) (Tang et al., 2007). The ISGF3 complex then 
translocates to the nucleus, where it can bind IFN-stimulated response elements (ISRE) 
present in the promoter of many ISGs, to initiate their transcription. Importantly, 
acetylation plays an important role in IFN signalling, as acetylation of IRF-9 is required for 
DNA binding, and STAT acetylation is thought to aid in the assembly of ISGF3 (Tang et 
al., 2007). The up-regulated ISGs can have direct antiviral activity, such as the interferon-
inducible transmembrane (IFITM) proteins, which inhibit virus entry by modulating 
membrane fluidity (S. Smith et al., 2014). Other ISGs can instead act indirectly, as positive 
or negative regulators of the IFN signalling pathways. For instance, the production of IRF3 
and IRF7 as a result of IFN signalling results in induction of more IFN, thus creating a 
positive feedback loop (Marié et al., 1998; Sato et al., 1998). In contrast, Tripartite motif-
containing protein (TRIM)-28 has been shown to act as a negative regulator of IFN 
induction, by binding directly to IRF-7 and preventing its translocation to the nucleus 
(Liang et al., 2011). Such immunomodulatory strategies are important because excessive 
IFN responses could harm the host, as demonstrated in patients with autoimmune disorders 
(Niewold, 2014). 
Whereas the formation of the ISGF3 heterotrimer is the canonical form of ISG induction, 
other transcription factor complexes with the ability to regulate the expression of ISGs 
have been described (Randall and Goodbourn, 2008). For instance, type I, II and III IFN 
can lead to the formation of STAT1-STAT1 homodimers (Gamma-activated Factor 
[GAF]), which can translocate to the nucleus to bind to and promote the transcription of 
the IFN-γ activated site (GAS) in the promoter of IFN-γ regulated genes (Ramana et al., 
2002). As opposed to type I and type III IFN signalling, in which ISGs are mainly induced 
by STAT hetero-dimers, type II IFN signalling is majorly mediated only by STAT1 
homodimers (Figure 1-14) (Borden et al., 2007; Platanias, 2005). 
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Figure 1-14. Simplified diagram of type I, II and III IFN signalling.  
Receptor chains undergo dimerization upon binding to their cognate interferon (IFN). 
Consequently, proteins of the Janus Kinase (JAK) family associated with the cytosolic domains of 
receptor chains become activated and phosphorylate (P) signal transducer and activator of 
transcription (STAT) proteins. Phosphorylated STATs can form homodimers such as the gamma-
activated factor (GAF), or heterodimers, which in association with the interferon regulatory factor 
9 (IRF-9) forms a heterotrimer complex referred to as IFN-stimulated gene factor 3  (ISGF3). GAF 
and ISGF3 can translocate to the nucleus to bind to promoters of IFN-stimulated genes (ISGs), 
namely the IFN-γ activated site (GAS) and the IFN-stimulated response elements (ISRE), 
respectively. Adapted from (Hoffmann et al., 2015). IFN: interferon; JAK: janus kinase; STAT: 
signal transducer and activator of transcription; GAF: gamma-activated factor; ISGF3: IFN-
stimulated gene factor 3; ISG: IFN-stimulated gene. 
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1.4.4 Phlebovirus NSs proteins as antagonists of the human IFN response 
IFN production can have protective effects against bunyavirus infection, which can be 
illustrated by the high susceptibility to RVFV infection in IFNAR knock out mice, 
compared to wild-type mice (Bouloy et al., 2001; Cyr et al., 2015; Yadani et al., 1999). 
During bunyavirus replication, products of each of the three viral RNA segments have the 
potential to activate IFN induction by the stimulation of RIG-I. As a consequence, 
bunyaviruses require efficient mechanisms to antagonise the IFN response. It is well-
known that the NSs protein of bunyaviruses acts as a major virulence factor, contributing 
to pathogenesis by assisting the virus to evade the host innate immune system, first 
demonstrated for BUNV NSs (Bridgen et al., 2001; Weber et al., 2002). The NSs proteins 
of phleboviruses have also evolved a plethora of countermeasures to block the IFN 
response. 
Within the Sandfly fever group of the Phlebovirus genus, the NSs protein of RVFV has 
been extensively studied. Unlike most phleboviruses, the NSs protein of RVFV localizes to 
the nuclei of infected cells, forming distinct filamentous structures (Brennan et al., 2014; 
Cyr et al., 2015; Struthers and Swanepoel, 1982; Yadani et al., 1999). Part of its IFN 
antagonistic activity is attributed to its nuclear localization, which enables RVFV to inhibit 
IFN-β mRNA synthesis. Initially, RVFV NSs was shown to inhibit general host cell 
mRNA transcription by inhibiting the assembly of the basal transcription factor IIH 
(TFIIH), as described in section 1.1.4 (Billecocq et al., 2004; Cyr et al., 2015; Kalveram et 
al., 2011; Le May et al., 2004). However, RVFV NSs was shown to employ a different 
mechanism for the suppression of IFN-β mRNA synthesis specifically. This mechanism 
involved an interaction between RVFV NSs and SAP30 (Sin3A associated protein 30), a 
protein which forms part of a repressor complex that regulates IFN-β gene expression (Le 
May et al., 2008). The interaction of SAP30 with RVFV NSs and its recruitment to the 
IFN-β promoter results in chromatin structure reorganization, which physically inhibits the 
recruitment of the CREB-binding protein (CBP) to the IFN-β promoter, therefore 
supressing histone acetylation and consequently transcriptional activation. RVFV NSs was 
also shown to support virus replication in infected cells by promoting the post-
transcriptional proteasome-dependent down-regulation of the double-stranded RNA-
dependent protein kinase (PKR) (Ikegami et al., 2009b; 2009a). Following IFN induction, 
PKR levels are up-regulated. A dsRNA-binding domain in PKR binds dsRNA generated 
during virus replication, which triggers its activation (F. Zhang, 2001). Once active, PKR 
can phosphorylate the eukaryotic initiation factor eIF2α (Srivastava et al., 1998). eIF2α is 
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a subunit of the IF2 initiation complex that is responsible for recruiting initiator MettRNA to 
the 40S ribosomal subunit in a guanosine triphosphate (GTP)-dependent manner. 
Phosphorylation of eIF2α by PKR inhibits the exchange of GDP for GTP, thereby 
resulting the inhibition of translation initiation due to the inability to recruit the initiator 
MettRNA to the 43S pre-initiation complex (de Haro et al., 1996). Thus, the proteasomal 
degradation of PKR by RVFV NSs supresses the phosphorylation of eIF2α and in this way 
prevents the inhibition of translation initiation induced by the IFN response (Habjan et al., 
2009b; Ikegami et al., 2009b). Recently, it was shown that the degradation of PKR is 
mediated by the interaction of RVFV NSs with the F-box proteins FBXW11 and/or 
FBCW1, through a ‘degron’ sequence in RVFV NSs, which, curiously overlaps with the 
ΩXaV motif at its C terminus (Kainulainen et al., 2016; Mudhasani et al., 2016). It was 
suggested that perhaps the down-regulation of PKR turns the unfavourable environment 
induced by suppression of host cell mRNA transcription (by RVFV NSs) in infected host 
cells to one that supports viral replication, by preventing the inhibition of viral translation 
(Ikegami et al., 2009a). In this way, the dual functions of RVFV NSs could function 
concomitantly to inhibit host innate immune responses and to enable efficient RVFV 
replication (Ikegami et al., 2009b).  
Early studies showed that TOSV induced IFN despite the ability of its NSs protein to 
antagonise the IFN response, which the authors indicate may be a result of a weak IFN 
antagonistic activity of TOSV NSs (Gori-Savellini et al., 2010). The ability to induce the 
proteasomal-mediated degradation of PKR by RVFV NSs is a property that is conserved in 
TOSV NSs (Kalveram and Ikegami, 2013). However, in comparison to RVFV, cellular 
transcription levels are unaffected following TOSV infection (Kalveram and Ikegami, 
2013). Additionally, the type I IFN response was shown to be blocked by TOSV NSs by a 
direct interaction with RIG-I, and its targeting for proteasomal degradation, thereby 
preventing RIG-I-mediated IFN induction (Gori-Savellini et al., 2013). In a study where 
recombinant RVFV encoding PTV or SFSV NSs proteins instead of RVFV NSs were 
generated, the viruses encoding PTV and SFSV NSs proteins did not affect PKR levels 
(Kalveram and Ikegami, 2013; Lihoradova et al., 2013). However, the virus encoding PTV 
NSs was able to supress host cell mRNA transcription similarly to RVFV, whereas that 
encoding SFSV NSs had no inhibitory effect of host cell mRNA synthesis (Kalveram and 
Ikegami, 2013; Lihoradova et al., 2013). 
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Whilst within the Phlebovirus genus most studies have focused on understanding the 
mechanism employed by mosquito-borne virus NSs proteins to antagonize the IFN 
response, the role of tick-borne phlebovirus NSs proteins in innate immunity was neglected 
until the emergence of the novel highly pathogenic SFTSV. Upon the discovery of SFTSV, 
research efforts focused on understanding its underlying molecular mechanisms of 
virulence and pathogenicity. Consequently, SFTSV NSs was quickly characterized and 
was found to form cytoplasmic viroplasm-like structures, also known as inclusion bodies 
(IBs). The structures were described in infected cells, but also when NSs is expressed in 
the absence of other viral proteins (Ning et al., 2014; Santiago et al., 2014). The IBs were 
found to colocalise with lipid droplets and viral dsRNA (X. Wu et al., 2014). Inhibitors of 
fatty acid synthesis hindered the formation of IBs and virus replication, thus suggesting 
that NSs-formed IBs play a role in virus replication (X. Wu et al., 2014). However, the 
confirmation of such conclusion would require the generation of a recombinant SFTSV 
lacking NSs. Another study found that IBs colocalised with the early endosomal marker 
Rab5, but not with Golgi apparatus or endoplasmatic reticulum markers, suggesting the 
endosomal system is utilised for the formation of IBs (Santiago et al., 2014). Finally, it 
was suggested that SFTSV NSs-formed IBs are secreted into the extracellular space, and 
that the extracellular vesicles containing infectious virions could mediate the receptor-
independent transmission of SFTSV, through endocytosis into uninfected neighbouring 
cells, where they could sustain virus replication (Silvas et al., 2015). As well as the roles 
suggested by NSs-induced IBs in virus replication and receptor-independent endocytosis, 
the IBs were described as a novel, elegant strategy that SFTSV employs to antagonise the 
IFN response.  In fact, SFTSV NSs was characterized as a potent antagonist of IFN 
induction through the spatial isolation and sequestration of TRIM25 and RIG-I (Santiago 
et al., 2014), TBK1 (Ning et al., 2014; X. Wu et al., 2014), and IRF-3 (Ning et al., 2014; 
X. Wu et al., 2014) into the IBs. The interaction between IKKε or IRF-3 and SFTSV NSs 
was reported to be indirect, facilitated by the interaction with TBK1 (X. Wu et al., 2014). 
However, one study also showed a direct interaction with IKKε (Ning et al., 2014). 
Similarly, while the direct interaction between SFTSV NSs and RIG-I was reported in one 
study (Santiago et al., 2014), such an interaction was not observed by others (Ning et al., 
2014). As well as inhibiting IFN induction, a potent inhibitory activity of SFTSV NSs on 
IFN signalling was described, and was attributed to the interaction between SFTSV NSs 
and STAT1 or STAT2. This interaction results in the spatial isolation of STAT1 and 
STAT2, therefore inhibiting the JAK/STAT signalling pathway (Chaudhary et al., 2015; 
Ning et al., 2015). Interestingly, a study using liver epithelial cells showed that while 
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SFTSV NSs strongly inhibited IFN-β promoter activation, NFκB activation was enhanced 
by SFTSV NSs (Q. Sun et al., 2015).  The differential effect of SFTSV NSs on IFN-β and 
NFκB promoter activities may explain elevated levels of proinflammatory cytokines and 
chemokines regulated by NFκB signalling in liver tissues of mice infected with SFTSV (Q. 
Sun et al., 2015).   
Despite our understanding of the role of SFTSV NSs in impairing the IFN response, little 
is known about the mechanisms utilised by other tick-borne phleboviruses. Recent reviews 
have highlighted the need of comparative studies to elucidate the countermeasures that 
phleboviruses have evolved to hinder the IFN response (Ly and Ikegami, 2016; Wuerth 
and Weber, 2016), as viruses belonging to this genus are continuously emerging and 
appear to have evolved divergent mechanisms to supress host cell responses to virus 
infection. 
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2 Aims 
It well-known that the main virulence factor evolved by bunyaviruses to counteract the 
host innate immune system is their non-structural protein NSs. However, it is also evident 
that we have limited information about the role of tick-borne phlebovirus NSs proteins in 
modulating the innate immune system. 
The overall aim of this project was to carry out a molecular characterization of the NSs 
protein of the tick-borne phleboviruses UUKV and HRTV, utilizing reverse genetics as a 
tool to assist with these investigations.  
Specifically, I aimed to: 
(i) Develop minigenome and virus-like particle assays for UUKV, as a first step 
towards developing a reverse genetics system for this virus. 
(ii) Rescue UUKV and exploit the ability to manipulate the UUKV genome to 
generate recombinant viruses lacking its NSs protein. 
(iii) Compare the ability of UUKV and recombinant UUKV lacking NSs to hinder 
interferon production. 
(iv) Compare the ability of UUKV and HRTV NSs proteins to block interferon 
production and interferon signalling, using the well-characterized SFTSV NSs 
as a comparison. 
(v) Investigate the molecular mechanisms of antagonism employed by UUKV and 
HRTV NSs proteins at the level of interferon induction and interferon 
signalling. 
(vi) Sequence the genome of the HRTV stock available in our laboratory and 
compare it to the published sequence. 
(vii) Develop a reverse genetics system for HRTV. 
(viii) Use the available reverse genetics systems of tick-borne phleboviruses as a 
molecular tool to assess the possibility of reassortment between tick-borne 
phleboviruses.
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3 Materials 
3.1 Cell culture 
3.1.1 Eukaryotic cell lines 
The following cell lines were used in this project: 
• A549: cell line derived from human lung adenocarcinomic basal epithelial cells. 
Maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Thermo Fisher 
Scientific), supplemented with 10% (v/v) FCS. Their derivative cell line 
A549/BVDV-Npro (A549/Npro) expresses the bovine viral diarrhea virus (BVDV) 
Npro protein, which acts as an IFN antagonist by targeting IRF-3 for proteasomal 
degradation (Hale et al., 2009; Hilton et al., 2006). The A549/PIV5-V (A549/V) 
cell line is also an A549 derivative, however constitutively expressing the V protein 
of parainfluenza virus type 5, which blocks type I IFN signalling by targeting 
STAT1 for degradation (Killip et al., 2013). Selection of the derivative A549 cell 
lines was maintained by supplementing the medium with 2 µg/ml (Melford 
Laboratories Ltd.).  
• BHK-21 (clone 13): cell line derived from baby hamster kidneys (MACPHERSON 
and STOKER, 1962). Maintained in Glasgow modified Eagle’s medium (GMEM) 
(Gibco) with 10% (v/v) newborn calf serum (NCS) and 10% (v/v) tryptose 
phosphate broth (TPB) (Gibco). 
• BSR: a BHK-21-derived clone. BSR-T7/5: BSR cells stably expressing the 
bacteriophage T7 RNA polymerase (Buchholz et al., 1999). Provided by Dr Karl-
Klaus Conzelmann (Ludwig-Maximilians-Universität München). Cells were 
maintained in GMEM with 10% (v/v) foetal calf serum (FCS) and 10% (v/v) TPB, 
supplemented with 1 mg/ml G418 (Promega) for the selection of cells expressing 
the T7 RNA polymerase. 
• DF-1: chicken fibroblast immortalised cell line derived from 10-day old East 
Lansing Line (ELL-0) eggs (Foster, 1998), and was maintained in DMEM, 
supplemented with 10% (v/v) FCS. 
• HeLa: cell line derived from human epithelial carcinoma cells (Gey and Coffman, 
1952). Maintained in DMEM supplemented with 10% (v/v) FCS. 
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• HEK-293T: cell line derived from human embryonic kidney cells. Maintained in 
DMEM with 10% (v/v) FCS, supplemented with 0.1 mM non-essential amino acids 
(Gibco). 
• Huh-Lunet-T7: cell line constitutively expressing the bacteriophage T7 RNA 
polymerase (Kaul et al., 2007), derived from Huh-7 cells,  which are derived from 
liver carcinoma cells (Nakabayashi et al., 1982). Provided by Dr Ralf 
Bartenschlager (Universitätsklinikum Heidelberg). The cells were maintained in 
DMEM supplemented with 10% (v/v) FCS and 0.1 mM non-essential amino acids. 
Selection was maintained by supplementing the medium with Zeocin (100 µg/ml) 
(Thermo Fisher Scientific).  
• Vero E6: cell line derived from African green monkey kidney cells. Maintained in 
DMEM, supplemented with 10% (v/v) FCS. 
Trypsin-EDTA (0.05%), phenol red was purchased from Gibco. 
3.1.2 Competent bacterial strains 
Plasmid stocks were generated using the bacterial strain of E. coli JM109, genotype 
endA1, recA1, gyrA96, thi, hsdR17 (rk–, mk+), relA1, supE44, Δ( lac-proAB), [F´ traD36, 
proAB, laqIqZΔM15] or CopyCutterTM Epi400 chemically competent E. coli (Epicentre) 
genotype F-mcrA Δ(mrr-hsdRMS-mcrBC)Φ80dlacZΔM15 ΔlacX74 recA1 endA1 
araD139Δ(ara, leu)7697 galΚλ- rpsL nupG tonA ΔpcnB dhfr. Competent bacteria were 
made chemically competent using the Mix & Go E. coli Transformation Kit and Buffer set 
(Zymo research).  
Bacteria were grown at 37°C or room temperature, either on Luria-Bertani (LB) broth or 
LB agar plates, in the presence of ampicillin (100 µg/ml) for selection of successfully 
transformed cells.  
3.2 Virus strains and sequence accession numbers 
3.2.1 Virus strains 
The UUKV strain used in this project was derived from the prototype tick isolate S-23 
(Oker-Blom et al., 1964), and plaque-purified in chicken embryo fibroblasts (Pettersson 
and Kääriäinen, 1973).  Working stocks of UUKV were generated by passaging the virus 
at a low multiplicity of infection (MOI) (0.001 FFU/cell) in BHK-21 cells and harvesting 
the medium 7 days post infection (p.i.).  
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The HRTV strain used was isolated from a 67-year-old man who received 20 daily tick 
bites approximately for a period of two weeks  (patient 2 in (McMullan et al., 2012)). The 
patient was hospitalised for twelve days and presented with fatigue, myalgia, severe 
thrombocytopenia and leukopenia. The patient isolate was a kind gift by Dr Robert Tesh 
(World Reference Center for Emerging Viruses and Arboviruses, Galveston, TX). 
The SFTSV strain used was a plaque-purified cell culture-adapted stock called Hubei 29pp 
(HB29pp), provided by Amy Lambert (CDC Arbovirus Diseases Branch, Division of 
Vector-Borne Infectious Diseases, Fort Collins, CO) (Brennan et al., 2015).  
Working stocks of HRTV and SFTSV were generated by passaging the viruses once in 
Vero E6 cells at a low MOI (0.001 PFU/cell), and harvesting the medium 7 days p.i.. 
Other viruses included in this study are Encephalomyocarditis virus (EMCV), 
Bunyamwera virus (BUNV), and rBUNVdelNSs2. rBUNVdelNSs2 is a recombinant 
BUNV that does not express the NSs protein (Hart et al., 2009). 
3.2.2 Virus sequence accession numbers 
Nucleotide sequences for the generation of plasmids were based on the following 
accession numbers: 
Table 3-1. Virus nucleotide sequence accession numbers used in this study 
Virus name Segment GenBank 
accession number 
UUKV 
S M33551.1 
M M17417.1 
L D10759.1 
HRTV 
S JX005843.1 
M JX005845.1 
L JX005847.1 
SFTSV 
S KP202165.1 
M KP202164.1 
L KP202163.1 
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3.3 Molecular biology 
2.3.1 Oligonucleotides 
Standard desalted synthetic oligonucleotides at 25nM scale were purchased from 
Integrated DNA Technologies. All primers used in this project and the purposes for their 
use are listed in the Appendices (Tables 10-1 to 10-6). 
3.3.2 Enzymes 
(i) Restriction enzymes 
Restriction enzymes were purchased from New England BioLabs (BamHI, PstI-HF, SalI-
HF) or Promega (BamHI, DpnI, NcoI, NotI, PstI, XhoI) and used throughout the project to 
confirm successful cloning by restriction enzyme digestion, prior to sequencing cloned 
plasmids. 
(ii) Modifying enzymes 
For PCR, either GoTaq® G2 Flexi DNA polymerase (Promega), KOD Hot Start DNA 
polymerase (Novagen, Merck Millipore) or Q5® high fidelity DNA polymerase (New 
England Biolabs) were used.  RQ1 RNase-Free DNase was purchased from Promega. 
Reverse-transcription (RT) reactions were performed using either GoScript reverse 
transcriptase (Promega) or PrimeScript RT Reagent Kit with gDNA Eraser (Takara) 
Quantitative PCR was carried out using SYBR® Premix Ex TaqTM II Mix (Takara). For 3’ 
Rapid Amplification of cDNA Ends (RACE) analysis, RNA was polyadenylated using a 
Poly(A) Tailing Kit (Thermo Fisher Scientific). Benzonase® Nuclease was purchased from 
Sigma. 
3.3.3 Cloning 
In-Fusion® HD Cloning Plus kit (Clontech) was used for restriction-free cloning. 
3.3.4. Plasmids 
The plasmids used in this project are described in Table 3-2. All listed plasmids contain an 
ampicillin resistance gene (ampR). 
 
 
3. Materials 60 
Table 3-2. Plasmids used in this study. 
Plasmid Description Source 
pT7UUKS(+) 
pT7UUKM(+) 
pT7UUKL(+) 
 
Full-length, antigenomic sense UUKV S, M and L 
segments, respectively, subcloned into the plasmid pTVT7 
(0,0)(Johnson et al., 2000). The segments are flanked by a 
bacteriophage T7 promoter at the 5’ end, and a hepatitis Δ 
ribozyme at the 3’ end, followed by a T7 terminator. A 
silent mutation was introduced in position 963 of 
pT7UUKS(+), which introduces an XhoI restriction site in 
UUKV S segment cDNA. 
Made during this 
project 
pT7UUKdelNSs(+) 
Modified pT7UUKS(+) plasmid, in which the UUKV NSs 
open reading frame (ORF) is excised (nucleotides 874-
1695), such that the intergenic region is followed directly 
by the genomic 5’ untranslated region (UTR) 
Made during this 
project 
pT7UUKdelNSseGFP(+) 
Modified pT7UUKS(+) plasmid, in which the UUKV NSs 
ORF is replaced by that of enhanced GFP (eGFP), in the 
same negative-sense orientation. 
Made during this 
project 
pTMUUKN 
pTMUUKL 
pTMUUKGnGc 
UUK N and L or GnGc glycoprotein precursor ORFs, 
respectively, cloned into the expression plasmid pTM1, 
originally provided by B. Moss (Moss et al., 1990). The 
plasmid backbone contains a bacteriophage T7 promoter to 
drive transcription, followed by an Internal Ribosome 
Entry Site (IRES) to drive translation. 
Made during this 
project 
pTMFFluc 
pTM1 plasmid encoding Photinus (firefly) luciferase 
ORF, as previously described (Weber et al., 2001). 
Provided by Prof 
Richard M. Elliott 
pT7UUKSRen(+) 
pT7UUKMRen(-) 
pT7UUKLRen(-) 
pTVT7 plasmids encoding Renilla luciferase in a negative 
sense, flanked by the genomic UUKV M or L UTRs, 
respectively. In the case of pT7UUKSRen(+), the NSs 
ORF in pT7UUKS(+) was replaced by the Renilla 
luciferase  ORF in the same (negative-sense) orientation. 
Made during this 
project 
pT7HRTS(+) 
pT7HRTM(+) 
pT7HRTL(+) 
Full-length, antigenomic sense HRTV S, M and L 
segments, respectively, subcloned into the plasmid pTVT7 
(0,0), as for UUKV. 
Made during this 
project 
pTMHRTN 
pTMHRTL 
HRTV N and L ORF, respectively, cloned into the 
expression plasmid pTM1. 
Made by Dr 
Benjamin Brennan 
pTM1HRTLA3309U Modified pTMHRTL with a A"T mutation at position Made during this 
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3309 (genomic sense) project 
pT7HRTSRen(+) 
pT7HRTMRen(-) 
pT7HRTLRen(-) 
pTVT7 plasmids encoding Renilla luciferase in a negative 
sense, flanked by genomic HRTV M or L UTRs, 
respectively. In the case of pT7HRTSRen(+), the NSs 
ORF in pT7HRTS(+) was replaced by the Renilla 
luciferase  ORF in the same (negative-sense) orientation. 
Made during this 
project 
pT7HRTSRen(+)A1751G  
Modified pT7HRTSRen(+) with a A"G mutation in the 
HRTV S segment genomic 5’ UTR (position 1751). 
Made during this 
project 
pTM1SFTSN 
pTM1SFTSL 
SFTSV N and L ORFs, respectively, cloned into the 
expression plasmid pTM1.  
Dr Benjamin 
Brennan 
From (Brennan et 
al., 2015). 
pCMVUUKNSs 
pCMVHRTNSs 
pCMVSFTSNSs 
Mammalian expression vector pCMV (Addgene) 
encoding wild-type UUKV, HRTV or SFTSV NSs ORFs, 
respectively, under the control of a cytomegalovirus 
(CMV) promoter. 
Made during this 
project 
pCMVUUKNSs-V5 
pCMVHRTNSs-V5 
pCMVSFTSNSs-V5 
Mammalian expression vector pCMV (Addgene) 
encoding UUKV, HRTV or SFTSV NSs ORF, 
respectively, which were tagged at the C-terminus with the 
simian virus 5 (SV5) V5 epitope tag. 
Made during 
project 
p(125)luc 
Firefly luciferase reporter construct driven by the murine 
interferon-β promoter.  
Provided by Ben 
Hale. From 
(Yoneyama et al., 
1998). 
pISREluc 
Firefly luciferase reporter construct driven by tandem 
repeats of the interferon stimulated response element 
(ISRE).  
Provided by Ben 
Hale. From (King 
and Goodbourn, 
1998). 
pNFκBluc 
Firefly luciferase reporter construct driven by five tandem 
copies of the canonical κB element (Chaudhary et al., 
2015). 
Provided by Prof 
Dong-Yan Jin 
pCMV-IκBαSR 
CMV-driven plasmid encoding IκBα mutant super-
repressor containing mutations S32A and S36A. This 
mutant acts as an antagonist of NFκB signalling by 
sequestering NFκB in the cytoplasm.  
Provided by Prof 
Dong-Yan Jin. 
Generated as 
described in (Karl 
et al., 2009)  
phRL CMV-driven Renilla luciferase, used as a transfection Provided by Ben 
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control for data normalisation.  Hale. Initially 
purchased from 
Promega. 
pCMVRIG-I-N 
Plasmid encoding the RIG-I N-terminus ORF under the 
control of a CMV promoter.  
Provided by Ben 
Hale. As described 
in (Varga et al., 
2011). 
  
pCMVRIG-I-N-FLAG 
pCMVMAVS-FLAG 
pCMVTBK-1-FLAG 
pCMVIKKε-FLAG 
pCMVTRIF-FLAG 
Plasmids encoding the RIG-I N-terminus, MAVS, TBK-1, 
IKKε and TRIF ORFs, respectively, under the control of a 
CMV promoter in the pcDNA3.1 N-FLAG vector. All 
ORFs are FLAG-tagged at their N-terminus. 
Provided by Mirco 
Schmolke. As 
described in 
(Varga et al., 
2011, Prins et al., 
2009). 
  
pCMVIRF-3(5D) 
 
Plasmid encoding the human IRF-3 ORF in its 
constitutively active form (IRF-3[5D]) , under the control 
of a CMV promoter. In the active, IRF-3(5D), form of 
IRF-3 the serine-threonine cluster from amino acid 396 to 
405 has been mutated to phosphomimetic aspartic acid. 
Provided by Mirco 
Schmolke. As 
described in (Lin 
et al., 1998). 
  
 
3.3.5 Antibodies 
(i) Primary antibodies 
Table 3-3. Primary antibodies used in this project. 
 Dilution 
Antibody Target WB IF IP 
Mouse anti-UUKV N (generated from 
hybridoma 8B11A3, kindly provided by Anna 
Overby) 
UUKV N 1:100 - - 
Rabbit anti-UUKV NSs (IgG purified, kindly 
provided by Anna Övererby) 
UUKV NSs 1:1000 1:200 - 
Rabbit anti-HRTV N (Eurogentec) HRTV N 1:1000 - - 
Rabbit anti-HRTV NSs (Eurogentec) HRTV NSs 1:1000 1:200 1:100 
Rabbit anti-SFTSV N (Eurogentec) SFTSV N 1:1000 - - 
Rabbit anti-SFTSV NSs (Eurogentec) SFTSV NSs 1:1000 1:200 - 
Mouse anti-α tubulin (Sigma) Tubulin 1:5000 - - 
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(ii) Secondary antibodies 
Table 3-4. Secondary antibodies used in this project. 
  Dilution 
Antibody Target WB IF 
Anti-mouse IgG HRP-linked (Sigma) Mouse IgG 1:5000 - 
Anti-rabbit IgG HRP-linked (Cell signalling) Rabbit IgG 1:5000 - 
Anti-mouse Alexa fluor 568 (Thermo Fisher Scientific) Mouse IgG - 1:500 
Anti-rabbit Alexa fluor 488 (Thermo Fisher Scientific) Rabbit IgG - 1:500 
Anti-mouse Alexa fluor 488 (Thermo Fisher Scientific) Mouse IgG - 1:200 
Anti-rabbit Alexa fluor 532 (Thermo Fisher Scientific) Rabbit IgG - 1:200 
 
3.4 Reagents and chemicals 
3.4.1 Bacterial culture 
• Ampicillin sodium was purchased from Formedium and used at 100 µg/mL. 
• LB agar: 4% (w/v) LB-Agar-Miller (Formedium) diluted in de-ionised H2O. 
• LB broth: 2.5% (w/v) LB-Broth-Agar-Miller (Formedium) diluted in de-ionised 
H2O. 
Mouse anti-β-Actin (Sigma) Actin 1:5000 - - 
Mouse anti-SV5 V5 epitope (Provided by 
Richard E. Randall) 
V5 epitope 1:3000 1:250 1:250 
Mouse anti-FLAG M2 (Sigma) FLAG M2 1:2000 - 1:500 
Rabbit anti-IRF-3 (Santa Cruz Biotech) IRF-3 1:2000 1:250 1:250 
Rabbit anti-IRF-3 Ser386P (Abcam) IRF-3 phosphorylated at 
Ser386 
1:1000 - - 
Rabbit anti-TBK-1/NAK (Cell signalling) TBK-1/NAK 1:1000 - - 
Rabbit anti-STAT 1 (Santa Cruz Biotech) STAT 1 1:1000 1:200 - 
Rabbit anti-STAT 2 (Santa Cruz Biotech) STAT 2 1:1000 1:200 - 
Rabbit anti-STAT 3 (Santa Cruz Biotech) STAT 3 1:1000 - - 
Rabbit anti-STAT 1 Tyr701P (Cell 
Signalling) 
STAT 1 phosphorylated at 
Tyr701 
1:1000 - - 
Rabbit anti-STAT 1 Ser727P (Cell Signalling) STAT 1 phosphorylated at 
Ser727 
1:1000 - - 
Rabbit anti-STAT 2 Tyr690P (Cell 
Signalling) 
STAT 2 phosphorylated at 
Tyr701 
1:1000 - - 
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3.4.2 Cell culture 
• PBS: 137 mM NaCl, 15 mM KCl, 10 mM Na2HPO4 ; pH 7.4 
• GMEM, DMEM and TPB were purchased from Gibco. 
• 2X MEM: 20% (v/v) 10X Modified Eagle’s Medium (MEM) (Gibco), 2% (v/v) L-
glutamine, 0.435% (v/v) NaHCO3, diluted in H2O. 
• 0.6% Avicel overlay: 1.2% Avicel (purchased from FMC) (w/v in H2O) was 
diluted in a 1:1 ratio with 2X MEM prior to use. 
• 10X Neutral Red: PBS, 0.6% neutral red (w/v). 
• Crystal violet staining solution: 20% (v/v) ethanol, 1% (v/v) methanol, 0.1% (w/v) 
crystal violet, diluted in H2O. 
• Formaldehyde fixing buffer: 8% or 4% (v/v) formaldehyde in PBS. 
• TransIT-LT1 transfection reagent was purchased from MirusBio. 
• GeneJuice transfection reagent was purchased from EMD Millipore. 
• Lipofectamine 2000 was purchased from Invitrogen. 
• Opti-Minimum Essential Medium (Opti-MEM) was purchased from Gibco 
• Dual Luciferase Assay Reporter Kit was purchased from Promega. 
• Ruxolitinib JAK1/2 inhibitor was purchased from Selleck Chemicals. 
3.4.3 DNA analysis 
• For plasmid isolation from bacterial cultures, the QIAprep Spin Miniprep kit 
(Qiagen), or the NucleoBond Xtra midiprep kit (Macherey-Nagel) were used.  
• Agarose gel: 1-2% (w/v) molecular grade agarose (Bioline) in TAE buffer. 
• 10X TAE buffer: 0.4M Tris, 1.142% (v/v) acetic acid, 0.01 M EDTA diluted in 
H2O. 
• 1 kb DNA ladder, DNA loading buffer and Ethidium Bromide solution were 
purchased from Promega. 
• Purification and extraction of DNA from agarose gels were performed using the 
NucleoSpin® Gel and PCR Clean-up kit (Macherey-Nagel), or the Wizard® SV Gel 
and PCR Clean-up System (Promega). 
3.4.4 Total cellular RNA extraction 
Total cellular RNA was extracted using TRIzol® (Thermo Fisher Scientific). 
3.4.5 Immunofluorescence 
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• Poly-L-lysine was purchased from Sigma and used at a concentration of 0.1 mg/mL 
in H2O. 
• Fixation agent: 4% (v/v) formaldehyde in PBS. 
• Permeabilisation solution: 0.5% (v/v) Triton X-100, 20mM sucrose in PBS. 
• Mounting medium: Fluoromont-G with DAPI (eBioscience) 
• Confocal microscopy was carried out in a Carl Zeiss LSM 710 microscope. 
3.4.6 Protein analysis and western blotting 
• Protein Disruption buffer (PDB): 50 mM Tris-HCl (pH 6.8), 10% (v/v) glycerol, 
4% (w/v) SDS, 0.02% (w/v) bromophenol blue. 200 mM dithiothreitol (DTT) was 
added prior to use. 
• NuPAGE Novex (4-12%) Bis-Tris protein gels were purchased from Thermo 
Fisher Scientific. 
• NuPAGE MES SDS running buffer was purchased from Thermo Fisher Scientific. 
• 10% Native-PAGE gels were made in house with the following reagents: 
Table 3-5. Reagents used for native PAGE gels. 
 
 
• Native gel running buffer: 25 mM Tris and 192 mM glycine. 
• NuPAGE transfer buffer was purchased from Thermo Fisher Scientific. 
• Amersham Hybond ECL nitrocellulose membrane was purchased from GE 
Healthcare Life Sciences. 
• Standard blocking buffer: 4% (w/v) skimmed milk powder in PBS/ 0.1% (v/v) 
Tween-20. 
• Standard washing buffer: PBS 0.1% (v/v) Tween-20. 
• Tris-buffered saline (TBS): 50 mM Tris-HCl pH 7.5, 150 mM NaCl. 
• Blocking buffer for phosphorylated proteins: 3% Bovine Serum Albumin (BSA) 
(Sigma) in TBS/ 0.1% (v/v) Tween-20. 
• Washing buffer for phosphorylated proteins: TBS 0.1% (v/v) Tween-20. 
Reagent Resolving gel Stacking gel 
Acrylamide/Bis-acrylamide 30%/0.8% (w/v) 3.4 mL 4.275 mL 
0.375 M Tris-HCl (pH 8.8) 6.49 mL 0.67 mL 
10% (w/v) ammonium persulfate 100 µL 50 µL 
TEMED 10 µL 5 µL 
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• Western blotting substrate: ClarityTM ECL western blotting substrate (BioRad). 
3.4.7 Focus-forming assays 
• Permeabilisation buffer: 0.5% Triton X-100, 20 mM sucrose in PBS. 
• Immunodetection substrate: TrueBlue Peroxidase Substrate was purchased from 
KPL. 
 
3.4.8 Immunoprecipitation 
• RIPA lysis buffer: 50 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 10% glycerol, 
1% nonidet P-40, supplemented with a cocktail of cOmplete protease inhibitors 
(Roche). 
• UUKV NSs immunoprecipitation lysis buffer: 25 mM HEPES pH 7.5, 150 mM 
NaCl, 50 mM MgCl2, 1% Triton X-100, supplemented with a cocktail of cOmplete 
protease inhibitors (Roche). 
• Washing buffer: 50 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 10% glycerol. 
• Magnetic protein A and protein G Dynabeads® were purchased from Thermo 
Fisher Scientific. 
• Protein G agarose beads were purchased from Sigma. 
• Anti-FLAG® M2 magnetic beads were purchased from Sigma. 
3.5 Software packages 
3.5.1 Bioinformatics 
Primer design and sequence analysis were performed with CLC Genomics Benchwork 
version 7. 
3.5.2 Graphing and statistical analysis 
Graphing and statistical analysis were performed using GraphPad Prism version 5. 
3.5.3 Imaging 
ZEN (Zeiss) software and ImageJ (Rasband, 1997) were used for imaging and processing 
of confocal microscopy images. 
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4 Methods 
4.1 Cell culture 
4.1.1 Maintenance of eukaryotic cell lines 
Cells grown in either 10 cm dishes, 75 cm2 or 175 cm2 vented flasks were split 1:10 when 
80-90 % cell confluence was reached. Briefly, after the removal of medium, the cells were 
washed two times with PBS before adding trypsin. Trypsin-treated cells were incubated for 
5 min at 37° C. Upon detachment, the cells were resuspended in appropriate fresh cell 
culture medium. Cultured cells were incubated in a humidified atmosphere at 37° C with 
5% CO2, except DF-1 cells, which where maintained in a humidified atmosphere at 39° C 
with 5% CO2. 
4.1.2 Transfection of eukaryotic cell lines 
Transfections were performed using Lipofectamine 2000 (Invitrogen), TransIT-LT1 
(MirusBio), or GeneJuice (EMD Millipore) at least 18h after seeding (or when cells 
reached 70-80% confluence). The total volumes of OptiMEM (Gibco) and transfection 
reagent used for cell culture vessels of different surface areas (independent of DNA 
amounts) are shown in Table 4-1. 
Table 4-1. Volumes used for transfections in different cell culture vessels. 
Cell culture 
vessel 
Volume per 
well (mL) 
Transfection reagent 
volume (µL) 
Total OptiMEM 
volume (µL) 
24-well plate 0.5 1.25 100 
12-well plate 1 2.5 150 
6-well plate 2 5 500 
 
Half of the total volume of recommended OptiMEM (Table 4-1) was mixed with the 
required amount of plasmid DNA in microcentrifuge tubes (Eppendorf). For experiments 
performed under Advisory Committee on Dangerous Pathogens (ACDP) category 3 
conditions, 2 mL screw-cap micro tubes (Starstedt) were used. The appropriate amount of 
transfection reagent was resuspended in the remaining OptiMEM, and mixed with the 
OptiMEM/DNA mix. After incubation at room temperature for 20 min, the mixture was 
added to the cell culture medium. 
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4.1.3 Minigenome assays 
UUKV, HRTV and SFTSV minigenome assays were based on a previously published 
protocol, developed for the minigenome system of BUNV (Weber et al., 2001). Briefly, 
sub-confluent monolayers of BSR-T7/5 cells in a 24-well plate were seeded at 
approximately 2.5x104 cells per well. The cells were co-transfected the next day with 25 
ng pTMFFluc (to measure firefly luciferase activity as an internal control of transfection 
efficiency and data normalisation), 125 ng of a Renilla luciferase-based minigenome 
plasmid pT7XSRen(+), pT7XMRen(-) or pT7XLRen(-), 250 ng of the expression plasmid 
pTMXN, and increasing amounts (0-375 ng) (or the indicated amount) of pTMXL (where 
X refers to UUKV, HRTV or SFTSV). The total amount of plasmid DNA in all reactions 
was kept constant by addition of empty control plasmid pTM1 to the DNA mix. 24 h post 
transfection, the cells were washed twice with PBS, lysed and firefly and Renilla luciferase 
activities measured using the Dual Luciferase Reporter Assay system (Promega), as per the 
manufacturer’s instructions.  
The Renilla luciferase activity was normalised to firefly luciferase activity in the negative 
control, where no pTMXL was transfected, unless stated otherwise.  
4.1.4 Virus-like particle assays 
UUKV virus-like particle assays were carried out in a similar manner to minigenome 
assays. Briefly, sub-confluent monolayers of BSR-T7/5 cells in a 24-well plate (seeded at 
approximately 5x104 cells per well) were co-transfected with the plasmids described for 
the UUKV M segment-based minigenome assays: 25 ng pTMFFluc, 125 ng of 
pT7UUKMRen(-), 250 ng of pTMUUKN, and 250 ng pTMUUKL per well. The 
minigenome transfection mix was supplemented with 125 ng or 250 ng of 
pTMUUKGnGc, encoding the UUKV glycoproteins. 48 h post transfection, the cell 
culture supernatant was harvested and clarified by centrifugation at 10,000 rpm for 5 min, 
digested with 0.5 u/µL benzonase nuclease (Sigma) for 4 h at room temperature, and used 
for infection of naïve subconfluent BSR-T7/5 cells seeded in 12 well plates, or cells pre-
transfected with 250 ng pTM1UUKN and 250 ng pTM1UUKL. Infections were carried out 
as described in section 4.1.6. Renilla and firefly activities were measured 18 h post 
infection (p.i.) using the Dual Luciferase Reporter Assay system (Promega), as per the 
manufacturer’s instructions.  
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4.1.5 Virus rescues 
Virus rescues from cDNA clones were carried out using a three- or five-plasmid, T7 RNA 
polymerase-driven rescue system, as described elsewhere (Lowen et al., 2004).  Briefly, 
BSR-T7/5 cells were seeded in 6-well plates at approximately 2x105 cells per well, to reach 
60-70% confluence the next day. Before transfection, the cell culture medium was replaced 
by fresh medium containing 2% FCS. In a three-plasmid rescue system, the sub-confluent 
cells were transfected with 1µg of each rescue plasmid; pT7UUKL(+), pT7UUKM(+), and 
either pT7UUKS(+),  pT7UUKdelNSs(+), or pT7UUKdelNSs(+) for the generation of 
recombinant UUKV (rUUKV), rUUKdelNSs, or rUUKdelNSsGFP, respectively. In a five-
plasmid rescue system, 250 ng pTM1UUKN and 250 ng pTM1UUKL were added to the 
DNA mix. Transfected cells were incubated at 37 °C for 7 days, the supernatant clarified by 
centrifugation at 10,000 rpm for 5 min, and stored at -80 °C for future use. Viral titres of 
rescued viruses were determined by focus-forming assays on BSR cells. 
HRTV rescues were carried out as described for UUKV, with the appropriate plasmids. 
4.1.6 Virus infections 
Cells were seeded at 1-3 x105 or 2-6 x105 cells per well in 12- or 6-well plates, 
respectively, to reach approximately 70% confluence the next day. Appropriate virus 
dilutions were made in PBS with 2% (v/v) FCS. The cell culture medium was removed, 
replaced with virus inoculum (150 or 300 µL per well in 12-well or 6-well plates) and 
incubated at 37 °C for one hour. Following virus adsorption, the inoculum was removed, 
the infected cells were washed three times with PBS, and replaced with the appropriate cell 
culture medium. Replacement with cell culture medium was considered time point 0 h p.i. 
4.1.7 Preparation of virus stocks 
Stocks of wild-type and recombinant UUKV were generated by passaging the viruses at a 
low multiplicity of infection (MOI) (0.01 focus forming units [FFU]/cell) in BSR cells. 
The cell culture medium from sub-confluent BSR cells in a 75 cm2 flask was removed and 
replaced with the virus inoculum in PBS 2% (v/v) FCS. After 1 h incubation at 37 °C, the 
inoculum was removed, infected cells washed three times with PBS, and fresh cell culture 
medium containing 2% (v/v) NCS added. Flasks were incubated at 33 °C and harvested 6 
or 7 days p.i. The supernatant was then clarified by centrifugation at 5,000 rpm for 10 min, 
aliquotted and stored at -80 °C for future use. 
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HRTV and SFTSV stocks were prepared by Dr Benjamin Brennan in a similar manner 
as described above, except the viruses were grown in Vero E6 cells (Brennan et al., 2015).  
4.1.8 Determination of virus titre by focus- or plaque-forming assays 
Focus-forming assays for UUKV were performed in monolayers of confluent BSR or 
BHK-21 cells. After removal of the medium, 10-fold serial dilutions of the virus inoculum 
(in PBS/2% (v/v) FCS) were added to the cell monolayers. Following 1 h incubation at 37 
°C, the cells were overlaid with an MEM overlay supplemented with 2% FCS or NCS and 
0.6% Avicel. The assays were incubated for 5 to 6 days, and fixed with formaldehyde 
fixing buffer for 1 h. After fixation, the monolayer was treated for 30 min with 
permeabilisation solution, and incubated for 2 h with mouse anti-UUKV N antibody 
8B11A3 (1:100 (v/v) in standard blocking buffer). Next, the plates were washed three 
times in standard washing buffer, and incubated for 1 h with anti-mouse HRP-linked 
antibody (1:5000 (v/v) in standard blocking buffer). After repeated washing with PBS, foci 
where detected by adding TrueBlue peroxidase substrate (enough to cover the wells) at 
room temperature for approximately 20 min. The plates were finally rinsed with distilled 
water and let to dry upside down protected from light. 
For HRTV and SFTSV, virus titres were determined through plaque assays in Vero E6 
cells, as described for UUKV, except following fixation, the cell monolayers were stained 
using crystal violet staining solution to visualise virus plaques. 
 Virus titres were calculating using the following equation:   
!"#$% !"!#$ !"# !" !!"!" = !"#$%& !" !"#$%&' !" !"#$ (!. !.!. !" !. !.!. )! ! ! (!")  
, where d= dilution for the well where the number of plaques was counted, v = volume of 
inoculum, PFU=plaque-forming unit and FFU= focus-forming unit. 
When investigating the effect of the JAK1/2 inhibitor Ruxolitinib (Selleck Chemicals) on 
focus size, focus assays were performed as described above for UUKV, and the avicel 
overlay was supplemented with 0.4 µM ruxolitinib, or the equivalent volume of the vehicle 
control DMSO.  For HRTV and SFTSV, the primary antibodies used in focus assays were 
rabbit anti-HRTV N antibody  (1:1000 (v/v) in blocking buffer), or rabbit anti-SFTSV N 
antibody  (1:1000 (v/v) in blocking buffer), and the secondary antibody used was anti-
rabbit HRP-linked antibody (1:5000 (v/v) in blocking buffer).  
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4.1.9 Immunofluorescence 
For immunofluorescence of infected cells, Vero E6, BHK-21, or A549 cells were seeded in 
12-well plates with 30 mm coverslips at a cell density of 1 x105 cells per well. For 
immunofluorescence of transfected cells, HEK293T cells were seeded in coverslips pre-
treated with poly-L-lysine (Sigma). Briefly, before seeding the cells, enough poly-L-lysine 
(0.1 mg/mL in H2O) was added to the coverslips to cover the surface, and incubated at 
room temperature for 30 min. Next, the poly-l-lysine was removed, the coverslips washed 
three times in distilled H2O, and the cells seeded at a cell density of 1.5 x105 cells per well 
in a 12-well plate. 
Transfections or infections were carried out as explained in sections 4.1.2 or 4.1.6, 
respectively. At the indicated time points, the cells were fixed in fixation agent for 1 h and 
permeabilised in permeabilisation solution for 30 min. The coverslips were then probed 
with the primary antibody diluted at the appropriate concentration (see Table 3-3) in PBS 
2% (v/v) FCS and incubated overnight at 4 °C in a humid chamber. Following washing 
five times with PBS 0.1% (v/v) Tween-20, the coverslips were incubated for 1 h at room 
temperature with the secondary antibodies diluted in PBS 2% (v/v) FCS (see Table 3-4). A 
second washing step was performed, followed by washing twice with distilled H2O, prior 
to mounting the coverslips in microscope slides using 5µL mounting medium with DAPI. 
The slides were stored at 4 °C until use. 
4.1.10 Luciferase assays 
(i) IFN-β reporter assays 
To assess the effect of tick-borne phlebovirus NSs proteins had on antagonising the IFN 
induction pathway, 5 x104 HEK293T cells were seeded per well in a 24-well plate. The 
next day, subconfluent cell monolayers were co-transfected with 250 ng pCMVXNSs or 
pCMVXNSs-V5 (where X refers to UUKV, HRTV or SFTSV), along with 50 ng of 
plasmids encoding various stimuli of the IFN-β promoter (pCMVRIG-I-N-FLAG, 
pCMVMAVS-FLAG, pCMVTBK-1-FLAG, pCMVIKKε-FLAG, or pCMVIRF-3[5D]) per 
well. Additionally, 375 ng p(125)luc and 2.5 ng of the Renilla control phRL per well were 
included in the plasmid mastermix. The total amount of plasmid added to each reaction was 
kept constant by topping up the DNA mix with empty pCMV plasmid. 18 h post 
tranfection, cell monolayers were washed once in PBS and lysed for Renilla and firefly 
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quantification using the Dual-Luciferase Reporter system (Promega) following the 
manufacturer’s instructions.  
(ii) ISRE reporter assay 
The protocol for investigating the effect of NSs proteins on antagonising IFN signalling 
was carried out similarly to the IFN-β reporter assays, except 375 ng of pISREluc (and not 
p[125]luc) was used per well. 24 h post transfection, the cell culture medium was replaced 
by fresh medium with or without 250 U of IFN-β per well. 18 h post treatment, the cell 
monolayers were washed with PBS and lysed for Renilla and firefly quantification using 
the Dual-Luciferase Reporter system (Promega) following the manufacturer’s instructions.  
(iii) NFκB reporter assay 
To assess the effect of NSs proteins on NF-κB signalling, HEK293T cells were seeded at a 
cell density of 5x104 cells per well in a 24-well plate. The next day, subconfluent cell 
monolayers were co-transfected with 150 ng pCMVXNSs, pCMVXNSs-V5, (where X 
refers to UUKV, HRTV or SFTSV) or the control pCMV-IκBαSR, along with 200 ng 
pNF-κBluc and 5 ng of the Renilla control phRL, per well. The total amount of plasmid 
added to each reaction was kept constant by topping up the DNA mix with empty pCMV 
plasmid. 18 h post tranfection, the cell culture supernatant was replaced by fresh medium 
containing TNF-α (5 ng per well), or mock-treated. 24 h post treatment with TNF-α, 
transfected cells were lysed using the Dual-Luciferase Reporter system (Promega), and 
Renilla and firefly values quantified following the manufacturer’s instructions.  
4.1.11 Biological interferon protection assays 
Biological IFN protection assays were performed upon transfection or infection of 
HEK293T cells or A549 cells, respectively. When measuring the biological IFN response 
following virus infection, IFN-competent A549 cells seeded at 3 x105 cells per well in a 6 
well plate were infected with the relevant virus at the indicated MOI, as described in 
section 4.1.6, and incubated at 37 °C. 24 h p.i. the cell culture supernatant was collected 
and transferred to a fresh 6-well plate for ultraviolet (UV) light inactivation. Virus was 
inactivated by UV irradiation using a UV lamp (8W, 254 nm at a distance of 
approximately 2 cm for 4 min with occasional shaking). 
In the case of transfections, HEK293T cells seeded at 4 x105 cells per well in 6-well plates 
were co-transfected with 0-250 ng pCMXNSs, or pCMVXNSs-V5 (where X refers to 
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UUKV, HRTV or SFTSV), along with and 12.5 ng pCMVRIG-I N-FLAG. 24 h post 
transfection, the cell culture supernatant was collected and handled as described below. 
Two-fold serial dilutions of the inactivated supernatant or supernatant from transfected 
cells were made in fresh cell culture medium containing 2 % (v/v) serum. The serial 
dilutions were used to replace the cell culture medium of IFN-incompetent A549/Npro 
cells, which were seeded the day before at 1 x104 cells per well in a 96-well plate. 24 h 
following pre-treatment of A549/Npro cells, 100 µL of encephalomyocarditis virus 
(EMCV) (which was diluted in cell culture medium) was added to each well, at an MOI 
0.03 PFU per cell. Four days post infection with EMCV, the cells were fixed with 
formaldehyde fixing buffer for 30 min and stained with crystal violet staining solution to 
visualize EMCV-induced destruction of monolayers. The relative amount of biological 
IFN produced was calculated as 2N, where N is the number of two-fold dilutions resulting 
in protection of A549/Npro cells. 
4.1.12 Biosafety 
All work involving infectious Hazard Group 3 pathogens (HRTV and SFTSV) was 
performed under containment level 3 conditions to ensure appropriate and effective 
biocontainment, as approved by the UK Health and Safety Executive. UUKV work was 
performed under containment level 2 conditions 
4.2 Manipulation of nucleic acids and cloning 
4.2.1 DNA amplification by PCR  
Polymerase Chain Reactions (PCR) were performed to amplify DNA, using KOD HotStart 
DNA polymerase (Merck) or Q5® high fidelity DNA polymerase (New England Biolabs) 
for high-fidelity reactions, and GoTaq® G2 Flexi DNA polymerase (Promega) for low-
fidelity PCR reactions. The following conditions for 50 µL reactions were used for each of 
the polymerases, according to the manufacturer’s instructions: 
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KOD HotStart DNA polymerase 
Reaction components PCR conditions 
5 µL  10X KOD polymerase buffer Initial denaturation  95 °C 5 min  
5 µL  dNTP mix (2 mM each) Denaturation 95 °C  30 sec 
3 µL  MgSO4 (25 mM) Annealing 52-56 °C  30 sec 30 cycles 
1.5 µL  Forward 5’ primer (10 µM) Extension 70 °C  25 sec/kb 
1.5 µL  Reverse 3’ primer (10 µM) Final extension 70 °C  10 min 
1 µL  template DNA (1-10 ng) Hold 95 °C  ∞ 
1 µL  KOD polymerase  (1 U) 
32 µL  ddH20  
Q5® high fidelity DNA polymerase 
 Reaction components PCR conditions 
10 µL  5X Q5 reaction buffer Initial denaturation  98 °C 5 min  
1 µL  dNTP mix (10 mM) Denaturation 98 °C  10 sec 
2.5 µL  Forward 5’ primer (10 µM) Annealing 52-56 °C  30 sec 30 cycles 
2.5 µL  Reverse 3’ primer (10 µM) Extension 72 °C  25 sec/kb 
1 µL  template DNA (1-10 ng) Final extension 72 °C  2 min 
0.5 µL  Q5 HF DNA polymerase (1 U) Hold 4 °C  ∞ 
32.5 µL  ddH20  
GoTaq® G2 Flexi DNA polymerase  
Reaction components PCR conditions 
5 µL  5X GoTaq Flexi buffer Initial denaturation  95 °C 5 min  
1 µL  dNTP mix (10 mM) Denaturation 95 °C  30 sec 
3 µL  MgSO4 (25 mM) Annealing 52 -56°C  30 sec 30 cycles 
1.5 µL  Forward 5’ primer (10 µM) Extension 72 °C  1min/kb 
1.5 µL  Reverse 3’ primer (10 µM) Final extension 72 °C  10 min 
1 µL  template DNA (1-10 ng) Hold 4 °C  ∞ 
0.25 µL  GoTaq G2 Flexi DNA polymerase (1 U) 
36.75 µLddH20  
PCR products were analysed by agarose gel electrophoresis, as described in section 4.2.1. 
Primer annealing temperatures varied between 52-56 °C, depending on the primer melting 
temperature. Extension times varied according to the length of the DNA to be amplified 
and the rate of DNA polymerase extension rate.  
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4.2.2 Site-directed mutagenesis 
Site-directed mutagenesis was performed by quick-change PCR, allowing the introduction 
of specific point mutations into plasmids. Complementary primers were designed such that 
they were between 30 and 40 nt long and the desired point mutation introduced in the 
center of the primer, flanked by nucleotides complementary to the target region of the 
plasmid. The PCR was performed using using KOD HotStart DNA polymerase or Q5® 
high fidelity DNA polymerase, as described in section 3.2.1, except 18 cycles were 
performed and 1 ng of template plasmid used. Following the PCR, the reaction was 
digested with 2 units of DpnI enzyme at 37 °C for 2-4 h. 4 µL of the Dpn-I treated PCR 
products were then used to transform JM109 bacteria, as described in section 4.1.5. 
4.2.3 Agarose gel electrophoresis and gel extraction 
PCR, or restriction digest DNA fragments were separated in agarose gels consisting of 1-
2% (w/v) agarose and 0.04 µg/mL ethidium bromide in 1X TAE buffer. The gel was 
submerged in 1X TAE buffer and samples with 1X loading dye (Promega) loaded, along 
with a 1kb DNA ladder (Promega). Electrophoresis was performed at 100V for at least 20 
min, until the desired separation of DNA fragments was achieved. DNA was visualized 
under a UV transilluminator. If the fragments were required for purification, gel extraction 
from the gel matrix was carried out using the NucleoSpin® Gel and PCR Clean-up kit 
(Macherey-Nagel), or the Wizard® SV Gel and PCR Clea-up System (Promega), according 
to the manufacturer’s instructions. 
4.2.4 Restriction-free cloning 
Insertion of desired gene targets into vectors was carried out using restriction-free cloning. 
Vectors were linearized using restriction enzymes, or by excision PCR, using excision 
primers designed such that their 5’ end would anneal to the 3’ boundary of the region to be 
excised, in order to generate blunt-ended products of the vector. Primers for the desired 
insert were designed such that their 5’ end contained 15 bases homologous to each end of 
the linearised vector. Their 3’ end was designed to be of 15-25 nucleotides in length and 
homologous to the target sequence that was going to be cloned into the vector. In this way, 
the target insert contains 15 nt overhangs at each end, which are complementary to the 
blunt-ended vector. Digests or amplified products were gel-purified as described above, 
and used for an In-Fusion cloning reaction using the In-Fusion® HD Cloning Plus kit 
(Clontech). Briefly, a reaction was set up containing 100 ng of insert with 15 nt overhangs, 
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100 ng of linearised vector, 2 µL 5X In-Fusion HD enzyme premix, and the volume 
adjusted to 10 µL with ddH2O. The reaction was incubated for 15 min at 50 °C and placed 
on ice. 5 µL of the reaction were used to transform 100 µL competent JM109 as described 
below. 
4.2.5 Bacterial transformation and plasmid isolation 
 (i) Bacterial transformation 
The E. coli strain JM109 were made chemically competent using the Z-competent E. coli 
Transformation kit and Buffer set (Zymo Research). 100 µL competent JM109 were 
thawed on ice and transformed with 2-10 µL plasmid DNA (1-50 ng) by incubating the 
cells with DNA for 5 min on ice. Cells were then spread on LB agar plates with ampicillin  
(100 µg/ml), and incubated at room temperature for 48 h, or at 37 °C overnight. 
(ii) Small scale, single colony bacterial culture plasmid preparation 
Single colonies of transformed E. coli were picked using a P200 pipette tip and incubated 
by shaking at 180 revolutions per minute (rpm) in 5 mL LB broth containing ampicillin  
(100 µg/ml). The culture was incubated at room temperature for 48 h, or at 37 °C 
overnight. Plasmid DNA was isolated using the Qiagen QIAprep Spin Miniprep Kit 
(Qiagen), according to the manufacturer’s instructions. To confirm whether cloning was 
successful, isolated plasmids were screened using restriction enzyme digestion (section 
3.2.6) and the DNA fragments analysed by agarose gel electrophoresis (section 3.2.3). If 
the digested plasmid DNA products were correct, the small-scale plasmid preparation was 
sent for Sanger sequencing (Source BioScience) before preparation of large-scale bacterial 
cultures. 
(iii) Large scale bacterial culture plasmid preparation 
Large-scale bacterial cultures were generated by inoculating 100 mL LB containing 
ampicillin (100 µg/ml) with 100 µL of a small-scale bacterial culture, and grown at room 
temperature for 48 h or at 37 °C overnight in a shaking incubator (180 rpm). Plasmid DNA 
isolation was carried out using the NucleoBond Xtra midiprep kit (Macherey-Nagel), 
following the manufacturer’s instructions. 
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(iv) Quantification of DNA  
Quality and quantity of isolated DNA was analysed using the NanoDrop-2000 
spectrophotometer (Thermo Fisher Scientific). 
4.2.6 Restriction enzyme digestion 
Endonuclease restriction digests were performed in order to linearise vectors for cloning, 
or to corroborate cloning results.  The reaction was made up to a final volume of 50 µL 
with nuclease-free water, 1X appropriate restriction enzyme buffer, 2 units of restriction 
enzyme, and 0.5-2 µg DNA. The reaction was incubated at 37 °C for 1-4 h, and subjected 
to agarose gel electrophoresis and gel extraction before use (if needed). 
4.2.7 Total cellular RNA extraction  
Total cellular RNA was extraction from infected or transfected cells was carried out by 
washing the cell monolayer in 6-well plates with PBS. This was followed by the addition 
of 1000 µL TriZol reagent (Thermo Fisher Scientific) and incubation for 5 min at room 
temperature. Next, the TriZol reagent was placed in 2 mL screw-cap micro tubes and 240 
µL chloroform added to the samples. The tube was inverted 10 times before centrifugation 
at 12,000 rpm for 20 min at 4 °C. The aqueous phase was removed, transferred to a fresh 
tube containing 500 µL isopropanol, mixed and incubated at room temperature for 5 min. 
The samples were centrifuged at 12,000 rpm for 10 min at 4 °C, the supernatant removed, 
and the pellet washed with 500 µL ice-cold 75% (v/v) ethanol. The ethanol-soaked pellets 
were then centrifuged at 12,000 rpm for 10 min at 4 °C, the supernatant removed, and the 
pellet left to air-dry prior to resuspension in 30-50 µL nuclease-free water. The quality and 
quantity of isolated RNA was analysed using the NanoDrop-2000 spectrophotometer 
(Thermo Fisher Scientific). 
4.2.8 cDNA synthesis  
Reverse-trancription (RT) was used for the generation of cDNA, which was used for real-
time qPCR analysis, or for sequencing of the HRTV genome and confirming sequences of 
recombinant UUKV.  
PrimeScript RT reagent kit with gDNA eraser (Takara) was used for generation of cDNA 
to perform gene expression analysis through real-time qPCR. Briefly, 1 µg of extracted 
RNA was mixed with 2 µL 5X gDNA eraser buffer and 1 µL gDNA eraser, and the 
volume adjusted to 10 µL with nuclease-free H2O before incubation at 42 °C for 2 min. 
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The reaction was mixed with 10 µL of a prepared mastermix, which contained 4 µL 5X 
PrimeScript Buffer 2, 1 µL  PrimeScript RT Enzyme mix I, 4 µL RT primer mix 
(containing Oligod(T) primer and random 6-mers), and 1 µL nuclease-free H2O. The 20 µL 
reaction was incubated at 37 °C for 15 min, followed by 85 °C for 5 sec, and stored at -20 
°C for future use in RT-qPCR. 
For the preparation of UUKV and HRTV cDNA for full-genome sequencing, the GoScript 
reverse transcription kit (Promega) was used. Briefly, 1 or 2 µg extracted RNA and 1 µL of 
the appropriate gene-specific primer (1 µM) were diluted to a total volume of 5 µL in 
nuclease-free water, and heated at 70 °C for 5 min. The reaction was immediately chilled 
on ice for at least 5 min, before adding 15 µL of a RT reaction mix (4 µL GoScript 5X 
reaction buffer, 3 µL MgCl2 [25 mM], 1µL PCR nucleotide mix [10 mM each dNTP], 20 
units RNasin, 1µL GoScript reverse transcriptase, made up to 15 µL with nuclease-free 
H2O). The 20 µL reaction was annealed at 25 °C for 5 min, extended at 42 °C for 60 min, 
and inactivated at 70 °C for 15 min. The cDNA was stored at -20°C for amplification by 
PCR as described in section 3.2.1. All incubations were performed in a thermocycler. 
4.2.9 Rapid amplification of complementary DNA ends (RACE) 
3’ Rapid Amplification of cDNA Ends (RACE) analysis on total cellular RNA of virus-
infected cells allowed the determination of 5’ and 3’ terminal viral S, M, and L sequences 
using sequence-specific primers, as described elsewhere (Tilston-Lunel et al., 2015). 
Briefly, DNase-treated extracted RNA was polyadenylated a Poly(A) Tailing Kit (Ambion) 
at 37 °C for 1 h, following the manufacturer’s instructions. The reaction was purified using 
an RNeasy kit (QIAGEN), and 12 µL of the polyadenylated RNA used for RT using an 
oligo-d(T) primer (Primer sequence found in Table 10-1, Appendices) and GoScript 
reverse transcriptase, as described in section 3.2.8. 2 µL of the cDNA reaction were then 
used for PCR using a 5’ gene-specific primer to amplify genomic or antigenomic S, M or L 
segment terminal sequences, and a 3’ PCR anchor primer (Roche) (Primer sequences 
found in Table 10-1, Appendices). The resulting PCR fragments were analysed through 
agarose gel electrophoresis, gel extracted, and subjected to Sanger sequencing. 
4.2.10 Real-time qPCR 
Real-time quantitative PCR (RT-qPCR) was used for gene expression analysis, to measure 
the mRNA levels of various genes in HEK293T cells in response to different stimuli. 
Following RT, the cDNA was diluted 1: 10 (v/v) in nuclease-free water, and 2 µL of the 
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diluted cDNA were used to set up a 20 µL RT-qPCR reaction. The remaining 18 µL 
were made as a mastermix which contained 0.4 µL forward primer (10 µM), 0.4 µL reverse 
primer (10 µM), 0.4 µL 50X ROX reference dye, 10 µL SYBR Premix Ex Taq II, and 6 µL 
nuclease-free H2O. These reagents were provided in the  SYBR® Premix Ex TaqTM II Mix 
(Takara). The RT-qPCR reactions were carried out in triplicate in a ABI StepOnePlus 
(Applied Biosystems) RT-PCR machine, using the following cycling conditions: 
Initial denaturation  95 °C 30 sec  
Denaturation 95 °C  5 sec 
Annealing and extension 60 °C  30 sec 40 cycles 
Melt curve 95 °C  15 sec 
 60 °C  1 min 
 95 °C  15 sec 0.1°C increase per second 
The relative expression of mRNA was calculated using a double delta Ct analysis, whereby 
the cycle threshold (Ct) of a target gene (CtX) is compared to a reference, housekeeping 
gene that has constitutive expression. In this project, GAPDH was used as the reference 
gene. The following steps were followed to calculate relative mRNA expression: 
The double ΔΔCt was calculated as: ΔΔCt = !"!,!"#$%"&  − !"!"#$%,!"#$%"& − !"!,!"#$%&  − !"!"#$%,!"#$%&  
, where  
 CtX,Control=Ct value of gene of interest in untreated, control sample 
 Ct GAPDH,Control= Ct value of GAPDH in untreated, control sample 
CtX,Sample =Ct value of gene of interest in experimental sample 
CtGAPDH,Sample= Ct value of reference gene GAPDH in experimental sample 
Assuming that the amount of PCR product for each sample and each primer is inversely 
proportional to 2Ct, then the ratio of the target gene to GAPDH is calculated as: 
Ratio = 2(!"!,!"#$%"& !!"!"#$%,!"#$%"&)2(!"!,!"#$%& !!"!"#$%,!"!"#$)  
Or  Ratio = 2!!!" 
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4.3 Protein analysis 
4.1.1 Luciferase assays 
Luciferase assays were carried out using the Dual-Luciferase Reporter system (Promega) 
following the manufacturer’s instructions. Renilla and firefly luciferase were measured 
using a GloMax 20/20 single tube luminometer (Promega), with a 10 second integration 
time for each reading.  
4.1.2 Western blot analysis 
(i) Preparation of cell lysates 
Cell monolayers in 12-well or 6-well plates were lysed in 150 or 300 µL protein disruption 
buffer (PDB), respectively, and collected in 2 mL screw-cap tubes.  The samples were 
boiled at 100 °C for 10 min and stored at -20 °C until use.  
(ii) Polyacrylamide gel electrophoresis (PAGE) 
20 to 30 µL of the cell lysates were loaded on to precast NuPAGE Novex 4-12% Bis-Tris 
gels for PAGE under denaturing conditions, or on 10% native PAGE gels for PAGE under 
native conditions. Gel electrophoresis for the separation of protein was achieved by using 
using 1X MES SDS running buffer for denaturing conditions, or native gel running buffer 
for native conditions, at 180 V for 50-60 min.  
(iii) Protein transfer 
Proteins were transferred using a semi-dry method on to a nitrocellulose membrane (0.45 
µm pore size, Amersham) with a Trans-Blot Turbo Blotting system (BioRad). All 
components of the transfer were soaked in 1X NuPage transfer buffer, and the transfer 
performed at a constant voltage of 10V for 50 min.  
(iv) Detection 
Following transfer, the membrane was blocked for 1h at room temperature in western 
blotting standard blocking buffer, or blocking buffer for phosphorylated proteins. Primary 
antibodies were diluted in blocking buffer and incubated with the membrane at either room 
temperature for 1 h or at 4 °C overnight in constant rotation in 50 mL falcon tubes. The 
overnight incubation step was especially important for the following antibodies: UUKV N, 
UUKV NSs, anti-IRF-3, anti-IRF-3 Ser386, anti-STAT 1, anti-STAT 2, anti-STAT 3, anti-
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STAT 1 Tyr701P, anti-STAT 1 Ser727P, anti-STAT 2 Tyr690P (Table 3-3). After 
washing, the membrane was washed at least three times with western blotting washing 
buffer, and incubated with the relevant secondary antibody diluted in blocking buffer for 1 
h at room temperature.  
Following incubation with the secondary antibody, the membrane was washed three times 
in washing buffer and placed on a plastic film. Proteins were detected using ClarityTM ECL 
western blotting substrate (BioRad) and visualised in a ChemiDoc MP Imaging system 
(BioRad). 
4.1.3 Co-immunoprecipitation 
 Co-immunoprecipitation (Co-IP) was carried out either on transfected or infected cell 
monolayers. For transfections, 4 x105 HEK293T cells were seeded in 6-well plates and 
transfected with 1 µg pCMVXNSs-V5 (where X refers to UUKV, HRTV or SFTSV), or 
mock-transfected. In some cases, the plasmids were transfected along with with 1 µg 
pCMVRIG-I-N-FLAG, pCMVMAVS-FLAG, pCMVTBK-1-FLAG, pCMVIKKε-FLAG, 
or pCMVIRF-3(5D). For Co-IP of NSs proteins in virus-infected cells, HEK293T or A549 
cells were infected with UUKV or HRTV at an MOI of 20 or 10 FFU/cell, respectively. At 
the indicated time point, cells were lysed in RIPA lysis buffer or UUKV NSs IP lysis buffer 
(specifically for UUKV NSs IP), and incubated by rotation at 4°C for 30 min. For the IP of 
HRTV NSs, cells were lysed on ice for 30 min, the cell lysates transferred to a tube and 
removed from containment level 3 conditions, before incubation by rotation for another 30 
min at 4°C. The cell lysates were clarified by centrifugation at 12,000 rpm for 20 min at 
4°C, and transferred to a fresh tube. Note at this stage the whole cell lysate (WCL) fraction 
was also taken. 
For co-IP of FLAG-tagged proteins, anti-FLAG M2 magnetic beads (Sigma) were used. For 
co-IP of UUKV or HRTV NSs proteins, clarified cell lysates were incubated overnight at 
4°C with rabbit polyclonal anti- UUKV or HRTV NSs antibodies, followed by the addition 
of Protein A magnetic Dynabeads® (Thermofisher). For co-IP of V5-tagged proteins, 
clarified cell lysates were incubated overnight at 4°C with mouse anti-V5 antibody, 
followed by the addition of Protein G magnetic Dynabeads® (Thermofisher). All beads 
were used according to the manufacturer’s instructions. Following incubation of the cell 
lysates with the beads for 1.5 h at 4°C, the beads were washed five times with RIPA lysis 
buffer (or UUKV NSs IP lysis bufer) without detergent, and two times with PBS before 
elution of antibody complexes. Elution of proteins was carried out by the addition of 
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reducing protein disruption buffer and boiling at 95°C for 10 min. Eluates were analysed 
by western blotting analysis as described in section 4.1.2. 
4.4 Statistical analysis 
 All data were analysed using Prism 5 software (GraphPad) and presented as mean ± 
standard deviation (SD) or standard error of the mean (SEM). Statistical significance for the 
comparison of means between groups was determined by one-way analysis of variance 
(ANOVA), followed by post-hoc tests. p-values ≤ 0.05 were considered significant (****, p 
≤ 0.0001; ***, p ≤ 0.001; **, p ≤ 0.01; *, p ≤ 0.05).  
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5 Establishment of a reverse genetics system for 
Uukuniemi virus 
5.1 Introduction 
Reverse genetics is an approach used for studying the effect of targeted gene modifications 
on phenotype. Reverse genetics tools in virus research range from minigenome systems to 
virus-like particles (VLPs) and virus rescue systems. While minigenome systems and 
VLPs allow studying specific aspects of a virus’ life cycle, virus rescue systems enable the 
investigation of the life cycle in its entirety. Minigenome systems consist of an analogue of 
the virus genome, in which the open reading frame (ORF) of a virus segment is replaced 
by a reporter gene. Supplementing the genome analogue with trans-acting viral 
nucleocapsid (N) and RNA-dependent RNA polymerase (L) proteins results in reporter 
gene activity, which can be measured to investigate the promoter strength of untranslated 
regions (UTRs), functionality of viral UTRs and N and L proteins, or the effect that other 
viral or cellular factors may have on minigenome activity. Therefore, minigenome systems 
allow modelling and simulating virus transcription and replication processes. So far, 
minigenome systems have been established for a number of bunyaviruses, such as BUNV 
(Kuismanen et al., 1984; 1982; Murphy et al., 1973), SBV (Elliott and Blakqori, 2012), 
OROV (Acrani et al., 2015), LACV (Blakqori et al., 2003), RVFV (Ikegami et al., 2005a), 
SFTSV (Brennan et al., 2015), and CCHFV (Devignot et al., 2015).  
Supplementing a minigenome system with viral glycoproteins allows the generation of 
transcription and replication-competent virus-like particles (VLPs), which have a lipid 
envelope embedded with the viral glycoproteins. VLPs can package the reporter 
minigenome and infect target cells to deliver ribonucleoprotein complexes (RNPs), which 
are able to undergo replication and transcription. In addition to enabling the study of 
transcription and replication, utilizing VLPs allows to investigate packaging and budding 
processes, as well as virus morphogenesis.    
Uukuniemi virus (UUKV) is a tick-borne phlebovirus originally isolated in 1964 in 
Finland (Oker-Blom et al., 1964). While antibodies to UUKV (or UUKV-like viruses) 
have been isolated in humans and other vertebrates such as birds, rodents and cows, there 
is no evidence of disease in these species (Hubálek and Rudolf, 2012; Saikku and 
Brummer-Korvenkontio, 1973). Therefore, it serves as a safe laboratory model to study 
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tick-borne phleboviruses. Indeed, UUKV has served as a prototype virus of the 
Bunyaviridae family for many years, contributing to advances in bunyavirus structure and 
architectural studies (Freiberg et al., 2008; Overby et al., 2008), glycoprotein studies 
(Overby et al., 2007) and bunyavirus entry into mammalian cells (Lozach et al., 2010) 
(Mazelier et al., 2016). 
For UUKV, an M segment-based minigenome system utilising chloramphenicol 
acetyltransferase (CAT) or GFP as reporter genes has already been reported (R. Flick and 
Pettersson, 2001). Moreover, the authors reported the generation of VLPs containing the 
reporter minigenomes following superinfection with UUKV. UUKV VLPs generated using 
a glycoprotein precursor expression plasmid instead of superinfection has also been 
reported (Överby et al., 2006). However, these systems rely on constructs driven by RNA 
polymerase I (Pol I), which is disadvantageous because while Pol I localises to the nucleus, 
bunyaviruses replicate exclusively in the cytoplasm (Plyusnin and Elliott, 2011). In fact, 
most bunyavirus reverse genetics systems have been developed using a bacteriophage T7 
RNA polymerase (RNAP) (Brennan et al., 2015; Tilston-Lunel et al., 2016) (Bergeron et 
al., 2015; Elliott et al., 2013; Lowen et al., 2004; Varela et al., 2013), which localises to 
the cytoplasm (Elroy-Stein and B. Moss, 1990). 
Finally, even though UUKV Pol I-driven minigenome and VLP systems have been 
developed, no virus rescue entirely from cDNA has been described. The availability of a 
rescue system allows the generation of recombinant infectious virus from cDNA clones, 
enabling the genetic engineering of the viral genome.  In this way, the effect of genetic 
changes on the viral life cycle in its entirety can be explored. There is a need to develop a 
reverse genetics system for UUKV for the ultimate manipulation of the UUKV genome. 
Such a system would facilitate the use of UUKV as a safe comparative model to 
understand the molecular basis for virulence and pathogenicity of highly pathogenic tick-
borne phleboviruses, such as Heartland virus  (HRTV) and Severe Fever with 
Thrombocytopenia Syndrome virus (SFTSV). 
5.2 Aims 
The primary aim of the studies described in this chapter was to establish a T7 RNAP-
driven reverse genetics system for UUKV. This included the development of a UUKV 
minigenome system for all segments using luciferase reporter genes, the generation of 
virus-like particles, and finally the recovery of UUKV entirely from cDNA clones. 
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Secondly, I aimed to manipulate the UUKV genome to generate recombinant viruses 
lacking the NSs protein, which could be used in the future to gain an understanding of the 
function that UUKV NSs may play in the virus life cycle. Finally, I aimed to generate a 
recombinant UUKV encoding eGFP in the NSs locus, such that it could be used as a quick 
tool to investigate permissibility of various mammalian cell lines to UUKV infection. 
5.3 Results 
5.3.1 Cloning of cDNA plasmids used for the rescue of UUKV  
cDNA plasmids used for virus rescue (henceforth referred to as ‘rescue plasmids’) were 
designed as it has been previously described for other bunyaviruses (Brennan et al., 2015; 
Bridgen and Elliott, 1996; Lowen et al., 2004). cDNA copies of the UUKV genome 
segments were amplified from Pol I-driven plasmids (provided by Dr Anna Överby, Umeå 
University, Sweden), which encode the full-length antigenome cDNA copies of the S, M 
and L UUKV RNA segments (pRF202, pRF7 and pRF280, respectively, unpublished).  
Using restriction-free cloning, the amplified cDNAs were inserted into a pTVT7 plasmid 
(0,0) (Johnson et al., 2000) which contains an extra G residue at the 5’ end of the 
antigenome cDNA copy (Billecocq et al., 2008). Inclusion of one or two non-viral G 
nucleotide residues at the 5’ end of the transcripts have been reported to enhance T7 RNAP 
transcription efficiency (Pattnaik et al., 1992).  
Thus, in the pTVT7 vector the RNA transcript produced by the T7 RNAP is in the 
antigenome sense, as illustrated in Figure 5-1. In addition, the antigenomic 3’ UTR is 
directly followed by a Hepatitis δ ribozyme (Hδr) and a T7 terminator sequence. While the 
T7 terminator sequence allows termination of transcription by the T7 RNAP, the Hδr 
enables self-cleavage of the antigenomic transcript to generate the exact end of the 3’ 
UTR. The rescue plasmids were sequenced and named pT7UUKS(+), pT7UUKM(+) and 
pT7UUKL(+) (encoding cDNA copies of the UUKV antigenomic S, M and L segments, 
respectively). The nucleotide sequences of the rescue plasmids are based on the sequences 
available on GenBank with the accession numbers: M33551.1 for UUKV S, M17417.1 for 
UUKV M and D10759.1 for UUKV L. Importantly, the UUKV strain used in this study 
(wtUUKV) was sequenced by the late Prof Richard Elliott (personal communication) and 
corresponds to the database sequences noted above. Finally, a silent point mutation was 
introduced as a genetic marker in pT7UUKS(+) at the nucleotide position 963 (A"G), 
which generates a XhoI restriction site in the S segment antigenomic cDNA (Figure 5-1). 
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Figure 5-1. Schematic representation of UUKV rescue plasmids.  
Full-length cDNA copies of the antigenomic UUKV S, M and L RNA segments were cloned into 
the pTVT7 plasmid (0,0) with an extra G residue at the 5’ end of the cDNA (in bold). Rescue 
plasmids were named pT7UUKS(+), pT7UUKM(+) and pT7UUKL(+). The A"G point mutation 
introduced at nucleotide position 963 in pT7UUKS(+) for the generation of an XhoI restriction site 
as a genetic marker is shown. UUKV: Uukuniemi virus; UTR: Untranslated region; ORF: Open 
reading frame. 
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5.3.2 Establishment of a UUKV minigenome system 
Minigenome systems and the generation of VLPs should be considered as the first step 
before attempting virus rescue, to ensure the accuracy and functionality of UTR sequences, 
viral N and L proteins in minigenome assays, and viral glycoproteins in VLP assays. 
Firstly, the transcription plasmids for the establishment of UUKV M and L segment-based 
minigenome systems were designed. The Renilla luciferase open reading frame (ORF) was 
used as a reporter gene in the negative sense orientation and was designed to be flanked by 
the genomic sense viral 3’ and 5’ UTRs in the pTVT7 plasmid (0,0) (Johnson et al., 2000). 
The cloning strategy carried out for the generation of minigenome plasmids is illustrated in 
Figure 5-2. Briefly, the viral ORFs in the rescue plasmids pT7UUKM(+) and 
pT7UUKL(+) was replaced with the humanised Renilla luciferase ORF (henceforth 
referred to as Renilla luciferase), such that Renilla luciferase was flanked by the 
antigenomic sense viral UTRs (Figure 5-2 A, first step). Next, the cassette containing 
luciferase flanked by the antigenomic viral UTRs was amplified and inverted in pTVT7  
(0,0) to enable the generation of genomic sense transcripts by the T7 RNAP (Weber et al., 
2001) (Figure 5-2 A, second step). In the case of the S segment minigenome system, the 
NSs ORF in pT7UUKS(+) was replaced by the Renilla luciferase ORF in the same 
(negative-sense) orientation (Figure 5-2 B). The correct sequence of the plasmids was 
confirmed by Sanger sequencing, and the UUKV S, M and L segment-based minigenome 
plasmids were named pT7UUKSRen(+), pT7UUKMRen(-) and pT7UUKLRen(-), 
respectively.  
Helper plasmids expressing UUKV N and L were generated by amplifying the UUKV N 
and L ORFs from pT7UUKS(+) and pT7UUKL(+), respectively, and sub-cloning  the 
ORFs into the expression vector pTM1 (Moss et al., 1990). The plasmids were sequenced 
and named pTM1UUKN and pTM1UUKL. pTM1 contains a T7 promoter and the 
encephalomyocarditis virus (EMCV) internal ribosome entry site (IRES), allowing efficient 
translation of proteins encoded in the transcripts generated by the T7 RNAP.  
Minigenome assays were performed in BSR-T7/5 cells, which are a clone derived from the 
BHK-21 cell line and constitutively express a T7 RNAP (Buchholz et al., 1999). Briefly, 
sub-confluent BSR-T7/5 cells were co-transfected with constant amounts of 
pT7UUKSRen(+), pT7UUKMRen(-) or pT7UUKLRen(-), pTM1UUKN, a plasmid 
expressing firefly luciferase (pTM1FFluc) as an internal control for transfection efficiency, 
and increasing amounts (0-375 ng) of pTM1UUKL. The total amount of plasmid DNA in 
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all reactions was kept constant by the addition of empty control plasmid pTM1 to the DNA 
mix. Cells were lysed 18 h post transfection, and Renilla and firefly luciferase activity 
measured. Experiments were performed in triplicate wells in three independent 
experiments. Renilla values were normalised to firefly values and minigenome activity 
expressed as fold increase of normalised luciferase units relative to the background control 
(absence of L protein). 
An increase in minigenome activity when the helper plasmid encoding the UUKV L 
protein was supplemented (compared to the background control) confirmed the 
functionality of the S, M and L segment-based minigenome assays (Figure 5-3). 
Interestingly, the highest increase in luciferase activity of the S and L segment-based 
minigenomes was observed when 125 ng of pTM1UUKL was supplemented, and 
increasing amounts of UUKV L-expressing plasmid resulted in a drop in minigenome 
activity (Figure 5-3 A and C). Relative to the background control, a peak 27-fold increase 
in activity was observed for the S segment-based minigenome, compared to a peak 22.5-
fold increase for the M segment-based minigenome (Figure 5-3 B), and a peak 14.6-fold 
increase for the L segment-based minigenome. Although this data would suggest that the S 
segment-based minigenome is the most active, it is important to note that this minigenome 
was constructed in the antigenomic sense, whereas the M and L segment-based 
minigenome constructs are in the genomic sense. Thus, the relative promoter strengths are 
not comparable. 
Taken together, these results show that the viral UTRs used in this study act as functional 
promoters and that the cDNA copies of the UUKV N and L proteins used in this study are 
also functional, leading to the activity of the reporter Renilla from the genome analogues. 
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Figure 5-2. Schematic representation of the construction of UUKV minigenome plasmids.  
(A) First step: Generation of an antigenomic intermediate plasmid. Primers were designed to bind 
the 3’ and 5’ UTR of pT7UUKM(+) and pT7UUKL(+), such that the viral ORF was excised, 
leaving the UTRs intact. The Renilla ORF was amplified from a Renilla encoding plasmid, using 
primers containing 15 nt overhangs complementary to the corresponding viral UTR. Second step: 
the Renilla ORF was cloned into the linearised UTR-containing pTVT7 vector using restriction-free 
cloning. The minigenome cassette was flipped to the viral genomic sense by amplification using 
primers containing 15 nt overhangs homologous to the T7 promoter (3’ end) and T7 terminator (5’ 
end). The amplified product was inserted into pTVT7 (0,0) with an extra G residue at the 5’ end of 
the cDNA (in bold) by restriction-free cloning. (B) Schematic representation of pT7UUKSRen(+). 
The NSs ORF of the S segment in pT7UUKS(+) was replaced by  the Renilla ORF. UTR: 
Untranslated region; ORF: Open reading frame.  
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Figure 5-3. UUKV minigenome assay.   
BSR-T7/5 cells were transfected with constant amounts of (A) pT7UUKSRen(+),  (B) 
pT7UUKMRen(-) or (C) pT7UUKLRen(-), pTM1UUKN, pTMFFluc, and the indicated amounts 
of pTMUUKL. The total amount of plasmid DNA in all reactions was kept constant by addition of 
empty control plasmid pTM1 to the DNA mix. Cells were lysed 18 h post transfection and the 
Renilla and firefly luciferase units measured. Minigenome activity is expressed as the fold increase 
of normalised luciferase units relative to the background control (no L). Error bars represent the 
standard deviation (SD) from the mean of one representative experiment of three, performed in 
triplicate (n=3). UUKV: Uukuniemi virus; RLU: Relative light units. 
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5.3.3 Generation of UUKV virus-like particles 
In order to determine whether the UUKV glycoprotein precursor gene was functional, a 
VLP assay was developed. Because many other bunyavirus VLP assays utilize an M 
segment-based minigenome (Acrani et al., 2015; Habjan et al., 2009a; Shi et al., 2006; 
Soldan et al., 2010), pT7UUKMRen(-)  was chosen as the reporter construct to be 
packaged by the VLPs. A plasmid expressing the UUKV glycoprotein precursor, named 
pTM1UUKGnGc, was generated by the amplification of UUKV M segment ORF from 
pT7UUKM(+), and sub-cloning the amplified ORF into the expression vector pTM1 
(Moss et al., 1990). For the generation of VLPs, BSR-T7/5 cells were transfected with 
pTM1UUKGnGc in combination with the plasmids transfected in the UUKV M segment-
based minigenome assay (Section 5.3.2). The transfected cells (donor cells) were lysed 48h 
post transfection and luciferase activities measured. Renilla values were normalised to 
firefly values and activity expressed as the fold increase in normalised luciferase units 
relative to the background control (absence of L protein). 
A mean 317-fold increase in minigenome activity was observed in control donor cells that 
were not supplemented with glycoprotein expressing plasmid. Minigenome activity was 
enhanced in cells which were supplemented with 125 ng pTM1UUKGnGc (mean 757-fold 
increase), presumably due to the generation and spread of VLPs within the donor cells, but 
not when supplemented with 250 ng pTM1UUKGnGc (Figure 5-4 A). This suggests that 
the UUKV glycoprotein precursor could have an inhibitory effect on minigenome activity, 
or that a fine balance of protein amounts is required for efficient VLP production.  
The supernatant was endonuclease-treated to remove contaminant DNA and used to infect 
naïve BSR-T7/5 cells, or BSR-T7/5 cells which were pre-transfected with pTM1UUKN 
and pTM1UUKL, in order to boost and supplement transcription of the incoming RNPs. 
These cells, which are infected with VLPs, are referred to as ‘recipient’ cells. Infected 
recipient cells were lysed at 24 h post infection (p.i.) and the Renilla and firefly luciferase 
activities measured. Renilla values normalised to firefly values and minigenome activity 
expressed as the fold increase in normalised luciferase units relative to the background 
control (recipient cells infected with VLPs generated in donor cells that were not 
supplemented with pTM1UUKL). 
As expected, no minigenome activity was detected in recipient cells infected with VLPs 
generated in donor cells that were not supplemented with the viral glycoprotein-expressing 
plasmid. 
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However, a mean 300-fold increase in minigenome activity was detected in recipient cells 
infected with supernatants from donor cells that were co-transfected with 125 ng 
pTM1GnGc, and a mean 135-fold increase detected in recipient cells infected with 
supernatants from donor cells that were co-transfected with 250 ng pTM1GnGc (Figure 5-
4 B). The lower minigenome activity observed in recipient cells that were infected with 
VLPs generated in donor cells transfected with higher amounts of pTM1GnGc is in 
agreement with the effect of pTM1GnGc on minigenome activity noted in donor cells 
(Figure 5-4 A). In addition, an overall increase in minigenome activity was observed when 
recipient cells were pre-transfected with pTM1UUKN and pTM1UUKL, with a mean 
19700 and 337- fold increase in minigenome activity detected in recipient cells infected 
with VLPs generated by co-transfection of 125 ng or 250 ng pTM1GnGc, respectively 
(Figure 5-4 B).  
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 Figure 5-4. UUKV VLP production assay.  
BSR-T7/5 cells were transfected with constant amounts of pTMFFluc as a transfection efficiency 
control, pT7UUKMRen(-), pTMUUKN, and pTMUUKL. The minigenome transfection mix was 
supplemented with the indicated amounts of pTMUUKGnGc. 48 h post transfection, the clarified 
cell culture supernatant was used for infection of naïve BSR-T7/5 cells, and luciferase activity 
measured 18 h p.i. (A) Minigenome activity in donor cells transfected with VLP production assay 
plasmids and harvested 48 h post transfection. (B) Minigenome activity following infection with 
VLP supernatant in recipient BSR-T7/5 cells, which were left untransfected, or pre-transfected 
with pTM1UUKN and pTM1UUKL. Error bars represent the SD from the mean of one 
representative experiment of two performed in triplicate (n = 3). VLP: Virus-like particle; RLU: 
Relative light units.  
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5.3.4 Rescue of recombinant UUKV from cDNA 
The ability of the UUKV UTR sequences to be recognized for the transcription and 
replication of a genome analogue by viral N and L proteins (demonstrated by minigenome 
assays), and the ability of the viral glycoproteins to package the UUKV M segment 
genome analogue (demonstrated by the successful generation of VLPs) were important 
pre-requisites for the successful generation of recombinant UUKV from cDNA clones. 
Thus, since the minigenome and VLP assays were functional, pT7UUKS(+), 
pT7UUKM(+) and pT7UUKL(+) (described in section 5.3.1) were used to attempt the 
rescue of recombinant UUKV entirely from cDNA. Briefly, subconfluent BSR-T7/5 cells 
were transfected with pT7UUKS(+), pT7UUKM(+) and pT7UUKL(+) in a 3-plasmid 
rescue system, or supplemented with pTM1UUKN and pTM1UUKL in a 5-plasmid rescue 
system. The supernatant from transfected cells was harvested 7 days post transfection and 
the viral titre determined by focus-forming assays on BSR cells. In 4 independent 
experiments, the 3-plasmid rescue system yielded a mean virus titre of 4.9 x104 (±1.9 x104) 
FFU/mL, and the 5-plasmid rescue system yielded 2.9 x104 (±2.7 x104) FFU/mL. These 
results suggested that supplementing the 3-plasmid rescue system with UUKV N and L 
had no effect on the efficiency of virus rescue. Working stocks of the recombinant viruses 
were prepared in BSR cells with low MOI infections (0.01 FFU/mL), and titres of about 
108 FFU/mL were obtained. 
In terms of focus phenotype, recombinant UUKV (rUUKV) exhibited similar foci size and 
shape to wtUUKV in BSR and BHK-21 cells  (Figure 5-5 A). Interestingly, foci were 
larger in BHK-21 cells (5-6 mm in diameter) than in BSR cells (3-4 mm in diameter).  
In order to confirm whether rUUKV was indeed generated from cDNA clones, BSR cells 
were infected with either wtUUKV or rUUKV at a multiplicity of infection (MOI) of 3 
focus forming unit/cell (FFU/cell). 48h p.i. the total cellular RNA from infected cells was 
extracted and the full S segment RNA subjected to RT-PCR using sequence-specific 
primers. The generated S segment cDNA products were subjected to XhoI digestion. As 
expected, no digestion was observed in cDNA derived from wtUUKV S segment, whereas 
two products of the expected size (963 bp and 757 bp) were visualised upon XhoI 
digestion of rUUKV S segment cDNA (Figure 5-5 B). RT-PCR products of the S segment 
were also sequenced to confirm the silent mutation introduced at nt position 963 in 
rUUKV (described in Section 5.3.1) (Figure 5-5 C). 
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Figure 5-5. Rescue of rUUKV.  
(A) Focus phenotypes of wtUUKV and rUUKV on BSR or BHK-21 cells. Infected cells were fixed 
6 days p.i. and probed with an anti-UUKV N antibody. (B) Confirmation of the insertion of a silent 
genetic marker into the rUUKV genome. RT-PCR products of the full-length S segment of 
wtUUKV and rUUKV were subjected to XhoI digestion and the digested products visualised on an 
agarose gel. (C) Sequencing results for RT-PCR products of full-length S segments of wtUUKV 
and rUUKV, showing the silent mutation introduced at nt position 963 in rUUKV. UUKV: 
Uukuniemi virus.  
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5.3.5 Rescue of recombinant UUKV lacking the non-structural protein NSs 
The established reverse genetics system was also used to generate recombinant UUK 
viruses lacking the non-structural protein NSs, with the aim of investigating the role of 
UUKV NSs in the virus life cycle. Two strategies were employed to generate NSs-lacking 
UUK viruses, illustrated in Figure 5-6 A. Firstly, pT7UUKSdelNSs(+) was cloned by 
excision of the NSs ORF from pT7UUKS(+) in such way that the intergenic region is 
immediately followed by the genomic 5’UTR, resulting in the generation of a smaller S 
segment (898 nt compared to the 1720 nt long wild-type S segment). Secondly, the NSs 
ORF in pT7UUKS(+) was replaced by that of the enhanced GFP (eGFP) ORF in the same 
orientation, using restriction-free cloning. This resulted in an eGFP-expressing S segment 
1618 nt in length, named pT7UUKSdelNSsGFP(+).  
3-plasmid rescues were performed as described in Section 5.3.4, and the mean titre 
obtained from 4 independent experiments was 3.75 X 104 (±1.2 X 104) FFU/mL for 
rUUKdelNSs and 1 X 104 (±5.2 X 103) FFU/mL for rUUKdelNSsGFP. These titres are 
similar to those obtained for the rescue of wild-type UUKV (noted in Section 5.3.4). 
Working stocks of the recombinant viruses were prepared in BSR cells with low MOI 
infections (0.01 FFU/mL), and titres of about 107 FFU/mL obtained. 
In order to sequence the S segment of the recombinant viruses, BSR cells were infected at 
a high MOI (3 FFU/cell), the total cellular RNA extracted 24 h p.i. and subjected to RT-
PCR for amplification of the full length UUKV S segment. The cellular RNA of infected 
cells was also subjected to 3’ Rapid amplification of cDNA ends (RACE) to determine 3’ 
and 5’ UTR S segment termini. Sanger sequencing confirmed that the RACE and RT-PCR 
products were correct and matched the cDNA sequences used for the rescue of the 
recombinant viruses. The sizes of the S segment RT-PCR products are shown in Figure 5-6 
B. Finally, to validate that NSs was not being expressed at the protein level, BSR cells 
were mock-infected or infected with wtUUKV or the recombinant viruses at a high MOI (5 
FFU/cell) and lysed at 18h post p.i. for western blotting. As expected, while N and NSs 
were detected in BSR cells infected with wtUUKV or rUUKV, only N was detected in 
BSR cells infected with rUUKdelNSs or rUUKdelNSsGFP (Figure 5-6 C). 
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Figure 5-6. Generation of recombinant UUKV lacking NSs.  
(A) Schematic diagram of the S segment (genomic sense) of wtUUKV and recombinant UUKV 
lacking the NSs ORF. (B) RT-PCR products of full-length S segments belonging to rUUKV, 
rUUKdelNSsGFP and rUUKdelNSs, showing size differences corresponding to the S segments 
designed in panel A. (C) Western blot analysis of BSR cells infected at an MOI of 5 with 
wtUUKV, rUUKV, rUUKdelNSsGFP, rUUKdelNSs, or mock-infected. Cell lysates were prepared 
18 h p.i. and western blots probed with anti-tubulin, anti- UUKV NSs, and anti-UUKV N 
antibodies.  UUKV: Uukuniemi virus.  
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5.3.6 Replication of rUUKV, rUUKdelNSs and rUUKdelNSsGFP in cell culture 
The focus phenotype and replication properties of the recombinant viruses rUUKV, 
rUUKdelNSs and rUUdelNSsGFP were compared to wtUUKV. In terms of focus 
phenotype, focus-forming assays showed that viruses lacking NSs exhibited smaller foci 
(1-2 mm or 0.5-1.5 mm in diameter) compared to wtUUKV and rUUKV (5-6 mm or 3-4 
mm in diameter) in BHK-21 or BSR cells (respectively) (Figure 5-7 A). 
A time course of BHK-21 cells infected with rUUKdelNSsGFP at a low MOI (0.01 
FFU/cell) shows that at 24 h p.i., eGFP expression can be detected in only a few cells. The 
number of cells exhibiting eGFP expression increases over time as the virus spreads 
through the cell monolayer, with most cells infected within 4 days (Figure 5-7 B). 
The growth properties of the recombinant viruses and wtUUKV were compared in BHK-
21 cells, which were infected at a low MOI (0.1 FFU/cell) and maintained at 37°C. The 
supernatant was harvested at the indicated time points, and the virus titre determined by 
focus-forming assays in BSR cells. At the same time points, infected cell lysates were 
prepared for western blot analysis. As shown in Figure 5-8 A, rUUKV exhibited similar 
growth properties as wtUUKV, reaching titres of 109 FFU/mL by 96 h p.i. As a general 
trend, recombinant viruses lacking NSs exhibited slower growth kinetics compared to 
wtUUKV and rUUKV. Interestingly, rUUKdelNSsGFP reached higher titres (peak titre 
108 FFU/mL) than rUUKdelNSs (peak titre 107 FFU/mL), which had no sequences added 
in the NSs locus. These results demonstrate that while NSs is not essential for virus 
replication, the slower growth kinetics of UUKV lacking NSs suggests that NSs may play 
a contributory role that enables efficient virus replication. 
Analysis of viral protein expression in the time course by western blotting showed that the 
NSs protein was detected as early as 24 h p.i., and accumulated thereafter in wtUUKV and 
rUUKV-infected cells, whereas N protein was only detected at 48 h p.i (Figure 5-8 B). As 
expected, no NSs was detected in rUUKdelNSs- and rUUKdelNSsGFP- infected cells. 
However, N was detected earlier in rUUKdelNSsGFP-infected cells compared to 
rUUKdelNSs-infected cells, reflecting the difference observed in virus growth kinetics 
between these viruses (shown in Figure 5-8 A). Because of the ambisense nature of the 
Phlebovirus S segment, NSs protein expression is delayed relative to N protein expression. 
This is because NSs mRNA is generated only after replication of the genome to 
antigenome, whereas N mRNA is generated from the viral genome. In fact, using pulse-
chase analysis, Simons et al have estimated that UUKV N is synthesized within 4 h p.i. 
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and is stable for several hours, whereas the NSs protein is synthesized only at 8 h p.i. and 
has a half-life of approximately 1.5 h (Simons et al., 1992). It is important to note that 
while in the time course carried out in this study UUKV NSs was detected earlier than N 
by western blotting (Figure 5-8 B), this may simply relate to differences in antibody 
affinity to the respective antigen epitopes. 
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Figure 5-7. Phenotypic characterization of recombinant viruses in cell culture.  
(A) Focus assay for wtUUKV, rUUKV, rUUKdelNSs, or rUUKdelNSsGFP on BSR or BHK-21 
cells 6 days p.i. Foci were detected using an anti-UUKV N antibody. (B) Time course of infection 
in BHK-21 cells with rUUKdelNSsGFP at 37°C over 5 days to monitor eGFP fluorescence. Cells 
were infected at an MOI of 0.01 FFU/cell. UUKV: Uukuniemi virus. 
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Figure 5-8. Growth kinetics of recombinant viruses in BHK-21 cells.  
Cells were infected at an MOI 0.1 FFU/cell. The cell culture supernatant or cell lysates were 
harvested at the indicated time points. (A) Growth curves. Infections were carried out in duplicate 
and error bars represent the standard error of the means (SEM), for a representative experiment 
(n=2) of three. (B) Analysis of viral protein synthesis. Cell lysates from the growth curve samples 
were harvested and western blots probed with anti-tubulin, anti-UUKV NSs and anti UUKV-N 
antibodies, as indicated.  UUKV: Uukuniemi virus.  
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5.3.7 Permissibility of mammalian cell lines to UUKV infection 
With the aim of investigating whether rUUKdelNSsGFP could be used as a quick tool to 
monitor virus infection, mammalian cell lines available in our laboratory (A549, A549/V, 
HeLa, HEK-293T, Huh-7, Vero E6, BHK-21, BSR-T7/5) were infected with 
rUUKdelNSsGFP at an MOI of 0.005 FFU/cell and eGFP expression monitored at 24 h, 48 
h and 72 h p.i. using an EVOS FL imaging microscope. 
To examine whether visualizing eGFP expression upon rUUKdelNSsGFP could be used as 
a method to assess permissibility of various cell lines to UUKV infection, the results of 
this experiment were compared to a yield assay of wtUUKV in the same cell lines. Briefly, 
cells were infected with wtUUKV at a low and high MOI (0.005 or 3 FFU/mL, 
respectively). At 72 h p.i. cell culture supernatants were harvested and virus titres 
determined by focus-forming assays in BSR cells. 
From all the human-derived cell lines tested, Huh-7 cells were the most susceptible to 
rUUKdelNSsGFP infection, as eGFP signal increased over time and yielded the highest 
wtUUKV titres (mean titre 4.3 x 103 FFU/mL for low MOI infections and 1.3 x 106 
FFU/mL for high MOI infections) (Figure 5-9 and Figure 5-10). HEK-239T cells yielded 
slightly lower wtUUKV titres compared to Huh-7 cells (mean titre 4 x 104 FFU/mL for 
low MOI infections and 3 x 105 FFU/mL for high MOI infections), and visibly less eGFP 
expression was observed following rUUKdelNSsGFP infection compared to Huh-7 cells. 
No eGFP expression was observed in HeLa cells, and this is in agreement with the 
wtUUKV yield assay results, as only a mean titre of 1.3 x 102 FFU/mL for low MOI 
infections and 2.3 x 103 FFU/mL for high MOI infections was observed. It must be noted 
that these titres could be residual from the virus inoculum. A549/V cells are human lung 
epithelial cells expressing the V protein of parainfluenza virus 5 (PIV5) which targets 
STAT1 for degradation, rendering cells unable to respond to interferon (Andrejeva et al., 
2002; Killip et al., 2013). In comparison to the IFN-competent parental cell line A549, a 
15- and 5-fold increase in wtUUKV titre was observed in A549/V cells at a low and high 
MOI infection, respectively (Figure 5-10 A and B). These results are in agreement with 
lower eGFP expression levels in A549 cells compared to A549/V cells in Figure 5-9. 
Vero E6 cells are African green monkey kidney epithelial cells commonly used in cell 
culture for the propagation of viruses, as they are type I IFN-incompetent and can result in 
the production of high virus yields. However, despite lacking an active type I IFN system, 
wtUUKV was unable to reach high titres at either a low MOI infection (mean titre 4.3 x 
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103 FFU/mL) or a high MOI infection (mean titre 4.7 x 104 FFU/mL) in Vero E6 cells. 
eGFP expression was noted in Vero E6 cells infected with rUUKdelNSsGFP, suggesting 
the virus is able to infect and enter the cells. However the eGFP expression signal was not 
amplified later than 48 h p.i., indicating poor virus growth in this cell line. 
The rodent cell lines BHK-21 and BSR-T7/5 cells were the most susceptible to virus 
infection. eGFP expression in these rodent-derived cell lines quickly increased over time 
following rUUKdelNSsGFP infection (Figure 5-9). Consistent with the results observed 
using rUUKdelNSsGFP, the highest wtUUKV yields of all cell lines screened were 
observed in BHK-21 and BSR-T7/5 cells (Figure 5-10). In BHK-21 cells, a mean titre of 
5.6 x 106 FFU/mL for low MOI infections and 1 x 107 FFU/mL for high MOI infections 
was observed, whereas in BSR-T7/5 cells the mean titre for a low MOI infection was 4.3 x 
106 FFU/mL and a mean titre of 1.3 x 107 FFU/mL for a high MOI infection. It is 
necessary to note that both cell lines are IFN incompetent, and BSR-T7/5 cells are derived 
from BSR cells, which are a clone of BHK-21. Therefore, it is not surprising that both cell 
lines have similar susceptibilities to UUKV infection. Increased susceptibility to UUKV 
infection in BHK-21 and BSR-T7/5 cells compared to other mammalian cell lines is also 
not surprising, because the viruses were propagated and titered in BSR cells. The wtUUKV 
stock used has also been propagated in BHK-21 cells previously (Elliott et al., 1992). 
Therefore, it is possible that the virus has adapted to rodent cell lines.  
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Figure 5-9. eGFP expression in rUUKdelNSsGFP-infected cells.  
The indicated cell lines were infected with rUUKdelNSsGFP at an MOI 0.005 and eGFP 
expression monitored 24 h, 48 h and 72 h p.i. using an EVOS fluorescent microscope. Scale bars 
indicate 1000 µm. 
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 Figure 5-10. wtUUKV yield assay in selected mammalian cell lines. 
The indicated cell lines were infected with wtUUKV at an MOI 0.005 or 3 FFU/cell and cell 
culture medium harvested 72 h p.i. Viral titres were determined by focus forming assays in BSR 
cells. The data presented are from a representative experiment of three, performed in duplicate with 
single data points plotted and with horizontal lines representing the mean. 
  
A   
  
  
  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
M
oc
k
A
54
9
A
54
9/
V
H
eL
a
H
EK
-2
93
T
H
uh
-7
V
er
o
B
H
K
-2
1
B
SR
-T
7/
510
0
101
102
103
104
105
106
107
108
Ti
tre
 (L
og
10
 F
FU
/m
l)
UUKV yield assay MOI 0.005 FFU/cell
Human Monkey Rodent
M
oc
k
A
54
9
A
54
9/
V
H
eL
a
H
EK
-2
93
T
H
uh
-7
V
er
o
B
H
K
-2
1
B
SR
-T
7/
510
0
101
102
103
104
105
106
107
108
Ti
tre
 (L
og
10
 F
FU
/m
l)
UUKV yield assay MOI 3 FFU/cell
Human Monkey Rodent
Chapter 5: Establishment of a reverse genetics system for Uukuniemi virus  108 
5.3.8 Basic characterisation of rUUKV, rUUKdelNSs and rUUKdelNSsGFP in the 
chicken DF-1 fibroblast cell line. 
It was suggested migratory birds could play a role in the widespread distribution of tick-
borne viruses in Europe (Hubálek and Rudolf, 2012). Therefore the growth properties of 
UUKV in an avian cell line were investigated. The growth kinetics of rUUKV and the 
recombinant viruses lacking NSs (rUUKdelNSs and rUUKdelNSsGFP) were compared by 
performing a growth curve at a MOI 0.1 FFU/cell on DF-1 cells, an immortalized cell line 
derived from chicken embryos (Himly et al., 1998).  
Interestingly, while rUUKV was able to reach titres as high as 106 FFU/mL by 48 h p.i., no 
increase in virus titre was observed for rUUKdelNSs or rUUKdelNSsGFP throughout the 
time course (Figure 5-11 A). These results suggested that UUKV NSs plays an essential 
role in virus replication in the DF-1 cell line. Western blotting analysis revealed that while 
in rUUKV-infected DF-1 cells NSs and N protein were detected by 48 h p.i. and 72 h p.i., 
respectively, N protein levels were undetectable for rUUKdelNSs and rUUKdelNSsGFP 
(Figure 5-11 B). 
To confirm that the NSs-lacking recombinant viruses were able to enter and infect the 
cells, the availability of rUUKdelNSsGFP as a quick tool to monitor virus infection was 
exploited. Briefly, eGFP expression levels were monitored following rUUKdelNSsGFP 
infection at the MOI utilized for the DF-1 growth curve (MOI 0.1 FFU/cell). eGFP signal 
was detected following infection with rUUKdelNSsGFP at 12 and 24 h p.i. (Figure 5-12 
A). This finding indicated that viruses lacking NSs are able to enter the cells and their 
genomes could undergo replication, in order for transcription of the eGFP subgenomic 
mRNA derived from the viral antigenome to occur. Because a decrease in the eGFP signal 
was detected in time points later than 24 h p.i., DF-1 cells were infected with 
rUUKdelNSsGFP at a higher MOI (5 FFU/cell) and the cell monolayer visualized at the 
indicated time points to examine DF-1 cell morphology. At 6 and 12 h p.i., most cells 
infected with rUUKdelNSsGFP appeared healthy, resembling uninfected cells, and only 
some cells rounded up, detached and floated (Figure 5-12 B). Within 24 h, most infected 
cells rounded up, detached and floated, showing severe cytopathicity. The eGFP signal 
decreased after 24h, and almost completely disappeared by 72h p.i., suggesting no 
infection of new cells. At 48 and 72 h p.i., the cell monolayer showed severe cytopathicity 
compared to the mock control (Figure 5-12 B, right panels).  
  
Chapter 5: Establishment of a reverse genetics system for Uukuniemi virus  109 
 
 
Figure 5-11.  Growth properties of recombinant UUKV in DF-1 cells.  
(A) Growth curves of recombinant viruses in DF-1 cells infected at an MOI 0.1 FFU/cell. Cell 
culture medium of duplicate samples was harvested at indicated time points and virus titres 
determined through focus-forming assays. Error bars represent the SD, for a representative 
experiment (n=2) performed in duplicate. (B) Analysis of viral protein synthesis in DF-1 cells. Cell 
lysates from the growth curve samples were harvested and western blots probed with anti- α 
tubulin, anti-UUKV NSs and anti-UUKV N antibodies, as indicated. UUKV: Uukuniemi virus. 
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 Figure 5-12. DF-1 cell morphology following rUUKdelNSsGFP infection.  
(A) eGFP visualisation in DF-1 cells following infection with rUUKdelNSsGFP at an MOI 0.1 
FFU/cell (B) eGFP visualisation in DF-1 cells following infection with rUUKdelNSsGFP at an 
MOI 5 FFU/cell. UUKV: Uukuniemi virus. Scale bars indicate 200 µm. 
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5.4 Discussion 
Minigenome and VLP assays based on UUKV cDNAs have already been described (K. 
Flick et al., 2004; R. Flick et al., 2002; Överby et al., 2006), but are driven by Pol I. The 
aim of this chapter was to develop a reverse genetics system for UUKV driven by a T7 
RNAP. T7 RNAP and Pol I -driven reverse genetics systems have been shown to be of 
similar efficiency for the rescue of RVFV (Billecocq et al., 2008; Habjan et al., 2008). 
However, some differences exist between these two systems. For instance, in a T7 RNAP 
driven reverse genetics system, the T7 RNAP must be provided in trans, commonly by cell 
lines stably expressing T7 RNAP such as BSR-T7/5 (Buchholz et al., 1999). In addition, 
neither T7 RNAP nor Pol I can generate 5’ capped or 3’ poly-adenylated transcripts. 
Therefore, the T7 RNAP-driven systems use helper expression plasmids encoding the 
ORFs of the viral N and L proteins behind an (EMCV) IRES. This ensures that the 
uncapped T7 transcripts are efficiently translated.  On the other hand, Pol I-driven systems 
commonly utilize helper plasmids which are under the control of Pol II or cytomegalovirus 
(CMV) promoters to generate capped and polyadenylated mRNA transcripts (Bouloy and 
Weber, 2010). 
As bunyaviruses replicate exclusively in the cytoplasm (Elliott, 2013) and the cellular 
RNA polymerase I is found in the nucleus, T7 RNAP-driven reverse genetics systems for 
bunyaviruses are the favoured approach in our laboratory, due to the cytoplasmic 
localization of the T7 RNA polymerase (Elroy-Stein and B. Moss, 1990). The T7 RNAP-
driven rescue system is based on three rescue plasmids encoding the full-length 
antigenomic cDNA copies of the viral S, M or L RNA segments, which are under the 
control of a T7 RNAP promoter. T7 RNAP can generate antigenome-sense RNA 
transcripts from the rescue plasmids. Leaky translation of the antigenome-sense RNA 
transcripts allows the generation of sufficient viral N and L proteins for the encapsidation 
of antigenome RNA. Subsequently, the antigenomic sense RNP can undergo replication, 
and genomic sense segments that can be packaged into viral particles are generated. 
Alternatively, N and L proteins can be supplied using T7 RNAP-driven expression 
plasmids (in a 5 plasmid system). It is important to note that, in the case of a 3 plasmid 
system, it is not well-understood why ‘leakage’ N and L expression from antigenome-
sense transcripts generated by the T7 RNAP (which are not capped or polyadenylated) 
occurs (Billecocq et al., 2008).  
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To initiate the development of a T7 RNAP-driven reverse genetics system for UUKV, a 
sensitive, luciferase- based minigenome system was developed. Addition of UUKV L 
protein to S, M, or L segment-based minigenome assays in BSR-T7/5 cells (constitutively 
expressing a T7 RNAP) resulted in an increase in reporter activity, compared to the 
negative control lacking the L protein (Figure 5-3). Importantly, in the M and L segment-
based minigenome systems, the plasmids pT7UUKMRen(-) or pT7UUKLRen(-) encode a 
genome analogue that is in the genomic sense. Therefore, the increase in luciferase activity 
in the UUKV M and L segment-based minigenomes suggests that T7 RNAP can generate 
genomic sense reporter RNA transcripts from the minigenome plasmids, and that these 
transcripts are able to be encapsidated by the UUKV N protein, to form functional RNPs 
together with the L polymerase. Subsequently, the viral polymerase can replicate the 
genomic sense minigenome to generate antigenomic sense RNPs, which serve as a 
template for the transcription of the Renilla subgenomic mRNA, consequently resulting in 
an increase in Renilla luciferase activity. This is in comparison to the UUKV S segment-
based minigenome, in which the antigenome-sense analogue transcript encoded by 
pT7UUKSRen(+) does not require to be replicated. Instead, the RNP formed by the 
antigenome analogue transcript generated by T7 RNAP and viral N and L proteins can 
serve directly for the transcription of the Renilla subgenomic mRNA. Thus, due to these 
inherent differences between the M or L segment-based minigenomes and the S segment-
based minigenome, the promoter strengths are not comparable, as transcription of the 
Renilla subgenomic mRNA will be driven by different promoters (3’ UTR promoters of 
the genomic or antigenomic RNA, respectively). 
Interestingly, a dose-dependent decrease in the S and L segment-based minigenome 
activity was observed with increasing amounts of UUKV L-expressing plasmid, in 
comparison to the M segment –based minigenome activity, which showed a dose-
dependent increase in minigenome activity with increasing amounts of UUKV L (Figure 5-
3). The dose-dependent decrease in minigenome activity with increasing amounts of viral 
L protein has also been reported for the SFTSV M segment-based minigenome (Brennan et 
al., 2015) and the LACV S, and L segment-based minigenomes (Blakqori et al., 2003). It 
was suggested these observations could be attributed to a tight regulatory function of the L 
protein to switch from replication to cap-snatching activity (Blakqori et al., 2003; Elliott 
and Schmaljohn, 2013). Another explanation could be that the UUKV L protein has an 
inhibitory effect on the generation of S and L RNA transcripts when found in high 
amounts, as a strategy to prevent the generation of 5’-triphosphorylated single-stranded 
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uncapped RNA, which can be detected by host cell helicases to induce an antiviral innate 
immune response.  
Taken together, the minigenome assays developed allowed me to confirm that the viral 
UTRs, as well the UUKV N and L proteins used in this study were functional. These 
assays could now be used as a sensitive method to simulate viral transcription and 
replication processes, with RNA transcript synthesis taking place in the cytoplasm, the site 
of bunyavirus replication. This is in contrast to the Pol I-driven minigenome systems, 
where RNA transcripts are generated in the nucleus and exported to the cytoplasm for RNP 
assembly (R. Flick and Pettersson, 2001).  
A luciferase-based system for the generation of UUKV VLPs was also developed, by 
supplementing the minigenome system with the UUKV glycoprotein precursor in the form 
of a T7 RNAP-driven expression plasmid. An increase in reporter activity was observed in 
recipient cells that were pre-transfected with N and L expression plasmids, in comparison 
to naïve recipient cells (Figure 5-4). This increase in efficiency can be attributed to the fact 
that transcription and replication processes in recipient cells pre-transfected with N and L 
will mostly be driven by these proteins, which are already expressed in the cells. In 
comparison, infection of naïve cells with VLPs will reflect primary transcription, carried 
out only by N and L proteins delivered by RNPs packaged in the VLPs. The latter system, 
although less efficient, serves to mirror more closely the first steps of the virus life cycle 
following infection of a naïve cell. Importantly, although VLPs are infectious and 
transcription and replication competent, they cannot mediate multi-cycle infections 
because not all genome segments required for virus replication are packaged in the VLPs. 
As they can only undergo a single-cycle infection, they remain a powerful tool to study 
highly pathogenic viruses outside of high containment laboratories. Therefore, the T7 
RNAP-driven VLP system developed for UUKV could be applied to other tick-borne 
phleboviruses such as HRTV and SFTSV, in order to study virus packaging and budding 
processes, as well as virus morphogenesis.  
The establishment of a working minigenome and VLP system allowed to confirm that all 
UUKV UTRs and N and L proteins were functional, and that the glycoprotein precursor 
could efficiently package RNPs and facilitate the delivery of minigenome analogues to 
naïve cells, an important prerequisite to enable rescue of UUKV from cDNA clones. 
Indeed, UUKV was successfully rescued entirely from cDNA clones, which exhibited 
similar properties to authentic wild-type UUKV, with similar focus size and phenotype, 
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and growth kinetics in BHK-21 cells (Figures 5-5 and 5-8). Comparison of a 3-plasmid 
rescue system and a 5-plasmid rescue system, where the rescue plasmids encoding the 
three antigenomic sense UUKV cDNA segments were supplemented with UUKV N- and 
L- expressing plasmids, resulted in no difference in virus yield.  
Furthermore, two recombinant UUK viruses lacking NSs were generated:  rUUKdelNSs, 
in which the NSs ORF was deleted from the genome, resulting in a virus with a shorter S 
segment, and rUUKdelNSsGFP, in which the NSs ORF was replaced with that of eGFP 
(Figure 5-6).  Deletion of NSs from the UUKV genome resulted in the recombinant viruses 
forming significantly smaller foci (Figure 5-7 A). Additionally, the growth kinetics of 
rUUKdelNSs and rUUKdelNSsGFP in BHK-21 cells was slower compared to wtUUKV 
and rUUKV (Figure 5-8). BHK-21 cells lack a competent IFN system (Otsuki et al., 1979). 
Therefore, the attenuation in growth kinetics of recombinant UUKV lacking NSs 
compared to wild-type UUKV is independent of the IFN status of the cell. This has been 
noted for other bunyaviruses such as BUNV (Bridgen et al., 2001), OROV (Tilston-Lunel 
et al., 2016) and SBV (Elliott et al., 2013; Varela et al., 2013), but intriguingly not for 
LACV (Blakqori and Weber, 2005). The attenuation in growth kinetics of viruses lacking 
NSs suggests that this protein could have some dispensable role in facilitating virus 
replication.  
Interestingly, a one-log difference in virus titre was observed in the growth kinetics of 
rUUKdelNSsGFP compared to rUUKdelNSs in BHK-21 cells, with rUUKdelNSsGFP 
growing slightly better than rUUKdelNSs (Figure 5-8). It seems unlikely that GFP could 
itself contribute to the enhancement of virus replication. Rather, it is possible that this is 
due to the S segment of rUUKdelNSsGFP resembling more closely the S segment of 
wtUUKV (Figure 5-6 A). The S segment of rUUKdelNSs on the other hand, in which the 
NSs ORF was deleted, has an intergenic region that directly abuts the viral S 5’ UTR, 
which could result in an impairment of antigenomic RNA synthesis. Investigating this 
hypothesis was beyond the scope of this study, however it would be interesting to examine 
virus RNA synthesis in all recombinant viruses, or to generate a recombinant UUKV 
where NSs expression is eliminated through for instance, the mutation of start codons, and 
comparing its growth kinetics to rUUKdelNSsGFP and rUUKdelNSs. 
Nevertheless, the results in this chapter demonstrate that rUUKdelNSsGFP serves as a 
quick tool to visualise virus infection. Infection of various mammalian cell lines with 
rUUKdelNSsGFP enabled the examination of their permissibility to support UUKV 
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replication, through direct visualisation of eGFP (Figure 5-9). The results obtained by 
visualizing eGFP following rUUKdelNSsGFP infection are in agreement with yield assays 
performed using wtUUKV in the same cell lines (Figure 5-10). Briefly, rodent BHK-21 
and BSR-T7/5 cells exhibited the highest permissibility to UUKV infection, which was not 
surprising since wtUUKV and the recombinant viruses were propagated in rodent cell lines 
in order to generate virus stocks. Of all the human cell lines tested, HEK-293T and Huh-7 
cells yielded the highest UUKV titres and showed the most susceptibility to 
rUUKdelNSsGFP infection, whereas no eGFP expression and the lowest wtUUKV yields 
were observed in HeLa cells. A one-log increase in wtUUKV titre was observed in 
A549/V cells compared to its IFN-competent parental cell line A549, which was also 
reflected by increased eGFP expression following rUUKdelNSsGFP infection in A549/V 
cells compared to A549 cells (Figures 5-9 and 5-10). As A549/V cells are unable to 
respond to IFN, these results suggest that the IFN response may play a role in limiting 
UUKV infection.  
Finally, various strains of UUKV, or UUKV-like viruses have been isolated from tick 
species collected in nesting areas of seabirds, passerine birds, or from tick nymphs 
collected on migrant birds (S. R. Moss, 1986; Nuttall et al., 1984; 1981; Traavik and Mehl, 
1977; Watret and Elliott, 1985). In 2012, Hubalek et al. suggested migratory birds could 
play a role in the widespread distribution of tick-borne viruses in Europe (Hubálek and 
Rudolf, 2012). A phylogenetic analysis of SFTSV and migratory bird routes in Asia 
proposed that migratory birds, well-known carriers of ticks, could be a potential source of 
the spread of SFTSV across countries (Yun et al., 2015). Furthermore, antibodies against 
SFTSV were detected in two migratory bird species in China (Li et al., 2016). Therefore, 
the growth properties of recombinant UUK viruses were also investigated in a cell line of 
avian origin, namely the chicken embryo DF-1 fibroblast cell line. Intriguingly, while 
rUUKV was able to reach titres of ~106 FFU/mL, no increase in virus titre was observed 
for recombinant viruses lacking NSs (Figure 5-11 A). Additionally, no N or NSs protein 
could be detected in the time course by immunoblotting of rUUKdelNSsGFP or 
rUUKdelNSs –infected cell lysates, compared to rUUKV-infected cells (Figure 5-11 B). 
Taken together, these results suggest that NSs is essential for UUKV replication in DF-1 
cells. Visualisation of eGFP in DF-1 cells following rUUKdelNSsGFP infection confirmed 
that rUUKdelNSsGFP is able to enter the cells and that the first steps of the viral cycle 
such as uncoating and genome replication must occur in order for the eGFP ORF, which is 
in the positive sense in the viral genome, to be transcribed and subgenomic eGFP mRNA 
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generated from antigenomic sense RNA (Figure 5-11 C and D). As DF-1 cells are IFN 
competent (Liniger et al., 2012; H. Qu et al., 2013), one possibility is that viruses lacking 
NSs induce an IFN response large enough to create an antiviral state in neighboring cells, 
rendering them resistant to virus infection. Alternatively, NSs could play an essential role 
in later stages of the viral life cycle, such as virus assembly and/or egress. As it stands, the 
finding that UUKV NSs has an essential role in the virus life cycle in DF-1 cells is an 
interesting finding, as the NSs protein of bunyaviruses is commonly regarded as a non-
essential gene product. 
To conclude, the T7 RNAP-driven minigenome assays developed and described in this 
chapter can be used in the future to resemble more closely the cytoplamic transcriptional 
and replicational processes utilized by UUKV, in comparison to the established Pol I-
driven UUKV minigenome system. The reverse genetics system described herein has 
allowed the successful rescue of UUKV entirely from cDNA clones, and enabled the 
targeted manipulation of the UUKV genome. The robustness of the T7 RNAP-driven 
UUKV reverse genetics system was highlighted by the generation of two viruses lacking 
NSs, rUUKdelNSs and rUUKdelNSsGFP. It was also demonstrated that rUUKdelNSsGFP 
can be used as a quick tool to monitor and visualize virus infection. Finally, the findings 
described in this chapter indicate that UUKV NSs has a dispensable role in facilitating 
virus replication in IFN-incompetent BHK-21 cells, whereas the presence of NSs seems to 
be essential for UUKV replication in chicken DF-1 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5: Establishment of a reverse genetics system for Uukuniemi virus  117 
5.5 Summary 
• A luciferase-based T7 RNAP-driven minigenome system for UUKV was 
developed, which showed that the UTR sequences as well as the N and L proteins 
used in this study are functional. The minigenome system will facilitate future 
studies on transcription and replication processes of UUKV. 
• A VLP assay for UUKV was developed, which shows increased efficiency when 
recipient cells are pre-transfected with N and L. 
• Recombinant UUKV was successfully rescued entirely from cDNA clones, and 
exhibited similar properties to authentic wild-type UUKV. 
• Comparison of 3- and 5-plasmid rescue systems revealed no difference in virus 
yield. 
• Two recombinant viruses lacking NSs were generated: rUUKdelNSs and 
rUUKdelNSsGFP. 
• rUUKdelNSsGFP now serves as a tool to visualise and monitor virus infection. 
• Attenuation in the growth kinetics of viruses lacking NSs compared to wild-type 
viruses in BHK-21 suggested that NSs could have a dispensable role in facilitating 
virus replication. 
• In comparison to rUUKV, rUUKdelNSs and rUUKdelNSsGFP were unable to 
replicate in chicken DF-1 cells, indicating an essential role of UUKV NSs in virus 
replication in DF-1 cells. 
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6 Role of tick-borne phlebovirus NSs proteins in 
suppressing the human interferon system 
6.1 Introduction 
Vertebrate hosts rely on the innate immune system as a first line of defence upon exposure 
to pathogens. Following infection of a susceptible vertebrate host, viruses are confronted 
by the interferon (IFN) system. The IFN system plays an important role in the innate 
immune system to ‘interfere’ with and control virus replication (Randall and Goodbourn, 
2008). Once an infected host cell detects ‘non-self’ products produced by viruses upon 
infection, intracellular signalling pathways are activated, which lead to the production and 
secretion of IFN. Secreted IFN can then signal neighbouring cells to begin the up-
regulation of a number of IFN-stimulated genes (ISGs) that can have anti-viral activity, 
rendering the cells in an anti-viral state (Goodbourn et al., 2000; Hoffmann et al., 2015; 
Randall and Goodbourn, 2008; Schneider et al., 2014). Viruses, in turn, utilise a plethora 
of countermeasures to overcome the IFN system. These countermeasures involve the 
modulation of IFN production or signalling, and/or the function of antiviral proteins 
induced by the IFN system (Haller et al., 2007; Randall and Goodbourn, 2008; Wuerth and 
Weber, 2016).  
The accessory protein of bunyaviruses NSs is known to act as an IFN antagonist that 
contributes to pathogenicity, a role first demonstrated for BUNV NSs (Bridgen et al., 
2001; Weber et al., 2002). One of the first indications that the NSs protein of a member of 
the Phlebovirus genus had an IFN antagonistic activity was the finding that different 
strains of Rift Valley fever virus (RVFV) were differentially sensitive to the action of IFN 
(Bouloy et al., 2001). Specifically, the virulent RVFV strain ZH548 failed to induce type I 
IFNs and replicated efficiently in both wild-type mice and mice lacking the type I IFN 
receptor. On the other hand, RVFV strains with mutations in the NSs gene (MP12 and 
clone 13) induced type I IFNs, and were highly virulent in mice lacking the type I IFN 
receptor but not in wild-type mice. These findings provided the first genetic evidence that 
RVFV NSs acts as an IFN antagonist. Indeed, the NSs protein of RVFV was later shown to 
act as an IFN antagonist by inhibiting transcription of IFN-induced genes (Billecocq et al., 
2004; Le May et al., 2008). The IFN inhibitory activity of RVFV NSs was also confirmed 
by the generation of recombinant RVFV lacking its NSs protein, which induced IFN 
compared to wild-type RVFV (Ikegami et al., 2006). Similar studies have also 
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demonstrated that other mosquito-borne phlebovirus NSs proteins have an IFN antagonist 
activity. TOSV NSs exhibits weak IFN antagonistic activity, which results in TOSV 
inducing IFN following infection of host cells (Gori-Savellini et al., 2013; 2010). 
Additionally, using transient transfection assays and recombinant RVFV where the RVFV 
NSs ORF was replaced by that of PTV and SFSV NSs, it was demonstrated that PTV and 
SFSV NSs proteins act as antagonists of IFN production (Lihoradova et al., 2013). 
Until recently, the role of the NSs protein of tick-borne phleboviruses in modulating the 
host IFN response was poorly understood.  It was the identification of the highly 
pathogenic tick-borne phlebovirus SFTSV in 2011 that prompted the need to understand 
the molecular biology and pathogenesis of tick-borne phleboviruses. Indeed, in 2014 a 
number of studies reported that the NSs protein of SFTSV acts as a potent antagonist of 
both IFN induction and IFN signalling (Ning et al., 2015; 2014; Santiago et al., 2014). 
Besides SFTSV, it remains unknown whether the NSs protein of other tick-borne 
phleboviruses play a role in blocking the human IFN response, and whether the efficiency 
of IFN antagonism by the NSs proteins contributes to viral pathogenicity.  Such studies are 
urgently required, as tick-borne phleboviruses are continuously emerging and their 
movement into naïve geographical locations pose a risk to human and animal health 
(Elliott and Brennan, 2014). The development of a reverse genetics system for the 
apathogenic UUKV and the generation of NSs-lacking viruses are tools that can be used to 
assess the ability of UUKV NSs to antagonise the IFN response, and to compare its IFN 
antagonist activity to the NSs protein of more pathogenic tick-borne phleboviruses such as 
HRTV and SFTSV. 
6.2 Aims 
The overall aim of this chapter was to determine whether the NSs protein of the tick-borne 
phleboviruses UUKV and HRTV exhibit an IFN antagonistic activity. Firstly, I aimed to 
exploit the established reverse genetics system for UUKV (described in Chapter 5), 
utilizing NSs-lacking viruses to evaluate whether UUKV NSs could inhibit the human IFN 
response in cell culture. Due to the lack of a working reverse genetics system for HRTV, I 
aimed to study the IFN antagonistic activity of its NSs protein using transient transfection 
assays. Furthermore, I intended to compare whether the NSs protein belonging to more 
pathogenic tick-borne phleboviruses (such as HRTV and SFTSV) could modulate the IFN 
system more efficiently than the NSs protein of the apathogenic UUKV. Finally, I aimed to 
investigate the sensitivity of UUKV, HRTV and SFTSV to IFN treatment. 
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6.3 Results 
6.3.1 Evaluation of UUKV NSs as an IFN antagonist 
With the aim of determining whether UUKV replication would be enhanced in cells 
lacking a functional IFN system, virus yields of wtUUKV, rUUKV and recombinant 
UUKV lacking NSs (rUUKdelNSs and rUUKdelNSsGFP) were compared following 
infection of IFN-competent A549 cells and of its IFN-incompetent derivative cell line 
A549/PIV5-V (henceforth referred to as A549/V). The A549/V cell line constitutively 
expresses the V protein of parainfluenza virus type 5, which blocks type I IFN signalling 
by targeting STAT1 for degradation (Killip et al., 2013). Briefly, A549 and A549/V cells 
were infected at an MOI of 2 FFU/cell and the cell culture supernatant harvested 72 h p.i. 
Virus titres were determined in BSR cells. While wtUUKV and rUUKV achieved titres of 
∼106 FFU/ml in A549 cells, a one-log increase in virus titre was observed in A549/V cells 
(Figure 6-1 A). rUUKdelNSs and rUUKdelNSs GFP reached titres of ∼105 FFU/ml in 
A549 cells, and titres were slightly higher in A549/V cells.  Importantly, in IFN-
incompetent A549/V cells, viruses lacking NSs did not reach the same titres as wild-type 
UUKV. If UUKV NSs only plays a role in IFN antagonism, then presumably UUKV 
lacking NSs should achieve similar titres as wild-type UUKV in IFN-incompetent cells. 
However, the lower titres achieved by NSs-lacking viruses in A549/V cells could be 
explained by a dispensable role NSs may be playing to facilitate virus replication, as it was 
noted in Chapter 5 (Section 5.3.6). Nonetheless, these results demonstrate that although 
UUKV is able to replicate in IFN-competent A549 cells, replication was enhanced in 
A549/V cells, which lack a functional IFN response. 
To determine whether UUKV NSs plays a role in suppressing the human IFN system, a 
biological IFN protection assay was carried out to measure the production of IFN in the 
cell culture medium of virus-infected cells. Briefly, the cell culture medium was collected 
at 24 h p.i. from A549 cells infected with wtUUKV, rUUKV, rUUKdelNSs or 
rUUKdelNSsGFP at a high MOI (3 FFU/cell). Wild-type Bunyamwera virus (BUNV) and 
recombinant BUNV lacking its NSs protein (rBUNdelNSs2) (van Knippenberg et al., 
2010) were used as controls because it is well known that BUNV NSs is a potent IFN 
antagonist and the major virulence factor of BUNV (Bridgen et al., 2001; Weber et al., 
2002). 24 h p.i. the cell culture medium was UV-inactivated and serially diluted to pre-
treat A549/BVDV-Npro cells (Hale et al., 2009) for 24 h, prior to infection with the IFN-
sensitive encephalomyocarditis virus (EMCV). A549/BVDV-Npro cells constitutively 
Chapter 6: Role of tick-borne phlebovirus NSs proteins in suppressing the human interferon system 121 
express the bovine viral diarrhea virus IFN antagonist NPro and therefore cannot produce 
IFN, but remain responsive to exogenously applied IFN (Hale et al., 2009; Hilton et al., 
2006). While no protection was observed from mock- or BUNV-infected cells, cells 
treated with recombinant IFN-β or with medium from rBUNdelNSs2-infected cells 
conferred protection from EMCV-induced cytopathic effect (CPE) (Figure 6-1 B). In 
contrast to cell culture medium from BUNV-infected cells, some protection (a mean of 
approximately 12 relative IFN units [RIU]) was provided by medium from cells infected 
with wtUUKV or rUUKV (Figure 6-1 B and C), suggesting that UUKV infection induces 
IFN production. However, a 10-fold increase in relative IFN production was observed in 
the cell culture medium of rUUKdelNSs or rUUKdelNSsGFP-infected cells compared to 
wtUUKV or rUUKV -infected cells. Taken together, these results demonstrate that UUKV 
viruses lacking NSs induce a larger IFN response than wild-type UUKV, as deletion of 
NSs leads to a 10-fold increase in IFN production during infection. The induction of IFN 
by wild-type UUKV suggests that UUKV is unable to fully ablate the IFN response 
induced by the virus, in comparison to BUNV, which induced no IFN. 
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Figure 6-1. Recombinant UUKV viruses lacking NSs are better inducers of IFN than wild-
type UUKV.  
(A) Yield assay of indicated viruses in A549 or A549/V cells. Cell monolayers were infected at an 
MOI of 2 FFU/cell. The cell culture medium was harvested at 72 h p.i., and virus titre determined 
by focus-forming assays in BSR cells. Bars represent the mean virus titre of a representative 
experiment of two ± SD (n=3). (B-C) Biological interferon protection assays. A549 cells were 
infected at an MOI of 3 FFU/cell with the indicated viruses, or mock-infected. Cell culture medium 
was harvested 24 h p.i. and serial dilutions of the UV-inactivated medium (or 500 units of IFN-β) 
were used to pretreat A549-Npro cells prior to infection with EMCV.  The cells were stained with 
crystal violet at 4 days p.i. (B) Assay plates. (C) Relative IFN units (RIU) produced, calculated as 
RIU = 2N, where N represents the number of wells that are protected from EMCV infection. The 
bars indicate the mean RIU values calculated from a representative experiment of two performed in 
triplicate (n=3) ± SD. UUKV: Uukuniemi virus, BUNV: Bunyamwera virus, IFN-β: Interferon-β. 
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6.3.2 Inhibition of IFN induction by tick-borne phlebovirus NSs proteins 
Next, the role of UUKV and HRTV NSs proteins in modulating IFN induction was 
investigated.  SFTSV NSs was used as a positive control, as it is a well-known potent 
antagonist of IFN induction. Firstly, the NSs proteins of UUKV, HRTV or SFTSV were 
cloned into a CMV-driven expression vector (pCMV) using restriction-free cloning. The 
NSs proteins were either left untagged, or tagged with a V5 tag at their C-terminus. The 
plasmids were called pCMV-XNSs or pCMV-XNSsV5, where X refers to the virus the 
NSs protein sequence was derived from, and V5 refers to the C-terminal V5-tagged NSs 
proteins. The reason for tagging the proteins with the V5 tag was to compare expression 
levels of the NSs proteins in subsequent assays by western blotting. The IFN induction 
assay was carried out by co-transfecting HEK293T cells with an inducer plasmid encoding 
the N-terminal 2CARD domain of RIG-I (pCMV-RIGI-N) along with increasing amounts 
of pCMVXNSs or pCMVXNSsV5. At 24 h post transfection, IFN production in the cell 
culture medium was quantified using a biological IFN protection assay (described in 
section 6.3.1). The percentage of induction was normalised against the induction control 
(RIG-I N plasmid alone), which was considered 100%. 
A dose-dependent inhibitory effect of IFN induction was observed with increasing 
amounts of the untagged and V5-tagged NSs proteins of all three viruses (Figure 6-2 A). In 
agreement with the results presented in section 6.3.1, the inhibitory activity of UUKV NSs 
was distinctly weak compared to HRTV or SFTSV NSs. At the highest dose (250 ng) of 
NSs-expressing plasmid, UUKV NSs expression resulted in approximately 60% inhibition 
of IFN production, whereas that of HRTV and SFTSV NSs was 100% (Figure 6-2 A). A 
difference in the strength of IFN induction antagonism was observed between HRTV and 
SFTSV NSs proteins. While the lowest dose (10 ng) of HRTV NSs expression plasmids 
resulted in approximately a 50% decrease in IFN production, the same dose of SFTSV NSs 
expression plasmids led to almost a 95% decrease in IFN production (Figure 6-2 A).  
Transfected cell lysates were analysed by immunoblotting to visualise the expression 
levels of V5-tagged NSs proteins. Interestingly, visibly lower expression levels of V5-
tagged HRTV NSs were detected in comparison to UUKV and SFTSV NSs proteins 
(Figure 6-2 B), which could account for the weaker inhibitory activity of HRTV NSs 
compared to SFTSV NSs. Indeed, 50 ng of V5-tagged HRTV NSs yielded similar protein 
expression levels to 10 ng of V5-tagged SFTSV NSs (Figure 6-2 B), and at these amounts 
similar inhibitory activity on IFN production was observed for the respective NSs proteins 
(Figure 6-2 A). 
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IRF-3 is a transcription factor that is ubiquitously expressed in cells. Upon activation of the 
IFN pathway, IRF-3 is phosphorylated by TBK1, which enables its homodimerization, 
prior to its translocation to the nucleus, where it acts as a transcription factor to enhance 
the activation of the IFN-β promoter (Fitzgerald et al., 2003; Lin et al., 1998; Panne et al., 
2007; Yoneyama et al., 1998). To investigate whether the inhibition of IFN production by 
tick-borne phlebovirus NSs proteins occurs by ultimately preventing the activation of IRF-
3 and its translocation to the nucleus, the levels of phosphorylated and dimerized IRF-3 in 
the presence of UUKV, HRTV and SFTSV NSs proteins were assessed. HEK293Ts were 
transfected with RIG-I N-expressing plasmid, along with 250 ng of pCMVXNSs or 
pCMVXNSsV5 (the highest amount used in Figure 6-2). Transfected cell lysates were 
harvested for analysis of IRF-3 phosphorylation. IRF-3 phosphorylated at Ser386 could be 
readily detected in mock cells stimulated with RIG-I N-expressing plasmid. Whilst some 
IRF-3Ser386 was detected in cells transiently expressing UUKV NSs, almost undetectable 
levels of phosphorylated IRF-3 were observed in the presence of HRTV or SFTSV NSs 
(Figure 6-3 A). In all experimental conditions the levels of total IRF-3 remained 
unchanged (Figure 6-3 A). Similar results were obtained when cell lysates were analysed 
under non-denaturing conditions. Stimulation of mock cells with RIG-I N resulted in the 
dimerization of IRF-3, and although some dimerized IRF-3 could be detected in the 
presence of UUKV NSs, no dimeric IRF-3 could be detected in the presence of HRTV or 
SFTSV NSs (Figure 6-3 B). Of note, a shift in molecular weight was observed for the V5-
tagged UUKV NSs under non-reducing conditions, presumably because the electrophoretic 
mobility of UUKV NSs under non-reducing conditions is affected by its charge and native 
conformation.  
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Figure 6-2. Inhibition of IFN production by tick-borne phlebovirus NSs proteins.  
(A) The inhibitory effect of UUKV, HRTV and SFTSV NSs proteins on IFN induction was 
investigated by measuring induction of IFN production in HEK293T cells transfected with a 
plasmid encoding the N terminus of RIG-I in the presence of increasing amounts of untagged or 
V5-tagged NSs proteins. Cell culture medium was harvested 24 h post transfection and the relative 
IFN units assayed using a biological IFN protection assay in A549/BVDV-Npro cells. Percentage 
induction was normalised against the induction control (mock cells induced with RIG-I N only), 
which was considered 100%. Bars indicate the mean percentage IFN production from three 
independent experiments performed in duplicate ± SEM (n=3). (B) Immunoblot of V5-tagged NSs 
proteins in cell lysates belonging to the IFN induction assay described in (A). UUKV: Uukuniemi 
virus, HRTV: Heartland virus, SFTSV: Severe fever with thrombocytopenia syndrome virus. 
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Figure 6-3. Inhibition of IRF-3 phosphorylation and dimerization by tick-borne phlebovirus 
NSs proteins.  
(A) Western blot showing the phosphorylation status of IRF-3 at Ser386 in HEK293T cells 
transfected with 250 ng untagged or V5-tagged UUKV, HRTV or SFTSV NSs proteins and IFN-
induced by co-transfection of RIG-I N-expressing plasmid. (D) Western blot of monomeric and 
dimeric forms of IRF-3 in HEK293T cells co-transfected with 250 ng untagged or V5-tagged 
UUKV, HRTV or SFTSV NSs proteins and induced by co-transfection of RIG-I N-expressing 
plasmid. 24 h post transfection the cell monolayer was lysed with non-reducing lysis buffer and the 
proteins separated on a non-reducing gel before western blotting and probing with IRF-3, actin and 
V5 tag antibodies. UUKV: Uukuniemi virus, HRTV: Heartland virus, SFTSV: Severe fever with 
thrombocytopenia syndrome virus. 
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Furthermore, the translocation of IRF-3 upon induction by RIG-I N in the presence of the 
NSs proteins was investigated. Briefly, HEK293T cells transiently expressing the 
untagged, or tagged NSs proteins and induced with the RIG-I N-expressing plasmid were 
fixed, permeabilized and probed with anti- V5 and anti-IRF-3 antibodies 24 h post 
transfection, and visualized by confocal microscopy. While in un-induced cells IRF-3 
remained cytoplasmic, nuclear translocation of IRF-3 was detected in 47% of mock cells 
transfected with the RIG-I N-expressing plasmid (Figure 6-4 A and B). In the presence of 
UUKV NSs, some nuclear IRF-3 could be observed, however the percentage of cells 
exhibiting nuclear translocation of IRF-3 was lower than in mock-transfected cells (nuclear 
IRF-3 was detected in 19% and 13% of cells in the presence of untagged, or V5-tagged 
UUKV NSs, respectively) (Figure 6-3 B). The presence of the V5 tag allowed me to 
confirm that in some (but not all) cells expressing UUKV NSs-V5, IRF-3 translocation 
was not inhibited (Figure 6-3 A). In contrast, in cells transiently expressing HRTV or 
SFTSV NSs proteins, the percentage of nuclear IRF-3 was similar to that in uninduced 
cells (Figure 6-3 B). A clear difference was observed in the subcellular localization of V5-
tagged HRTV and SFTSV NSs proteins: whereas SFTSV NSs formed distinct cytoplasmic 
inclusion bodies (IBs) which sequestered IRF-3, IRF-3 remained diffused in the cytoplasm 
in the presence of HRTV NSs (Figure 6-3 A). Though overall this assay was informative, 
the quantification of nuclear translocation of IRF-3 was carried out blindly. Specifically, it 
was not possible to confirm that the counted cells had been transfected with the RIG I N-
expressing plasmid, and thus perhaps not all counted cells have been induced. Tagging the 
N-terminus of RIG-I in the RIG-I N-expressing plasmid would certainly improve the 
reliability of this experiment. 
Taken together, these data suggest that HRTV and SFTSV NSs proteins efficiently 
antagonize IFN induction by ultimately hindering the activation of IRF-3, thus inhibiting 
the activation of the IFN-β promoter. On the other hand, UUKV NSs acts as a weak IFN 
antagonist, and is capable of blocking the activation of IRF-3 or the subsequent production 
of IFN, but with decreased efficiency compared to HRTV or SFTSV NSs proteins. 
  
	
	
 Figure 6-4. RIG-I -induced nuclear translocation of IRF-3 in the presence of tick-borne phlebovirus NSs proteins. (A) HEK293T cells were 
cotransfected with a RIG-I N-expressing plasmid, and untagged or V5-tagged UUKV, HRTV or SFTSV NSs proteins. 24 h post transfection, the cells 
were fixed, permeabilised and probed with IRF-3 and V5 antibodies to visualise the nuclear translocation of IRF-3 (green), V5-tagged NSs proteins 
(red), and DAPI-stained nuclei (blue) by confocal microscopy. The images shown are representative of one randomly selected area on a confocal slide, 
of two independent experiments. White arrows indicate nuclear translocation of IRF-3 in cells transiently expressing V5-tagged UUKV NSs. (B) 
Quantification of cells exhibiting nuclear or cytoplasmic staining IRF-3 in (A). Cells from two randomly selected areas were counted and the total 
number of counted cells in each image (n=43-95) considered 100%. Cells showing no nuclear staining of IRF-3 were considered cytoplasmic, whereas 
cells exhibiting only nuclear or nuclear and cytoplasmic IRF-3 staining were considered nuclear.  The results shown indicate the mean percentage of 
cells with nuclear or cytoplasmic IRF-3 staining in two independent experiments ± SD. 
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 6.3.3 Effect of tick-borne phlebovirus NSs proteins on NF-κB signalling 
The ability of UUKV, HRTV or SFTSV NSs proteins to inhibit NF-κB signalling was also 
investigated. Subconfluent HEK293T were transfected with 200 ng pNF-κBluc and 5 ng of 
a plasmid encoding Renilla luciferase under the control of a CMV promoter (phRL), along 
with 150 ng pCMVXNSs or pCMVXNSsV5 (where X refers to UUKV, HRTV or 
SFTSV). pNF-κBluc encodes firefly luciferase under the control of an NF-κB promoter 
containing five tandem copies of the canonical κB elements. A plasmid encoding the IκBα 
super-repressor (pCMV-IκBαSR) was used as a positive control for the inhibition of NF-
κB signalling. IκBαSR is a IκBα molecule that inhibits NF-κB signalling due to mutations 
at serine residues required for its phosphorylation and proteasomal degradation (Gupta et 
al., 2010). In this way, NF-κB remains sequestered in the cytoplasm, thus the induction of 
NF-κB target genes is supressed. 18 h post transfection the cells were mock-treated or 
treated with tumor necrosis factor (TNF)-α. 24 h post treatment, the cells were lysed and 
firefly and Renilla luciferase activities analysed. Firefly activity was normalised against 
the Renilla luciferase activity and fold induction was calculated relative to the uninduced 
control. 
As expected, IκBαSR impeded NF-κB activation. However, no inhibition of NF-κB 
signalling by untagged or V5-tagged UUKV, HRTV or SFTSV NSs proteins was observed 
(Figure 6-5). 
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Figure 6-5. The effect of tick-borne phlebovirus NSs proteins on NF-κB activation.  
HEK293T cells were transfected with a firefly luciferase reporter plasmid under the control of five 
tandem copies of the canonical κB elements (pNF-κBluc) and phRL in the presence of expression 
plasmids encoding untagged, or V5-tagged UUKV, HRTV or SFTSV NSs proteins, or IκBαSR. 18 
h post transfection, the cells were mock-stimulated, or stimulated with TNF-α and lysed 24 h later. 
Firefly luciferase activity was normalised to Renilla luciferase and fold induction was calculated 
relative to the uninduced mock control. The data shown belongs to four experimental repeats 
performed in duplicate, and are shown as mean fold induction ± SEM (n=4). TNF: Tumor necrosis 
factor, RLU: Relative light Units, UUKV: Uukuniemi virus, HRTV: Heartland virus, SFTSV: 
Severe fever with thrombocytopenia syndrome virus, IκBαSR: IκBα super-repressor. 
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6.3.4 Effect of tick-borne phlebovirus NSs proteins on type I and type II IFN signalling 
To determine whether UUKV and HRTV NSs could block IFN signalling, the ability of 
the NSs proteins to inhibit the activation of the Interferon-sensitive response element 
(ISRE) was analysed. SFTSV NSs was used as a control, as this protein is known to act as 
a strong antagonist of IFN signalling. ISRE acts as a promoter for the upregulation of type 
I IFNs (IFN-α/β), which play an important role in inducing a large number of ISGs with 
anti-viral activity (Randall and Goodbourn, 2008). Briefly, subconfluent HEK293T cells 
were transfected with a Renilla luciferase-expressing plasmid (phRL) as a transfection 
control, increasing amounts of untagged, or V5-tagged UUKV, HRTV, or SFTSV NSs-
expression plasmids, and a reporter plasmid encoding firefly luciferase under the control of 
an ISRE promoter (p[9-27]4tkΔ]-39]lucter, henceforth referred to as pISRE-luc) (King and 
Goodbourn, 1998). 24 h post transfection, cells were stimulated with IFN-β and lysed 18 h 
later for analysis of firefly and Renilla luciferase activities. The firefly luciferase activity 
was normalised against the Renilla activity and percentage induction calculated relative to 
the mock induction control (i.e. mock cells treated with IFN-β), which was considered 
100%. 
UUKV NSs showed no inhibitory effect on the activation of the ISRE promoter following 
IFN treatment. In comparison, HRTV and SFTSV NSs proteins showed a potent, dose-
dependent inhibitory activity on ISRE promoter activation (Figure 6-6 A). Although a 
stronger inhibitory effect on type I IFN signalling by SFTSV NSs (95% inhibition at the 
highest dose) was noted compared to HRTV NSs (80% inhibition at the highest dose), 
lower expression levels of V5-tagged HRTV NSs were detected in comparison to SFTSV 
NSs (Figure 6-6 B), as noted earlier.  
A large number of cytokines which are regulated by type II IFN signalling have been 
shown to be elevated in the blood of SFTSV-infected patients (Deng et al., 2012), and 
were correlated with SFTS severity (Liu et al., 2017). Hence, the ability of the tick-borne 
phlebovirus NSs proteins to supress type II IFN signalling was examined. HEK293T cells 
were transfected with the highest dose of NSs-encoding plasmids used in the ISRE reporter 
assay (100 ng). 24h post transfection, transfected cells were treated with IFN-γ for a further 
24 h, prior to isolation of total cellular RNA. mRNA levels of IRF-1 and CXCL10 (which 
are ISGs induced by IFN-γ (Der et al., 1998; Luster et al., 1985)) relative to GAPDH 
mRNA levels (a housekeeping gene control) in the total cellular RNA were determined by 
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RT-pPCR. Curiously, none of the NSs proteins had an inhibitory effect on IRF-1 or 
CXCL10 mRNA levels following IFN-γ treatment (Figure 6-7 A and B, respectively). 
Thus, the results described in this section suggest that while the weak role of UUKV NSs 
as an IFN antagonist is mediated at the level of IFN induction only, HRTV and SFTSV 
NSs proteins antagonise both IFN induction and type I IFN signalling. Interestingly, while 
type I IFN signalling was potently inhibited by HRTV and SFTSV NSs proteins, these 
proteins did not exhibit antagonism of type II IFN signalling.  
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Figure 6-6. Inhibition of type I IFN signalling by tick-borne phlebovirus NSs proteins.  
(A) ISRE reporter assay in the presence of tick-borne phlebovirus NSs proteins. HEK293T cells 
were transfected with a firefly luciferase reporter plasmid under the control of an ISRE promoter 
(pISREluc), and a control plasmid encoding Renilla luciferase (phRL) in the presence of the 
indicated amounts of pCMVXNSs or pCMVXNSsV5 expression plasmids. 24 h post transfection, 
transfected cells were stimulated with IFN-β (500 U/mL) and lysed 18h later. Percentage induction 
was calculated by normalising the values to the mock induction control (mock cells treated with 
IFN-β), which was considered 100%. The data shown belong to three independent experiments 
performed in duplicate (n=3), and are shown as mean induction ± SEM. (B) Cell lysates from (A) 
were subjected to western blotting and probed with anti-tubulin and anti-V5 antibodies.  
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Figure 6-7. Inhibition of type II IFN signalling by tick-borne phlebovirus NSs proteins.  
(A-B) HEK293T cells transiently expressing untagged or V5-tagged UUKV, HRTV or SFTSV 
NSs proteins were treated with 50 ng IFN-γ 24 h post transfection. 24 h post treatment, the total 
cellular RNA was isolated and subjected to RT-qPCR to determine mRNA levels of IRF-1 (A) or 
CXCL10 (B). Fold increase in mRNA levels was derived by normalising relative mRNA levels of 
the target genes to GAPDH mRNA, using a ΔΔCt method. Bar graphs represent the mean fold 
induction in relative mRNA levels of the target from three experimental repeats performed in 
triplicate (n=3) ± SEM. ISRE: Interferon-Stimulated Response Element; IRF-1: Interferon 
regulatory factor-1; CXCL10: C-X-C motif chemokine 10. 
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6.3.5 IFN sensitivity of tick-borne phleboviruses 
It has previously been shown that different strains of RVFV exhibit differential sensitivity 
to IFN treatment, depending on the capacity of the virus’ NSs protein to efficiently block 
the type I IFN response (Bouloy et al., 2001). Thus, the sensitivity of tick-borne 
phleboviruses relevant to this study (UUKV, HRTV and SFTSV) to IFN was also assessed. 
First the sensitivity of UUKV, HRTV and SFTSV to exogenously applied type I IFN was 
assessed. Briefly, low MOI (0.1 FFU/cell) yield assays were carried out in A549/BVDV-
Npro cells, which were pre-treated 24 h prior to infection with increasing amount of 
universal IFN-α. A549/BVDV-Npro cells were selected as they cannot produce IFN. This 
allows for a comparison of virus sensitivity to exogenously applied IFN without the 
contribution of IFN produced by cells in response to virus infection. The cell culture 
supernatant of infected cells was harvested 48 h p.i., and UUKV, HRTV and SFTSV titres 
determined by focus- or plaque-forming assays. While no infectious UUKV was detected 
by focus-forming assays upon pre-treatment of A549/BVDV-Npro cells with 10 IFN units, 
a 2-log and a 4-log reduction in HRTV and SFTSV titre was observed, respectively, 
compared to the virus yield in untreated cells. Infectious HRTV or SFTSV was 
undetectable in cells pre-treated with 100 IFN units or greater (Figure 6-8 A). These results 
demonstrate that UUKV, HRTV and SFTSV are highly sensitive to pre-treatment of cells 
with exogenously applied IFN. 
A similar assay was carried out in A549/BVDV-Npro cells infected with UUKV, HRTV or 
SFTSV at a high MOI (3 FFU/cell). In this case the cells were infected prior to IFN 
treatment. Thus, presumably (and unlike in the previous assay) the cells were not in an 
IFN-induced antiviral state prior to infection. 100 IFN units were added at 0h, 1h, 2h, or 4h 
p.i. The cell culture supernatant of infected cells was harvested 48 h p.i., and the UUKV, 
HRTV and SFTSV titres determined by focus- or plaque-forming assays. Whereas a 5-fold 
decrease in UUKV titre was observed upon IFN treatment at all times post infection 
compared to mock-treated cells, HRTV or SFTSV replication was not hampered by IFN 
treatment following infection (Figure 6-8 B).  
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Figure 6-8. Sensitivity of tick-borne phleboviruses to exogenous IFN.  
(A) A549/BVDV-Npro cells were pre-treated with the indicated amount of universal type I IFN-α 
for 24 h prior to infection with UUKV, HRTV or SFTSV (MOI 0.1 FFU/cell). (B) A549/BVDV-
Npro cells were infected at a high MOI (3 FFU/cell) with UUKV, HRTV or SFTSV, and 100 
universal IFN-α added to the cell culture medium at 0 h, 1 h, 2 h or 4 h p.i. At 48 h p.i. the cell 
culture medium of duplicate (A) or triplicate (B) wells was harvested and the virus titre determined 
by focus- or plaque-forming assay. The data presented are from a representative experiment of two, 
performed in triplicate with single data points plotted and with horizontal lines representing the 
mean. UUKV: Uukuniemi virus, HRTV: Heartland virus, SFTSV: Severe fever with 
thrombocytopenia syndrome virus. 
 
 
 
A 
B 
0 10 10
0
10
00 0 10 10
0
10
00 0 10 10
0
10
00
0
1
2
3
4
5
6
7
Universal IFN units (U)
Ti
tre
 (L
og
10
 F
FU
/m
l)
UUKV
HRTV
SFTSV
Mo
ck 0h 1h 2h 4h
Mo
ck 0h 1h 2h 4h
Mo
ck 0h 1h 2h 4h
0
1
2
3
4
5
6
7
Time of addition of IFN (1000 U) post infection
Ti
tre
 (L
og
10
 F
FU
/m
l)
UUKV
HRTV
SFTSV
Chapter 6: Role of tick-borne phlebovirus NSs proteins in suppressing the human interferon system 137 
The sensitivity of UUKV, HRTV and SFTSV to virus-induced IFN was also investigated 
by examining the effect of a JAK1/2 inhibitor (Ruxolitinib, previously described in 
(Stewart et al., 2014)) on foci formation in IFN-competent A549 cells. In this assay the 
focus size is determined by the kinetics of the IFN response mounted to the pathogen-
associated molecular patterns (PAMPs) associated with the infecting virion and the ability 
of the virus to circumvent this IFN response. Thus, the use of an inhibitor that can block 
IFN signalling in focus-forming assays is a convenient strategy to assess virus sensitivity 
to virus-induced IFN. While UUKV foci were undetectable in mock-treated A549 cells, 
Ruxolitinib treatment rescued the ability of UUKV to form foci in these cells. 
Comparatively, no significant increase in HRTV focus size was observed in Ruxolitinib-
treated A549 cells in comparison to mock-treated cells, indicating that HRTV must have 
the capacity to evade IFN induction. Surprisingly, although SFTSV has evolved a potent 
IFN antagonist (NSs) that is able to suppress IFN induction and IFN signalling (Figures 6-
2 and 6-6)(Chaudhary et al., 2015; Ning et al., 2015; 2014; Santiago et al., 2014), a 
significant increase in SFTSV focus size was observed in A549 cells treated with 
Ruxolitinib (Figure 6-9 A and B). In order to ensure that this effect was not due to the 
presence of defective interfering particles in the laboratory SFTSV stock, the virus was 
plaque-purified. Four different newly plaque-purified SFTSV stocks yielded similar results 
to those obtained with the laboratory SFTSV stock (data not shown). Therefore, despite 
being equipped with a potent antagonist of the IFN system, SFTSV infection still results in 
IFN induction, which limits virus infection in neighboring cells. 
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Figure 6-9. Sensitivity of tick-borne phleboviruses to virus-induced IFN.  
(A) Focus-forming assays of UUKV, HRTV and SFTSV on A549 cells 6 days p.i. The overlay was 
supplemented with JAK/STAT inhibitor Ruxolitinib (0.4µM) or the equivalent volume of the 
vehicle control DMSO. Foci were detected using anti-UUKV, HRTV or SFTSV N antibodies. (B) 
Box plot for foci diameter of the focus-forming assays in (A) (n=10). Statistical significance for the 
comparison of means between groups was determined by two-way ANOVA followed by Tukey’s 
multiple comparisons post-hoc test. n.s.= non-significant, **** p ≤0.0001. UUKV: Uukuniemi 
virus; HRTV: Heartland virus; SFTSV: Sever Fever with Thrombocytopenia syndrome virus. 
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To corroborate the results obtained with Ruxolitinib treatment, the replication kinetics of 
UUKV, HRTV and SFTSV were compared in A549 cells infected at either low or high 
MOI (0.1 FFU/cell and 3 FFU/cell, respectively). At various time points throughout the 
time course, the cell culture medium was harvested, virus titre determined through focus- 
or plaque-forming assays, and the relative amount of IFN produced quantified by a 
biological IFN protection assay, as described in section 6.3.1. At a low MOI, the peak 
mean titres of UUKV and SFTSV were of 2 x104 FFU/ml and 8.2 x105 FFU/ml (at 72 h 
p.i.), approximately 1 log lower than the peak mean titre of these viruses following a high 
MOI infection (Figure 6-10 A and C). Using a high MOI infection, UUKV induced IFN by 
24 h p.i., whereas no IFN could be detected at any point during the time course carried out 
at a low MOI (Figure 6-10 D). The lack of IFN production by UUKV at a low MOI could 
be explained by the slow replication kinetics of UUKV throughout the time course, with 
only a one-log increase in virus titre detected (Figure 6-10 A). On the other hand, the faster 
replication kinetics exhibited by SFTSV during the low MOI time course (a 3-log increase 
in virus titre) resulted in increased induction of IFN (Figure 6-10 C and F). In contrast to 
UUKV and SFTSV, HRTV infections at a high and low MOI yielded similar mean titres 
by 72 h p.i. (low MOI: 1.7 x105 FFU/ml and high MOI: 3.3 x105 FFU/ml) (Figure 6-10 B). 
Furthermore, even at a high MOI, HRTV infection resulted in very little induction of IFN 
(4 RIU) by 72 h p.i. (Figure 6-10 E).  
Taken together, these results demonstrate that UUKV and SFTSV cannot efficiently inhibit 
IFN production following virus infection, which results in reduced spread of the virus to 
neighbouring cells. On the other hand, HRTV limits IFN production upon infection, as 
little IFN was induced throughout the time course.  
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Figure 6-10. Replication kinetics and IFN production following tick-borne phlebovirus 
infection. 
(A-C) Growth curves of UUKV (A), HRTV (B) or SFTSV (C) at low (0.1 FFU/cell) and high MOI 
(3 FFU/cell) in A549 cells. Cell culture supernatant of triplicate wells was collected at the indicated 
time points and virus titre determined through focus- or plaque-forming assays. (D-F) Samples 
from A-C were UV-inactivated and the relative IFN units measured through a biological IFN 
protection assay. Error bars indicate standard deviation (SD) of the mean (n=3) of a representative 
experiment of two experimental repeats. UUKV: Uukuniemi virus; HRTV: Heartland virus; 
SFTSV: Sever fever with thrombocytopenia syndrome virus.  
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6.4 Discussion 
Viruses require mechanisms to antagonise the IFN response in order to replicate efficiently 
in host cells. The NSs protein of viruses within the Bunyaviridae family is best 
characterised by its IFN antagonist function. This role was shown to be of particular 
importance for the pathogenicity of BUNV (Bridgen et al., 2001; Weber et al., 2002). 
Within the mosquito-borne viruses of the Phlebovirus genus, RVFV, TOSV, PTV and 
SFSV NSs proteins were all shown to act as IFN antagonists (Billecocq et al., 2004; Gori-
Savellini et al., 2013; 2010; Ikegami et al., 2006; Lihoradova et al., 2013). With the 
exception of SFTSV NSs (Ning et al., 2015; 2014; Santiago et al., 2014), no other tick-
borne phlebovirus NSs protein has been shown to act as an IFN antagonist, and their role 
in modulating host immune responses remains poorly understood. The aim of this chapter 
was to investigate whether the NSs protein of the apathogenic UUKV and pathogenic 
HRTV block the human IFN response at the level of IFN induction and/or signalling. 
Additionally, the efficiency of their IFN antagonistic activities was compared to that of 
SFTSV NSs, which is a potent IFN antagonist. 
The results in this chapter show that UUKV can replicate in a human IFN-competent cell 
line (A549), and thus must be able to overcome the human IFN response (Figure 6-1 A). 
The enhanced replication of UUKV in A549/V cells (in which the IFN response is lacking) 
suggested that IFN generated as a result of virus infection plays a role in inhibiting UUKV 
replication. The generation of NSs-lacking UUK viruses by reverse genetics in Chapter 5 
provided the tools necessary to investigate the role of UUKV NSs as an IFN antagonist in 
the context of a virus infection. It has previously been shown that following infection, PTV 
and TOSV induce IFN in cell culture (Gori-Savellini et al., 2010; Perrone et al., 2007), 
which was also noted for UUKV in this Chapter (Figures 6-1 B and C). Similarly to PTV 
and TOSV, the NSs protein of UUKV also plays a role in antagonizing the host cell IFN 
response, as infection of A549 cells with NSs-lacking viruses (rUUKdelNSs and 
rUUKdelNSsGFP) yielded a 10-fold increase in IFN production compared to wild-type 
UUKV (Figures 6-1 B and C). These results indicate that UUKV NSs acts as an IFN 
antagonist in human cells. However, its antagonistic activity is weak because upon 
infection UUKV induces IFN (unlike the control BUNV which encodes an NSs protein 
with potent IFN antagonism characteristics). These results suggest that UUKV NSs is 
unable to completely inhibit the production of IFN mounted as a result of UUKV infection. 
This observation may provide an explanation for the inability of UUKV to cause disease in 
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humans. As various strains of UUKV (or UUKV-like viruses) have been isolated from 
ticks collected from passerine birds, migrant birds, or within nesting areas of seabirds (S. 
R. Moss, 1986; Nuttall et al., 1984; 1981; Traavik and Mehl, 1977; Watret and Elliott, 
1985), it would be interesting to investigate whether UUKV NSs has evolved to act as a 
potent antagonist of the avian IFN response. 
The role of UUKV NSs as a regulator of the human innate immune system was compared 
to that of the NSs belonging to more pathogenic tick-borne phleboviruses HRTV and 
SFTSV. Transient transfection assays were carried out to investigate and compare at which 
stages of the IFN system the NSs proteins exerted an inhibitory activity. The weak IFN 
antagonistic activity of UUKV NSs reported in the context of a virus infection (Figure 6-1) 
was also reflected at the level of IFN induction in transient transfection assays. In 
comparison to HRTV and SFTSV NSs proteins, which potently inhibited RIG-I N-
mediated IFN production, UUKV NSs exhibited lower efficiency in inhibiting RIG-I N-
mediated IFN production (Figure 6-2 A). These findings were also reflected in RIG-I N-
mediated IRF-3 phosphorylation (Figure 6-3 A), dimerization (Figure 6-3 B) and nuclear 
translocation (Figure 6-4). Thus, UUKV, HRTV and SFTSV NSs proteins are able to 
modulate the IFN system by suppressing RIG-I N-mediated IFN induction, albeit with 
different efficiencies, ultimately hindering the phosphorylation, dimerization and 
translocation of IRF-3 to the nucleus. The nuclear translocation of IRF-3 is important, as it 
is in the nucleus that IRF-3 can form part of the IFN enhanceosome complex to activate 
the transcription of the IFN-α/β gene (Wathelet et al., 1998). Furthermore, the results 
presented in this chapter denote a correlation between the reported pathogenicity of the 
viruses in nature and the efficiency with which their respective NSs proteins antagonise the 
IFN response. 
In comparison to the inhibitory effect of UUKV, HRTV and SFTSV NSs proteins on IFN 
induction, none of the proteins were able to inhibit NFκB signalling (Figure 6-4). NFκB 
signalling controls the expression of many inflammatory cytokines, chemokines and cell 
surface adhesion molecules, playing a major role in the regulation of inflammation 
(Lawrence, 2009; X. Li and Stark, 2003). The role of tick-borne phlebovirus NSs proteins 
in modulating NFκB signalling has only been investigated for SFTSV NSs, and some 
discrepancies exist in the literature. Initial reports indicated that although NFκB activation 
facilitated SFTSV replication, SFTSV NSs was capable of supressing NFκB signalling in 
HEK293T cells (B. Qu et al., 2012). This finding, in addition to the finding that SFTSV 
doesn’t induce apoptosis (thus extending host cell survival), led the authors to suggest that 
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these strategies may be employed by SFTSV to reduce viral loads and therefore contribute 
to persistent infections. At odds with this report, another study showed no inhibitory 
activity of SFTSV NSs in similar experiments (Chaudhary et al., 2015). The data presented 
in Figure 6-5 agrees with the latter report and, regardless of the disparity with the report 
suggesting an inhibitory role of SFTSV NSs on NFκB signalling, it is consistent with the 
upregulation of many NF-kB-regulated cytokines reported in SFTSV-infected humans and 
non-human primates (Deng et al., 2012; Jin et al., 2015; Y. Sun et al., 2012). 
Upon IFN induction, secreted IFNs engage with receptors on the cell surface of 
neighboring cells and activate intracellular signalling pathways that lead to the 
upregulation of a number of ISGs, consequently conferring an anti-viral state. Some 
redundancy exists between the signalling pathways activated by type I and type III IFNs, 
which converge in the regulation of the ISRE promoter by activation of both STAT1 and 
STAT2. The type II IFN signalling pathway differs slightly from type I and III, as it is 
majorly mediated by the activation of STAT1, and promotes the transcription of GAS 
promoter-regulated genes through STAT1 homodimers (known as GAF) (Figure 1-12) 
(Borden et al., 2007; de Weerd and Nguyen, 2012; Platanias, 2005). The findings in this 
chapter demonstrate that some tick-borne phlebovirus NSs proteins are capable of blocking 
IFN signalling in an IFN-specific manner to hamper the IFN response. Transient 
transfections assays indicated that unlike UUKV NSs, the NSs protein of pathogenic 
HRTV and SFTSV strongly inhibit the activation of the ISRE promoter following IFN 
treatment (Figure 6-6 A and B). In contrast, none of the tick-borne phlebovirus NSs 
proteins studied showed inhibitory activity on type II IFN signalling (Figure 6-7 C and D). 
Mechanistically, the ability of HRTV or SFTSV NSs to block the type I but not type II IFN 
signalling pathways could presumably lie within the inherent differences between these 
two pathways. For instance, it is possible that HRTV and/or SFTSV NSs proteins are able 
to interact with STAT2 or IRF-9, or inhibit STAT2 phosphorylation, thus preventing the 
formation of ISGF3 and blocking the major route of type I and III, but not type II IFN 
signalling. Alternatively, the NSs proteins may be able to block signalling at the level of 
the IFN receptors, thus providing an IFN-specific inhibitory action on IFN signalling. 
Further experiments are required to determine the molecular mechanism of IFN signalling 
inhibition of HRTV and SFTSV NSs proteins, which are discussed in Chapter 7. The 
activation of GAS elements by STAT1 homodimers in type II IFN signalling leads to the 
transcription of pro-inflammatory cytokines such as TNF, IL-6 and P40 (X. Hu and 
Ivashkiv, 2009). Therefore, it is possible that the inability of HRTV and SFTSV NSs 
Chapter 6: Role of tick-borne phlebovirus NSs proteins in suppressing the human interferon system 144 
proteins to block type II IFN signalling enables the activation of pro-inflammatory 
responses that lead to severe disease following virus infection, as evidenced in SFTS 
mouse models and SFTSV-infected patients (Deng et al., 2012; Jin et al., 2012; Liu et al., 
2017). Of note, although to date there is no literature available relating to the upregulation 
of cytokines regulated by type II IFN signalling in HRTV-infected patients, HRTV-
infected patients show identical symptoms to SFTSV-infected patients (McMullan et al., 
2012; Muehlenbachs et al., 2014).  
The first indication that the NSs protein of a phlebovirus had an IFN antagonist role was 
the finding that the virulent RVFV strain ZH548 failed to induce IFN following infection 
and replicated efficiently in wild-type mice and mice lacking the type I IFN receptor. This 
was in comparison to RVFV strains bearing mutations in the NSs gene (MP12 and clone 
13), which induced IFN and were virulent in mice lacking the type I IFN receptor but not 
in wild-type mice (Bouloy et al., 2001). The fact that the sensitivity of RVFV strains to 
IFN is dictated by the capacity of the virus to efficiently block IFN production upon 
infection led me to investigate the IFN sensitivity of the tick-borne phleboviruses relevant 
to this study. UUKV, HRTV and SFTSV were all shown to be sensitive to pre-treatment of 
human A549/BVDV-Npro cells with exogenous type I IFN (Figure 6-8 A), presumably 
because of their inability to replicate in cells that are in an IFN-induced anti-viral state 
prior to infection. While pre-treating the cells with the lowest dose of IFN resulted in a 2-
log and 4-log decrease in HRTV and SFTSV titre respectively 48 h p.i., no infectious 
UUKV was detected under the same conditions, suggesting UUKV is more sensitive to 
IFN pre-treatment than HRTV and SFTSV. Furthermore, while UUKV replication was 
impaired when IFN was added upon virus infection, no effect was observed on HRTV or 
SFTSV replication (Figure 6-8 B). These findings are in agreement with the observation 
that UUKV NSs is unable to block type I IFN signalling, while HRTV and SFTSV NSs act 
as potent antagonists of type I IFN signalling. Presumably, in HRTV- and SFTSV-infected 
cells the NSs proteins encoded by the respective viruses can readily control IFN signalling 
pathways triggered by exogenously applied IFN after infection, and thus prevent the 
development of an antiviral state in these cells. In contrast, the lack of IFN signalling 
inhibitory activity by UUKV NSs could explain the impairment of UUKV replication in 
UUKV-infected cells treated with exogenous IFN. 
In an attempt to assess the sensitivity of the tick-borne phleboviruses relevant to this study 
to virus-induced IFN, focus-forming assays in mock-treated and Ruxolitinib treated A549 
cells were carried out. Ruxolitinib is a drug that inhibits IFN signalling (specifically 
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JAK1/2). Thus, in comparison to the assays where virus sensitivity to exogenous IFN was 
examined in cells that are unable to produce IFN, these focus-forming assays account for 
factors such as the kinetics of the IFN response mounted to virus-associated PAMPs and 
the ability of the viruses to circumvent the virus-induced IFN response only (Stewart et al., 
2014). In IFN-competent A549 cells, HRTV and SFTSV formed small foci, while UUKV 
did not form detectable foci. The addition of Ruxolitinib to the overlay rescued the ability 
of UUKV to form foci in these cells, and gave rise to significantly larger SFTSV foci 
(Figures 6-9 A and B). Therefore, these findings suggest that the IFN response mounted as 
a result of UUKV and SFTSV infection leads to the development of an antiviral state in 
neighbouring infected cells, which limits virus spread.  In a similar manner, the sensitivity 
of UUKV and SFTSV to virus-induced IFN was demonstrated by the inability of both 
UUKV and SFTSV to reach similar peak titres during low and high MOI infections 
(Figure 6-10 A and C). In principle, if no IFN is produced during replication, or if the virus 
is able to efficiently block IFN signalling, infection at a low MOI would yield similar peak 
titres to a high MOI infection.  
Notably, some differences were observed in the ability of UUKV and SFTSV to replicate 
in IFN-induced cells. UUKV exhibited poor replication kinetics, with low and high MOI 
infections showing a one-log increase in virus titre (Figure 6-10 A), which could explain 
the lack of IFN production by UUKV during the time course carried out at a low MOI 
(Figure 6-10 D). Comparatively, SFTSV exhibited faster replication kinetics than UUKV 
at a low MOI (with a 3-log increase in virus titre) and consequently induced more IFN 
throughout the time course (Figures 6-10 A, C, D and F). The induction of IFN following 
infection and the sensitivity of SFTSV to virus-induced IFN is surprising, as the NSs 
protein of SFTSV has very potent IFN induction and signalling supressing activities (Ning 
et al., 2015; 2014; Santiago et al., 2014) (Figures 6-2 A and 6-6 A). The results described 
here suggest that despite encoding a potent and efficient IFN antagonist, the amount of IFN 
induced during SFTSV infection is not completely overcome by the action of its IFN 
antagonist NSs. During the writing of this chapter, a study emerged which claimed that 
sera from SFTSV-infected patients show high concentrations of IFN-α compared to sera 
from healthy patients. Additionally, the concentration of IFN-α in patients with severe 
SFTSV was significantly higher than that in patients with mild SFTS (Liu et al., 2017). 
The authors speculated that perhaps the potent IFN induction antagonistic activity of 
SFTSV NSs suggested in in vitro studies (Ning et al., 2014; Santiago et al., 2014) may not 
play such an important role in inhibiting the production of type I IFNs in vivo. The 
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surprising high levels of IFN-α in SFTSV-infected patients is in agreement with the IFN 
induction detected in SFTSV-infected cells in this study (Figure 6-10 C).  Perhaps, SFTSV 
has evolved such a potent antagonist of IFN induction because it generates a large amount 
of PAMPs during virus replication, resulting in the rapid induction of the IFN response; an 
interesting hypothesis and avenue for future studies. 
Interestingly (and in contrast to UUKV and SFTSV), no significant difference was 
observed in HRTV focus size in A549 cells when comparing functional and non-functional 
IFN signalling responses (Figures 6-9 A and B). In agreement with these results, both low 
and high MOI HRTV infections resulted in similar peak titres with little IFN produced 
over the time course (Figures 6-10 B and E). Thus, despite encoding NSs proteins with 
similar efficiencies to block IFN induction and IFN signalling (Figures 6-2 and 6-4), 
HRTV (unlike SFTSV) is able to efficiently control IFN production upon infection, which 
presumably favours virus replication by preventing the development of an IFN-induced 
state, and allows HRTV to reach similar peak titres following low and high MOI 
infections. It is possible that this is due to HRTV generating less PAMPs than SFTSV, 
which allows HRTV NSs protein to control IFN production more efficiently than SFTSV 
NSs in the context of a virus infection.  
Taken together, the data presented in this chapter shows that UUKV, HRTV and SFTSV 
are all sensitive to IFN pre-treatment, but only UUKV is sensitive to IFN treatment after 
virus infection presumably due to the lack of inhibitory activity of its NSs protein on IFN 
signalling. Additionally, whereas UUKV and SFTSV replication is limited by virus-
induced IFN, HRTV infection produces such little IFN that it does not affect its 
replication, suggesting that the virus has acquired more efficient strategies than UUKV or 
SFTSV to hamper IFN production. The results in this chapter also show that UUKV NSs 
acts as an IFN antagonist at the level of IFN induction only. This is in comparison to 
HRTV and SFTSV NSs proteins, which antagonise both IFN induction and type I IFN 
signalling. Moreover, the antagonist activity of the NSs protein of apathogenic UUKV at 
the level IFN induction is weak, in comparison to the NSs protein belonging to highly 
pathogenic HRTV and SFTSV, indicating a correlation between the reported pathogenicity 
of the viruses in nature and the efficiency with which their respective NSs proteins 
antagonise the IFN response. Finally, while type I IFN signalling was potently inhibited by 
HRTV and SFTSV NSs proteins, these proteins did not exhibit antagonism of type II IFN 
signalling, which could serve as an explanation for the increased pro-inflammatory 
responses that lead to severe disease in HRTV and SFTSV patients (McMullan et al., 
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2012; Muehlenbachs et al., 2014). As the IFN antagonistic activities of UUKV NSs (at the 
level of IFN induction) and HRTV NSs (at the level of IFN induction and signalling) 
described in this chapter are novel, the molecular mechanism by which they exert their 
inhibition is unknown. These mechanisms are investigated further in Chapter 7. 
6.5 Summary 
• Recombinant UUK viruses lacking NSs were utilized to show that the relative 
amount of IFN produced upon infection of A549 cells is greater than that produced 
by wtUUKV. Induction of IFN by wtUUKV suggests that its NSs protein is unable 
to completely abrogate virus-induced IFN production. 
• Using transient transfection assays, a correlation was observed between the strength 
of IFN system inhibition by UUKV, HRTV and SFTSV NSs proteins and the 
pathogenicity exhibited by their cognate viruses in nature. 
• UUKV, HRTV and SFTSV NSs proteins all inhibit IFN induction with different 
efficiencies, by ultimately preventing IRF-3 phosphorylation, dimerization and 
consequently its nuclear translocation. However, none of the NSs proteins 
hampered NF-kB signalling. 
• While UUKV NSs is unable to inhibit type I or II IFN signalling, HRTV and 
SFTSV NSs proteins are potent antagonists of type I, but not II, IFN signalling. 
• UUKV, HRTV and SFTSV are all sensitive to IFN pre-treatment, but only UUKV 
replication is impaired if IFN is applied 0-4 h after virus infection. 
• UUKV and SFTSV induce IFN, which limits their replication and spread to 
neighboring cells. In contrast, HRTV produces little IFN upon infection and its 
replication is unaffected by the virus-induced IFN. This presumably is because 
HRTV employs more efficient strategies to inhibit IFN production than UUKV or 
SFTSV. The induction of IFN by SFTSV and its sensitivity to IFN  in comparison 
to HRTV was surprising, since both viruses encode NSs proteins that exhibit 
similar efficiencies in inhibiting IFN induction and signalling in transient 
transfection assays. Perhaps SFTSV induces more PAMPs than HRTV and its NSs 
protein is unable to control the induction of IFN, unlike HRTV NSs. 
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7 Molecular mechanism of IFN antagonism by 
tick-borne phlebovirus NSs proteins 
7.1 Introduction 
The results presented in the previous chapter demonstrated that UUKV, HRTV and SFTSV 
NSs proteins are capable of supressing IFN induction. In addition, whereas UUKV NSs 
showed no inhibition at the IFN signalling level, HRTV and SFTSV NSs proteins were 
potent antagonists of type I, but not type II IFN signalling.  
The molecular mechanism employed by SFTSV NSs to subvert the human IFN system 
quickly became characterised following the emergence of SFTSV.  Initial reports indicated 
that SFTSV NSs mediated the formation of NSs-containing cytoplasmic inclusion bodies 
(IBs), which have a granule-like appearance and are found in virus-infected cells, as well 
as in cells expressing SFTSV NSs in the absence of other viral proteins (Ning et al., 2014; 
Santiago et al., 2014). Ning et al have showed that these structures are highly dynamic, 
and could undergo fusion to form larger aggregosomes, or fission to disperse into smaller 
IBs during their development (Ning et al., 2014). In addition, Santiago et al showed that 
the NSs-induced IBs colocalised with the early endosomal marker Rab5, but not with 
Golgi or Endoplasmatic reticulum markers, indicating that the endosomal system is 
exploited for the formation of these IBs (Santiago et al., 2014). The IBs were also found to 
co-localise with lipid droplets and viral dsRNA. As inhibition of fatty acid synthesis 
disrupted the formation of SFTSV NSs-induced IBs and hindered SFTSV replication, it 
was suggested that these structures may also function as virus replication factories 
(Santiago et al., 2014). The studies described above also investigated the role of SFTSV 
NSs in supressing the IFN system. Intriguingly, it was found that the NSs-induced IBs 
served to sequester and spatially isolate key components of IFN induction and signalling 
pathways, which was described as a novel and elegant strategy to modulate the IFN 
system. Specifically, SFTSV NSs was found to act as a potent antagonist of IFN induction 
by sequestering TRIM25 and RIG-I (Santiago et al., 2014), TBK1 (Ning et al., 2014; X. 
Wu et al., 2014), and IRF-3 (Ning et al., 2014; X. Wu et al., 2014) into NSs-induced IBs, 
therefore depriving these signalling molecules from participation in the IFN induction 
cascade. Although the direct interaction between SFTSV NSs and TBK1 is a consistent 
finding in all reported studies (Ning et al., 2014; Santiago et al., 2014; X. Wu et al., 2014), 
some discrepancies exist with regards to the interactions driving the imprisonment of other 
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IFN effector proteins into NSs-induced IBs. While Wu et al reported that the interaction 
between SFTSV NSs and IKKε or IRF-3 is indirect and facilitated via the interaction of 
SFTSV NSs with TBK1 (X. Wu et al., 2014), another study described a direct interaction 
with IKKε (Ning et al., 2014). Similarly, whereas no direct interaction was observed 
between SFTSV NSs and RIG-I by Ning et al (Ning et al., 2014), another study reported a 
weak interaction between SFTSV NSs and RIG-I, which the authors indicated may be 
indirect and promoted via a direct interaction between SFTSV NSs and TRIM25 (Santiago 
et al., 2014).  
In addition to the IFN antagonist role at the level of IFN induction, SFTSV NSs was also 
shown to potently disrupt IFN signalling. This function was attributed to its interaction 
with and spatial isolation of STAT1 and STAT2, acting as an immunomodulator of the 
JAK/STAT signalling pathway (Chaudhary et al., 2015; Ning et al., 2015). Initially, a 
direct interaction between SFTSV NSs and the DNA-binding domain of STAT2 was 
reported only, which resulted in the inhibition of STAT2 phosphorylation and nuclear 
translocation of both STATs (Ning et al., 2015). However, a later report indicated that the 
inhibitory activity of SFTSV NSs on IFN signalling was additionally mediated through a 
direct interaction between SFTSV NSs and STAT1, which inhibited STAT1 
phosphorylation and its recruitment to IFN-stimulated promoters (Chaudhary et al., 2015).  
While the molecular mechanism utilized by SFTSV NSs protein to inhibit the IFN system 
has been extensively studied, that employed by UUKV and HRTV NSs proteins remain to 
be elucidated. Unfolding the mechanisms employed by the NSs proteins of tick-borne 
phleboviruses other than SFTSV to subvert the IFN system will serve to expand our 
knowledge on the viral immune evasion strategies utilized by these emerging pathogens. 
7.2 Aims 
The overall aim of this chapter was to perform a comparative characterization of the 
mechanisms employed by tick-borne phlebovirus NSs proteins to antagonise the IFN 
response. I aimed to elucidate whether the strategies utilized by UUKV, HRTV and 
SFTSV NSs proteins to hamper the IFN response are conserved or divergent. In particular, 
I aimed to identify interacting partners of UUKV and HRTV NSs proteins within the IFN 
induction and signalling cascades, and to investigate their subcellular localization, utilizing 
the well-characterized SFTSV NSs as a control. 
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7.3 Results 
7.3.1 Subcellular localization of UUKV, HRTV and SFTSV NSs 
In comparison to other viral proteins, the NSs proteins of bunyaviruses exhibit notoriously 
low conservation at the amino acid level (Elliott, 2014; Yu et al., 2011). To begin the 
characterization of tick-borne phlebovirus NSs proteins, the amino acid identity of UUKV 
(AAA47959.1), HRTV (AFP33392.1) and SFTSV (AJD86041.1) NSs proteins was 
compared using CLUSTAL Omega (McWilliam et al., 2013; Sievers et al., 2011) (Table 
6-1). While UUKV NSs shares a low amino acid sequence identity with HRTV (22.73%) 
and SFTSV (22.22%) NSs proteins, the identity between the NSs protein of the closely 
related HRTV and SFTSV is higher (62.76%) (Table 6-1).  
Table 6-1. Percentage amino acid identity of the tick-borne phlebovirus NSs proteins 
used in this study. 
 
 
 
 
* Based on accession numbers AAA47959.1, AFP33392.1 and AJD86041.1 for UUKV, 
HRTV and SFTSV NSs proteins, respectively. Generated using Clustal Omega. 
 
An alignment of the amino acid sequences of the three NSs proteins is shown in Figure 7-
1. Interestingly, a PxxP motif (P refers to Proline and x to any amino acid) which was 
identified in SFTSV NSs as a motif required for IB formation and its IFN antagonist 
activity (Ning et al., 2014) was conserved in HRTV NSs (Figure 7-1, highlighted in red). 
  
 Amino acid identity (%)* 
Virus UUKV HRTV SFTSV 
UUKV 100   
HRTV 22.73 100  
SFTSV 22.22 62.67 100 
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Figure 7-1. Amino acid sequence alignment of UUKV, HRTV and SFTSV NSs proteins.  
UUKV (AAA47959.1), HRTV (AFP33392.1) and SFTSV (AJD86041.1) NSs amino acid 
sequences were aligned using CLUSTAL Omega. “*” depicts conserved amino acids, “:” amino 
acids with similar properties, and “.”amino acids with weakly similar properties. The PxxP motif 
found in HRTV and SFTSV NSs is highlighted in red. UUKV: Uukuniemi virus; HRTV: Heartland 
virus; SFTSV: Sever fever with thrombocytopenia syndrome virus. 
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Given that the characteristic IBs formed by SFTSV NSs are key for its IFN antagonist 
activity, the subcellular localization of UUKV or HRTV NSs proteins was compared to 
that of SFTSV NSs. As well as IFN competent human A549 cells, cell lines which are IFN 
incompetent but can be readily infected by each of the viruses (namely BHK-21 cells for 
UUKV and Vero E6 for HRTV and SFTSV) were also used. Subconfluent cell monolayers 
were infected at a high MOI (3 FFU/cell), fixed at 24 h p.i. and probed with the 
appropriate anti-NSs antibodies prior to analysis by confocal microscopy. In agreement 
with a previous study (Simons et al., 1992), UUKV NSs showed cytoplasmic distribution, 
with small punctate staining in A549 and BHK-21 cell lines (Figure 7-2 A). Despite the 
higher amino acid conservation between HRTV and SFTSV NSs proteins, HRTV NSs was 
diffused in the cytoplasm of both A549 and Vero E6 cells (Figure 7-2 B). This is in 
comparison to SFTSV NSs, which formed characteristic cytoplasmic IBs (Figure 7-2 C). 
Because SFTSV NSs-induced IBs play an important role in the suppression of the IFN 
response via the sequestration of various components of the IFN pathways (Ning et al., 
2015; 2014; Santiago et al., 2014), the divergent subcellular localization of UUKV and 
HRTV NSs proteins in comparison to SFTSV NSs indicated that these proteins may utilise 
a disparate mechanism to that of SFTSV NSs to circumvent the IFN response.  
As detailed in chapter 6, C-terminal V5-tags were added to UUKV, HRTV and SFTSV 
NSs-expressing plasmids to be utilized in the transient expression assays. The aim of 
tagging the NSs proteins was to compare their expression levels by western blotting. To 
ensure that the subcellular localization of V5-tagged NSs proteins in the cell line used for 
transient transfection assays was similar to that of native NSs proteins upon virus infection, 
HEK293T cells were transfected with expression plasmids encoding the V5-tagged 
UUKV, HRTV or SFTSV NSs proteins. 24 h post transfection the transfected cells were 
fixed, permeabilized and probed with an anti-V5 antibody. Analysis by confocal 
microscopy revealed that the subcellular localization of V5-tagged UUKV, HRTV or 
SFTSV NSs proteins in HEK293T cells was similar to that described for the wild-type 
protein in other cell lines infected with the cognate viruses (Figure 7-3 and 7-2). 
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Figure 7-2. Subcellular localization of UUKV, HRTV and SFTSV NSs proteins. 
The subcellular localization of UUKV (A), HRTV (B) and SFTSV (C) was analysed by confocal 
microscopy following virus infection. The indicated cell lines were infected at a high MOI (3 
FFU/cell), or mock-infected. 24 h p.i. Cells were fixed, permeabilised and probed with the 
appropriate anti-NSs antibody. NSs proteins (green) and cell nuclei (blue) were visualized by 
confocal microscopy. Scale bars indicate 20 µm. UUKV: Uukuniemi virus; HRTV: Heartland 
virus; SFTSV: Sever Fever with Thrombocytopenia syndrome virus. 
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Figure 7-3. Subcellular localization of V5-tagged UUKV, HRTV and SFTSV NSs proteins. 
The subcellular localization of V5-tagged UUKV, HRTV and SFTSV NSs was investigated by 
confocal microscopy. HEK293T cells were transfected with plasmids encoding UUKV, HRTV or 
SFTSV NSs proteins tagged at their C terminus with a V5 tag (pCMVUUKNSsV5, 
pCMVHRTNSsV5 and pCMVSFTSNSsV5, respectively). 24 h post transfection cells were fixed, 
permeabilised and probed with an anti-V5 antibody. DAPI-stained nuclei (blue) and the V5-tagged 
NSs proteins (red) were visualized by confocal microscopy. Scale bars indicate 20 µm. UUKV: 
Uukuniemi virus; HRTV: Heartland virus; SFTSV: Sever fever with thrombocytopenia syndrome 
virus. 
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7.3.2 Dissection of the IFN induction pathway to study the inhibitory effect of UUKV, 
HRTV and SFTSV NSs proteins. 
To examine at which stage of IFN induction UUKV and HRTV NSs proteins exerted their 
IFN antagonist function, an IFN-β reporter assay was performed. In this assay a firefly 
luciferase reporter gene under the control of a murine IFN-β promoter is activated by the 
overexpression of various effectors of the IFN induction pathway (in this case 
constitutively active RIG-I N terminus [RIG-I N], MAVS, TBK1, IKKε, or a 
phosphomimetic, active form of IRF-3 [IRF-3 5D]). Similar assays have been commonly 
used to study the IFN antagonistic properties of the Ebola virus VP35 protein (Prins et al., 
2009), influenza virus PB1-F2 protein (Varga et al., 2011), the Nipah virus matrix protein 
(Bharaj et al., 2016), and the V protein of paramyxoviruses (Andrejeva et al., 2004). 
Firstly, the assay was optimised by examining the activation of the IFN-β promoter by 
various IFN induction effectors. Briefly, HEK293T cells were transfected with increasing 
amounts of expression plasmids encoding FLAG-tagged RIG-I N, MAVS, TBK1, IKKε, 
or untagged IRF-3 5D (kindly provided by Mirko Schmölke, University of Geneva), as 
well as a plasmid encoding firefly luciferase under the control of a murine IFN-β promoter 
(p[125]luc), and the transfection control plasmid encoding for Renilla luciferase under a 
CMV promoter (phRL). 18 h post transfection, the firefly and Renilla activities were 
measured, and firefly activity normalised against the Renilla control. Fold induction was 
expressed as the fold increase in normalised luciferase activity, relative to the non-
stimulated mock control that was transfected without any IFN induction effector 
expression plasmid. Overexpression of RIG-I N, MAVS, TBK1, IKKε, or IRF-3 5D 
resulted in transactivation of the IFN-β promoter. TBK1 exhibited the highest efficiency, 
resulting in a mean 1278-fold increase relative to the mock-transfected cells when the 
highest amount (100 ng) of TBK1 expression plasmid was added (Figure 7-4). Overall, at 
least a 100-fold increase in IFN-β promoter activation relative to the mock-transfected 
cells was detected when the lowest dose of all IFN induction effector expression plasmids 
was used (5 ng), indicating that the assay was functional with the overexpression all IFN 
induction effector components. 
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Figure 7-4. IFN-β promoter activation by effectors of the IFN induction pathway.  
HEK293T cells were transfected with the indicated amounts of IFN induction effector expression 
plasmids or with empty plasmid, along with a plasmid encoding firefly luciferase under the control 
of an IFN-β promoter  (p[125]luc), and a control CMV-driven expression plasmid encoding Renilla 
luciferase (phRL). The total amount of plasmid DNA in all reactions was kept constant by the 
addition of empty control plasmid to the DNA mix. 18 h post transfection the cell lysates were 
harvested, firefly and Renilla luciferase activities measured and firefly activity normalised against 
Renilla activity. Fold induction of the IFN-β promoter was calculated as the fold increase in 
normalised luciferase activity relative to the non-stimulated mock control. Dashed line indicates 
100-fold induction. The bars indicate mean fold induction in normalised luciferase activity (± SD) 
from a single experiment performed in duplicate (n=2). 
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Next, the effect of untagged or V5-tagged UUKV or HRTV NSs on the activation of the 
murine IFN-β promoter by overexpression of RIG-I N, MAVS, TBK1, IKKε, or IRF-3 5D 
was examined, utilizing SFTSV NSs as a control. Assays were performed in HEK293T 
cells as described above, utilizing 50 ng of IFN induction effector expression plasmids, to 
allow detection of the effector proteins by western blotting. Additionally, 250 ng of 
untagged or V5-tagged NSs protein-expressing plasmids were co-transfected (the highest 
dose of plasmid utilised in Section 6.3.3). 
While no inhibition by UUKV NSs was observed in RIG-I N, TBK1, IKKε, or IRF-3 5D-
induced IFN-β reporter assays, the presence of untagged or V5-tagged UUKV NSs resulted 
in a mean 55% or 45% inhibition of the MAVS-induced IFN-β promoter activation, 
respectively (Figure 7-5 A-E). Although a difference of 10% inhibition was observed 
between untagged and V5-tagged UUKV NSs at the level of MAVS, this difference was 
not statistically significant. Given that the N terminus of RIG-I is implicated in the 
subsequent activation of MAVS for signalling in the IFN induction pathway and that 
UUKV NSs impaired MAVS-induced IFN-β promoter activation, the lack of inhibition of 
RIG-I N-induced IFN-β promoter activation by UUKV NSs was surprising (Figure 7-5 A). 
However, the results presented in chapter 6 showed that UUKV NSs weakly inhibited the 
RIG-I N-induced production of IFN in a dose-dependent manner (Figure 6-4). Therefore, it 
is possible that transactivation of the murine IFN-β promoter via the overexpression of 
RIG-I N allows for the detection of an inhibitory effect by UUKV NSs when IFN 
production is measured by a biological IFN assay (Figure 6-4), whereas measuring IFN-β 
promoter-driven luciferase activity upon RIG-I N induction saturates the weak inhibitory 
effect of UUKV NSs at the level of RIG-I N (Figure 7-5 A). 
In comparison to UUKV NSs, the NSs protein of HRTV and SFTSV impaired RIG-I N, 
MAVS and TBK1 (Figure 7-5 A-C), but not IKKε, or IRF-3 5D -induced activation of the 
IFN-β promoter (Figure 7-5 D-E). Notably, whereas SFTSV NSs yielded 99.7% inhibition 
of TBK1-induced IFN-β promoter activation, only ~ 45% inhibition was observed by 
untagged and V5-tagged HRTV NSs (Figure 7-5 C). Nevertheless, the difference in 
inhibitory efficiency by SFTSV and HRTV NSs proteins on TBK1-induced IFN-β 
promoter activation may be due to the lower expression levels of HRTV NSs compared to 
SFTSV NSs, as detected by immunoblotting of the transfected cell lysates (Figure 7-5 C).  
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Figure 7-5. UUKV NSs protein inhibits IFN-β induction at the level of MAVS, whereas 
HRTV NSs antagonises at the level of TBK1.  
HEK293T cells were transfected with p(125)luc and phRL plasmid in the presence of untagged or 
V5-tagged UUKV, HRTV or SFTSV NSs proteins. The IFN-β promoter was stimulated by co-
transfection of FLAG-tagged inducer plasmids RIG-I N (A), MAVS (B), TBK1 (C), IKKε (D) or a 
plasmid expressing untagged IRF-3 5D (E). 18 h post transfection the cell lysates were harvested, 
firefly and Renilla luciferase activities measured and firefly activity normalised against Renilla 
activity. Fold induction of the IFN-β promoter was calculated as the fold increase in normalised 
luciferase activity relative to the non-stimulated mock control. Western blots for cell lysates of the 
transfected samples are shown in the lower panels. Data depicts three independent experiments 
performed in duplicate (n=3), presented as mean fold induction ± SEM. Statistical significance for 
the comparison of means between groups was determined by one-way ANOVA followed by 
Dunnet multiple comparisons post-hoc test. ****, p ≤ 0.0001; ***, p ≤ 0.001; **, p ≤ 0.01; *, p ≤ 
0.05. 
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7.3.3 Interaction between UUKV, HRTV and SFTSV NSs proteins and the IFN 
induction pathway 
The dissection of the IFN induction pathway enabled to pinpoint at which stage of the IFN 
induction pathway the tick-borne phlebovirus NSs proteins exhibited an inhibitory activity. 
In order to corroborate whether the inhibitory activity was due to direct interactions 
between the NSs proteins with individual effectors of the IFN induction pathway, 
immunoprecipitation (IP) studies were carried out. Briefly, HEK293T cells were 
transfected with each of the FLAG-tagged effectors of the IFN induction pathway or 
untagged IRF-3 5D individually, in the presence of the V5-tagged UUKV, HRTV or 
SFTSV NSs proteins. 18 h post transfection, the cell lysates were subjected to co-IP using 
FLAG-conjugated beads. Immunoprecipitated eluates as well as whole cell lysate samples 
(included to confirm that the transfected proteins were expressed) were analysed by 
western blotting. 
 V5-tagged UUKV NSs could only be precipitated with FLAG-tagged RIG-I N and 
MAVS, but not with TBK1, IKKε, or IRF-3 5D (Figure 7-6 A). This is in comparison to 
HRTV NSs, which behaved similarly to SFTSV NSs, as both the NSs proteins could be 
pulled down only with FLAG-tagged TBK1, but not RIG-I N, MAVS, IKKε, or IRF-3 5D. 
(Figure 7-6 B and C). No V5-tagged NSs proteins could be pulled down when cell lysates 
of cells transiently expressing only the individual V5-tagged proteins NSs proteins were 
subjected to IP with anti-FLAG beads, or using the anti-IRF-3 antibody (used for the 
aforementioned co-IPs) (Figure 7-6 D). 
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Figure 7-6. UUKV NSs interacts with RIG-I N and MAVS, whereas HRTV and SFTSV NSs 
interact with TBK1 in a transient overexpression system.  
HEK293T cells were co-transfected with V5-tagged UUKV (A), HRTV (B) or SFTSV (C) NSs 
proteins along with FLAG-tagged RIG-I N, MAVS, TBK1, IKKε or untagged IRF-3 5D. Cell 
lysates were subjected to co-IP with beads conjugated to FLAG or IRF-3 antibodies. V5-tagged 
UUKV, HRTV and SFTSV NSs proteins in the co-IP eluates (indicated with a black arrow) were 
detected by western blot using an anti-V5 antibody. (D) Control IP for V5-tagged NSs proteins 
pull-down. HEK293T cells were transfected with V5-tagged UUKV, HRTV or SFTSV NSs 
proteins only, and the cell lysates subjected to IP with beads conjugated to FLAG or IRF-3 
antibodies. IP eluates were analysed by western blot with an anti-V5 antibody. The results shown 
are representative of two independent experiments. IP: immunoprecipitation; WB: Western 
blotting; WCL: whole cell lysate. 
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7.3.4 UUKV NSs protein interacts with MAVS. 
In a transient overexpression system, V5-tagged UUKV NSs showed a direct interaction 
with the N terminus of RIG-I and MAVS (Figure 7-6 A). However, UUKV NSs blocked 
the MAVS- but not RIG-I N-induced activation of the IFN-β promoter in reporter assays 
(Figure 7-5 A and B), despite showing the dose-dependent inhibition of RIG-I N-mediated 
IFN production (chapter 6, Figure 6-4 A). To clarify these observations further and to 
confirm the interaction observed in a transient overexpression system between V5-tagged 
UUKV NSs and RIG-I N or MAVS, a reverse immunoprecipitation of UUKV NSs in the 
context of a virus infection was performed.  
Briefly, HEK293T cells were infected with UUKV at a high MOI (20 FFU/cell). Rather 
than aiming to detect endogenous RIG-I or MAVS, UUKV-infected cells were transfected 
with FLAG-tagged RIG-I N and MAVS 8 h p.i, because their overexpression allows for a 
more convenient approach for detection by western blotting. 30 h p.i. the cell lysates were 
subjected to co-IP using a rabbit polyclonal anti-UUKV NSs antibody (kindly provided by 
Anna Överby, Umeå University), followed by western blotting. While no RIG-I N could 
be detected in the IP eluates from UUKV-infected cells (Figure 7-7 A, left panel), FLAG-
tagged MAVS was precipitated in the IP eluates from UUKV-infected cells (Figure 7-7 A, 
right panel). The band detected belonging to FLAG-tagged MAVS was only visible upon 
long exposure of the membrane, and was weak relative to the expression levels observed in 
the whole cell lysate, suggesting a weak interaction (Figure 7-7, right panel).  These 
findings are at odds with the results obtained when both UUKV NSs and the FLAG-tagged 
IFN induction effector proteins were overexpressed and FLAG-tagged MAVS or RIG-I N 
subjected to IP. Under the latter conditions, a direct interaction was found between V5-
tagged UUKV NSs and both FLAG-tagged RIG-I N or MAVS (Figure 7-6 A). One 
explanation for such discrepancy could be that MAVS and RIG-I interact with each other 
through their 2CARD domains. Thus, the detection of UUKV NSs in IP eluates following 
immunoprecipitation of FLAG-tagged RIG-I N (which is in excess) could be a result of the 
direct interaction between UUKV NSs and endogenous MAVS, but not with 
overexpressed RIG-I N. On the other hand, immunoprecipitation UUKV NSs may result in 
undetectable amounts of FLAG-tagged RIG-I N pulled down as a result of the direct 
interaction of FLAG-tagged RIG-I N and endogenous MAVS. 
In order to corroborate these results, a reverse co-IP was also carried out under the same 
conditions as in the previous section (7.3.3) (i.e. HEK293T cells transiently expressing 
Chapter 7: Molecular mechanism of IFN antagonism by tick-borne phlebovirus NSs proteins 162 
both V5-tagged UUKV NSs and FLAG-tagged RIG I N or MAVS). 24 h post transfection, 
the cell lysates of transfected cells were utilized for co-IP using an anti-V5 antibody for the 
pull-down of V5-tagged UUKV NSs instead of immunoprecipitation of FLAG-tagged 
RIG-I N or MAVS. As observed in the context of UUKV infection (Figure 7-7 A), no 
FLAG-tagged RIG-I N could be detected in the IP eluate containing V5-tagged UUKV 
NSs (Figure 7-7 B, left panel) but a weak band corresponding to FLAG-tagged MAVS was 
detected (Figure 7-7 B, right panel). Therefore, these results suggest that UUKV NSs 
exhibits a weak, direct interaction with MAVS, but not with RIG-I N. This finding is in 
agreement with the weak inhibition of the MAVS-induced IFN-β reporter activity by 
UUKV NSs reported in section 7.3.2 (Figure 7-5). 
To confirm whether UUKV NSs could co-localise with MAVS, their subcellular 
localization was examined in HEK293T cells transiently expressing FLAG-tagged MAVS 
and V5-tagged UUKV NSs. Upon its activation, MAVS has been reported to adopt a 
speckled-like staining pattern (Onoguchi et al., 2010). Overexpression of FLAG-tagged 
MAVS in HEK293T cells resulted in the speckled-like staining characteristic of the active 
form of MAVS (Figure 7-8 C). V5-tagged UUKV NSs showed the distinct cytoplasmic, 
punctate staining described earlier (Figures 7-2 A, 7-3 and 7-8 B). Although in some 
HEK293T cells transiently expressing V5-tagged UUKV NSs and FLAG-tagged MAVS 
co-localization of UUKV NSs and MAVS was not obvious, close examination revealed 
partial co-localization of the small punctate UUKV NSs staining with MAVS speckles 
(Figure 7-8 D). The partial co-localization of UUKV NSs with MAVS is in agreement with 
the aforementioned hypothesis that the interaction between these two proteins is weak, and 
could explain the weak IFN antagonistic activity of UUKV NSs. 
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Figure 7-7. Interaction between UUKV NSs and MAVS detected by immunoprecipitation. 
(A) Co-IP of UUKV NSs protein upon UUKV infection in the presence of FLAG-RIG-I N or 
FLAG-MAVS. HEK293T cells were mock infected or infected with UUKV at a high MOI (20 
FFU/cell) for 8h, followed by a mock-transfection or transfection of FLAG-tagged RIG-I N (left 
panel) or MAVS-encoding plasmids (right panel). At 30 h p.i., the cell lysates were subjected to 
co-IP using an anti-UUKV NSs antibody, followed by detection of FLAG-tagged RIG-I N or 
MAVS and UUKV NSs by western blotting. (B) Co-IP of V5-tagged UUKV NSs in the presence 
of FLAG-RIG-I N or FLAG-MAVS. HEK293T cells were mock transfected, or transfected with 
V5-tagged UUKV NSs and FLAG-tagged RIG-I N (left panel) or MAVS (right panel). Cell lysates 
were subjected to co-IP with an anti-V5 antibody. FLAG-tagged RIG-I N and MAVS in the co-IP 
eluates were detected by western blotting with an anti-FLAG antibody. The results shown in this 
figure are representative of two experimental repeats. IP: immunoprecipitation, WB: Western 
blotting, WCL: whole cell lysate. 
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Figure 7-8. Subcellular localization of V5-tagged UUKV NSs and FLAG-tagged MAVS. 
Subcellular localization of UUKV NSs-V5 and MAVS-FLAG. HEK293T cells were mock-
transfected (A), or transfected with UUKV NSs-V5 (B), MAVS-FLAG (C) or both (D). 24 h post 
transfection the cells were fixed, permeabilised and probed with V5 (red) and FLAG (green) 
antibodies. DAPI-stained nuclei (blue) and subcellular localization of the proteins was analysed by 
confocal microscopy. Intensity profile graphs are shown at the bottom of the images. Scale bars 
indicate 10 µm. The results shown in this figure are representative of two experimental repeats. 
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7.3.5 HRTV NSs protein interacts with TBK1. 
Whereas the interaction between SFTSV NSs and TBK1 is well characterised, that of 
HRTV NSs with TBK1 is novel. To confirm the interaction observed between HRTV NSs 
and TBK1 in the context of HRTV infection, A549 cells were infected with HRTV at a 
high MOI (10 FFU/cell). 48 h p.i. the cell lysates were subjected to co-IP using an anti-
HRTV NSs antibody and immunoblotting. Endogenous TBK1 could be pulled down in 
HRTV-infected cells, when the NSs protein was immunoprecipitated (Figure 7-9 A). These 
data, along with the interaction observed between HRTV and TBK1 when overexpressed 
in immunoprecipitation studies (Figure 7-6 B), is in agreement with the inhibitory activity 
of HRTV NSs in TBK1-induced activation of the IFN-β promoter (Figure 7-5 C). 
In order to compare the interaction between HRTV NSs and TBK1 to that between SFTSV 
NSs and TBK1, the subcellular localization of TBK1 in the presence or absence of HRTV 
or SFTSV NSs proteins in HEK293T cells was examined. Briefly, HEK293T cells 
transiently expressing FLAG-tagged TBK1 and either V5-tagged HRTV or SFTSV NSs 
proteins were fixed, permeabilised and probed with anti-TBK1 and anti-V5 antibodies 24 h 
post transfection. Of note, an anti-TBK1 antibody rather than an anti-FLAG antibody was 
utilized, due to issues in detecting FLAG-tagged TBK1 by immunofluorescence using the 
latter antibody (data not shown). Whereas TBK1 showed diffused cytoplasmic staining on 
its own, TBK1 was clearly sequestered into IBs formed by SFTSV NSs in cells transiently 
expressing SFTSV NSs, as it has been previously described (Ning et al., 2014; Santiago et 
al., 2014; X. Wu et al., 2014). In contrast, in cells transfected with HRTV NSs, TBK1 
remained diffused in the cytoplasm, but co-localised with the HRTV NSs signal (Figure 7-
8 B).  
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 Figure 7-9. Interaction between HRTV NSs and TBK1.  
(A) co-IP of HRTV NSs in HRTV infected cells. Cell lysates of HRTV-infected A549 cells (MOI 
10 FFU/cell) were subjected to co-IP with an anti-HRTV NSs antibody. Western blotting was 
performed on eluates in order to detect endogenous TBK1 and HRTV NSs in infected cells. (B) 
Immunofluorescence studies of HEK293T cells transiently expressing TBK1-FLAG and V5-tagged 
HRTV or SFTSV NSs. HEK293T cells were fixed and permeabilised 24 h post transfection and 
probed with anti-TBK1 and anti-V5 antibodies. The subcellular localization of NSs proteins (red), 
TBK1 (green) and nuclei stained with DAPI (blue) were analysed by confocal microscopy. 
Intensity profile graphs are shown to the right of the image. Scale bars indicate 20 µm. The results 
shown are representative of at least two experimental repeats. IP: immunoprecipitation, WB: 
Western blotting, WCL: whole cell lysate. 
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7.3.6 Interaction between HRTV or SFTSV NSs and the IFN signalling pathway 
The results in chapter 6 indicated that while UUKV NSs was unable to inhibit type I and 
type II IFN signalling, HRTV and SFTSV NSs strongly blocked type I, but not type II IFN 
signalling. Other groups have shown that the mechanism by which SFTSV NSs blocks 
type I IFN signalling is by interacting with and sequestering STAT1 and STAT2 into IBs 
(Chaudhary et al., 2015; Ning et al., 2015).  To elucidate whether HRTV and SFTSV NSs 
have conserved the same interacting partners of the JAK/STAT signalling pathway, 
immunoprecipitation of V5-tagged tick-borne phlebovirus NSs proteins in HEK293T cells 
was carried out. The co-immunoprecipitation of endogenous STAT1 and STAT2 in the 
presence of HRTV and SFTSV NSs proteins was assessed, utilizing UUKV NSs as a 
negative control, as UUKV NSs does not block IFN signalling (Figure 6-6 and 6-7). In 
agreement with previous assays that showed no inhibition of IFN signalling by UUKV NSs 
(Figure 6-6 and 6-7), no STAT1 or STAT2 was co-immunoprecipitated in the presence of 
UUKV NSs (Figure 7-10 A). In contrast, endogenous STAT1 and STAT2 were co-
immunoprecipitated in the presence of V5-tagged HRTV or SFTSV NSs proteins (Figure 
7-10 A), suggesting the IFN signalling interacting partners of HRTV and SFTSV NSs 
proteins are conserved. Intriguingly, STAT2 levels in IP eluates were visibly higher than 
those of STAT1 (relative to the respective expression levels in the whole cell lysates).  
Indeed, long exposure was required in order to detect STAT1 in IP samples.  
STAT3 is a pleiotropic STAT that has been implicated in modulating inflammatory 
responses (Oh et al., 2011; Takeda et al., 1998; Yu et al., 2013). With this in mind, the 
ability of tick-borne phlebovirus NSs proteins to interact with STAT3 was investigated 
using an assay similar to the one described in the previous paragraph. No STAT-3 was co-
immunoprecipitated along with the tick-borne phlebovirus V5-tagged NSs proteins (Figure 
7-10 B).  
One study has reported that only STAT2 (but not STAT1) phosphorylation is inhibited by 
SFTSV NSs (Ning et al., 2015). Another study has shown that the phosphorylation of  
STAT2 as well as STAT1 at position Ser727 is blocked by SFTSV NSs (Chaudhary et al., 
2015). The ability of HRTV or SFTSV NSs proteins to hamper STAT1 or STAT2 
phosphorylation was examined utilizing UUKV NSs as a negative control. Briefly, 
HEK293T cells transiently expressing untagged, or V5-tagged UUKV, HRTV or SFTSV 
NSs proteins were treated with recombinant IFN-β for 30 min, and the cell lysates 
harvested for immunoblotting analysis 24 h post transfection. At odds with the findings by 
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Chaudhary et al (Chaudhary et al., 2015), no difference in phosphorylated STAT1 (at 
positions Ser727 or Tyr701) or STAT1 levels was observed in the presence of UUKV, 
HRTV or SFTSV NSs proteins, compared to the mock control (Figure 7-10 C). While in 
the presence of the tick-borne phlebovirus NSs proteins STAT2 levels also remained 
unchanged compared to the mock control, the presence of HRTV and SFTSV NSs proteins 
resulted in a reduction of STAT2 phosphorylation at position Tyr690, compared to the 
levels found in the mock control and the UUKV NSs-transfected controls (Figure 7-10 C).   
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Figure 7-10. Interaction between UUKV, HRTV or SFTSV NSs and STAT proteins.  
Cell lysates from HEK293T cells transiently expressing V5-tagged UUKV, HRTV or SFTSV NSs 
were immunoprecipitated with an anti-V5 antibody and analysed by western blot with STAT1 and 
STAT2 antibodies (A), or a STAT3 antibody (B). (C) Phosphorylation of STAT1 and STAT2 in 
HEK293T cells upon treatment with recombinant IFN-β. HEK293T cells transiently expressing 
untagged or V5-tagged UUKV, HRTV or SFTSV NSs were treated with recombinant IFN-β 24 h 
post transfection. Upon 30 min of IFN-β treatment, cell lysates were harvested and utilised for 
immunoblotting of STAT2, STAT2 phosphorylated at Tyr690, STAT1, STAT1 phosphorylated at 
Ser727 and Tyr701, actin and V5 with the appropriate antibodies. The results shown are 
representative of at least two experimental repeats. IP: immunoprecipitation, WB: Western 
blotting, WCL: whole cell lysate. 
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7.3.7 The effect of HRTV and SFTSV NSs proteins on STAT1 and STAT2 nuclear 
translocation. 
In this section, the ability of HRTV and SFTSV NSs proteins to inhibit the IFN-induced 
nuclear translocation of STAT1 and STAT2 were compared. As HeLa cells have been 
previously utilised to visualise the sequestration of STAT1 and STAT2 into SFTSV NSs-
formed IBs (Chaudhary et al., 2015), and because this cell line was commonly used for 
similar studies in Prof Jin Dong-Yan’s laboratory (University of Hong Kong, where these 
assays were carried out), the HeLa cell line was chosen for  this part of the study. Briefly, 
HeLa cells transiently expressing V5-tagged HRTV or SFTSV NSs proteins were treated 
with recombinant IFN-β for 30 min 24 h post transfection, prior to immunofluorescence 
using anti-V5 and anti- STAT1 or STAT2 antibodies. As expected, in untransfected cells 
STAT1 remained cytoplasmic (Figure 7-11 A), whereas nuclear translocation of STAT1 
was observed following IFN-β treatment (Figure 7-11 B). Although in cells transiently 
expressing SFTSV NSs STAT1 was sequestered into the characteristic IBs, its 
translocation to the nucleus as a result of IFN-β stimulation was not completely inhibited, 
as nuclear STAT1 could also be detected (Figure 7-11 C). Expression of HRTV NSs did 
not result in an accumulation of STAT1 into IBs as noted for SFTSV NSs, but instead 
STAT1 appeared diffused throughout the cytoplasm, as well as in the nucleus (Figure 7-11 
D). In contrast to STAT1, no nuclear translocation of STAT2 was observed following IFN-
β stimulation in cells transiently expressing HRTV or SFTSV NSs proteins (Figure 7-12 
B-C). As observed with TBK1 (Figure 7-8 B) and STAT1 (Figure 7-11 C), STAT2 
remained diffused in the cytoplasm in the presence of HRTV NSs, whereas a clear 
sequestration of STAT2 into IBs formed by SFTSV NSs was observed (Figure 7-12 B-C). 
Thus, these results indicate that the interaction between HRTV or SFTSV NSs proteins 
with STAT2 (but not STAT1) results in the efficient inhibition of IFN-β induced STAT2 
(but not STAT1) nuclear translocation. 
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Figure 7-11. Inhibition of IFN-β-induced STAT1 nuclear translocation by HRTV and SFTSV 
NSs proteins.  
Mock HeLa cells (A-B) or HeLa cells transiently expressing V5-tagged SFTSV (C) or HRTV NSs 
(D) proteins were treated with IFN-β (1000 U/mL) for 30 min, or left untreated 24 h post 
transfection. Upon IFN treatment, the cells were fixed, permeabilized and probed with V5 and 
STAT1 antibodies. The subcellular localization of endogenous STAT1 (red), V5-tagged NSs 
proteins (green) and DAPI-stained nuclei (blue) was analysed by confocal microscopy. Scale bars 
indicate 20 µm. The results shown are representative of at least two experimental repeats. 
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Figure 7-12. Inhibition of IFN-β-induced STAT2 nuclear translocation by HRTV and SFTSV 
NSs proteins.  
Mock HeLa cells (A-B) or HeLa cells transiently expressing V5-tagged SFTSV (C) or HRTV NSs 
(D) proteins were treated with IFN-β (1000 U/mL) for 30 min, or left untreated 24 h post 
transfection. Upon IFN treatment, the cells were fixed, permeabilized and probed with V5 and 
STAT2 antibodies. The subcellular localization of endogenous STAT2 (red), V5-tagged NSs 
proteins (green) and DAPI-stained nuclei (blue) was analysed by confocal microscopy. Scale bars 
indicate 20 µm. The results shown are representative of at least two experimental repeats. 
 
 
A 
+ 
IF
N
-β
 (1
00
0U
/m
L)
 
M
oc
k 
H
RT
V
 N
Ss
-V
5 
SF
TS
V
 N
Ss
-V
5 
M
oc
k 
STAT-2 V5 
V5 
V5 
V5 
DAPI 
DAPI 
DAPI 
DAPI 
STAT-2 
STAT-2 
STAT-2 
DAPI 
V5 
STAT-2 
DAPI 
V5 
STAT-2 
DAPI 
V5 
STAT-2 
DAPI 
V5 
STAT-2 
B 
D 
C 
Chapter 7: Molecular mechanism of IFN antagonism by tick-borne phlebovirus NSs proteins 173 
The results in chapter 6 showed that none of the tick-borne phlebovirus NSs proteins 
concerning this study are able to inhibit type II IFN signalling (Figure 6-7 A and B). Type 
II IFN signalling is majorly mediated by STAT1 homodimers. Thus, I aimed to investigate 
whether the lack of inhibitory activity of HRTV and SFTSV NSs proteins on type II IFN 
signalling was due to their inability to hinder the nuclear translocation of STAT1 following 
IFN-γ treatment. In mock-transfected, mock-treated cells STAT1 remained cytoplasmic 
(Figure 7-13 A), and IFN-γ stimulation resulted in its nuclear translocation (Figure 7-13 
B). As observed upon IFN-β stimulation, nuclear translocation of STAT1 was also 
detected in cells transiently expressing V5-tagged HRTV or SFTSV NSs proteins when 
stimulated with IFN-γ (Figure 7-13 C and D). Additionally, some STAT1 was sequestered 
in SFTSV NSs-formed IBs, which were absent in HRTV NSs-expressing cells (Figure 7-
13 C and D). Taken together, these findings suggest that the weak interaction of HRTV or 
SFTSV NSs proteins with STAT1 (Figure 7-10 A) does not lead to the inhibition of type II 
IFN signalling (described in Chapter 6, Section 6.3.4, Figure 6-7). Presumably, this is due 
to their inability to efficiently block the translocation of STAT1 homodimers to the 
nucleus, the major route of IFN-γ signalling utilized to activate the transcription of GAS 
elements. 
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Figure 7-13. Inhibition of IFN-γ-induced STAT1 nuclear translocation by HRTV and SFTSV 
NSs proteins.  
Mock HeLa cells (A-B) HeLa cells transiently expressing V5-tagged SFTSV (C) or HRTV (D) 
NSs proteins were treated with IFN-γ (100 ng) for 30 min, or left untreated 24 h post transfection. 
Upon IFN treatment, the cells were fixed, permeabilized and probed with V5 and STAT1 
antibodies. The subcellular localization of endogenous STAT1 (red), V5-tagged NSs proteins 
(green) and DAPI-stained nuclei (blue) was analysed by confocal microscopy. Scale bars indicate 
20 µm. The results shown are representative of at least two experimental repeats. 
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7.4 Discussion 
In this chapter, a comparative study was carried out to characterize the molecular 
mechanisms employed by tick-borne phlebovirus NSs proteins to block the human IFN 
response. The results in chapter 6 indicated that UUKV, HRTV and SFTSV NSs proteins 
are able to supress IFN induction. However, HRTV and SFTSV NSs, but not UUKV NSs, 
are capable of blocking type I IFN signalling. In addition, none of the tick-borne 
phlebovirus NSs proteins relevant to this study were able to suppress type II IFN 
signalling. Understanding the approaches employed by UUKV and HRTV NSs proteins to 
hinder IFN induction and/or signalling serves to expand our knowledge on the viral 
immune evasion strategies utilised by emerging tick-borne phleboviruses. 
The NSs proteins of bunyaviruses show notoriously low conservation at the amino acid 
level in comparison to other viral proteins (Elliott, 2014; Yu et al., 2011). In fact, among 
the NSs proteins relevant to this study, UUKV NSs shares only 23% amino acid sequence 
identity with HRTV and SFTSV NSs proteins (Table 6-1). The amino acid sequence 
identity of the NSs proteins belonging to the more closely related HRTV and SFTSV is 
higher (62.76%) (Table 6-1). However, the higher conservation between the latter two is 
not reflected in their subcellular localization. In UUKV-infected cells and cells expressing 
only V5-tagged UUKV NSs in the absence of other viral proteins, UUKV NSs showed 
small, punctate cytoplasmic staining, which is in agreement with previous studies (Simons 
et al., 1992) (Figure 7-2 A). While SFTSV NSs formed distinct round, cytoplasmic IBs 
(Ning et al., 2015; 2014; Santiago et al., 2014), the subcellular localization of HRTV NSs 
resembled more closely that of UUKV NSs, exhibiting diffused cytoplasmic distribution 
(7-2 B and C). A PxxP motif located at the N terminus (amino acid residues 66-69) of 
SFTSV NSs was suggested to be required for the formation of SFTSV NSs-induced IBs, 
and for its IFN antagonistic function (Ning et al., 2014). In fact, simultaneous substitution 
of SFTSV NSs P66 and P69 resulted in the cytoplasmic localization of SFTSV NSs and 
the loss of its IFN inhibitory activity in transient transfection assays. Curiously, the PxxP 
motif was conserved in the HRTV NSs amino acid sequence (Figure 7-1) despite the 
diffused cytoplasmic distribution of HRTV NSs. It should be considered that prolines are 
unique amino acids with a cyclic structure that gives the amino acid conformational 
rigidity. The biochemical properties of proline residues play a key role in determining a 
protein’s secondary and tertiary structure, commonly introducing kinks and turns. 
Therefore, it is possible that the mere presence of the PxxP motif in SFTSV NSs may be 
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required but not sufficient for IB formation, as HRTV NSs is unable to form IBs despite 
the conservation of the PxxP motif. However, this motif may be one of the contributing 
factors in the overall protein structure required for IB formation for SFTSV NSs. 
Determining the structure of these two NSs proteins could provide insights into the 
relevance of the PxxP motif in the formation of SFTSV NSs IBs in comparison to HRTV 
NSs. 
Collectively, given that the IBs formed by SFTSV NSs play a key role in its IFN 
antagonist activity (Ning et al., 2014; Santiago et al., 2014), the low amino acid sequence 
identity and the divergent subcellular localization between UUKV or HRTV NSs and that 
of SFTSV NSs led me to hypothesize that these proteins may have acquired disparate 
strategies to that of SFTSV NSs to circumvent the IFN response. The findings presented in 
this chapter provide an insight into the diverse strategies tick-borne phleboviruses utilise to 
supress IFN induction and IFN signalling.  
Firstly, transient transfection assays indicated that UUKV NSs weakly inhibits MAVS-
induced IFN-β promoter activation (Figure 7-5 B). These results correlate with the 
interaction detected in co-IP experiments between UUKV NSs and MAVS in the context 
of overexpression assays (Figures 7-6 A and 7-7 B) and virus infection (Figure 7-7 A). In 
addition, this interaction was examined using confocal microscopy, which revealed that 
some of the punctate cytoplasmic UUKV NSs staining co-localised with the speckle-like 
structures formed by MAVS (Figure 7-8). These findings suggest that the weak IFN 
antagonistic activity of UUKV NSs at the level of IFN induction (described in Chapter 6) 
occurs through a weak interaction with MAVS. TOSV NSs protein, similarly to UUKV 
NSs, also inhibits the induction of type I IFN at early stages of the IFN induction pathway, 
but targets RIG-I for proteasomal degradation (Gori-Savellini et al., 2013). As it stands, 
targeting MAVS is a novel strategy described for phlebovirus NSs proteins to block the 
IFN response.  Other viruses such as Influenza A virus can also block MAVS-mediated 
IFN induction. Specifically, the Influenza A virus PB1-F2 protein inhibits IFN synthesis 
by binding to MAVS and altering the mitochondrial membrane potential (Varga et al., 
2011; 2012), which is known to mediate IFN induction through the rearrangement of 
MAVS (Koshiba et al., 2011). It would be interesting to investigate whether UUKV NSs 
utilizes similar mechanisms to that of Influenza virus PB1-F2 protein to block MAVS-
mediated IFN induction.  
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The data presented herein also indicates that the IFN induction and signalling interacting 
partners of HRTV NSs and SFTSV NSs are conserved, despite exhibiting contrasting 
subcellular localization and sharing 63% amino acid identity. Co-IP studies demonstrated 
that, similarly to SFTSV NSs, HRTV NSs interacts with TBK1 in overexpression assays 
(Figure 7-6 B) as well as in the context of a virus infection (Figure 7-9 A). These results 
correlate with the inhibition of the RIG-I N, MAVS, and TBK1-induced IFN-β promoter 
activation by HRTV NSs (Figure 7-5). While in the presence of SFTSV NSs TBK1 was 
clearly sequestered into NSs-formed IBs, TBK1 exhibited diffused cytoplasmic staining in 
the presence of HRTV NSs, but co-localised with HRTV NSs signal (Figure 7-9 B). Taken 
together, these findings suggest that some key characteristics between HRTV and SFTSV 
NSs are conserved, such as their ability to interact with TBK1. However, the strategy used 
by HRTV NSs to exert its antagonistic function is not identical to that of SFTSV NSs, 
which sequesters TBK1 into NSs-formed IBs. It is possible that HRTV NSs prevents the 
activation of TBK1 by hindering its phosphorylation by IKKβ, trans-autophosphorylation 
or K63-linked polyubiquitination, all of which have been proposed to contribute to TBK1 
activation (Kishore et al., 2002; Ma et al., 2012; Tu et al., 2013).  Whether any of these 
mechanisms are utilized by HRTV NSs to inhibit TBK1-mediated signalling pathways 
remains to be elucidated. 
In addition to IFN induction, the findings in this chapter provide insights into the 
mechanism of IFN signalling inhibition by HRTV NSs. Co-IP experiments showed that 
STAT1 and STAT2, but not STAT3 could be immunoprecipitated with HRTV and SFTSV 
NSs proteins (Figure 7-10 A and B). This finding suggested that the IFN signalling 
inhibitory activity of HRTV NSs protein is mediated by its interactions with STAT1 and 
STAT2, as it has already been demonstrated for SFTSV NSs (Chaudhary et al., 2015; Ning 
et al., 2015). STAT3 is known to play a role in regulating inflammatory responses by 
regulating T cell proliferation by preventing apoptosis (Takeda et al., 1998), and CD4+ and 
CD8+ T cell survival and differentiation (Oh et al., 2011; Yu et al., 2013).  Therefore, the 
lack of interaction between the NSs proteins and STAT3 (Figure 7-10 B) may be a 
contributing factor to the strong inflammatory responses that could play a role in HRTV or 
SFTSV –infected patients.  
Importantly, a stronger interaction between HRTV or SFTSV NSs and STAT2 than that 
between the NSs proteins and STAT1 was observed in co-IP assays (Figure 7-10 A), which 
could explain the ability of these NSs proteins to block type I but not type II IFN 
signalling. While type I IFN signalling is mediated majorly through the activation of ISRE 
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elements by STAT1-STAT2 heterodimers, type II IFN signalling is mediated via the 
activation of GAS elements by STAT1 homodimers. Therefore, the interaction of HRTV 
and SFTSV NSs proteins with STAT2 may result in inhibition of type I IFN signalling, 
while the weak interaction with STAT1 may explain the lack of type II IFN signalling 
inhibitory activity by the NSs proteins. However, it remains a possibility that, in the 
presence of HRTV or SFTSV NSs proteins, STAT1-STAT2 heterodimers are precipitated, 
and therefore the STAT1 detected in the IP eluates is not a result of a direct interaction 
with the NSs proteins, but rather an indirect interaction mediated via an interaction with 
STAT2 and pulldown of STAT1-STAT2 heterodimers.  
Additionally, the results described in this chapter show that the IFN-β-induced STAT2 (but 
not STAT1) phosphorylation appears to be reduced in the presence of HRTV and SFTSV 
NSs proteins (Figure 7-10 C). These results are in agreement with previous reports which 
showed that SFTSV inhibits STAT2, but not STAT1 phosphorylation (Ning et al., 2015).  
The ability of HRTV NSs to hamper the IFN-induced nuclear translocation of STAT1 and 
STAT2 in a similar manner to SFTSV NSs was also examined. In the presence of SFTSV 
NSs, both STAT1 and STAT2 were sequestered into SFTSV NSs-induced IBs. However, 
while no IFN-β-induced nuclear translocation of STAT2 was detected in cells expressing 
SFTSV NSs, the IFN-β and IFN-γ -induced nuclear translocation of STAT1 was not 
efficiently inhibited (Figures 7-11, 7-12, and 7-13). Similarly, only the IFN-β-induced 
nuclear translocation of STAT2, but not the IFN-β or IFN-γ -induced nuclear translocation 
of STAT1 was efficiently inhibited in the presence of HRTV NSs (Figures 7-11, 7-12, and 
7-13). The ability of both NSs proteins to block IFN-induced STAT2 nuclear translocation 
more efficiently than STAT1 nuclear translocation is consistent with the finding that the 
NSs proteins can partially inhibit STAT2 but not STAT1 phosphorylation (Figure 7-10 C). 
Perhaps the ability of STAT1 to translocate to the nucleus upon IFN stimulation in the 
presence of HRTV or SFTSV NSs proteins (in contrast to STAT2) is a result of the weak 
or indirect interaction between STAT1 and the NSs proteins, as noted above.  Additionally, 
it has also been shown that STAT1-STAT1 homodimers can also form and play a role in 
the transcriptional activation of ISGs during type I IFN signalling, albeit a less critical role 
than STAT1-STAT2 heterodimers (Li et al., 1996; Ramana et al., 2000). Therefore, if the 
interaction between the NSs proteins and STAT1 is indirect (facilitated by the interaction 
of the NSs proteins with STAT2 in STAT1-STAT2 heterodimers), the detection of nuclear 
STAT1 may result due to the inability of the NSs proteins to directly interact with STAT1 
and inhibit the nuclear traslocation of STAT1 homodimers. On the other hand, the 
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cytoplasmic localization of STAT1 may be a result of the ability of the NSs proteins to 
interact with and efficiently inhibit the nuclear translocation of STAT1-STAT2 
heterodimers. 
 In comparison to SFTSV NSs, HRTV NSs did not result in the sequestration of STAT1 or 
STAT2 to IBs, but instead the proteins remained diffused in the cytoplasm (Figures 7-11, 
7-12 and 7-13). Thus, in contrast to SFTSV NSs, STAT1 and STAT2 are not sequestered 
into IBs by HRTV NSs, but instead simply an interaction between STAT2 and HRTV NSs 
may inhibit STAT2 phosphorylation and thus the translocation of STAT1-STAT2 
heterodimers to the nucleus, consequently resulting in abrogation of type I IFN signalling.    
Taken together, the findings presented in this chapter expand our knowledge of the 
plethora of immune evasion strategies that tick-borne pheboviruses have acquired to 
suppress the IFN response. The proposed model of the tick-borne phlebovirus NSs 
antagonist role is summarised in Figure 7-14. Whereas UUKV NSs inhibits IFN induction 
through a direct interaction with MAVS, the NSs protein of HRTV and SFTSV target the 
immunomodulatory kinase TBK1 to supress the production of IFN. HRTV and SFTSV 
NSs proteins have an additional IFN signalling inhibitory role, which occurs mainly in a 
STAT2-dependent manner. As it stands, the weak or indirect interaction between HRTV or 
SFTSV NSs and STAT1, in addition to the direct interaction with STAT2 may play a role 
in the differential regulation of type I and type II IFN signalling: it is possible that the NSs 
proteins inhibit the STAT1-STAT2 heterodimer-dependent activation of the ISRE 
promoter through a direct interaction with STAT2, but not that of the STAT1 homodimer-
dependent activation of the GAS promoter. However, further experiments such as 
chromatin immunoprecipitation studies are required to confirm this hypothesis. 
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Figure 7-14. Schematic summary of the mechanisms utilized by tick-borne phlebovirus NSs 
proteins to inhibit the canonical IFN induction and signalling pathways.  
(A) Following bunyavirus infection, the generation of single stranded RNA (ssRNA) with 
uncapped 5’ triphosphate ends during uncoating, transcription or replication results in ssRNA 
binding to the RNA helicase RIG-I. RIG-I is in turn activated and exposure of its associated CARD 
domains allows the recruitment of the adaptor MAVS through CARD-CARD interactions. 
Activation of MAVS leads to the subsequent activation of kinases TBK1 and/or IKKε, which 
concomitantly phosphorylate IRF-3 or IRF-7 at specific serine residues. Phosphorylation of IRF-3 
or IRF-7 leads to their dimerization and translocation to the nucleus, where they ultimately 
stimulate transcription of genes under the control of the IFN α/β promoter, resulting in the 
secretion of IFN α/β. The kinase IKKβ can also be ultimately activated in the signalling pathway, 
which leads to the phosphorylation of IκB. IκB phosphorylation results in its ubiquitination and 
proteasomal degradation, freeing NF-κB for translocation to the nucleus, where it can also 
assemble on the IFN α/β promoter. (B) Signal transduction of type I, II and III IFNs initiates 
through the binding of secreted IFN to the respective IFN receptors and the activation of multiple 
downstream signalling pathways. Type I and type III IFN signalling pathways are majorly 
mediated via STAT1-STAT2 heterodimers. Receptor-associated kinases JAK1 and TYK2 become 
activated and phosphorylate STAT1 and STAT2, respectively, on specific tyrosine and/or serine 
residues. Phosphorylated STATs can heterodimerise and recruit IRF9 for the assembly of the 
heterotrimer complex ISGF3. ISGF3 translocates to the nucleus and binds to ISRE, leading to the 
induction of many IFN stimulated genes (ISG). Type III IFN signalling is more commonly 
associated with signalling by homodimerization of STAT1, which can translocate to the nucleus 
and activate GAS promoters, also initiating ISG transcription. Tick-borne phlebovirus NSs proteins 
have evolved a number of countermeasures to block the IFN pathway. SFTSV NSs directly 
interacts with and sequesters TBK1, and STAT2 into inclusion bodies, in order to spatially isolate 
these elements. Additionally, through its interaction with TBK1 and STAT2, SFTSV NSs can also 
indirectly sequester IKKε, IRF-3 and STAT1 into the inclusion bodies. An interaction between 
SFTSV NSs and TRIM-25 also facilitates the spatial isolation of RIG-I, in an indirect manner. 
HRTV NSs can also block IFN induction through a direct interaction with TBK1 and IFN 
signalling by a direct interaction with STAT2. However, as HRTV NSs does not form inclusion 
bodies as SFTSV NSs does, its mechanism of antagonism is different to that of SFTSV NSs. 
UUKV NSs block IFN induction only, targeting MAVS. For references, see text. Dashed red lines 
indicate indirect interactions. Solid red lines indicate direct interactions. CARD: caspase 
recruitment domain; GAS: γ-activated sequence; IFNAR: interferon-α/β receptor; IKKε: IκB 
kinase-ε; IRF: IFN-regulatory factor; ISGF3: IFN-stimulated gene factor 3; ISGs: IFN-stimulated 
genes; ISRE: IFN-stimulated response element; JAK: janus kinase; MAVS: mitochondrial antiviral 
signalling protein; RIG-I: retinoic acid-inducible gene I; STAT: signal transducer and activator of 
transcription; TBK1: TANK-binding kinase 1; TYK: tyrosine kinase.   
Chapter 7: Molecular mechanism of IFN antagonism by tick-borne phlebovirus NSs proteins 182 
7.5 Summary 
• Although HRTV NSs is more highly conserved in amino acid sequence with 
SFTSV NSs (sharing 63% amino acid identity) than with UUKV NSs (sharing 23% 
amino acid identity), the subcellular localization of HRTV NSs in infected cells and 
in cells transiently expressing HRTV NSs resembles that of UUKV NSs more 
closely, displaying diffused cytoplasmic staining. This is in comparison to SFTSV 
NSs, which forms characteristic round, cytoplasmic IBs, which are important for 
the sequestration of effectors of the innate immune signalling pathways 
• While UUKV NSs inhibited MAVS-induced IFN-β reporter activity in transient 
transfection assays, both HRTV and SFTSV NSs proteins blocked RIG-I N, MAVS 
and TBK1-induced IFN-β reporter activity.  
• UUKV NSs is able to weakly interact with MAVS in overexpression assays and in 
the context of a virus infection. Small, punctate structures formed by UUKV NSs 
partially co-localized with characteristic speckles formed by MAVS. The weak 
interaction between UUKV NSs and MAVS may serve as an explanation for the 
weak IFN antagonistic activity of UUKV NSs.  
• Similar to the NSs protein of SFTSV, HRTV NSs can interact with TBK1 to inhibit 
IFN induction. However, while the mechanism of inhibition by SFTSV NSs occurs 
through the spatial isolation of TBK1 into IBs, these structures are not formed by 
HRTV NSs. Instead, in the presence of HRTV NSs TBK1 remains diffused in the 
cytoplasm, but colocalises with HRTV NSs signal. 
• HRTV and SFTSV NSs proteins can interact with STAT1 and STAT2, but not 
STAT3. Co-IP experiments showed a stronger interaction between the NSs proteins 
and STAT2 than with STAT1, suggesting that the interaction of the NSs proteins 
with STAT1 may be indirect, facilitated by their direct interaction with STAT2. 
This observation was also reflected in the ability of the NSs proteins to efficiently 
block the nuclear translocation of STAT2 upon IFN-β treatment, but not that of 
STAT1 following IFN-β or IFN-γ treatment. These results may indicate why 
HRTV and SFTSV NSs proteins are able to inhibit type I, but not type II IFN 
signalling.
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8 Development of a HRTV minigenome system to 
assess tick-borne phlebovirus genome reassortment 
8.1 Introduction 
Like other bunyaviruses, tick-borne phleboviruses have a tri-segmented genome of 
negative- or ambi-sense. Their S segment utilizes an ambi-sense coding strategy, where the 
nucleocapsid protein N is translated from subgenomic mRNA transcribed from the 
genomic RNA, and non-structural protein NSs is translated from subgenomic mRNA 
transcribed from antigenomic RNA (Figure 1-4 B) (Bouloy and Weber, 2010). The M and 
L segments utilize a negative-sense coding strategy. While the M segment encodes the 
glycoprotein precursor, which is cleaved for the generation of the glycoproteins Gn and 
Gc, the L segment encodes the viral RNA-dependent RNA polymerase (RdRp, or L 
protein). Because of the segmented nature of these viruses, if closely related viruses co-
infect the same host or vector cell, it is possible that RNA segments from either of the 
parental viruses are incorporated into progeny virions, and thus the genome of the 
reassortant progeny virions will be composed of a mixture of RNA segments belonging to 
the parental viruses.  
This genetic exchange phenomenon, known as genome reassortment, plays an important 
role in the evolution of segmented viruses. Genome reassortment can accelerate the rate of 
acquisition of markers that can alter virus phenotype, tropism, transmissibility, and host 
range, as well as introducing new immunogenic characteristics that could enable 
reassortant viruses to escape immune surveillance (Briese et al., 2013; Elliott, 2014).  
Within the Phlebovirus genus, genome analyses have suggested that a number of 
mosquito-borne viruses are reassortants of existing or unidentified viruses (Bird et al., 
2007; Collao et al., 2010; Palacios et al., 2011). Homologous recombination of the L 
segment of the recently emerged tick-borne Severe fever with thrombocytopenia syndrome 
virus (SFTSV) was suggested to play a role in the evolution of this virus (Lam et al., 
2013). Homologous recombination is a different form of genetic reassortment, driven by a 
template switch mechanism in which the replicating RdRp can dissociate from one genome 
and continue replication using the genome of a co-infecting virus as the template, resulting 
in a new mosaic-like genome (Vijaykrishna et al., 2015).  
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Little is known about the possibility of reassortment between tick-borne phleboviruses. In 
addition, no experimental evidence exists to support the above-mentioned phylogenetic 
studies that suggest that certain members of the Phlebovirus genus are reassortant progeny. 
The availability of phlebovirus reverse genetics systems could aid to understand the 
potential of genome reassortment under experimental conditions, by assessing the 
compatibility of viral proteins of one virus with another to form viable progeny. So far, 
reverse genetics systems for the tick-borne phleboviruses Uukuniemi virus (UUKV) 
(described in Chapter 5), and SFTSV (Brennan et al., 2015) have been described. Apart 
from UUKV and SFTSV, Heartland virus (HRTV) is another tick-borne phlebovirus 
available in our laboratory. HRTV is closely related to SFTSV but was isolated in the 
United States and was associated with two deaths (McMullan et al., 2012; Muehlenbachs 
et al., 2014; Williams, 2014). The availability of a reverse genetics system for HRTV 
could provide an additional tool to investigate the molecular biology of tick-borne 
phleboviruses. Additionally, in conjunction with the reverse genetics systems developed 
for UUKV and SFTSV, the ability of tick-borne phlebovirus proteins to replicate, 
transcribe and package the genome of related viruses could be tested. These tools could 
help to understand whether genome reassortment acts as a force to drive the evolution of 
these emerging viruses, and to predict possible outcomes of reassortant viruses in nature 
under an experimental setting. Such studies could enable better preparedness for the 
emergence of new reassortant tick-borne phleboviruses with the timely development of 
vaccines. 
8.2 Aims 
The aims of this chapter were to: (i) sequence the HRTV laboratory stock, (ii) develop a 
HRTV minigenome system, (iii) attempt to rescue infectious HRTV entirely from cDNA 
clones, and (iv) utilise the HRTV minigenome in combination with the minigenomes 
available for other tick borne phleboviruses. The aim of the latter experiment was to 
examine the compatibility of the N and L proteins of a particular tick-borne phlebovirus 
with the UTRs from a different tick-borne phlebovirus at the molecular level, in order to 
assess the potential for reassortment to take place. 
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8.3 Results 
8.3.1 Sequencing of the laboratory HRTV stock 
The HRTV strain used in this study was a patient-derived isolate (MO-4), provided by Dr 
Robert Tesh  (World Reference Center for Emerging Viruses and Arboviruses, Galveston, 
TX). The patient, referred to as ‘patient two’ in (McMullan et al., 2012), was a 67 year old 
man from northern Missouri who received approximately 20 daily tick bites for a period of 
two weeks and was hospitalised for twelve days, presenting with fatigue, myalgia, severe 
thrombocytopenia and leukopenia. The genome of the patient-derived HRTV was 
sequenced and published (McMullan et al., 2012). The working stock of HRTV available 
for this project was generated by Dr Benjamin Brennan (MRC-Centre for Virus Research, 
University of Glasgow, UK), by passaging HRTV at a low MOI (0.001 PFU/cell) in Vero 
E6 cells, and harvesting the medium 7 days p.i. (personal communication). 
When developing a reverse genetics system for a particular virus, it is important to 
determine the correct full-genome sequence of that virus in order to generate cDNA clones 
that reflect the virus’ genome (Acrani et al., 2015; Brennan et al., 2015). In order to 
determine whether the HRTV stock available in our laboratory had any cell culture adapted 
mutations, and to confirm its genome sequence in comparison to the published sequence, 
full genome sequencing of the HRTV laboratory stock was carried out. Briefly, total 
cellular RNA from duplicate HRTV-infected Vero E6 cells (MOI 5 PFU/cell) was 
extracted, and used for RT-PCR to sequence the entire S, M and L segments, except their 
termini. To sequence the 3’ and 5’ termini of all segments, 3’ rapid amplification of cDNA 
ends (RACE) analysis was performed on the extracted RNA (which contained genomic 
and antigenomic segments) using sequence-specific primers. The amplified products were 
sequenced using conventional Sanger sequencing and the results compared to the database 
entries with GenBank accession numbers JX005843, JX005845 and JX005847, for the 
HRTV S, M and L segments, respectively. 
In total, 3 mutations in the HRTV laboratory stock genome were identified (Figure 8-1). 
One mutation was present in the genomic-sense 5’ UTR of the S segment, at position 1751 
(A"G). The other two mutations, found in the ORF of the M and L segments resulted in 
amino acid changes. In the M segment, a C"U mutation at the nucleotide position 1764 
(genomic sense) results in a His"Tyr amino acid change at the N terminus of Gc. In the L 
segment, the A"U mutation at nucleotide position 3309 (genomic sense) results in a 
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Tyr"Phe amino acid change in the viral polymerase. Of note, while in the S and M 
segment the mutations were identified as clear peaks in the sequencing chromatogram 
corresponding to the nucleotide change, two peaks were observed in the L segment 
A3309U mutation, with the more predominant peak corresponding to T (U in RNA) signal, 
and the smaller peak corresponding to A signal (Figure 8-1), suggesting a mixed 
population of the virus genome. The mutations identified from duplicate infections were 
confirmed using primers annealing to the complementary strand for all samples.  
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Figure 8-1. Differences in the sequence of the HRTV laboratory stock compared to the 
published HRTV sequence.  
Alignment showing the chromatograph of S, M and L segment RACE and RT-PCR cDNA 
sequencing results of the HRTV laboratory stock, in comparison to RNA published sequences 
(GenBank accession numbers: S: JX005843; M: JX005845; L: JX005847). Arrows denote 
identified mutations (highlighted) and their nucleotide position. Sequences are shown in the 
genomic sense, and the ORF translation indicated below the DNA or RNA sequences.  Adenine 
(A): green; Thymine (T): red; Cytosine (C): Blue; Guanine (G): Black. 
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8.3.2 Development of a minigenome system for HRTV 
Next, a minigenome system for HRTV was developed to: (i) enable the basic molecular 
characterization of the HRTV UTR sequences as promoters of replication and 
transcription, and to (ii) assess the functionality of the HRTV N and L proteins. As 
described in chapter 5, the minigenome system of bunyaviruses comprises an analogue of 
the virus genome under the control of a T7 RNAP promoter, in which a reporter gene (such 
as Renilla) in the negative sense replaces the ORF of a particular segment such that it is 
flanked by the viral 3’ and 5’ UTRs. In this way, transcription of a genome analogue by T7 
RNAP and co-expression of viral N and L proteins enables the subsequent formation of 
RNP complexes that, if functional, lead to reporter gene activity.  
T7 RNAP promoter-driven minigenome plasmids for the HRTV S, M and L segments 
were generated based on the published HRTV sequence, and named pT7HRTSRen(+), 
pT7HRTMRen(-) and pT7HRTLRen(-) respectively. The templates used for generating the 
HRTV minigenome clones were kindly provided by Dr Benjamin Brennan (MRC Centre 
for Virus Research, University of Glasgow), and involved HRTV rescue plasmids in which 
the full-length antigenomic-sense cDNA copies of the published HRTV S, M and L RNA 
segment sequences were cloned into pTVT7 (0,0) (Johnson et al., 2000) (pT7HRTS(+), 
pT7HRTM(+) and pT7HRTL(+), respectively). The HRTV minigenome clones were 
generated as described in chapter 5 (section 5.3.2) for UUKV, using restriction-free 
cloning. Briefly, the viral coding sequence in pT7HRTM(+) and pT7HRTL(+) was 
replaced by that of humanised Renilla (hereafter referred to as Renilla), in the same 
(positive) sense. Next, the cassette containing the Renilla ORF flanked by the viral UTRs 
was amplified for its inversion in pTVT7 (0,0), such that the transcripts generated by the 
T7RNAP would be in the viral genomic sense. Therefore, pT7HRTMRen(-) and 
pT7HRTLRen(-) constructs contain the Renilla ORF sequence in the negative sense, 
flanked by the viral UTR in the genomic sense. On the other hand, pT7HRTSRen(+) was 
generated by replacing the NSs ORF in pT7HRTS(+), with Renilla, in the same (negative) 
orientation. Of note, whereas in the plasmids pT7HRTMRen(-) and pT7HRTLRen(-) the 
minigenome analogues are encoded in the genomic sense, the minigenome analogue in 
pT7HRTS(+) is encoded in the antigenomic sense. Therefore, in the M and L segment-
based minigenomes, T7 RNAP generates genomic sense RNA that can be encapsidated by 
the N protein, and together with the L protein RNPs are formed. Subsequently, the viral 
proteins N and L can replicate the minigenome into an antigenomic sense minigenome, 
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which serves as a template for the transcription of Renilla mRNA. In contrast, in the S 
segment -based minigenome is in the antigenomic sense. Thus, the antigenome-sense 
minigenome generated from pT7UUKSRen(+) can serve for the transcription of the 
Renilla subgenomic mRNA without the need of a replication step. Therefore, due to these 
inherent differences between the M and L segment-based minigenomes and the S segment-
based minigenome, the UTR promoter strengths are not comparable, as transcription of the 
Renilla subgenomic mRNA will be driven by different promoters (3’ UTR promoters of 
the genomic or antigenomic RNA, respectively). To ensure that the sequence of the 
generated plasmids was correct, the sequence of all constructs was confirmed by Sanger 
sequencing.  
Helper plasmids expressing HRTV N and L proteins in the T7 RNAP-driven expression 
vector pTM1 (Moss et al., 1990) were also provided by Dr Benjamin Brennan and are 
called pTM1HRTN and pTM1HRTL. In addition to the minigenome constructs derived 
from the published HRTV sequence, constructs containing the mutations identified in the 
HRTV laboratory stock were also generated (Section 8.3.1). Briefly, site-directed 
mutagenesis was used to introduce the A1751G and A3309U mutations in the 5’ UTR 
region (genomic sense) and in the L ORF of pT7HRTSRen(+) and pTM1HRTL, 
respectively. These plasmids were named pT7HRTSRen(+)A1751G and 
pTM1HRTLA3309U, respectively.  
In order to determine whether the published sequences would allow the generation of 
functional RNPs that are transcription and replication competent, a minigenome assay 
using the plasmids corresponding to the published HRTV sequences was carried out.  
Briefly, sub-confluent monolayers of BSR-T7/5 cells (a BHK-21 clone which 
constitutively express a T7 RNAP) (Buchholz et al., 1999) were transfected with constant 
amounts of pT7HRTSRen(+), pT7HRTMRen(-) or pT7HRTLRen(-), pTM1HRTN, a 
plasmid expressing firefly luciferase (pTMFFluc) as an internal control for transfection 
efficiency, and increasing amounts (0-375 ng) of pTMHRTL. The total amount of DNA 
per well was kept constant by supplementing the DNA reactions with empty pTM1. 18 h 
post transfection, the cells were harvested and Renilla and firefly activities measured. The 
Renilla values were normalised to firefly values and minigenome activity expressed as fold 
increase of normalised luciferase units relative to the background control (absence of L 
protein). 
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Collectively, all minigenome constructs resulted in a dose-dependent increase in 
normalised luciferase activity when pTM1HRTL was provided (Figure 8-2). The highest 
fold increase in normalised luciferase activity was observed for the HRTV M segment-
based minigenome, which resulted in a mean 10241-fold increase when 375 ng of 
pTM1HRTL was supplied, relative to the background control. This is in comparison to the 
S and L segment based-minigenomes, which yielded a peak mean 76- and 155-fold 
increase in luciferase activities, respectively (Figure 8-2). These results confirmed that the 
cDNA clones of the N and L proteins, as well as the viral UTRs belonging to the three 
segments in the published HRTV sequences are functional and enable replication and 
transcription processes to occur. 
  
Chapter 8: Development of a HRTV minigenome system to assess tick-borne phlebovirus genome 
reassortment 
191 
Figure 8-2. HRTV S, M and L minigenome assays using constructs based on published 
HRTV sequences.  
BSR-T7/5 cells were transfected with constant amounts of pT7HRTSRen(+) (black), 
pT7HRTMRen(-) (dark grey) or pT7HRTLRen(-) (light grey), pTM1HRTN, pTMFFluc and 
increasing amounts (0-375 ng) of pTMHRTL. The total amount of plasmid DNA in all reactions 
was kept constant by the addition of empty control plasmid pTM1 to the DNA mix. Cells were 
lysed 18 h post transfection and the Renilla and firefly luciferase units measured. Minigenome 
activity is expressed as the fold induction of normalised luciferase units relative to the background 
control (no pTM1HRTL). The mean minigenome activities calculated are shown above the bars. 
Error bars represent the standard deviation (SD) from the mean of one representative experiment of 
three, performed in triplicate (n = 3). HRTV: Heartland virus; RLU: Relative light units. 
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To investigate whether the mutations identified in the HRTV stock could have an effect on 
the efficiency of replication and transcription of the viral genome, a S segment-based 
minigenome assay comparing pT7HRTSRen(+) and pT7HRTSRen(+)A1751G 
minigenome constructs was carried out. In addition, the minigenome assays were 
performed utilising helper expression plasmids encoding either the published sequence-
based L protein, or that with the A3309U mutation identified in the HRTV laboratory stock 
(pTM1HRTL and pTM1HRTLA3309U, respectively). In comparison to the published 
sequence-based L protein, the A3309U mutation in the HRTV L protein did not confer any 
difference in minigenome activity when using either pT7HRTSRen(+) and 
pT7HRTSRen(+)A1751G minigenome constructs (Figure 8-3). The constructs containing 
the A1751G mutation identified in the 5’ UTR of the S segment belonging to the HRTV 
laboratory stock resulted in a slight decrease in S segment minigenome activity, compared 
to the S segment minigenome activity of the plasmids encoding the published sequence 
UTRs (Figure 8-3). However, it must be noted that the 5’ UTR mutation identified still 
resulted in an increase in reporter gene activity when the viral polymerase was provided, 
suggesting that although the mutation leads to a decrease in minigenome activity, the 5’ 
UTR of the HRTV laboratory stock is still able to act as a functional promoter of 
transcription and replication. 
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Figure 8-3. HRTV S segment minigenome assay using constructs based on published and 
newly identified sequences.  
BSR-T7/5 cells were transfected with constant amounts of pT7HRTSRen(+) or 
pT7HRTSRenA1751G(+), pTM1HRTN, pTMFFluc and increasing amounts (0-375 ng) of 
pTMHRTL or pTM1HRTLA33909T. The total amount of plasmid DNA in all reactions was kept 
constant by the addition of empty control plasmid pTM1 to the DNA mix. Cells were lysed 18 h 
post transfection and the Renilla and firefly luciferase units measured. Minigenome activity is 
expressed as the fold induction of normalised luciferase units relative to the background control. 
Bars represent the mean fold induction ±SEM of three experiments performed in duplicate or 
triplicate (n=3). HRTV: Heartland virus; RLU: Relative light units. 
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8.3.3 Investigating the ability of UUKV, HRTV and SFTSV N and L proteins to utilize 
the M segment minigenome of heterologous tick-borne phleboviruses. 
Minigenome systems serve as a useful tool to investigate transcription and replication 
processes. The ability of N and L proteins of a particular virus to recognize the viral UTRs 
as promoters of transcription and replication will determine the functionality of a 
minigenome. Therefore, the availability of working tick-borne phlebovirus minigenome 
systems was exploited to investigate whether the N and L protein of a particular virus 
could transcribe and replicate the M segment genome analogue of other tick-borne 
phleboviruses. These studies would enable to assess under an experimental setting the 
potential of reassortment between tick-borne phleboviruses. For the purpose of this study, 
activity of the M-segment based minigenome of a particular virus was considered as an 
indication of potential of reassortment between the viruses tested. The M segment-based 
minigenome system was chosen because reassortant viruses with a novel M segment are of 
major concern. This is because the gene products of reassortant viruses with a novel M 
segment (the surface envelope glycoproteins Gn and Gc) can introduce new immunogenic 
characteristics, alter tropism and host range, and can allow escape from immune 
surveillance (Briese et al., 2013; Elliott, 2014). The available tick-borne phlebovirus M 
segment-based minigenome systems include that of UUKV (described in chapter 5), 
HRTV (present study, Section 8-3), and SFTSV (Brennan et al., 2015).  
Compatible viral components (such as the ability of N and L proteins of a particular virus 
to recognize the viral UTRs of a segment belonging to a heterologous virus) are a key 
requirement that favour reassortment between closely related viruses. Therefore, the amino 
acid identity of UUKV, HRTV and SFTSV N and L protein was compared, to assess the 
relatedness between these proteins. While UUKV N shares 27% and 28.3% amino acid 
identity with HRTV and SFTSV N proteins (respectively), the amino acid identity between 
HRTV and SFTSV N proteins is of 61.6% (Table 8-1). Similarly, UUKV L shares only 
34.2% and 35.4 % amino acid identity with HRTV and SFTSV L proteins (respectively), 
whereas the L protein of HRTV and SFTSV share 73.3% amino acid identity (Table 8-2). 
Therefore, the amino acid identity shared between HRTV and SFTSV N and L proteins is 
noticeably higher than that shared between HRTV or SFTSV and UUKV N and L. An 
amino acid alignment of the N and L proteins used in this study is shown in Figures 10-1 
and 10-2 (Appendices).  
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 Table 8-1. Percentage amino acid identity of UUKV, HRTV and SFTSV N proteins. 
 
 
 
 
 
* Based on the GenBank accession numbers AAA47958.1, AFP33391.1 and AJD86040.1 
for UUKV, HRTV and SFTSV N proteins, respectively. Generated using Clustal Omega 
(Sievers et al., 2011). 
 Table 8-2. Percentage amino acid identity of UUKV, HRTV and SFTSV L proteins. 
 
 
 
 
 
* Based on the GenBank accession numbers BAA01590.1, AFP33396.1 and AJD86038.1 
for UUKV, HRTV and SFTSV L proteins, respectively. Generated using Clustal Omega 
(Sievers et al., 2011). 
The UTR sequences of bunyaviral segments also play a key role in transcription and 
replication. Particularly, specific sequences found at the terminal ends of the 5’ and 3’ 
UTRs act as promoters of transcription, and contain cis-acting RNA replication signals 
(Schmaljohn and Nichol, 2007). Phleboviral 3’ and 5’ UTR of all three segments contain 8 
terminal nucleotides that are complementary to each other, and were initially thought to be 
strictly conserved in all three segments across the Phlebovirus genus (3’-
ACACAAAG…CUUUGUGU-5’) (Elliott and Blakqori, 2011; Freiberg and Flick, 2013). 
To analyse the conservation and diversity in nucleotide sequence which may determine M 
segment promoter activity or recognition by the N and L proteins, a nucleotide sequence 
alignment of the M segment 3’ and 5’ UTR of UUKV, HRTV and SFTSV was carried out. 
 N amino acid identity (%)* 
Virus UUKV HRTV SFTSV 
UUKV 100   
HRTV 27.05 100  
RVFV 28.28 61.63 100 
 L amino acid identity (%)* 
Virus UUKV HRTV SFTSV 
UUKV 100   
HRTV 35.36 100  
SFTSV 34.24 73.32 100 
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Hereafter 3’ and 5’ UTR refer to the genomic sense UTRs. Whereas the UUKV M 
segment 3’ and 5’ UTRs contain the consensus 8-nucleotide long terminal sequences that 
are complementary to each other, the HRTV and SFTSV M segment 3’ UTR contain a G 
at position 6 instead of an A, deviating from the consensus sequence. The inter-segment 
variations at this position have been described for the 3’ UTR of HRTV S and M segments, 
SFTSV M and L segments, Bhanja virus (BHAV) L segment and the 5’ UTR of Lone Star 
Virus (LSV) S segment (Elliott and Brennan, 2014). Thus, it appears that the nucleotide 
identity at this position of the 3’ and 5’ UTR termini of tick-borne phlebovirus S, M and L 
segments is not strictly conserved. 
 Importantly, the M segment 5’ UTR terminal sequences of HRTV and SFTSV do not 
deviate from the consensus sequence (Figures 8-4 and 8-5). This would result in a 
‘mismatch’ in complementarity at this position (3’-ACACAGAG…CUUUGUGU-5’; 
mismatched nucleotides in bold) in the HRTV and SFTSV, but not UUKV M segment 
UTR termini. In addition, whereas the UUKV and SFTSV 3’ UTRs are relatively short (17 
and 18 nt, respectively), that of HRTV was significantly longer (50 nt) (Figure 8-4). 
Despite high conservation of the 10 terminal residues of the 5’ UTR between UUKV, 
HRTV and SFTSV M segments, little conservation of the rest of the 5’ UTRs was noted 
(Figure 8-5). Finally, while the 5’ UTR of the UUKV M segment is 185 nt in length, 
HRTV and SFTSV have shorter M segment 5’ UTRs of 146 nt and 138 nt, respectively 
(Figure 8-5).  
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	Figure 8-4. Sequence alignment of the M segment 3’ UTR of three tick-borne phleboviruses. 
The M segment 3’ UTR sequences of UUKV, HRTV and SFTSV are presented in the RNA 
genomic sense. GenBank accession numbers used: M17417.1, JX005845.1 and KP202164, 
respectively. Adenine (A) residues are highlighted in green, Uracil (U) in green, Cytosine (C) in 
blue and Guanine (G) in red. The consensus sequence is in black. ‘-’ denotes gaps and ‘N’ denotes 
absence of consensus. Generated with CLC Genomics Workbench 7. The dashed line denotes 3’ 
UTR termini, which were thought to be strictly conserved within the S, M and L segments of all 
phleboviruses. 
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Figure 8-5. Sequence alignment of the M segment 5’ UTR of three tick-borne phleboviruses. 
The M segment 5’ UTR sequences of UUKV, HRTV and SFTSV are presented in the RNA 
genomic sense. GenBank accession numbers used are M17417.1, JX005845.1 and KP202164, 
respectively. Adenine (A) residues are highlighted in green, Uracil (U) in green, Cytosine (C) in 
blue and Guanine (G) in red. The consensus sequence is in black. ‘-’ denotes gaps and ‘N’ denotes 
absence of consensus. Generated with CLC Genomics Workbench 7. The dashed line denotes 3’ 
UTR termini, which were thought to be strictly conserved within the S, M and L segments of all 
phleboviruses. 
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The ability of the N and L proteins of UUKV, HRTV or SFTSV to replicate and transcribe 
the M segment-based minigenome belonging to heterologous viruses was tested, using the 
minigenome of homologous viruses as a control. Most bunyavirus reassortants identified to 
date possess the S and L segments derived from one virus, and the M segment derived 
from another virus, indicating that reassortment may be restricted to the M segment (Briese 
et al., 2013). In addition, similar studies with viruses belonging to the Orthobunyavirus 
genus were carried out previously by Dr Natasha Tilston-Lunel (Boston University), and 
showed that N and L proteins belonging to different orthobunyaviruses were unable to 
function together in the context of a minigenome setting, therefore suggesting that the sole 
determinant of orthobunyavirus reassortment capacity lies in the recognition of the M 
segment UTRs of virus ‘Y’ by the N and L proteins of virus ‘X’ (unpublished). Therefore, 
for simplicity the assays were carried out utilizing N and L from homologous viruses only 
and the ability of N and L proteins from different viruses to collectively recognize, 
replicate and transcribe a particular minigenome was not tested.  
The SFTSV M segment-based minigenome construct (pTVT7HB29M:hRen), as well 
SFTSV N- and L- expression plasmids  (pTM1HB29N and pTM1HB29L, respectively) 
which are under the control of a T7RNAP promoter and EMCV IRES have been 
previously described and were provided by Dr Benjamin Brennan (Brennan et al., 2015). 
Briefly, BSR-T7/5 (constitutively expressing T7 RNAP) (Buchholz et al., 1999) were 
transfected with constant amounts of each of the M segment-based minigenomes 
(pT7XMRen(-) or pTVT7HB29M:hRen; [X= UUKV or HRTV]), the firefly luciferase 
expression plasmid pTMFFluc and 125 ng of the indicated N- and L-expressing plasmids 
(pTM1XN and pTM1XL, [X= UUKV, HRTV or SFTSV strain HB29]). Control wells 
lacked L-expressing plasmids and the DNA reactions were supplemented with empty 
pTM1 to keep the total amount of DNA constant in all conditions. 18 h post transfection, 
the cells were harvested and Renilla and firefly values measured. Renilla values were 
normalised to firefly values and minigenome activity expressed as the normalised 
luciferase activity relative to the background control (absence of L-expressing plasmid). 
As expected, the M segment-based minigenomes of UUKV, HRTV and SFTSV exhibited 
the highest activity when each minigenome system was supplied with the N and L proteins 
of the cognate viruses (Figure 8-6 A-C). Interestingly, HRTV and SFTSV N and L proteins 
were able to recognize the UUKV M segment UTRs as a promoter for transcription and 
replication. Whereas a mean 72-fold increase in UUKV M minigenome activity was 
observed in the presence of UUKV N and L proteins, HRTV or SFTSV N and L proteins 
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resulted in a mean 24- or 14- fold increase in UUKV M minigenome activity, respectively 
(Figure 8-6 A).  UUKV and SFTSV N and L proteins were also able to promote HRTV M 
minigenome activity, resulting in a mean 507- and 1491-fold increase in minigenome 
activity, respectively. This is in comparison to the mean 7569-fold increase detected in 
HRTV M minigenome activity in the presence of HRTV N and L (Figure 8-6 B). Finally, 
SFTSV N and L proteins yielded a mean 2157-fold increase in SFTSV M minigenome 
activity, and only HRTV N and L (but not UUKV N and L) proteins promoted SFTSV M 
minigenome activity, with a mean 30-fold increase detected, relative to the background 
(Figure 8-6 C). 
Taken together, these results demonstrate that UUKV N and L proteins are able to 
recognize and utilize the HRTV M UTRs but not the SFTSV M UTRs as a promoter, 
whereas HRTV N and L can recognize both UUKV and SFTSV M UTRs and that SFTSV 
N and L proteins can recognize UUKV and HRTV M UTRs for the transcription and 
replication of M segment-based minigenomes (summarized in Table 8-3).  
Table 8-3. Summary of UUKV, HRTV and SFTSV M-segment based minigenome 
activities detected in the presence of N and L proteins from cognate or heterologous 
viruses. 
 
 
 
 
 
Note: Ticks depict an increase in minigenome activity for the indicated M segment-based 
minigenome in the presence of the indicated N and L proteins. Crosses depict no increase 
in minigenome activity. The numbers shown between brackets depict the fold increase in 
minigenome activity (relative to the background control in the absence of L protein). 
  
N+ L proteins 
M minigenome 
UUKV HRTV SFTSV 
UUKV ✓ (72) ✓ (24) ✓ (14) 
HRTV ✓ (507) ✓ (7569) ✓ (1491) 
SFTSV ✗ ✓ (30) ✓ (2157) 
  
 
Figure 8-6. Activity of the UUKV, HRTV and SFTSV M segment-based minigenomes using UUKV, HRTV or SFTSV N and L proteins.  
BSR-T7/5 cells were transfected with pT7UUKMRen(-), pT7HRTMRen(-) or pTVT7HB29M:hRen, pTMFFluc, pTM1XN and pTM1XL, where X refers to 
UUKV, HRTV or SFTSV. Cells were lysed 18 h post transfection and the Renilla and firefly luciferase units measured. Minigenome activity is expressed as 
the fold induction of normalised luciferase units relative to the background control (absence of L-expressing plasmid). Bars and the number above represent 
the mean fold induction ±SEM of two experiments performed in duplicate or triplicate (n=2). UUKV: Uukuniemi virus; HRTV: Heartland virus; SFTSV: 
Severe Fever with Thrombocytopenia Syndrome virus; RLU: Relative light units. 
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8.3.4 Efforts to generate cDNA clones of the HRTV M segment 
Previous attempts to rescue HRTV entirely from cDNA clones taking the T7 RNAP-driven 
approach routinely used in our laboratory have failed (personal communication, Dr 
Benjamin Brennan). However, the results in Section 8.3.2 indicated that HRTV UTRs, as 
well as the N and L proteins were functional, leading to measurable minigenome activity 
and suggesting successful replication and transcription of the HRTV minigenomes. In 
order to revisit the failure to rescue HRTV from cDNA clones, HRTV rescue plasmids 
pT7HRTS(+), pT7HRTM(+) and pT7HRTL(+)  were utilized as templates to introduce the 
mutations identified in the full genome sequencing of the HRTV laboratory stock (Section 
8.3.1).  
While the S and L segment mutations were successfully introduced by site-directed 
mutagenesis in pT7HRTS(+) and pT7HRTL(+) (respectively) to generate 
pT7HRTSA1751G(+) and pT7HRTLA3309U(+), problems were encountered when 
attempting to generate the correct HRTV M segment clone.  Initially, an approximately 1.4 
kbp insertion corresponding to an E. coli sequence was identified within the HRTV M 
segment ORF in the pT7HRTM(+) template.  This finding provided an explanation for the 
inability to rescue HRTV entirely from cDNA clones at first. In an attempt to generate the 
correct pT7HRTM(+) clone, (i) the foreign E. coli sequence were removed by excision 
PCR, followed by ligation, and (ii) the full-length antigenome cDNA of the HRTV 
laboratory stock was cloned into into pTVT7 (0,0) (Johnson et al., 2000). However, 
despite successfully removing foreign E. coli sequences and cloning the full length cDNA 
of the HRTV M segment into the pTVT7 plasmid in the antigenome sense, all clones 
sequenced had either insertions, deletions and/or multiple mutations within the M segment 
ORF, which would result in a frame-shift or amino acid mutations within the glycoprotein 
precursor (data not shown). These findings indicated that presumably, the clone was toxic 
to bacteria. Therefore, several methods were tested to successfully clone the construct. 
These included the incubation of transformed E. coli at either 37 °C, 30 °C or at room 
temperature, in combination with using the following E. coli strains for generation of the 
plasmid: JM109, SURE2, BL21(DE3), Stellar™ and CopyCutter™ EPI400™. All 
bacterial strains generated pT7HRTM(+) clones with insertions, deletions and/or multiple 
mutations. However, altering the manufacturer’s protocol for the growth of CopyCutter™ 
EPI400™ yielded the correct pT7HRTM(+)  sequence. These cells contain a gene that 
controls the vector copy number under an inducible promoter (pcnB [plasmid copy number 
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B]). Therefore, the plasmid is kept at a low copy number to enhance plasmid stability 
following transformation, and a short incubation with induction solution provided by the 
manufacturer leads to the subsequent raise in copy number, enhancing plasmid yields for 
DNA recovery. Because induction to raise the plasmid copy number in CopyCutter™ 
EPI400™ bacteria gave rise to mutations in pT7HRTM(+), the transformed uninduced 
bacteria were incubated at 37° for 30 h without induction, which resulted in low plasmid 
yield. However, most pT7HRTM(+) clones isolated carried the correct HRTV sequence.  
The recovery of infectious, recombinant HRTV using plasmids derived from the published 
sequences was attempted in BSR-T7/5 cells (Buchholz et al., 1999) and Huh-Lunet-T7 
cells (Kaul et al., 2007), both of which constitutively express a T7 RNAP. Huh-Lunet-T7 
cells were used in addition to the routinely used BSR-T7/5 cells because HRTV replicates 
more efficiently in Huh-7 cells than BHK-21 cells (cell line which the BSR-T7/5 cell line 
is derived from; personal communication with Dr Benjamin Brennan). Briefly, 
subconfluent cells in 6 well plates were transfected with 1µg of pT7HRTS(+), 
pT7HRTM(+) and pT7HRTL(+) in a 3-plasmid rescue system, or supplemented with 250 
ng pTM1HRTN and pTM1HRTL in a 5-plasmid rescue system. The supernatant was 
harvested 7 days post transfection and plaque assays carried out in Vero E6. None of the 
conditions tested yielded infectious HRTV. However, it must be mentioned that due to 
time constraints, the rescue was attempted once, using plasmids based on the HRTV 
published sequences only. It is worth repeating the rescue under different experimental 
conditions, such as varying plasmid amounts to optimise transfection conditions, or 
attempting the rescue using plasmids containing the mutations identified in the HRTV 
laboratory stock.  
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8.4 Discussion 
The tick-borne phlebovirus reverse genetics systems developed so far include that of 
UUKV (Chapter 5) and SFTSV (Brennan et al., 2015). Developing a reverse genetics 
system for another tick-borne phlebovirus available in our laboratory, such as HRTV, 
would provide the tools to take a comparative approach for investigating further the 
molecular biology of these viruses. Moreover, as tick-borne phleboviruses continue to 
emerge in naïve geographical locations with increasing host range (Elliott and Brennan, 
2014), there is a need to understand the viral determinants that contribute to the evolution 
of these viruses and their escape from immune surveillance. Genome reassortment (or 
antigenic shift) has long been acknowledged as a key force driving the evolution of the 
Bunyaviridae (Weber and Elliott, 2002) and other segmented viruses. In fact, Briese et al., 
hypothesised that it is possible that all known bunyaviruses represent reassortants of 
existing or extinct viruses (Briese et al., 2013). This hypothesis emphasizes the need of 
working reverse genetics systems for emerging bunyaviruses, as such tools could allow to 
assess the potential of genome reassortment under experimental conditions. 
 In order to develop a reverse genetics system for HRTV, the stock of HRTV available in 
the laboratory was sequenced to confirm that the sequences available in the database were 
correct, and to identify possible mutations that may have arised while passaging the virus 
in cell culture. Compared to the published sequence for the HRTV patient isolate number 2 
(McMullan et al., 2012), three mutations present in the laboratory HRTV stock were 
identified, one in each of the viral segments (Figure 8-1). The S segment contained a 
A1751G mutation in the 5’ UTR (genomic-sense), the M segment contained a C1764U 
mutation which results in a His"Tyr amino acid change in the Gc glycoprotein, and the L 
segment contained an A3309U mutation which results in a Tyr"Phe amino acid change in 
the viral RNA-dependent RNA polymerase (RdRp, or L protein) (Figure 8-1). Minigenome 
analysis revealed that while the mutation in the viral polymerase had no effect in 
minigenome activity, the mutation in the genomic 5’ UTR of the S segment led to a 
decrease in minigenome activity compared to the published sequences.  However, although 
less efficient, the S segment-based minigenome containing the mutation identified in the 
genomic 5’ UTR still resulted in a functional minigenome (Figure 8-3). These results 
suggested that under the experimental conditions used in this study, the mutations 
identified in the S and L segments of our HRTV laboratory stock did not confer any 
advantage in terms of replication and transcription of the viral genome. Due to time 
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constraints, it remains to be determined whether the mutations could grant advantages in 
the cell line used to propagate HRTV (Vero E6), or if the mutation identified in the M 
segment could aid in other stages of the virus life cycle, such as entry, packaging or egress. 
Such studies could be carried out using virus-like particle (VLP) assays, or by introducing 
the mutations in the viral genome by reverse genetics to examine their effect on virus 
phenotype.  
In this Chapter, the development of a minigenome system for HRTV is described. A dose-
dependent increase in S, M and L minigenome activities with increasing amount of HRTV 
L-expressing plasmid was observed. This is in contrast to the dose-dependent decrease in 
UUKV S and L (but not M) minigenome activities with increasing amount of UUKV L-
expressing plasmid described in Chapter 5 (Figure 5-3), and the reported dose-dependent 
decrease in SFTSV M minigenome activity with increasing SFTSV L-expressing plasmid 
(Brennan et al., 2015). These differences may be attributed to the fact that the optimal L 
protein levels required for efficient minigenome activity may differ between UTR 
sequences. Similar results have been observed for other bunyaviruses, and were attributed 
to a tight regulatory function of the L protein to switch from replication to cap-snatching 
activity (Blakqori et al., 2003; Elliott and Schmaljohn, 2013). Nevertheless, the HRTV N 
and L –encoding plasmids used in this study were shown to be functional and driving 
reporter gene expression from minigenomes. The developed HRTV minigenome system 
will serve as a useful tool for future studies to facilitate functional studies of the HRTV 
UTR sequences, N and L proteins and other transcriptional and replication processes.  
Because bunyaviruses have a tripartite segmented genome, infection of the same host cell 
by two closely related bunyaviruses can in theory result in eight potential progeny viruses, 
with different genome combinations: AAA, ABA, BAA, AAB, BBA, ABB, BAB and 
BBB (where A and B refer to parental viruses with genomes SA, MA, LA and SB, MB, LB, 
respectively) (Briese et al., 2013). Perhaps the most well known example of natural 
genome reassortment occurrence within the Bunyaviridae is that of Ngari virus, which 
emerged in 1997 and caused a large outbreak of hemorrhagic fever in East Africa. The 
virus was later reported to be a reassortant virus, progeny of two closely related 
orthobunyaviruses: BUNV (S and L segment donor) and Batai virus (M segment donor) 
(Briese et al., 2006). Intriguingly, two years before the outbreak, Dunn et al. had predicted 
that BUNV and Batai virus could reassort, a hypothesis based on experimental evidence 
showing that BUNV and Batai viral proteins were compatible for the transcription of RNA 
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template minigenome assays (Dunn et al., 1995). Another orthobunyavirus, named 
Schmallenberg virus, emerged in 2012 and was reported to cause congenital defects in 
newborn calved, goats and lambs (Hoffmann et al., 2012). It was later found that 
Schmallenberg virus was a reassortant of two other orthobunyaviruses, namely Sathuperi 
virus (M segment donor) and Shamonda virus (S and L segment donor) (Yanase et al., 
2012). Within the Phlebovirus genus, a genome analysis of RVFV strains indicated that 
reassortment events among RVFV lineages occurred over the evolutionary history of these 
virus strains (Bird et al., 2007). Additionally, Aguacate virus has been suggested to be a 
natural reassortant from an as-yet unknown virus (Palacios et al., 2011), and Granada virus 
is likely a reassortant of Massilia virus (S and L segment donor) and a yet unidentified 
phlebovirus (M segment donor) (Collao et al., 2010).  
Briese et al. also suggested that the intricate play between the viral polymerase, 
nucleocapsid protein and the viral RNA may explain why most recognized bunyavirus 
reassortants possess the S and L segments derived from one virus, and the M segment 
derived from another virus (Briese et al., 2013). With this in mind, the newly developed 
HRTV minigenome system, as well as the already developed UUKV (Chapter 5) and 
SFTSV (Brennan et al., 2015) minigenome systems were utilized as a first step to assess 
whether the N and L proteins of UUKV, HRTV or SFTSV could recognize, transcribe and 
replicate the M segment-based minigenome of each of these tick-borne phleboviruses. As 
expected, the highest minigenome activity was detected when the N and L proteins UUKV, 
HRTV or SFTSV were used in combination with the M segment-based minigenome of the 
respective viruses, demonstating that utilizing N and L proteins and the M segment UTRs 
from homologous viruses results in optimal minigenome activity.  Despite the fact that the 
N and L proteins of UUKV were less closely related in amino acid identity to HRTV and 
SFTSV N and L (Tables 8-1 and 8-2), the latter two were able to utilize UUKV M UTRs 
as a functional promoter (Figure 8-6 A). Interestingly, the results from this work revealed 
that UUKV N and L proteins are able to recognize HRTV M UTRs but not SFTSV M 
UTRs as a functional promoter (Figures 8-6 B and C). These results indicate that possibly, 
sequence differences or secondary structure differences found within the HRTV and 
SFTSV M UTRs could allow recognition, transcription and replication of the HRTV M 
UTRs but not SFTSV M UTRs by UUKV N and L. Finally, the higher conservation in 
amino acid identity between HRTV and SFTSV N and L was reflected in their ability to 
recognize each others’ M segment UTRs as functional promoters (Figure 8-6 B and C). 
The ability of the N and L proteins of virus ‘X’ to recognize the M segment UTRs of virus 
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‘Y’ for subsequent transcription and replication indicates that, provided that the 
glycoproteins from virus ‘Y’ are able to package the S and L segments of virus ‘X’, a new 
reassortant virus with the S and L segments of virus ‘X’ and the M segment of virus ‘Y’ 
could be generated upon co-infection of the same host cell. Therefore, the findings 
described here show that from the six possible reassortment outcomes examined 
(UM/HS/HL, UM/SS/SL, HM/US/UL, HM/SS/SL, SM/US/UL and SM/HS/HL; where 
the first letter refers to UUKV, HRTV or SFTSV and the second letter refers to the 
segment S, M or L), five reassortment combinations (UM/HS/HL, UM/SS/SL, 
HM/US/UL, HM/SS/SL and SM/HS/HL) could be possible amongst the tick-borne 
phleboviruses tested. However, further studies are required to confirm this hypothesis, 
such as utilizing virus-like particle assays to assess whether the M segment of a particular 
virus is capable of packaging the S and L segments of other tick-borne phleboviruses to 
produce viable progeny. Additionally, attempting to rescue reassortant viruses using 
reverse genetics under the appropriate biosafety conditions could help in predicting 
possible outcomes of natural reassortant viruses, as has previously been demonstrated for 
Ngari virus emergence (Dunn et al., 1995), and could allow the timely development of 
vaccines for these emerging viruses that can escape immune surveillance. It must be noted 
that factors such as geographic and ecological conditions should also be taken into account 
when assessing the possibility of reassortment between tick-borne phleboviruses. For 
instance, the two potential donor viruses must be circulating in close proximity to each 
other in order to infect the same vector or host cell. Although it appears that the 
distribution of the tick-borne phleboviruses analysed in this study are distinct (UUKV = 
northern Europe, HRTV = United States, SFTSV= China, Japan, South Korea), the 
geographic distribution of tick-borne phleboviruses in general is global (Matsuno et al., 
2015), and climate change may induce alterations in the distribution of the vector tick 
species of these viruses, or routes of migratory birds carrying the vector ticks  (Elliott, 
2009). Donor viruses must also be able to infect the same vector or host species. While 
UUKV has been isolated from Ixodes ricinus tick species (Oker-Blom et al., 1964), the 
primary tick vector of HRTV and SFTSV are believed to be Amblyomma americanum 
(lone star tick) (Savage et al., 2013) and Haemaphysalis longicornis (Yu et al., 2011; 
Zhang et al., 2012b), respectively. Despite the differences in vector species carrying the 
three viruses relevant to this study, the vertebrate hosts of these viruses remain unclear. 
Although a number of serological surveys were reported, which examined the distribution 
of UUKV-, HRTV-, or SFTSV- specific antibodies in a number of different species 
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(Bosco-Lauth et al., 2015; Hubálek and Rudolf, 2012; Li et al., 2016; 2014; Ni et al., 
2015; Niu et al., 2013; Riemersma and Komar, 2015; Saikku and Brummer-Korvenkontio, 
1973), there is a need for further surveillance of animal and human populations to assess 
the risks of genome reassortment to occur. 
Finally, the findings described in this chapter indicate that the HRTV M segment clone 
pT7HRTM(+)  is unstable. The availability of this clone is crucial for enabling the rescue 
of HRTV entirely from cDNA clones using the T7 RNAP-driven system routinely used in 
our laboratory, which has enabled the rescue of many other bunyaviruses (Brennan et al., 
2015; Tilston-Lunel et al., 2016) (Bergeron et al., 2015; Elliott et al., 2013; Lowen et al., 
2004; Varela et al., 2013). The conditions required to generate a pT7HRTM(+)  clone with 
the correct sequence was optimized after 18 months of failed attempts. However, a single 
attempt at rescuing HRTV entirely from cDNA clones derived from published HRTV 
sequences using either a 3-plasmid or 5-plasmid rescue system failed. Further experimental 
repeats are required to (i) optimise transfection conditions, and (ii) to attempt to rescue 
HRTV utilizing plasmids containing the mutations identified in the HRTV laboratory 
stock. Developing a reverse genetics system for HRTV that allows the rescue of infectious 
virus entirely from cDNA clones will prove invaluable for advancing our understanding of 
the molecular biology of tick-borne phleboviruses.  
 
8.5 Summary 
• The laboratory HRTV stock was sequenced. Three mutations were identified in the 
HRTV genome: A1751G in the S segment 5’ UTR, C1764U in the M segment, and 
A3309U in the L segment (nucleotide positions in the genomic sense). 
• A minigenome system for HRTV was developed, which will facilitate future 
studies on transcription and replicational processes of HRTV. 
• Using available tick-borne phlebovirus minigenome systems, the results in this 
chapter demonstrate that the UUKV M UTRs act as a functional promoter in the 
presence of HRTV and SFTSV N and L proteins and that the HRTV M UTRs act 
as a functional promoter for UUKV and SFTSV N and L proteins. In contrast, 
SFTSV M UTRs can be recognized and used for transcription and replication of 
reporter RNA by HRTV N and L, but not by UUKV N and L. These findings can 
be used to predict the capability of tick-borne phleboviruses to undergo genome 
reassortment. 
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• pT7HRTM(+) is an unstable clone and the conditions to recover the correct clone 
in E. coli were optimized. The correct pT7HRTM(+) clone  can be utilized for 
further attempts to recover infectious HRTV entirely from cDNA clones. 
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9 Conclusions 
9.1 Fulfilment of the project aims 
The primary aim of this project was to carry out a molecular characterization of the NSs 
proteins belonging to the tick-borne phleboviruses UUKV and HRTV, and utilize reverse 
genetics systems to aid with these investigations.  
The availability of a reverse genetics system for tick-borne phleboviruses was key to this 
project, as it would enable the genetic manipulation of the virus’ genome and could 
therefore be utilized to investigate the phenotype of viruses engineered to lack their NSs 
protein. Using molecular tools that have enabled the establishment of reverse genetics 
systems for other bunyaviruses, I developed a T7 RNAP-driven minigenome system for 
UUKV, which could also be used for the generation of virus-like particles in the presence 
of UUKV glycoproteins (Chapter 5). These assays were of great value before attempting 
the rescue of UUKV, because they confirmed that the cDNA clones of the nucleocapsid 
(N) and RNA-dependent RNA polymerase (L) proteins, as well as the viral UTRs and 
glycoproteins were functional. Indeed, I successfully rescued recombinant UUKV entirely 
from cDNA clones (which exhibited similar properties to the authentic wild-type UUKV) 
(Chapter 5). The reverse genetics system also enabled the generation of recombinant 
viruses lacking NSs: rUUKdelNSs and rUUKdelNSsGFP, which highlighted the 
robustness of the system to recover mutant viruses. In addition, the results presented 
indicated that rUUKdelNSsGFP can serve as a tool to visualize and monitor virus infection 
(Chapter 5).  
Although UUKV or UUKV-like antibodies have been found in humans, there is no 
association of UUKV with human disease. Taking advantage of the established reverse 
genetics system, I demonstrated that UUKV acts as a weak antagonist of the human IFN 
response in cell culture, as upon infection UUKV lacking NSs induced more IFN than 
wild-type viruses, although wild-type UUKV still induced IFN (Chapter 6).  These results 
raised the question whether the NSs protein belonging to more pathogenic tick-borne 
phleboviruses have evolved a more efficient IFN antagonistic function to facilitate 
replication in the host upon infection. Using transient transfection assays, I showed that in 
general, the NSs protein of apathogenic UUKV is a weaker IFN antagonist than that 
belonging to the pathogenic HRTV and SFTSV. Additionally, similar assays allowed me 
to demonstrate that while UUKV, HRTV and SFTSV NSs proteins were able to inhibit 
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IFN induction with different efficiencies, none of the proteins were able to hinder NFkB 
signalling. Furthermore, while UUKV NSs was unable to inhibit type I or type II IFN 
signalling, HRTV and SFTSV NSs proteins were potent antagonists of type I, but not type 
II IFN signalling (Chapter 6). 
The molecular mechanisms by which SFTSV NSs blocks IFN induction and signalling 
pathways are well characterized, wheras that of UUKV and HRTV NSs proteins remain 
unknown. Reporter assays, immunoprecipitation and immunofluorescence studies allowed 
me to elucidate the signalling proteins targeted by UUKV and HRTV NSs proteins to 
facilitate their IFN antagonistic activity. I showed that while UUKV interacts with MAVS 
to inhibit IFN induction, HRTV NSs behaves in a similar manner to SFTSV NSs and 
interacts with TBK1 to inhibit IFN induction and STAT2 to inhibit type I IFN signalling 
(Chapter 7). 
Finally, developing a reverse genetics system for HRTV would benefit comparative studies 
that entail genetic engineering of the genomes of tick-borne phleboviruses. In this study, I 
sequenced the full genome of the HRTV stock available in our laboratory and identified 
three mutations compared to the published sequences (McMullan et al., 2012): A1751G in 
the S segment 5’ UTR, C1764U in the M segment, and A3309U in the L segment 
(nucleotide positions in the genomic sense). Using minigenome assays, I showed that 
while the mutation found in the S segment UTR resulted in a decrease in minigenome 
efficiency, the mutation in the L segment conferred no difference in minigenome activity 
compared to the wild-type sequences. Unfortunately, the aim of recovering infectious 
HRTV entirely from cDNA clones remained unfunfilled. This is due to time constraints 
and major hurdles encountered while attempting to generate the HRTV M segment cDNA 
clone, which was found to be unstable. Nevertheless, the extensive optimization carried out 
to obtain the correct HRTV M segment cDNA clones will provide a basis for the 
continuation of this work. The successful development of a minigenome system for HRTV 
allowed me to utilize this tool in combination with the minigenome systems available for 
UUKV and SFTSV to assess the ability of the N and L proteins from a particular tick-
borne phlebovirus to recognize, replicate and transcribe the M-segment based minigenome 
of heterologous tick-borne phleboviruses. These assays were informative and enabled me 
to shed light on possible outcomes of genome reassortment between tick-borne 
phleboviruses under experimental conditions (Chapter 8).  
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9.2 Future directions 
Tick-borne phleboviruses have become recognized as a public health threat only recently 
due to the emergence of SFTSV, which caused significant morbidity and mortality in 
China, Japan, and South Korea. Understanding how SFTSV and other related tick-borne 
phleboviruses cause disease is of great importance as these viruses continue to emerge 
worldwide. 
The studies described in this thesis have enabled to advance our understanding of how the 
NSs protein of the tick-borne phleboviruses UUKV, HRTV and SFTSV can counteract a 
key component of the first line of defence against viral infections: the interferon system. 
Initial transient transfection assays indicated that the NSs protein of UUKV is a weak IFN 
antagonist compared to the NSs belonging to HRTV and SFTSV (Chapter 6). Because 
HRTV and SFTSV can cause severe disease in humans and UUKV is apathogenic, these 
results indicated that the NSs protein of these tick-borne phleboviruses could act as an 
important virulence factor that contribute to pathogenicity. The results were confirmed in 
the context of a virus infection for UUKV, by using reverse genetics to generate 
recombinant UUKV lacking NSs (chapter 6). However, there is a need to develop similar 
NSs-lacking viruses for HRTV and SFTSV to confirm the results observed in transient 
transfection assays, as in these assays the NSs proteins were overexpressed and the IFN 
system induced artificially. In the context of a virus infection, factors that differ between 
viruses and may contribute to the evasion of antiviral immunity can be taken into account. 
These factors include differences in the half-life of NSs proteins expressed exclusively 
from S segment-specific promoters, or the ability to minimize the detection of PAMPs 
associated with the respective virus. Thus, a comparison of the ability of each particular 
virus to utilize the NSs protein to block the IFN response induced by the virus itself would 
be a more informative approach to understand the relevance of the NSs proteins in the 
context of a virus infection. This is highlighted by the observation that although transient 
transfection assays indicated that SFTSV NSs potently inhibits type I IFN induction, 
SFTSV infection induced IFN, which limited viral replication (chapter 6). The latter 
finding is in agreement with a recent study that found significantly higher levels of IFN-α 
in sera from SFTSV-infected patients compared to healthy patients (Liu et al., 2017). In 
fact, the authors suggested that perhaps the ability of SFTSV NSs to potently block type I 
IFN production in vitro may not play such an important role in vivo. Therefore, the kinetics 
between induction of IFN by the PAMPs associated with the viruses and the ability of their 
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NSs proteins to block such induction would be an interesting follow-up study stemming 
from this work, and could be aided by the generation of NSs-lacking viruses using reverse 
genetics.  
The development of a reverse genetics system for UUKV (chapter 5) can now facilitate a 
vast number of studies that require the manipulation of the UUKV genome, and serves as a 
starting point for the generation of, and comparison with other NSs-lacking tick-borne 
phleboviruses. Unfortunately, time constraints prevented further attempts to rescue HRTV 
from cDNA clones to genetically manipulate its genome. Additionally, although a reverse 
genetics system for SFTSV was described (Brennan et al., 2015), the generation of NSs-
lacking SFTSV has not yet been reported. As well as serving as convenient tools to 
understand the molecular basis for virulence and pathogenicity, developing a reverse 
genetics system that allows the recovery of infectious HRTV from cDNA and the 
generation of NSs-lacking HRTV and SFTSV could also be further explored as an avenue 
for the design of recombinant live-attenuated vaccines, as it has been described for RVFV 
(Bird et al., 2011). 
During the progress of this PhD study, in vivo models of SFTSV infection have become 
available, which demonstrated that whilst mice engineered to lack α/β IFN receptors or 
STAT2 are highly susceptible to SFTSV infection, wild-type mice do not become ill 
(Gowen et al., 2016; Liu et al., 2014). This suggests that the type I IFN response plays a 
key role in determining disease outcome. The results in this thesis indicate that the NSs 
protein of HRTV and SFTSV have the ability to block type I but not type II IFN signalling 
(Chapter 7). HRTV and SFTSV engineered to lack their NSs proteins and rUUKdelNSs 
could be used in combination with these in vivo models. Such projects would serve as an 
excellent resource to understand the role that the NSs protein of tick-borne phleboviruses 
and type II IFN signalling play during disease progression in vivo, and to evaluate live 
attenuated vaccines which could be generated using reverse genetics tools. 
In addition, studies to identify additional roles of tick-borne phlebovirus NSs proteins are 
worthy of further investigation. For instance, findings from this thesis suggested that 
UUKV NSs could have a dispensable role in facilitating virus replication, as UUK viruses 
lacking NSs exhibited slower replication kinetics than wild-type UUKV (Chapter 5). 
Moreover, SFTSV NSs has been implicated to act as a scaffold for the formation of 
characteristic inclusion bodies, which are thought to function as virus replication factories 
(Bird et al., 2011). Therefore, SFTSV NSs could also play a role in facilitating replication. 
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Mass spectrometry-based analyses to map the interaction between viral and host proteins 
(interactome studies) could facilitate the identification of unknown host or viral interacting 
partners of tick-borne phlebovirus NSs proteins, and could give an insight into unknown 
roles of these proteins.  
An interesting area of research outwith the scope of this study would be investigating 
whether tick-borne phlebovirus NSs proteins play any role in tick cells. Persistence of 
RVFV in mosquito cells was suggested to be mediated by antiviral RNA interference by 
downregulating the expression of RVFV NSs upon virus infection, which would otherwise 
inhibit host cell transcription (Léger et al., 2013). Little is known about antiviral responses 
in tick cells, and studies have suggested that the RNA interference system in ticks is 
different and more complex than that in mosquitoes (Schnettler et al., 2013). Future 
projects focused on understanding whether NSs proteins play a role in tick cells, whether 
tick-borne phleboviruses can establish persistence in tick cells, and if similar mechanisms 
to that described for RVFV NSs in mosquitoes enable persistence of tick-borne 
phleboviruses to occur in ticks would be beneficial for the better understanding of the 
replication of tick-transmitted viruses in their vectors. Indeed, studies investigating UUKV 
entry, replication and and persistence in tick cells have recently begun (Mazelier et al., 
2016). 
The research I carried out during my PhD project enabled me to characterize at the 
molecular level how the NSs protein of UUKV and HRTV can block IFN induction only 
or IFN induction and IFN signalling, respectively, in comparison to the well-characterized 
SFTSV NSs. UUKV NSs was able weakly inhibit IFN induction through a direct 
interaction with MAVS, whereas HRTV and SFTSV NSs proteins inhibited IFN induction 
and type I IFN signalling via an interaction with TBK1 and STAT2, respectively (Chapter 
7). The molecular basis for IFN induction or signalling inhibition by these interactions 
deserves further investigation. The Influenza virus PB1-F2 protein was shown to inhibit 
IFN synthesis by binding to MAVS, altering mitochondrial membrane potential levels 
(Varga et al., 2012; 2011), which are known to mediate antiviral signalling via the 
rearrangement of MAVS (Koshiba et al., 2011). Whether the weak antagonistic activity of 
UUKV NSs observed at the level of IFN induction and shown to be mediated through a 
direct interaction with MAVS could have similar consequences to those described for 
Influenza PB1-F2 is a hypothesis worth pursuing. Work from this project also suggested 
that, in order to inhibit IFN induction and type I IFN signalling, HRTV NSs has conserved 
the same interacting partners as SFTSV NSs: TBK1 and STAT2, respectively (Chapter 7). 
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However, the strategy employed by HRTV NSs to exert its antagonistic activity must be 
divergent to the one used by SFTSV, because HRTV NSs is unable to form inclusion 
bodies which are used by SFTSV NSs to spatially isolate these two proteins. In this PhD 
project, I showed that in the presence of HRTV NSs, STAT2 nuclear translocation was 
inhibited (chapter 7). However, the effect of HRTV NSs on TBK1 activation needs to be 
explored further. TBK1 serves as an integrator of multiple signalling pathways that are 
activated upon pathogen recognition, and therefore plays a key role in innate immunity. To 
date, the mechanisms of TBK1 activation are not clearly understood, although trans-
autophosphorylation, K63-linked polyubiquitination and phosphorylation at position serine 
172 by IKKβ have all been suggested to be required for its activation (Kishore et al., 2002; 
Ma et al., 2012; Tu et al., 2013). Therefore, it would be worth exploring whether HRTV 
NSs inhibits TBK1-mediated IFN production by hindering any of the proposed models of 
TBK1 activation. Efforts to understand in more detail the molecular basis of the IFN 
antagonistic properties of UUKV and HRTV NSs proteins could unveil not only novel 
mechanisms evolved by viruses to counteract the IFN response, but also to provide insight 
into how these signalling molecules work. After all, viruses are the best cell biologists and 
thus can be utilized to uncover unknown cellular processes that are naked to our eyes. 
Some evidence suggests that birds may play a role in the widespread distribution of some 
tick-borne phleboviruses (Hubálek and Rudolf, 2012). For instance, various strains of 
UUKV (or UUKV-like viruses) have been isolated from ticks collected from passerine 
birds, migrant birds, or within nesting areas of seabirds (S. R. Moss, 1986; Nuttall et al., 
1984; 1981; Traavik and Mehl, 1977; Watret and Elliott, 1985).  Furthermore, a study 
proposed that migratory birds are responsible for the spread of SFTSV across countries 
(Yun et al., 2015), and antibodies against SFTSV (or SFTSV-like viruses) were detected in 
migratory birds in China in another study (Li et al., 2016). Preliminary data in this PhD 
project showed that, while UUKV was able to achieve high viral titres in the chicken 
embryo fibroblast cell line DF-1, UUK viruses lacking NSs were unable to replicate in this 
cell line (Chapter 5). These results suggested that perhaps, unlike in the mammalian cells 
that have been used in this study (BHK-21 and A549), UUKV NSs plays an essential role 
in virus replication in avian cells. NSs proteins of bunyaviruses are believed to be non-
essential gene products. Therefore, the inability of UUK viruses lacking NSs to replicate in 
DF-1 cells is an interesting finding worth pursuing that could change our views on the 
canonical accessory role that bunyaviral NSs proteins are attributed. Furthermore, this 
finding raised the question whether the NSs protein of UUKV, which has a weak IFN 
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antagonistic role in human cells (Chapter 6), may act as a potent antagonist of the avian 
IFN response. It is possible that the inability of UUK viruses lacking NSs to replicate in 
DF-1 cells is due to large amounts of IFN produced following infection, which may be 
efficiently counteracted by its NSs protein. Therefore, follow up studies stemming from 
the work described in this thesis could involve comparing the antagonist activity of the 
tick-borne phlebovirus NSs proteins in the human IFN system (this PhD project) to the 
avian IFN system. Such studies would be interesting because they would allow a 
comprehensive analysis of the molecular adaptations of different viruses to their hosts in 
order to replicate efficiently. 
Finally, despite interesting reports suggesting that it is possible that all known 
bunyaviruses represent reassortants of existing or extinct viruses (Briese et al., 2013), 
Phlebovirus reassortment is an area of research that remains largely unexplored. In an 
attempt to shed light on the possibility of reassortment between tick-borne phleboviruses, 
minigenome results showed that except UUKV N and L and SFTSV M segment UTRs, the 
N and L proteins of each of the viruses (UUKV, HRTV or SFTSV) were compatible with 
M segment-based minigenome belonging to heterologous viruses (Chapter 8). The 
preliminary results from this assay highlighted the plasticity of interactions between the N 
and L proteins and UTR sequences from heterologous tick-borne phleboviruses, and 
allowed me to assess the possibility of genome reassortment between tick-borne 
phleboviruses. Although the significance of the potential reassortants were not confirmed 
due to time constraints, this assay can now be easily adapted for the use with other 
bunyaviruses. Future work could involve utilizing virus-like particles and reverse genetics 
to attempt to rescue potential reassortant viruses (under the appropriate biosafety 
conditions). Such studies would be beneficial to predict outcomes of genome reassortment 
under an experimental setting, and could help to develop better immune surveillance 
strategies. 
Collectively, work from this PhD study provided significant progress towards the 
molecular characterization of tick-borne phlebovirus NSs proteins (other than SFTSV) as 
IFN antagonists, and expanded our knowledge on the plethora of immune evasion 
strategies acquired by tick-borne phleboviruses to supress the IFN response. In addition, 
the reverse genetics system described for UUKV and the minigenome system described for 
HRTV provide a basis for advancing our understanding of the molecular biology of these 
important pathogens that continue to emerge and pose a public health threat. 
  
 
 
 
 
 
Chapter 10 
APPENDICES 
 
 
 
 
 
 
Chapter 10: Appendices 219 
10 Appendices 
10.1 Oligonucleotide primers used in this study 
Table 10-1. Common oligonucleotide primers used throughout this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primer Sequence (5’ "  3’) Purpose 
pT7exi1 
pT7exi2 
gggtcggcatggcatctccacctc 
ctatagtgagtcgtattaatttcg 
Linearization of the 
pTVT7 plasmid (0,0) 
 
pUC118F agcgcccaatacgcaaac 
Forward sequencing of 
pTVT7 plasmids 
pTM1 fwd ggtgcacatgctttacatgtg 
Forward sequencing of 
pTM1 plasmids 
pTM1 Rev caactcagcttcctttcgggc 
Reverse sequencing of 
pTM1 plasmids 
PCR anchor primer gaccacgcgtatcgatgtcgac 3’ RACE  
Oligod(T)-Anchor gaccacgcgtatcgatgtcgactttttttttttttttv 3’ RACE 
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Table 10-2. Oligonucleotide primers used for the generation of UUKV reverse 
genetics plasmids. 
 
 
 
 
 
Primer Sequence (5’ "  3’) Purpose 
UUK ST7F 
UUK ST7R 
UUK MT7F 
UUKMT7R 
UUK LT7F 
UUKLT7R 
tacgactcactatagacacaaagacctcca 
atgccatgccgacccacacaaagaccctcc 
tacgactcactatagacacaaagacggcta 
atgccatgccgacccacacaaagacacggc 
tacgactcactatagacacaaagacgccaag 
atgccatgccgacccacacaaagtccgcca 
Amplification of full-length 
segments for insertion into 
pTVT7 plasmid in the 
antigenomic sense 
 
UUKSdelNSs:eGFPexi1 
UUKSdelNSs:eGFPexi2 
tttgggccgaagcccttttagagtcc 
gcttaatgttggagggtctttgtgtgg 
Amplification of pT7-UUKS 
lacking NSs for eGFP insertion 
UUK GFPexi1 
UUK GFPexi2 
ggcttcggcccaaattacttgtacagc 
ccaacattaagcatggtgagcaagg 
Amplification of eGFP for 
insertion in pT7UUKS lacking 
NSs 
UUK SdelNSsexi1 
UUK SdelNSsexi2 
tttgggccgaagcccttttagagtcc 
cggcccaaagcttaatgttggaggg 
Amplification of pT7-UUKS 
lacking NSs, followed by 
religation 
UUK SF1 
UUK SR1 
acacaaagaccctccaacattaagc 
acacaaagacctccaacttagc 
RT-PCR for full S segment 
amplification 
UUK NpTM1F 
UUK NpTM1R 
UUK LpTM1F 
UUK LpTM1R 
gaaaaacacgataataccatggctatgccggag 
attaggcctctcgagtcagatcaatgatct 
gaaaaacacgataataccatgcttttagcgatt 
attaggcctctcgagtcaaccaaacatgtc 
UUKV N and L ORF 
amplification for insertion into 
pTM1 expression plasmid 
UUK SNSs:hRenF 
UUK SNSs:hRenR 
UUK MhRenF 
UUK MhRenR 
UUK LhRenF 
UUK LhRenR 
ggcttcggcccaaattactgctcgttcttc 
cctccaacattaagcatggcttccaaggtg 
gggaatagggggactttactgctcgttctt 
cacaaagacggctaccatggcttccaaggt 
ccaaagaaaagtcacttactgctcgtt 
acacaaagacgccaagatggcttccaaggtg 
Amplification of humanised 
Renilla for the generation of 
UUK S, M and L minigenome 
plasmids. 
UUK ShRenexi1 
UUK ShRenexi2 
UUK MhRenexi1 
UUK MhRenexi2 
UUK LhRenexi1 
UUK LhRenexi2 
gcttaatgttggagggtctttgtgtgg 
tttgggccgaagcccttttagagtcc 
agtccccctattccccatccccctcta 
ggtagccgtctttgtgtgggtcgg 
cttggcgtctttgtgtgggtcggcatgg 
gtgacttttctttgggttggatgctgg 
Excision of NSs, GnGc and L 
ORFs from UUK pT7S (+), M 
(-) and L(-) for recombination 
with hRen amplicons for the 
generation of minigenome 
plasmids. 
UUK GnGcpTM1F 
UUK GnGcpTM1R 
gaaaaacacgataataccatggtaaaggacatat 
attaggcctctcgagtcacgattttttaac 
Amplification of GnGc ORF for 
insertion into pTM1. 
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Table 10-3. Oligonucleotide primers used for sequencing the UUKV genome and 
plasmids.  
Primer* Sequence (5’ "  3’) Purpose 
UUK S Fwd 1 
UUK S Fwd 2 
UUK S Fwd 3 
UUK S Fwd 4 
UUK S Rev 1 
UUK S Rev 2 
UUK S Rev 3 
acacaaagacccttccaacattaagc 
ataaggagaatgaagctcactg 
gctcagcaggtaagctctcttctg 
atgtccctcagcatctggtccc 
acacaaagacctccaacttagc 
ccagcaggctgcaactgtcctc 
cccttgtgactagtcttttctgg 
Sequencing the S 
segment of UUKV 
UUK M Fwd 1 
UUK M Fwd 2 
UUK M Fwd 3 
UUK M Fwd 4 
UUK M Fwd 5 
UUK M Fwd 6 
UUK M Fwd 7 
UUK M Rev 1 
acacaaagacacggctacatgg 
gacttttcaagcgtgttcttcac 
gaaactttgtgccgtgtagatcc 
gatcctaatagagtccactgctg 
gacctcactgcaactagtattag 
gcatgtgaattctgtgcaaaac 
gtgattgacactgacttcatcaatg 
acacaaagacggctaccatggtaag 
Sequencing the M 
segment of UUKV 
UUK L Fwd 1 
UUK L Fwd 2 
UUK L Fwd 3 
UUK L Fwd 4 
UUK L Fwd 5 
UUK L Fwd 6 
UUK L Fwd 7 
UUK L Fwd 7 
UUK L Fwd 8 
UUK L Fwd 9 
UUK L Fwd 10 
UUK L Fwd 11 
UUK L Fwd 12 
UUK L Rev 1 
acacaaagtccgccaagatggaag 
ctctgctgagaccatccagcatc 
gaaggacgcttttgagaatctc 
cagaatgcctgctgcttcaattc 
cagctgtgccggagtcaacctgg 
gtacttgaatcctgatagaccag 
ctgagctctgcaagacatccac 
gaatggccagtttttgctttgg 
catcactaggagggtccccaag 
ctcattcccagcccagaagggtac 
gtgctcattgttgaacatcaagtc 
ccttaaccatgttcaagctctcc 
gagattgttcctggtctgaccgg 
acacaaagacgccaagatgctttta 
Sequencing the L 
segment of UUKV 
UUK S Rev 1 acacaaagacctccaacttagc Generation of UUKV S 
segment cDNA 
UUK S Fwd 1 
UUK S Rev 1 
acacaaagacccttccaacattaagc 
acacaaagacctccaacttagc 
PCR of the full-length 
UUKV S segment from 
cDNA 
 
* Primers used in chapter 5 for the full-genome sequencing of recombinant UUKV by 3’ 
RACE and RT-PCR, as well as for sequencing reverse genetics plasmids are shown. 
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Table 10-4. Oligonucleotide primers used in Chapter 6.  
Primer* Sequence (5’ "  3’) Purpose 
pCMVexi1 
pCMVexi2 
ttctagagcggccgcttcgagcagacatgataag 
ggtggctagcctatagtgagtcgtattaagtactc 
Linearization of pCMV 
for restriction-free 
cloning 
pCMV-UUKNSsFwd 
pCMV-UUKNSsRev 
gcggccgctctagaactacagtgatcctacgactggcc 
ctataggctagccaccatgtcttacttcactatccagaac 
Amplification of UUKV 
NSs for insertion in into 
pCMV 
pCMV-HRTNSsFwd 
pCMV-HRTNSsRev 
ctataggctagccaccatgtccttgtctaaagcctctcagcccagcgtc 
gcggccgctctagaactagggggagctggaaagtgctggccagtcc 
Amplification of HRTV 
NSs for insertion in into 
pCMV 
pCMV-SFTSNSsFwd 
pCMV-SFTSNSsRev 
gcggccgctctagaattagacctccttcgggaggtc 
ctataggctagccaccatgtcgctgagcaaatgctccaac 
Amplification of SFTSV 
NSs for insertion in into 
pCMV 
UUKNSsV5Fwd 
UUKNSsV5Rev 
gcagtgggttagggatgggcttgcccagtgatcctacgactggcc 
taggtttagacagcacctaatagttctagagcggccgcttcgagc 
PCR for ligation of 
pCMVUUKNSs with V5 
at C terminus 
HRTNSsV5Fwd 
HRTNSsV5Rev 
gcagtgggttagggatgggcttgccgggggagctggaaagtgctgg 
taggtttagacagcacctaatagttctagagcggccgcttcgagc 
PCR for ligation of 
pCMVHRTNSs with V5 
at C terminus 
SFTSNSsV5Fwd 
SFTSNSsV5Rev 
gcagtgggttagggatgggcttgccgacctccttcgggaggtcacc 
taggtttagacagcacctaatagttctagagcggccgcttcgagc 
PCR for ligation of 
pCMVSFTSNSs with V5 
at C terminus 
CXCL10Fwd 
CXCL10Rev 
ccattctgatttgctgcctt 
tttccttgctaactgctttcagta 
Real-time qPCR for 
determination of 
CXCL10 mRNA levels 
in total cellular RNA 
IRF1Fwd 
IRF1Rev 
ctgtgcgagtgtaccggatg 
atccccacatgacttcctctt 
Real-time qPCR for 
determination of IRF-1 
mRNA levels in total 
cellular RNA 
GAPDHFwd 
GAPDHRev 
ggagcgagatccctccaaaat 
ggctgttgtcatacttctcatgg 
Real-time qPCR for 
determination of 
GAPDH mRNA levels in 
total cellular RNA 
 
* Primers used for the generation of pCMVXNSs and pCMVXNSsV5 (where X refers to 
UUKV, HRTV or SFTSV), and for real-time qPCR are shown. 
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Table 10-5. Oligonucleotide primers used for the full-genome sequencing of the 
HRTV laboratory stock.  
* 3’ RACE, RT-PCR and sequencing primers used in Chapter 8 are shown. 
Primer* Sequence (5’ "  3’) Purpose 
HRT S 5’ 
HRT S 3’ 
HRT M 5’ 
HRT M 3’ 
HRT L 5’ 
HRT L 3’ 
cataaactctagccagatttgtc 
gagcagcctgcaggaaatggac 
aggaaacacttggcctccccttc 
gccattcatcaaagctgttgcttaag 
ctagtcttgtgtgtatcacatc 
ggaaatgggagaagctatgg 
Sequencing the genomic 
3’ and 5’ UTR of HRTV 
S, M and L segments by 
3’ RACE following 
cDNA synthesis 
HRT S seq 1 
HRT S seq 2 
HRT S seq 3 
HRT S seq 4 
HRT S seq 5 
HRT S seq 6 
HRT S seq 7 
HRT S seq 8 
acacagagaacccctttgaatc 
cataaactctagccagatttgtc 
gtctcaattgaagtcataaaggac 
aatttggcgccaaattcaaaatttatc 
tccaaggggttgagagggtcatcc 
cgagggggacatggtcattgac 
gagcagcctgcaggaaatggac 
acacaaagaaccccttgaattttcaa 
Full-length sequencing 
of the HRTV S segment 
by RT-PCR 
HRT M seq 1 
HRT M seq 2 
HRT M seq 3 
HRT M seq 4 
HRT M seq 5 
HRT M seq 6 
HRT M seq 7 
HRT M seq 8 
HRT M seq 9 
HRT M seq 10 
HRT M seq 11 
HRT M seq 12 
HRT M seq 13 
HRT M seq 14 
acacagagacggctatacattaagg 
aggaaacacttggcctccccttc 
ctaagccactctggcacatattg 
catggcagttgcccttactc 
tgtgaattatggaggcgtctctgtaag 
gtaacattgtgggtttctcagg 
catgggtttttgctccaataaag 
atgcagacttgcatgtgatag 
gtaagaaggtgcaggtgggcaggtgac 
tagagtcttaacctctcctgatggc 
aagcgcaaagcacatcagatctgatgg 
atctgaatcacatttaagatg 
gccattcatcaaagctgttgcttaag 
acacaaagaccggctatacaaattg 
Full-length sequencing 
of the HRTV M segment 
by RT-PCR 
HRT L seq 1 
HRT L seq 2 
HRT L seq 3 
HRT L seq 4 
HRT L seq 5 
HRT L seq 6 
HRT L seq 7 
HRT L seq 8 
HRT L seq 9 
HRT L seq 10 
HRT L seq 11 
HRT L seq 12 
HRT L seq 13 
HRT L seq 14 
HRT L seq 15 
acacaaagacgtccagatg 
cgaataagagcacagtgaag 
gagcttgttactctcacgag 
tacaaccaagttggccatgg 
gatgcaacaactggtggaac 
atgctgctgaggttgtgaag 
ggaaatgggagaagctatgg 
acccttaagaagacctcatc 
tctgcttttgactatgttcc 
tgccaaagagcgggtttatg 
acacagagacggctatacattaagg 
ctctctcctccaagctttgc 
ttgataagccattttggtgc 
ttgatgcatcaggcattatg 
gatatctgggacggtctttgtgt 
Full-length sequencing 
of the HRTV L segment 
by RT-PCR 
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Table 10-6. Oligonucleotide primers utilised for the generation of HRTV minigenome 
constructs.  
Primer* Sequence (5’ "  3’) Purpose 
HRT ShRenexi1 
HRT ShRenexi2 
HRT MhRenexi1 
HRT MhRenexi2 
HRT LhRenexi1 
HRT LhRenexi2 
ttgaattttcaaaacatggcttccaaggt 
gttttgaaaattcaaggggttctttgtgt 
ctcagtggattacggtttacctctacctta 
ttggcattaattaacaaataagcaagcctc 
accaaccaggactggggctcgggttga 
ctggacgtctttgtgtctatagtgagtcgt 
Amplification of 
humanised Renilla for 
the generation of 
HRTV S, M and L 
minigenome 
constructs. 
HRT SexiRen1 
HRT SexiRen2 
HRT MexiRen1 
HRT MexiRen2 
HRT LexiRen1 
HRT LexiRen2 
ggggagctaatttagatcgaattcatttg 
gttttgagaattcaaggggttctttgtgt 
ccgtaatccactgagatggcttccaaggtg 
gttaattaatgccaattactgctcgttcttc 
cacaaagacgtccagatggcttccaaggtg 
cccagtcctggttggtttactgctcgttc 
Excision of NSs, GnGc 
and L ORFs from UUK 
pT7HRTS (+), M (+) 
and L(+) for 
recombination with 
hRen amplicons. 
HRTMFlip1 
HRTMFlip2 
HRTLFlip1 
HRTLFlip2 
tacgactcactatagacacaaagaccggctatacaaattgaaaacccacc 
atgccatgccgacccacacagagacggctatacattaaggtagaggtaaaccg 
tacgactcactatagacacaaagaccgtccagatatcaacctttagg 
gccatgccgacccacacaaagacgtccagatggcttccaaggtgtacg 
Amplification of 
minigenome cassette in 
genomic sense to flip 
in antigenomic sense 
into pTVT7. 
HRT S A1751G F 
HRT S A1751G R 
HRT L A3309T F 
HRT L A3309T R 
cacacaaagaaccccttgaatctcaaa 
tttagacaaggacatgttttgagaattca 
caaaaaatatgccttgaaaaaactttggacgcatgaatgcagtag 
ctactgcattcatgcgtccaaagttttttcaaggcatattttttg 
Site-directed 
mutagenesis of the 
HRTV S and L 
segments. 
* Primers used for the generation of S, M and L segment-based minigenome constructs, 
and for the introduction of mutations identified in the HRTV laboratory stock in chapter 8 
are shown. 
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10.2 Amino acid alignments of UUKV, HRTV and SFTSV N and L 
proteins 
 
Figure 10-1. Amino acid sequence alignment for UUKV, HRTV and SFTSV N proteins. 
UUKV, HRTV and SFTSV N amino acid sequences  (GenBank accession numbers AAA47958.1, 
AFP33391.1 and AJD86040.1, respectively) were aligned using Jalview 2 (Waterhouse et al., 
2009). Residues are highlighted using the ClustalX colour scheme such that the colour of a 
particular residue depends on the residue type and its conservation (Thompson et al., 1994). Blue: 
hydrophobic; Magenta: negative charge; Red: positive charge; Green: polar; Pink: cysteine; 
Orange: glycine; Yellow: proline; Cyan: hydrophobic.  The conservation histogram below the 
alignment depicts conservation scores for each position (0-10, ‘*’ refers to a score of 11, indicating 
conserved amino acids).  
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Figure 10-2. Amino acid sequence alignment for UUKV, HRTV and SFTSV L proteins.  
UUKV, HRTV and SFTSV N amino acid sequences  (GenBank accession numbers BAA01590.1, 
AFP33396.1 and AJD86038.1, respectively) were aligned using Jalview 2 (Waterhouse et al., 
2009). Residues are highlighted using the ClustalX colour scheme such that the colour of a 
particular residue depends on the residue type and its conservation (Thompson et al., 1994). Blue: 
hydrophobic; Magenta: negative charge; Red: positive charge; Green: polar; Pink: cysteine; 
Orange: glycine; Yellow: proline; Cyan: hydrophobic.  The conservation histogram below the 
alignment depicts conservation scores for each position (0-10, ‘*’ refers to a score of 11, indicating 
conserved amino acids).  
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